Document:

EX-10.3

 Exhibit 10.3 

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 
 Private & Confidential 

 
  

							
		 	 Dated    16 April    2019

 
	  		  	
				
		 	INNATE PHARMA S.A.	  	(1)	  	
				
		 	AND	  		  	
				
		 	MEDIMMUNE LIMITED	  	(2)	  	
				
		 		  		  	
		 		
		 	 AMENDMENT AND RESTATEMENT AGREEMENT OF THE COLLABORATION AND
OPTION AGREEMENT RELATING TO CD39
  
	  		  	

 CD39 OPTION 

This Deed (the “Deed”) is made on ______16 April ____2019 by and between: 

 

	(1)	 INNATE PHARMA S.A., a company incorporated in France having its principal place of business at 117, Avenue de Luminy -
BP 30191 13 009 Marseille, France (“Innate”); and 

  

	(2)	 MEDIMMUNE LIMITED, a company incorporated in England and Wales with company number 2451177 and with its registered
office at Milstein Building, Granta Park, Cambridge, CB21 6GH, United Kingdom (“MedImmune”). 

 Background

  

	(A)	 Innate and MedImmune entered into a Collaboration and Option Agreement relating to CD39 on 22 October 2018
(“Original Agreement”). Under the Original Agreement, Innate has granted to MedImmune an exclusive option to take an exclusive license under the CD39 Option Technology (as defined in the Original Agreement), and the Parties agree to
collaborate to perform certain development activities with respect to the CD39 program, in each case, in accordance with the terms of the Original Agreement. 

 

	(B)	 Innate and MedImmune now wish to amend and restate the Original Agreement in its entirety, in the form set out in the
Schedule to this Deed, in accordance with the terms of this Deed. 

 NOW, THEREFORE, each of Innate and MedImmune, intending to be
legally bound, agree as follows: 
  

	 	1	 DEFINITIONS 

  

	1.1	 In this Deed, unless the context otherwise requires, the provisions in this Section 1 apply. Unless otherwise
stated, terms defined in the Original Agreement shall have the same meaning in this Deed. 

  

	1.2	 “Amended Agreement” shall have the meaning set out Section 3.1. 

 

	1.3	 “Effective Date” means 22 October 2018. 

 CD39 OPTION 
  

	1.4	 “Original Agreement” shall have the meaning set out in the preamble to this Deed.

  

	 	2	 INTERPRETATION 

  

	2.1	 The principles of interpretation set out in Section 2.1 of the Original Agreement shall have effect as if set out
in this Deed, save that references to “this Agreement” shall be construed as references to “this Deed”. 

  

	2.2	 References to this Deed include its Schedule. 

 

	 	3	 AMENDMENT 

  

	3.1	 In accordance with Section 26 of the Original Agreement, the Parties agree that the Original Agreement shall be
amended and restated in its entirety, in the form set out in the Schedule to this Deed (the “Amended Agreement”). 

  

	3.2	 The amendment and restatement of the Original Agreement pursuant to Section 3.1 shall take effect from the Effective
Date, as if the Amended Agreement had been entered into on the Effective Date. Accordingly, upon this Deed being entered into, the Amended Agreement shall supersede the Original Agreement in its entirety. 

 

	 	4	 INCORPORATION OF TERMS; CONFIDENTIALITY 

 

	4.1	 The provisions of Sections 11.1, 11.2 (with the reference to “and the obligations set forth in
Section 11.5” deleted), 11.3 (with each reference to “and the License Agreement” deleted), 11.4, 18.1 (first paragraph) and 20 to 28 of the Amended Agreement shall apply to this Deed as if set out in full in this Deed and as if
references in those Sections to “this Agreement” shall be construed as references to this Deed. 

  

	4.2	 The Parties acknowledge and agree that the terms of this Deed shall be deemed to be each Party’s Confidential
Information (and each Party shall be deemed to be the Disclosing Party and also the Receiving Party with respect to such Confidential Information). 

 CD39 OPTION 
 IN
WITNESS this Deed has been executed by the Parties as a deed and is intended to be and is delivered on the date first appearing above. 
  

							
	 EXECUTED as a DEED by

MEDIMMUNE LIMITED
	  		  		  	
				
	acting by a director:	  		  	 /s/ Adrian Kemp
 Name: Adrian Kemp

Title: Director
	  	
				
	in the presence of:	  		  	 /s/ Svetlana Dmukh
 Witness
	  	
				
		  		  	   Name of witness
   /s/ Svetlana Dmukh

 
   Address of witness

  Academy House
   136 Mills Road

  Cambridge, CB2 8PA, UK
  

  Occupation of witness
   Company Secretarial

  Administrator
	  	

 CD390PTION 
  

			
	 EXECUTED as a DEED by
 INNATE PHARMA S.A.
	  	/s/ Mondher Mahjoubi
	 acting by a person under the authority of the company in accordance with the laws of its jurisdiction of incorporation.
	  	 Name: Mondher Mahjoubi
 Title: CEO

		  	
		
	 in the presence of:
	  	
		  	Witness
		
		  	/s/ Irene Berkowitz
		
		  	 Address of witness
 A2 Impasse Gaveliere

A3007 Marseille, France

 CD39  OPTION 

SCHEDULE 

 CD39  OPTION 

Private & Confidential 
 Execution version 

 

							
		 	 Dated October 22, 2018

 
	  		  	
				
		 	INNATE PHARMA S.A.	  	(1)	  	
				
		 	AND	  		  	
				
		 	MEDIMMUNE LIMITED	  	(2)	  	
				
		 		  		  	
		 		
		 	 COLLABORATION AND OPTION AGREEMENT RELATING TO CD39

 
	  		  	

 CD39  OPTION 

This Collaboration and Option Agreement (the “Agreement”) is made as of the 22 October 2018 (the “Effective
Date”) by and between: 
  

	(1)	 INNATE PHARMA S.A., a company incorporated in France having its principal place of business at 117, Avenue de Luminy -
BP 30191 13 009 Marseille, France (“Innate”); and 

  

	(2)	 MEDIMMUNE LIMITED, a company incorporated in England and Wales with company number 2451177 and with its registered
office at Milstein Building, Granta Park, Cambridge, CB21 6GH, United Kingdom (“MedImmune”). 

 Background 

 

	(A)	 Innate is the owner of certain proprietary technology relating to monoclonal antibodies which allows the inhibition of
the CD39 human enzyme and is the owner or exclusive licensee or sublicensee of certain Patents and Know-How associated therewith (capitalised terms are defined below); 

 

	(B)	 MedImmune, which is directly or indirectly wholly owned by AstraZeneca PLC, and its Affiliates have experience in the
research, development, manufacturing and commercialization of pharmaceutical products worldwide (capitalised terms are defined below); 

  

	(C)	 By entering this Agreement MedImmune is obtaining an exclusive option to take an exclusive license under Patents and Know-How in and to the CD39 Lead and the CD39 Back-Ups and Innate is willing to grant such option to MedImmune, in each case, on the terms and conditions set forth below and
in the License Agreement (capitalised terms are defined below); 

  

	(D)	 The Parties intend to collaborate to perform certain Development activities (including Collaboration Studies) to
further develop the Innate’s research and development programme with respect to CD39, and Innate intends to assist MedImmune in its Evaluation and determination as to whether or not to exercise CD39 Option (capitalised terms are defined below),
all in accordance with the terms and conditions set forth below. 

  
 2 

 CD39  OPTION 

NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, each of Innate and MedImmune, intending to be legally bound, agree as follows: 
  

	 	1	 DEFINITIONS 

As used in this Agreement, the following terms will have the meanings set forth in this Section 1, unless context dictates
otherwise: 
  

	1.1	 “Affiliate” means, with respect to a Person, any Person that from time to time directly, or
indirectly through one or more intermediaries, controls, is controlled by or is under common control with such first Person. For purposes of the definition in this Section 1.1 only, “control”, and with correlative meanings, the terms
“controlled by” and “under common control with” mean (a) to possess, directly or indirectly, the power to direct the management or policies of a Person, whether through ownership of voting securities, by contract relating to
voting rights or corporate governance, resolution, regulation or otherwise, or (b) to own, directly or indirectly, more than fifty percent (50%) of the outstanding voting securities or other ownership interest of such Person.

  

	1.2	 “Agreement” shall have the meaning set forth in the preamble to this Agreement.

  

	1.3	 “Anti-Corruption Laws” means the US Foreign Corrupt Practices Act 1977, the UK Bribery Act 2010 and
any other Applicable Law for the prevention of fraud, corruption, racketeering, money laundering or terrorism. 

  

	1.4	 “Applicable Law” means the laws, rules, regulations and guidelines in the world, including any rules,
regulations, guidelines or other requirements of the Governmental Bodies that are applicable to the Parties or any particular activity under this Agreement, in each case as may be in effect from time to time, including, without limitation,
(i) GCP, (ii) GMP, (iii) GLP, (iv) GVP and (v) the principles that form the basis of the Helsinki Declaration of the World Medical Association, in each case to the extent they apply to a Party’s performance of its obligations
under this Agreement. 

  
 3 

 CD39 OPTION 
  

  

	1.5	 “Background IP” means, with respect to a Party, the Intellectual Property Rights owned by or licensed
to such Party as of the Effective Date, and the Intellectual Property Rights that come into the ownership of or become licensed to such Party during the term of this Agreement, other than by operation of this Agreement. 

 

	1.6	 “BLA” means a Biologics License Application submitted to the FDA under subsection (a) or (k) of
Section 351 of the PHSA or any corresponding application outside the United States. 

  

	1.7	 “Business Day” means a day other than Saturday or Sunday or a public holiday in England or France.

  

	1.8	 “CD39” means the enzyme NTPDase 1. 

 

	1.9	 “CD39 [***] Bispecific” means those molecules (including antibodies) and any fragment or derivative
thereof, that simultaneously bind to: 

 (i) CD39, and (ii) [***]. 

 

	1.10	 “CD39 [***] Combo” means any product or treatment involving sequential or concomitant administration
or otherwise a combination of (a) a CD39 Program Antibody; and (b) a molecule (including antibody) targeting any therapeutic target within [***], whether on their own or in combination with other active ingredient(s). For the avoidance of
doubt, CD39 [***] Combo includes a CD39/[***] Combination Product. 

  

	1.11	 “CD39 [***] Studies” means any Clinical Trial with respect to a CD39 [***] Bispecific or a
CD39 [***] Combo. 

  

	1.12	 “CD39 Back-Ups” means those (i) antibodies described in
Schedule 1.12, or (ii) other antibodies (or any fragment or derivative thereof) which bind to CD39, in each case (i) and (ii), including any fragment or derivative of such antibody, but excluding the CD39 Lead and the CD39 Bi-Specific Molecules. 

  
 4 

 CD39 OPTION 
  

 

  

	1.13	 “CD39 Bi-Specific Molecules” means those molecules (including
antibodies) and any fragment or derivative thereof, that simultaneously bind to: (i) CD39, and (ii) other therapeutic target(s). 

  

	1.14	 “CD39 Competing Product” means a protein, including an antibody (or any fragment or derivative
thereof), that [***]. 

  

	1.15	 “CD39/[***] Combination Product” means any product or treatment involving sequential or
concomitant administration or otherwise a combination of: (a) any molecule (including antibody) or any fragment or derivative thereof which binds to CD39; and (b) any molecule (including antibody) or any fragment or derivative thereof
which binds to [***], whether on their own or in combination with other active ingredients(s). 

  

	1.16	 “CD39 Lead” means the CD39 Program Antibody identified as [***]. 

 

	1.17	 “CD39 Option” shall have the meaning set forth in Section 4.1. 

 

	1.18	 “CD39 Option Fee” shall have the meaning set forth in Section 3.1. 

 

	1.19	 “CD39 Option Know-How” means all Know-How which is Controlled by Innate or its Affiliates, as of the Effective Date or at any time during the term of this Agreement, that is or may become necessary or useful for the Research, Development,
commercialization or other Exploitation of the CD39 Option Products, including: (a) the Innate Study Results, (b) the Know-How within the Innate Collaboration IP and (c) Innate’s interest
in the Know-How within the Joint Collaboration IP (together (a) to (c), the “Innate Collaboration Know-How”), but excluding Know-How licensed under the [***], unless otherwise agreed between the Parties. 

  
 5 

 CD39 OPTION 
  

  

	1.20	 “CD39 Option Notice” shall have the meaning set forth in Section 4.8. 

 

	1.21	 “CD39 Option Patents” means all of the Patents: (a) listed in Appendix A, as may be supplemented
by Innate from time to time, together with (b) all Patents which are Controlled by Innate or its Affiliates, as of the Effective Date or at any time during the term of this Agreement, that (i) claim any CD39 Option Product or
(ii) claim any invention that is or becomes (subject to Section 12.12) necessary or useful for the Research, Development, commercialization or Exploitation, as applicable, of any CD39 Program Antibody, but excluding in each case
(1) any Patent exclusively related to any active ingredient within a Combination (other than a CD39 Program Antibody) [***], unless otherwise agreed between the Parties. 

 

	1.22	 “CD39 Option Period” means the period beginning upon [***] 

 

	1.23	 “CD39 Option Products” means any and all pharmaceutical products including a 

  
 6 

 CD39 OPTION 
  

 CD39 Program Antibody as an active ingredient (including Combinations). 

 

	1.24	 “CD39 Option Technology” means the CD39 Option Patents and the CD39 Option Know-How. 

  

	1.25	 “CD39 Program Antibody” means any of: (a) the CD39 Lead, (b) any CD39 Back- Up; and
(c) CD39 Bi-Specific Molecule, in each case within the scope of the claims of any of the CD39 Option Patents at any time, regardless of jurisdiction. In any case, antibodies listed as Schedule 1.12,
including any fragment or derivative thereof, shall be CD39 Program Antibodies. 

  

	1.26	 “CD39 Program” means the programme of research and development with respect to CD39 Option Products
conducted or to be conducted under this Agreement. 

  

	1.27	 “Change of Control” has the meaning set forth in the License Agreement. 

 

	1.28	 “Clinical Trial” means a Phase 1 Clinical Trial, a Phase 2 Clinical Trial, or a Phase 3 Clinical
Trial. 

  

	1.29	 “CMC” means optimization of Manufacturing processes to provide reproducible supply of drug substance
at commercialization scale, including formulation and development work to ensure stability and purity, and to otherwise meet the requirements under Applicable Law to be approved by a Regulatory Health Authority for marketing, sale and distribution.

  

	1.30	 “Collaboration Budget” means the budget set out in the Development Plan with respect to the
forecasted Innate Development Costs to be incurred by Innate during the CD39 Option Period, as amended or updated from time to time by the OC in accordance with this Agreement. 

 

	1.31	 “Collaboration IP” means the Know-How and other Intellectual
Property Rights arising from, generated from or reduced to practice in connection with the performance of the Development activities under the Development Plan. 

  
 7 

 CD39 OPTION 
  

  

	1.32	 “Collaboration Study” means any clinical study conducted or to be conducted in accordance with the
Development Plan. 

  

	1.33	 “Collaboration Study Preliminary Report” means the preliminary report in respect of each
Collaboration Study written by or on behalf of Innate and summarising the Primary Endpoint Results of each Collaboration Study. 

  

	1.34	 “Collaboration Study Protocol” means each clinical trial protocol describing a Collaboration Study
and outlining the activities to be conducted by the Party assigned to perform such Collaboration Study under the Development Plan and the anticipated timelines for carrying out such activities, which protocol shall (i) be in accordance with the
Collaboration Study outline contained in the Development Plan; and (ii) be prepared by or on behalf of such Party and the applicable Principal Investigator, as may be amended from time to time in accordance with Section 7.3(b).

  

	1.35	 “Combination” means the combination of a CD39 Program Antibody as an active ingredient with one or
more other active ingredients including but not limited to MedImmune Products, whether sold or anticipated to be sold as a fixed dose or as separate co-prescribed doses or in a physically co-packaged form. 

  

	1.36	 “Commercially Reasonable Efforts” means, with respect to the efforts to be expended by a Party [***].

  

	1.37	 “Competition Law Filing” shall have the meaning set forth in Section 2.2. 

 

	1.38	 “Confidential Information” means any and all Know-How and
information with respect to a Party’s or its Affiliates’ business, whether oral or in writing or in any other form, disclosed before, on or after the date of this Agreement by one Party to the other Party that is either marked or
identified as confidential or proprietary or that is of such a nature that would be considered by a reasonable person to be confidential or proprietary. 

  

	1.39	 “Control” means, with respect to any item of Know-How or a
Patent, the ability and authority of a Party or its Affiliates, whether arising by ownership, possession, or pursuant to a licence or sublicense (other than pursuant to a licence or

  
 8 

 CD39 OPTION 
  

	 	 
sublicense granted under this Agreement or the License Agreement), to assign, disclose or grant a licence, sublicence or other right to the other Party under or to such item of Know-How or such Patent as provided for herein or under the License Agreement, and without breaching the terms of any agreement between such Party and any Third Party. 

 

	1.40	 “Costs” means both internal and external costs and expenses. Unless otherwise mutually agreed between
the Parties, internal costs incurred by a Party shall be determined by multiplying the applicable FTE Rate by the number of FTEs utilized to conduct the applicable activities. Costs shall exclude any payment obligations owed to the head licensors
under any Head License. 

  

	1.41	 “CRO” means a contract research organisation selected by Innate for the performance of the
Collaboration Studies or parts thereof and identified in the relevant Collaboration Studies Protocol, including the CROs engaged by Innate in 

  
 9 

 CD39 OPTION 
  

 relation to the CD39 Program. 

 

	1.42	 “CTA Materials” means those Clinical Trial Applications for the Collaboration Studies, together with
all supporting documentation and data, to be submitted after the Effective Date to the European Medicines Agency or other appropriate Regulatory Health Authorities in respect of the Collaboration Studies. 

 

	1.43	 “CTA” or “Clinical Trial Application” means any and all applications to the European
Medicines Agency or other appropriate Regulatory Health Authorities for the permission to perform a clinical study as required by Applicable Law. 

  

	1.44	 “Data Protection Law” means any law or regulation in force in the relevant jurisdiction from time to
time which implements or supplements the General Data Protection Regulation 2016/679 dated 27 April and any other Applicable Law replacing adding to or amending, extending, reconstituting or consolidating it or any equivalent national laws and
regulations which otherwise regulate the processing of Personal Data, privacy, direct marketing or the interception or communication of electronic messages. 

  

	1.45	 “Data Subject” means a natural person who is an identified or identifiable natural person. An
identifiable natural person is one who can be identified, directly or indirectly, in particular by reference to an identifier such as a name, an identification number, location data, an online identifier or to one or more factors specific to the
physical, physiological, genetic, mental, economic, cultural or social identity of that natural person. 

  

	1.46	 “Develop” or “Development” means activities relating to the development of CD39
Option Products, and activities to develop manufacturing capabilities for CD39 Option Products. Development includes pre-clinical activities, toxicology studies, formulation, manufacturing process development
and scale-up (including bulk antibody production and CMC activities), manufacturing CD39 Option Products for clinical trials, quality assurance and quality control, initial biomarker studies, technical
support, pharmacokinetic studies, clinical studies, pharmacovigilance and regulatory affairs activities. 

  
 10 

 CD39 OPTION 
  

  

	1.47	 “Development Plan” means the Development Plan for the CD39 Program, as reviewed, updated and approved
by the OC from time to time pursuant to Section 5.1; containing the outline of each of the currently envisaged pre-clinical activities, the Collaboration Studies and timelines for the commencement and
completion of such studies, as well as certain CMC activities and the supply of CD39 Option Products, the related timelines for such activities as well as the assumptions set forth therein. 

 

	1.48	 “Disclosing Party” shall have the meaning set forth in Section 11.1. 

 

	1.49	 “EMA” means the European Medicines Agency, a Regulatory Health Authority for the purposes of this
Agreement. 

  

	1.50	 “Evaluation” and “Evaluate” means MedImmune’s and its Affiliates’ internal
evaluation of the CD39 Program for purposes of determining whether or not to exercise the CD39 Option. 

  

	1.51	 “Exploit” means to undertake, or have undertaken, any or all of the following activities: to make,
import, use, sell, or offer for sale, research, study, Develop, register, modify, enhance, improve, manufacture, hold or keep (whether for disposal or otherwise), formulate, optimise, use, export, transport, distribute, promote, market or otherwise
dispose or offer to dispose of, a product or process and “Exploitation” shall have the correlative meaning. 

  

	1.52	 “Exploratory Study” shall have the meaning set forth in Section 4.5. 

 

	1.53	 “FDA” means the United States Food and Drug Administration, a Regulatory Health Authority for the
purposes of this Agreement. 

  

	1.54	 “Force Majeure” has the meaning set out in the License Agreement. 

 

	1.55	 “France - UK Double Tax Treaty” means the convention between the Government of the United Kingdom of
Great Britain and Northern Ireland and the Government of France for the avoidance of double taxation and the prevention of fiscal evasion with respect to taxes on income and on capital gains signed in 

  
 11 

 CD39 OPTION 
  

 London on 19 June 2008 as well as any convention that would replace it in the
future. 
  

	1.56	 “FTE” means a full time equivalent person year of [***] of scientific, technical or operational work
(excluding administrative services). 

  

	1.57	 “FTE Rate” means, for the period commencing on the Effective Date until such time as adjusted
pursuant to the following sentence or the Parties agree otherwise, [***] for all activities. The FTE Rate will be increased or decreased on each anniversary of the Effective Date by a percentage equivalent to the change over the preceding twelve
month period in the Consumer Price Index for Urban Wage Earners and Clerical Workers with respect to MedImmune and the index of salaries of the pharmaceutical industry published by LEEM with respect to Innate. The FTE Rate shall include costs of
salaries, benefits, supplies, travel, other employee costs, and supporting general and administration allocations. 

  

	1.58	 “GCP” or “Good Clinical Practices” means, to the extent applicable in the country
where Regulatory Approval is sought, the current standards for good clinical practices relating to clinical trials for pharmaceuticals, as set forth in the United States Code of Federal Regulations or ICH guidelines and applicable regulations, laws
or rules as promulgated thereunder, in each case as amended from time to time, and all other standards of good clinical practice as are required by any Regulatory Health Authority. 

 

	1.59	 “GLP” or “Good Laboratory Practices” means good laboratory practices required under
the regulations set forth in 21 C.F.R. Part 58, as in effect during the term of this Agreement, and the requirements thereunder imposed by the FDA, and the equivalent thereof in any jurisdiction. 

 

	1.60	 “GMP” or “Good Manufacturing Practice” means the principle of good
manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use as required by Applicable Law, including the laws of the European Community and Directive 2003/94/EC as well as any national
legislation implementing the aforesaid Directive and any relevant 

  
 12 

 CD39 OPTION 
  

 guidance relating thereto. 

 

	1.61	 “GVP” or “Good Pharmacovigilance Practices” means, in addition to the provisions
under the any pharmacovigilance agreement between the Parties, all applicable good pharmacovigilance practices promulgated and published by FDA, EMA or any other Regulatory Health Authorities having jurisdiction over the Development, Manufacture or
commercialization of the CD39 Option Products pursuant to its regulations, guidelines or otherwise, including as applicable, major pharmacovigilance process and product or population specific considerations as defined in (a) European Commission
Regulation code relating to medicinal products for human use, Directives 2010/84/EU and 2012/26/EU respectively, as well as by the Commission Implementing Regulation (EU) No 520/2012 on the Performance of Pharmacovigilance Activities Provided for in
Regulation (EC) No 726/2004 and Directive 2001/83/EC, Title IX of the Directive, Article 108a (a) of Directive 2001/83/EC, and principles detailed in the ICH guidelines for pharmacovigilance as well as (b) principles detailed in the United
States 21 CFR and Guidance for Industry Good Pharmacovigilance Practices and Pharmacoepidemiological Assessment. 

  

	1.62	 “Government Official” means any Person employed by or acting on behalf of a Governmental Body,
government-controlled entity or public international organization. 

  

	1.63	 “Governmental Body” means any: (i) nation, state, commonwealth, province, territory, county,
municipality, district or other jurisdiction of any nature; (ii) federal, state, local, municipal, foreign or other government; (iii) governmental or quasi-governmental authority of any nature (including any governmental division,
department, agency, commission, instrumentality, official, ministry, fund, foundation, centre, organization, unit, body or entity and any court or other tribunal); or (iv) self-regulatory organization (including the NASDAQ Global Market and the
NASDAQ Global Select Market). For the avoidance of doubt, Governmental Bodies includes Regulatory Health Authorities. 

  

	1.64	 “Head License” means any of the [***] or any license from a Third Party described under
Section 12.12 or Section 12.14, and “Head Licenses” means all of them. 

  
 13 

 CD39 OPTION 
  

	1.65	 “HSR Act” means the United States Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended,
including all rules promulgated thereunder. 

  

	1.66	 “ICH” means the International Conference on Harmonization of Technical Requirements for Registration
of Pharmaceuticals for Human Use. 

  

	1.67	 “IND” or “Investigational New Drug Application” means an application to the FDA for
permission to perform a clinical study as required by Applicable Law. 

  

	1.68	 “Independent Ethics Committee” or “IEC” means an independent body, institutional,
regional, national or supranational committee or review board, whose responsibility it is to ensure the protection of rights, safety and well-being of human subjects in a clinical study and who is responsible for, among other things, reviewing and
approving or providing opinions on, the Collaboration Study Protocol, the suitability of the investigator(s), facilities, subject recruitment materials, methods and the information to be provided to potential Subjects in a Collaboration Study to
secure their informed consent. 

  

	1.69	 “Indication” means a cancerous condition resulting from a separate and distinct tumor type and line
of therapy that is the basis for a separate and distinct Regulatory Approval. 

  

	1.70	 “Indirect Taxes” means value added taxes, sales taxes, consumption taxes and other similar taxes.

  

	1.71	 “Innate” shall have the meaning set forth in the preamble to this Agreement. 

 

	1.72	 “Innate Data Room” means the dataroom with respect to Innate’s CD39 research and development
programme which is maintained by or on behalf of Innate and to the extent available for access by MedImmune on or before the Effective Date. 

  

	1.73	 “Innate Development Costs” has the meaning set out in Section 6.1. 

 

	1.74	 “Innate Standards” means, with respect to the performance of any activities allocated to Innate under
the Development Plan with respect to a CD39 Option 

  
 14 

 CD39 OPTION 
  

 

	 	 
Product, the performance of such activities (a) with substantially the same degree of skill, quality and care utilized by Innate in performing such activities for itself with respect to such
CD39 Option Product or products at a similar stage of development as such CD39 Option Product; and (b) in compliance in all material respects with Applicable Laws. 

 

	1.75	 “Innate Study Results” shall have the meaning set forth in Section 12.6(a).

  

	1.76	 “Innate Third Party Claim” shall have the meaning set forth in Section 15.2.

  

	1.77	 “Intellectual Property Rights” means Patents, trademarks, service marks, trade secrets (including
patentable inventions), trade names, registered designs, design rights, copyrights (including rights in computer software), domain names, database rights and any rights or property similar to any of the foregoing in any part of the world, whether
registered or not, together with the right to apply for the registration of any such rights. 

  

	1.78	 “Joint Collaboration IP” shall have the meaning set forth in Section 12.3(c).

  

	1.79	 “Know-How” means all inventions, discoveries, data,
information (including scientific, technical or regulatory information), trade secrets, processes, means, methods, practices, formulae, instructions, procedures, techniques, materials, technology, results, analyses, designs, drawings, computer
programs, apparatuses, specifications, technical assistance, laboratory, pre-clinical and clinical data (including laboratory notes and notebooks), and other material or
know-how, in written, electronic or any other form, whether or not confidential, proprietary or patentable, including without limitation: development technology; biology, chemistry, pharmacology, toxicology,
drug stability, CMC, Manufacturing and formulation, initial biomarker studies, test procedures, synthesis, purification and isolation techniques, quality control data and information, methodologies and techniques; information regarding clinical and non-clinical safety and efficacy studies, including study designs and protocols, marketing studies, absorption, distribution, metabolism and excretion studies; assays and biological methodology.

  
 15 

 CD39 OPTION 
  

 

	1.80	 “knowledge” means the good faith understanding of the officers of Innate and its Affiliates, with
respect to relevant facts and information after performing a commercially reasonable inquiry of the employees having responsibilities in Innate’s organisation with respect to the relevant subject matters and external patent agents of Innate and
its Affiliates with respect to such facts and information relating to the CD39 Option Patents, that the patent agent is responsible for prosecuting and maintaining. For purposes of the foregoing, Innate will not be deemed to have knowledge of any
given fact or information, which (i) was known or should have been known by any external patent agents of Innate and its Affiliates but was not disclosed to Innate’s officers or (ii) was not known by the employees of Innate and its
Affiliates. 

  

	1.81	 “License Agreement” shall mean the agreed form license attached at Schedule 1.80.

  

	1.82	 “Listed Patents” means the Patents listed in Schedule 1.81, and any Patents filed after the
Effective Date claiming priority to the Patents listed on Schedule 1.81, as such schedule may be updated from time to time by agreement of the Parties. 

 

	1.83	 “Loss” or “Losses” means any and all direct liabilities, claims, actions, damages,
losses or expenses, including interest, penalties, and reasonable lawyers’ fees and disbursements. In calculating Losses, the legal duty to mitigate on the part of the Party suffering the Loss shall be taken into account. 

 

	1.84	 “Manufacture” or “Manufacturing” means activities in connection with the synthesis,
manufacture, processing, formulating, testing (including, without limitation quality control, quality assurance and lot release testing), bulk packaging, labelling or storage and delivery of CD39 Option Products (including any component thereof).

  

	1.85	 “Material Anti-Corruption Law Violation” means a violation of an Anti-Corruption Law relating to the
subject matter of this Agreement which would if it were publically known have a material adverse effect on a Party or on the reputation of a Party because of its relationship with the other Party. 

  
 16 

 CD39 OPTION 
  

 

	1.86	 “Material Issues” means issues material to the governance of or performance of the Development Plan,
including any of the following with respect to the CD39 Program: 

  

	 	(a)	 discontinuing commencement of Collaboration Studies, or prolonging or postponing commencement of Collaboration Studies
by more than [***]; 

  

	 	(b)	 any Safety or Regulatory Issues; 

 

	 	(c)	 conducting the Collaboration Studies across fewer than [***] sites per Collaboration Study; 

 

	 	(d)	 selecting and using any contract research organisation that is not a CRO other than those with international
recognition for conducting the Collaboration Studies; 

  

	 	(e)	 delay in the CMC work set forth in the Development Plan likely to cause a delay in commencing the first Phase 3
Clinical Trial in respect of a CD39 Option Product, with reference to the target date set forth in the Development Plan, by more than [***]; and 

  

	 	(f)	 review and approve supply forecast (including for Exploratory Studies). 

 

	1.87	 “MedImmune” shall have the meaning set forth in the preamble to this Agreement.

  

	1.88	 “MedImmune Collaboration IP” shall have the meaning set forth in Section 12.3(a).

  

	1.89	 “MedImmune Collaboration Studies” shall have the meaning set forth in Section 9.1(a).

  

	1.90	 “MedImmune Indemnitees” shall have the meaning set forth in Section 15.1. 

  
 17 

 CD39 OPTION 
  

 

	1.91	 “MedImmune Manufacturing Information” means any Know-How with
respect to the Manufacture of any MedImmune Product or other proprietary product of MedImmune, including the CMC data with respect thereto. 

  

	1.92	 “MedImmune Manufacturing IP” shall have the meaning set forth in Section 12.4.

  

	1.93	 “MedImmune Product” shall mean any proprietary product of MedImmune and with which either Party
conducts a Collaboration Study or a pre-clinical study under the Development Plan. For the avoidance of doubt, MedImmune Product excludes the CD39 Option Products. 

 

	1.94	 “MedImmune Study Results” shall have the meaning set forth in Section 12.6(b).

  

	1.95	 “MedImmune Third Party Claim” shall have the meaning set forth in Section 15.1.

  

	1.96	 “Objectives” means the objectives of Party which are: 

 

	 	(a)	 providing proof of the concept of the CD39 Option Products as cancer treatments; 

 

	 	(b)	 carrying out the Collaboration Studies, CMC and other activities assigned to such Party as set forth in the
Development Plan taking into account the assumptions set out in the Development Plan; 

  

	 	(c)	 [***]; 

  

	 	(d)	 [***]; 

  

	 	(e)	 [***]; 

  

	 	(f)	 [***]; and 

  
 18 

 CD39 OPTION 
  

 

	 	(g)	 [***]. 

  

	1.97	 “Oncology Field” means the treatment, diagnosis and prevention of cancer in humans and animals.

  

	1.98	 “Option Committee” or “OC” shall have the meaning set forth in Section 7.3.

  

	1.99	 [***]. 

  

	1.100	 [***]. 

  

	1.101	 “Parties” means MedImmune and Innate and “Party” means either of them.

  

	1.102	 “Patent Action” shall have the meaning set forth in Section 12.21. 

 

	1.103	 “Patents” means (a) all national, regional and international patents and patent applications,
including provisional patent applications, (b) all patent applications filed either from such patents, patent applications or provisional applications or from an application claiming priority from either of these, including divisionals,
continuations, continuations-in-part, non- provisional applications, and continued prosecution applications, (c) any and all patents that have issued or in the
future issue from the foregoing patents or patent applications ((a) and (b)), including utility models, petty patents and design patents and certificates of invention, (d) any and all extensions or restorations by existing or future extension
or restoration mechanisms, including revalidations, reissues, re-examinations and extensions (including any supplementary protection certificates, patent term extensions and the like) of the foregoing patents
or patent applications ((a), (b) and (c)), and (e) any similar rights, including so-called pipeline protection, or any importation, revalidation, confirmation or introduction patent or registration patent
or patent of additions to any such foregoing patent applications and patents. 

  

	1.104	 “Payments” shall have the meaning set forth in Section 8.1. 

  
 19 

 CD39 OPTION 
  

 

	1.105	 “Person” means an individual, sole proprietorship, partnership, limited partnership, limited
liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political subdivision, department or
agency of a government. 

  

	1.106	 “Personal Data” means any information relating to a Data Subject. 

 

	1.107	 “Phase 1 Clinical Trial” means any clinical study conducted on human subjects [***].

  

	1.108	 “Phase 2 Clinical Trial” means any clinical study that is not intended to be used as a pivotal study
for purposes of seeking Regulatory Approval in any country within the Territory that is conducted on human patients [***]. 

  

	1.109	 “Phase 3 Clinical Trial” means any clinical study used as a pivotal study for purposes of seeking
Regulatory Approval, [***]. 

  

	1.110	 “Primary End Point Results” means with respect to any given Clinical Trial, the primary end point
results in accordance with the applicable protocol which, for the avoidance of doubt, might include items such as overall response rate, disease control rate, durability of response, progression free survival or safety data, as will be specified in
the applicable protocol. 

  

	1.111	 “Principal Investigator” means the person(s) appointed to lead and
co-ordinate one or several Collaboration Studies under this Agreement and identified as Principal Investigator on the relevant Collaboration Studies Protocol, or any other person who may be appointed to such
role. 

  

	1.112	 “Processing” means any operation or set of operations that is performed on Personal Data or on sets
of Personal Data, whether or not by automated means, such as collection, recording, organisation, structuring, storage, adaptation or alteration, retrieval, consultation, use, disclosure by transmission, dissemination or otherwise making available,
alignment or combination, restriction, erasure or destruction. 

  
 20 

 CD39 OPTION 
  

 

	1.113	 “Product Trademark” mean trademarks to be used specifically for the marketing and sale of the CD39
Option Products. 

  

	1.114	 “Receiving Party” shall have the meaning set forth in Section 11.1. 

 

	1.115	 “Regulatory Approval” means any and all approvals, product or establishment

  
 21 

 CD39 OPTION 
  

 

	 	 
licenses, registrations, or authorizations of any regional, federal, state, or local Regulatory Health Authority, department, bureau, or other governmental entity, necessary to test, manufacture,
commercially distribute, sell or market a CD39 Option Product in a regulatory jurisdiction, including, where applicable, (a) pricing or reimbursement approval in such jurisdiction if necessary or desirable, (b)
pre- and post-approval marketing authorizations (including any prerequisite Manufacturing approval or authorization related thereto), and (c) labelling approval. 

 

	1.116	 “Regulatory Documentation” means all applications, registrations, licenses, authorizations and
approvals, all correspondence submitted to or received from Regulatory Health Authorities (including minutes and official contact reports relating to any communications with any Regulatory Health Authority) and all supporting documents, including
documentation arising in the course of all clinical trials, in each case relating to obtaining or maintaining Regulatory Approval of Option Products, including all INDs, regulatory drug lists, advertising and promotion documents, adverse event files
and complaint files, including safety information, excluding source documentation associated with individual case safety reports other than such source documentation that is part of the clinical trial master file. 

 

	1.117	 “Regulatory Exclusivity” shall mean any exclusive marketing rights or data exclusivity rights
conferred by any applicable Regulatory Health Authority, other than an issued and unexpired Patent, including any regulatory data protection exclusivity (including, where applicable, paediatric exclusivity or orphan drug exclusivity) or any other
exclusivity afforded by restrictions which restrict the granting by a Regulatory Health Authority of Regulatory Approval to market a generic product. 

  

	1.118	 “Regulatory Health Authority” means any applicable national (for example, FDA or Japan’s
Pharmaceuticals and Medical Devices Agency), supranational (for example, the EMA), regional, state, provincial or local regulatory health authority, department, bureau, commission, council, or other government entity regulating or otherwise
exercising authority with respect to the Exploitation of Option Products in the Territory, including any such entity involved in the granting 

  
 22 

 CD39 OPTION 
  

 

	 	 
of Regulatory Approval for pharmaceutical products. 

  

	1.119	 “Research” means the discovery, identification, research, characterisation, modification,
derivatisation, optimisation and preclinical testing of pharmaceutical products. 

  

	1.120	 “Restricted Party” shall have the meaning set forth in Section 13.2. 

 

	1.121	 “Right of Reference” means the non-exclusive right to cross
reference, copy, incorporate by reference or rely upon any Study Results solely for the purposes of obtaining or maintaining Regulatory Approval for a pharmaceutical product, including (1) a “Right of Reference or Use” as that term is
defined in 21 C.F.R. §314.3(b) in the United States, (2) any analogous procedures with respect to biologics or BLAs in the United States and (3) any equivalents thereof outside the United States. 

 

	1.122	 “S/R Notice” shall have the meaning set forth in Section 9.7. 

 

	1.123	 “Safety or Regulatory Issue” means: 

 

	 	(a)	 Serious Adverse Event; 

  

	 	(b)	 requirement or request by a Regulatory Health Authority that one or more of the Collaboration Studies should cease in
the interests of the health, safety or well-being of Subjects; 

  

	 	(c)	 a reasonable, good faith determination by Innate, as notified to the OC, that one or more of the Collaboration Studies
should cease in the interests of the health, safety or well-being of Subjects and that such issue cannot be rectified or overcome without adversely jeopardizing the aforementioned interests; or 

 

	 	(d)	 any decision or requirement of a Regulatory Health Authority which occurs prior to or during any of the Collaboration
Studies and which prevents Innate from initiating or completing one or more of the Collaboration 

  
 23 

 CD39 OPTION 
  

 

 Studies or from causing one or more of the Collaboration Studies to be initiated or
completed. 
  

	1.124	 [***]. 

  

	1.125	 [***]. 

  

	1.126	 [***]. 

  

	1.127	 “Senior Executives” means (i) [***] and (ii), [***]. A Party shall be entitled, effective upon
written notice thereof to the other Party, to designate one of its other representatives having equivalent seniority and experience to replace such foregoing representative as that Party’s Senior Executive for the purpose of this Agreement.

  

	1.128	 “Serious Adverse Event” shall have the meaning given and defined by ICH from time to time.

  

	1.129	 “Specification” means the specification applicable to the Manufacture, packaging, labelling and
storage of a relevant product, as current at any given time. 

  

	1.130	 “Study Documentation” means all records, accounts, notes, laboratory notebooks, reports and data,
collected, generated or used in connection with the Collaboration Studies, Exploratory Studies or where applicable, pre-clinical activities performed by a Party under the Development Plan, whether in written,
electronic, optical or other form, including all recorded original observations and notations of clinical activities such as reports and records necessary for the evaluation and reconstruction of the relevant Collaboration Study or Exploratory
Study. 

  
 24 

 CD39 OPTION 
  

 

	1.131	 “Study Results” means any data and information generated as a result of the Collaboration Studies,
including any of the Collaboration Study Preliminary Reports. 

  

	1.132	 “Study Site Staff” means all those researchers, students, employees, agents or others who are engaged
by or on behalf of Innate in the conduct of any of the Collaboration Studies, including any sub-investigator (but excluding, for the avoidance of doubt, MedImmune and its researchers, students, employees and
agents). 

  

	1.133	 “Subject” means a person recruited to participate in a Collaboration Study. 

 

	1.134	 “Tech Transfer Period” shall have the meaning set forth in Section 17.3. 

 

	1.135	 “Territory” means the world. 

 

	1.136	 “Third Party Agreements” means those agreements listed in Schedule 1.135.

  

	1.137	 “Third Party” means any Person other than the Parties or the Parties’ respective Affiliates.

  

	1.138	 “Third Party Claim” means an Innate Third Party Claim or a MedImmune Third Party Claim.

  

	1.139	 “Transferred Data” means the Personal Data transferred by MedImmune to Innate pursuant to this
Agreement. 

  

	 	2	 CONSTRUCTION; COMPETITION LAW FILING 

 

	2.1	 Except where the context requires otherwise, whenever used the singular includes the plural, the plural includes the
singular, the use of any gender is applicable to all genders and the word “or” has the inclusive meaning represented by the phrase “and/or”. Whenever this Agreement refers to a number of days, unless otherwise specified, such
number refers to calendar days. The headings of this Agreement are for convenience only and do not define, describe, extend or limit the scope 

  
 25 

 CD39 OPTION 
  

 

 or intent of any provision in this Agreement. The term “including” or
“includes” as used in this Agreement means including, without limiting the generality of any description preceding such term. The wording of this Agreement shall be deemed to be the wording mutually chosen by the Parties and no rule of
strict construction shall be applied against any Party. The Parties hereby agree to act in good faith with respect to their performance of the rights and obligations pursuant to this Agreement. 

 

	2.2	 If MedImmune reasonably determines during the CD39 Option Period that a filing under the HSR Act or any equivalent
competition law statute or regulation (a “Competition Law Filing”) is required for the performance of this Agreement or any License Agreement, promptly upon MedImmune’s request, the Parties shall prepare and submit the required
notification forms as soon as reasonably practicable (and for any filing under the HSR Act within [***] after such determination) and use reasonable efforts to obtain clearance for the transactions contemplated hereunder as soon as practicable.
Subject to Applicable Law relating to the exchange of information, MedImmune shall have the right to direct all matters with respect to Competition Law Filings hereunder, consistent with its obligations hereunder after consulting with Innate. Each
Party will consult with the other on, and consider in good faith the views of the other Party in connection with, all of the information relating to such other Party that appears in any Competition Law Filing. MedImmune shall bear all fees in
connection with any Competition Law Filing and each Party shall bear their respective attorneys’ fees in connection therewith. 

  

	 	3	 OPTION FEE 

  

	3.1	 In consideration of the grant of the CD39 Option by Innate to MedImmune and Innate’s obligations to perform the
activities contemplated under this Agreement to facilitate MedImmune’s Evaluation, MedImmune shall, subject to the terms of this Agreement, pay to Innate: 

 

	 	(a)	 a non-creditable and non-refundable
fee of fifty million US dollars ($USD 50,000,000) (the “CD39 Option Fee”); and 

  
 26 

 CD39 OPTION 
  

 

	 	(b)	 the following non-creditable and
non-refundable fee upon the first achievement of the applicable milestone event set out below by or on behalf of MedImmune or Innate: 

 

			
	Milestone Event for a CD39 Option Product	  	Payment
	 	 
	
[***]
  
	  	
[***]

	
[***]
  

 
	  	
[***]

 For the avoidance of doubt, each payment set out above shall be payable by MedImmune only once. 

 

	3.2	 The CD39 Option Fee shall be payable by MedImmune in accordance with Section 8 in cash in two lump sums.
MedImmune shall pay to Innate: (a) the first amount of twenty six million US dollars ($USD 26,000,000) within [***] after the Effective Date, and (b) the remaining amount of twenty four million US dollars ($USD 24,000,000) on [***] 2019.

  

	3.3	 Upon achievement of the corresponding milestone event by or on behalf of Innate or MedImmune set forth in
Section 3.1(b) Innate may issue an invoice to MedImmune with respect to the corresponding payment, and MedImmune shall pay such amount to Innate no later than [forty five (45) days] following receipt of such invoice. 

 

	3.4	 For the avoidance of doubt, the CD39 Option Fee is in addition to those fees payable on valid exercise of the CD39
Option. 

  
 27 

 CD39 OPTION 
  

 

	4	 CD39 OPTION 

  

	4.1	 Innate hereby grants to MedImmune the exclusive option (the “CD39 Option”) to 

obtain the rights and licenses under the CD39 Option Technology to Exploit CD39 Option Products pursuant to the terms of the License
Agreement. 
  

	4.2	 During the CD39 Option Period, each Party shall be responsible for the performance of the Development activities
assigned to it under the Development Plan, in accordance with Section 5. 

  

	4.3	 MedImmune agrees to fund and shall finance those pre-clinical studies under
the Development Plan allocated to Innate, in accordance with the Collaboration Budget for such studies contained in the Development Plan. 

  

	4.4	 MedImmune shall use its Commercially Reasonable Efforts to formulate the CMC part of any data package required for any
IND/CTA or Regulatory Approval contained in the Development Plan in accordance with the expected timeline indicated in the Development Plan. 

  

	4.5	 During the CD39 Option Period, Innate may conduct exploratory clinical trials (including any Phase 1 Clinical Trials
or Phase 2 Clinical Trials) (“Exploratory Studies”) with respect to any CD39 Option Product (other than CD39 Bi-Specific Molecules), including in combination with one or more active
ingredient(s), at its discretion and own expense, provided that Innate shall, at least [***] prior to the initiation of the Exploratory Study, propose to MedImmune through the OC to include the Exploratory Study in the Development Plan, and provide
to MedImmune a copy of the study protocol for such Exploratory Study (with respect to a CD39 [***] Study, Innate shall provide a high level clinical trial design summary that includes tumor type, patient population, dose range and schedule of each
agent to be administered (a “CD39 [***] Plan”)). MedImmune shall consider such proposal in good faith in light of the Objectives. Within [***] after the receipt of such study protocol (or clinical trial design summary, as
applicable), MedImmune shall also indicate whether or not such Exploratory Study satisfies the criteria set forth in (a) to (c) below. If MedImmune does not approve the inclusion of such Exploratory Study in the Development Plan, then Innate
may perform such Exploratory Study at its Cost (subject to Section 4.7), but only if the criteria set out in (a) to (c) below are satisfied (otherwise, Innate may not 

  
 28 

 CD39 OPTION 
  

 

	 	 
perform such Exploratory Study): 

  

	 	(a)	 [***]; 

  

	 	(b)	 [***]; and 

  

	 	(c)	 [***]. 

Notwithstanding the foregoing, clauses (a) to (c) shall not apply with respect to any Exploratory Study to be conducted by Innate
on a CD39/[***] Combination Product, provided that, [***]. 
  

	4.6	 MedImmune shall use Commercially Reasonable Efforts to provide to Innate, upon Innate’s reasonable request
(including reasonable manufacturing timelines) at Cost payable by Innate, and in a reasonably timely manner so as not to delay the filing of any IND/CTA or any other Regulatory Approval: 

 

	 	(a)	 quantities of the CD39 Lead or other CD39 Option Product as might be required to conduct each Exploratory Study,
subject to MedImmune’s then-current stock of such CD39 Option Product, its manufacturing capacity, and its obligations under Section 5.3(a); and 

  

	 	(b)	 a complete data package with respect to CMC as is required to enable 

  
 29 

 CD39 OPTION 
  

 

 Innate to make the relevant submission for each IND/CTA or any other Regulatory
Approval for such Exploratory Study. Provision of such data package may be in a form or method as enables MedImmune to retain its confidentiality in the MedImmune Manufacturing Information. 

 

	4.7	 If a Phase 3 Clinical Trial is initiated by or on behalf of MedImmune or its Affiliates and: 

 

	 	(a)	 [***]; 

  

	 	(b)	 [***]; and 

  

	 	(c)	 [***]. 

then MedImmune shall reimburse to Innate the reasonable and documented Costs of such Exploratory Study undertaken by Innate together
with an additional amount equal to [***] of such reasonable and documented Costs, such additional [***] being a premium reflecting the risk undertaken by Innate in conducting such Exploratory Study. Such Costs and premium shall be Payments, payable
in accordance with Section 8 and shall be paid no later than the date of recruitment of the first Subject into such Phase 3 Clinical Trial initiated by or on behalf of MedImmune or its Affiliates. For the avoidance of doubt, any such payment
shall be in addition to any other Payment hereunder or in the License Agreement, including any milestone payments. 
 Exercising
the CD39 Option 
  

	4.8	 MedImmune may exercise the CD39 Option by giving Innate written notice that it is

  
 30 

 CD39 OPTION 
  

 

 exercising the CD39 Option (“CD39 Option Notice”) at any time within
the CD39 Option Period. No later than [***] prior to the expected expiry of the CD39 Option Period (if the CD39 Option Notice has not been given), Innate shall notify MedImmune of such occurrence through the Option Committee, and the Parties shall
discuss MedImmune’s intention to exercise or not to exercise the CD39 Option. Innate will provide to MedImmune an updated set of Schedules (including disclosure Schedules with respect to Innate’s representations and warranties) in the
License Agreement. 
  

	4.9	 Upon Innate’s receipt within the CD39 Option Period of a CD39 Option Notice, the License Agreement shall,
automatically and without any further measures having to be taken by either Party, enter into force in accordance with its terms. The Parties shall cooperate in good faith to prepare as promptly as possible after the effective date of the License
Agreement all filings and other actions required by Applicable Laws to be made and taken in order to continue to conduct the Development of CD39 Option Products. All such filings and actions shall be approved in advance by MedImmune and be made and
taken by or on behalf of MedImmune. 

  

	4.10	 Upon valid exercise of the CD39 Option, MedImmune may assume from Innate the right to lead and conduct such ongoing
early-stage Development activities as Innate may have been conducting prior to exercise of the CD39 Option. 

  

	4.11	 Upon valid exercise of the CD39 Option, MedImmune will assume responsibility from Innate to undertake all late-stage
development activities (which shall include sponsorship of all Phase 3 Clinical Trials), as set out in and subject to the terms of the License Agreement. 

Lapse of the CD39 Option 
  

	4.12	 If: (a) MedImmune has not on or prior to the expiry of the CD39 Option Period furnished Innate with a CD39 Option
Notice; or (b) either Party terminates this Agreement pursuant to Sections 16.2 to 16.4, then the CD39 Option shall terminate and the CD39 Option shall lapse, and shall have no force or effect, and the consequences set forth in Section 17
applicable to such expiry or termination (as 

  
 31 

 CD39 OPTION 
  

 

 applicable) shall apply. 

 

	4.13	 Upon the termination of the CD39 Option pursuant to Section 4.12, if Innate subsequently Develops, commercialises
or otherwise Exploits any CD39 Option Product or any product developed using or otherwise incorporating any Collaboration IP or Study Results (each, an “Innate Licensed Product”), then Innate shall pay to MedImmune the payments
calculated in accordance with Schedule 4.13 with respect to such Innate Licensed Product, up to a maximum amount equal to [***] of the aggregate of: [***] (the “Total Reimbursement Amount”). 

 

	4.14	 Upon the expiry or termination of the CD39 Option pursuant to Section 4.12 MedImmune shall grant to Innate:

  

	 	(a)	 a non-exclusive, royalty free, fully paid up (subject to Section 4.15)
worldwide licence, with the right to sublicense through multiple tiers, under MedImmune’s interest in the Joint Collaboration IP to research, Develop, manufacture, commercialise and otherwise Exploit any product; and 

 

	 	(b)	 a royalty free, fully paid up (subject to Section 4.15) worldwide licence, with the right to sublicense through
multiple tiers, under the MedImmune Collaboration IP (excluding any MedImmune Collaboration IP claiming or related to any CD39 Bi-Specific Molecule or CD39 [***] Combo) and the MedImmune Study Results
(excluding the Study Results with respect to any CD39 Bi-Specific Molecule or CD39 [***] Combo), to research, Develop, manufacture, commercialise and otherwise Exploit any CD39 Option Product, such licence
shall be exclusive with respect to any MedImmune Collaboration IP that claims the CD39 Option Products existing as of the date the termination of the CD39 Option and such licence shall be non-exclusive with
respect to any other MedImmune Collaboration IP. 

  

	4.15	 Upon the termination of the CD39 Option pursuant to Section 4.12, if Innate wishes to acquire a licence under any
MedImmune Collaboration IP claiming any CD39 Bi- Specific Molecule or [***] Combo or any MedImmune Study Results with respect to 

  
 32 

 CD39 OPTION 
  

 

	 	 
any CD39 Bi-Specific Molecule or CD39-[***] Combo, Innate may notify MedImmune of such wish. If MedImmune wishes to grant to Innate such licence, the
Parties shall negotiate in good faith a licence under such Collaboration IP or Study Results, which shall include any financial terms. 

  

	 	5	 DEVELOPMENT PLAN AND REPORTING 

 

	5.1	 Within [***] of the Effective Date, the OC will meet to discuss and agree on an initial version of the Development
Plan and the Collaboration Budget, recognising that in so doing, the ultimate purpose is to design a plan that gives the Parties the best opportunity to achieve the Objectives. The Development Plan shall specify which of the Parties shall be the
sponsor of each of the Collaboration Studies, and that Party’s responsibilities will include compliance with all obligations imposed on study sponsors under Applicable Law. The Collaboration Budget shall be broken down by agreed activities in
applicable areas, including research, preclinical activities, Clinical Trials, pharmacovigilance or other activities. The Development Plan will include, among other things, (i) the initial indication(s) for which the CD39 Option Product is
planned to be Developed, (ii) other indications for which the CD39 Option Product may be developed, (iii) the proposed overall program of Development for the CD39 Option Product for any indications elected by MedImmune, including without
limitation all material nonclinical studies, toxicology, pharmacology studies, formulation, process development, CMC, clinical studies, and regulatory plans, (iv) critical activities anticipated to be undertaken, estimated timelines, decision
points and relevant decision criteria, and (v) allocation of responsibilities between the Parties for the various activities to be undertaken under the Development Plan and estimated timelines; all based on what can reasonably be foreseen and
planned at the time of preparation of the Development Plan. MedImmune shall review and submit an updated Development Plan and Collaboration Budget to the OC for approval at least 

  
 33 

 CD39 OPTION 
  

 

	 	 
annually during the term of this Agreement. Each Party shall use Commercially Reasonable Efforts to perform the Collaboration Studies outlined in, and other activities (including any
Manufacturing and technology transfer activities) contemplated in, the Development Plan and assigned to such Party in the Development Plan, such performance shall be in accordance with: 

 

	 	(a)	 this Agreement, 

  

	 	(b)	 the applicable Collaboration Study Protocols, 

 

	 	(c)	 all Applicable Law; and 

  

	 	(d)	 the Development Plan. 

Without limiting the foregoing, each Party shall obtain and maintain all permissions, consents, licences and patient consents required
for the performance of its obligations under this Agreement, including the Collaboration Studies assigned to such Party under the Development Plan. 
  

	5.2	 Without limiting Section 5.1, each Party shall, with respect to Collaboration Studies assigned to it under the
Development Plan shall: 

  

	 	(a)	 perform, or cause to be performed, such Collaboration Studies in good scientific manner and in compliance with all
Applicable Law, as well as any condition required by a Regulatory Health Authority or an IEC; 

  

	 	(b)	 use Commercially Reasonable Efforts to complete such Collaboration Studies (meaning delivery of all final reports with
respect to such Collaboration Studies) within the timescales specified in the applicable Collaboration Study Protocols and the Development Plan; and 

  

	 	(c)	 cause the Principal Investigator and the Study Site Staff to conduct such Collaboration Studies in accordance with the
provisions set out above in this Section 5. 

  
 34 

 CD39 OPTION 
  

 

	 	 
In relation to Collaboration Studies assigned to a Party under the Development Plan for which there is no detailed Collaboration Study Protocol as at the Effective Date of this Agreement or
Collaboration Studies that are conceived after the Effective Date of this Agreement, such Party shall produce Collaboration Study Protocols for such Collaboration Study, as soon as reasonably practicable after the Effective Date of this Agreement or
conception of those Collaboration Studies, respectively and provide them to the OC for review. 

  

	5.3	 Medimmune shall: 

  

	 	(a)	 use Commercially Reasonable Efforts to provide, at its own cost, such GMP quantities of CD39 Lead as are specified in
the Collaboration Study Protocols or otherwise required for the conduct of the Collaboration Studies and the Development Plan. Without limiting the foregoing, MedImmune shall provide a near-term manufacturing slot for CD39 Lead to enable supplies of
the CD39 Lead to be Manufactured to the Specification for the purposes of GLP toxicology studies and Phase 1 Clinical Trials in accordance with the Development Plan; and 

 

	 	(b)	 use Commercially Reasonable Efforts to conduct the activities assigned to MedImmune in the Development Plan, including
any Collaboration Studies assigned to MedImmune and any CMC activities as might be specified therein. 

  

	5.4	 Promptly upon MedImmune’s request, the Parties shall negotiate in good faith a separate quality assurance
agreement (the “QAA”) that shall define the manufacturing and supply quality responsibilities of the Parties. The QAA shall further include provisions obligating the supplying Party to report to the other any regulatory compliance
issues with its suppliers as well as any critical quality non- conformances relating to the CD39 Option Product (or MedImmune Product, as applicable). 

 

	5.5	 If any Innate Collaboration Study involves the use of any MedImmune Product, the Parties shall negotiate in good faith
a clinical supply agreement providing for the supply of such MedImmune Product, which shall include terms with respect to 

  
 35 

 CD39 OPTION 
  

 

	 	 
Intellectual Property Rights allocation and other customary terms with respect to clinical supply agreements of a similar nature. 

 

	5.6	 Each Party shall: 

  

	 	(a)	 obtain and maintain all filings and applications and all other actions required by Applicable Law to conduct the
Collaboration Studies (and the Exploratory Studies in the case of Innate); 

  

	 	(b)	 procure that complete, current, accurate and legible Study Documentation is retained and stored in a manner consistent
with customary industry practices, for: (i) further Developing the CD39 Option Products, (ii) Patent purposes, and (iii) the collection of data for submission to, or review by, a Regulatory Health Authority, in full compliance with
the Collaboration Study Protocols and all Applicable Law and kept clearly separated from all records pertaining to other activities that may be carried out by or on behalf of such Party outside the scope of this Agreement. Without limiting clause
(d), except to the extent prohibited under Applicable Law, upon prior written request by MedImmune no more than twice per consecutive [***] period during the term of this Agreement, Innate shall make all Study Documentation available for
MedImmune’s review pursuant to Section 7 and for inspection, analysis and use by or on behalf of MedImmune during the term of this Agreement for the sole purpose of the Evaluation; 

 

	 	(c)	 ensure that no such Study Documentation is destroyed without the prior written approval of the other Party;

  

	 	(d)	 if such Party is Innate, with respect to all Collaboration Studies assigned to Innate and all Exploratory Studies:

  

	 	(i)	 promptly provide the OC (and, in the case of Exploratory Studies, MedImmune) with copies of all relevant study
documents including protocol, annotated Case Report Forms (“CRFs”), database structure, coding dictionaries related information, Data Validation 

  
 36 

 CD39 OPTION 
  

 

	 	 
Plan, Statistical Analysis Plan, mock Tables, Figures, Listings (“TFL”) shells, Study Data Tabulation Model (“SDTM”) and Analysis Data Model
(“ADaM”) data specifications, existing standards (for CRFs, data, TFLs, programs, operating procedures). Innate shall retransfer any components if and when they undergo amendments; 

 

	 	(ii)	 promptly provide the OC (and, in the case of Exploratory Studies, MedImmune) with copies of all Dose escalation
committee (or any other study safety committee) reports, minutes and review materials including raw data snapshot, SDTM, ADaM, TFL and programs within [***] of the relevant committee meeting; 

 

	 	(iii)	 in addition to the review packages for planned periodic committee reviews, procure for regular data transfers after
first two dose escalations and then quarterly thereafter of all clinical and available biomarker data from such Collaboration Studies or Exploratory Studies which are ongoing, such data to include raw data, SDTM and Adam. In addition, Innate shall
enable ad-hoc data transfer upon request from MedImmune; 

  

	 	(A)	 transfer all data and documents described in this clause (d) through a secure portal which is jointly established by
the Parties (eg: sFTP or BOX); 

  

	 	(B)	 provide to the OC a quarterly report summarising all adverse drug reaction experiences related to CD39 Option Products as
required to be reported to the appropriate Regulatory Health Authorities in the countries in which such trials are being conducted in accordance with the Applicable Law; and 

 

	 	(e)	 if such Party is MedImmune, provide to Innate monthly clinical summary reports including efficacy and safety data.

  

	5.7	 Each Party shall provide the other Party with (i) drafts and final versions of all top line data and other
reports obtained in each of the Collaboration Studies assigned 

  
 37 

 CD39 OPTION 
  

 

	 	 
to it (as such data may be specified in the Development Plan or the relevant Collaboration Study Protocol) within [***] after its receipt thereof from a CRO or such time when such drafts and
reports otherwise become available to such Party; (ii) a draft of each Collaboration Study Preliminary Report within [***] after its receipt of such draft from a CRO or such time when such draft otherwise becomes available to such Party; and
(iii) the relevant Collaboration Study Preliminary Report within [***] after availability of the Primary End Point Results. 

  

	 	6	 INNATE DEVELOPMENT COSTS 

 

	6.1	 Each Party acknowledges and agrees that MedImmune shall reimburse Innate any Costs incurred by Innate: (a) in
accordance with the Collaboration Budget (subject to Section 6.3) and (b) in the performance of the Development activities (which are assigned to Innate under the Development Plan) in accordance with this Agreement (the “Innate
Development Costs”). 

  

	6.2	 Within [***] after the end of each Calendar Quarter, Innate shall provide MedImmune with detailed, itemized accounting
of the Innate Development Costs incurred by Innate during such Calendar Quarter, which report shall be itemized on a CD39 Option Product-by-CD39 Option Product basis, in
such other form as the Parties may mutually agree from time to time. For clarity, for calculation of Costs pursuant to this Section 6 with respect to any activity performed by a CRO, the Costs shall be the actual costs charged to Innate by such
Third Party, with no additional mark-up. For the avoidance of doubt, subject to Section 8, income and withholding taxes imposed on Innate hereunder shall not be included as part of such Costs.

  

	6.3	 Overruns. Innate shall promptly notify MedImmune upon becoming aware that the anticipated Innate Development Costs to
be incurred by Innate for a given Calendar Year are likely to exceed the Collaboration Budget for such Calendar Year. The aggregate amount of any Innate Development Costs reported by Innate pursuant to this Section 6 with respect to a Calendar
Year, which exceed [***] of the aggregate amounts budgeted to be incurred by or on behalf of such Party for its activities under the Development Plan in such 

  
 38 

 CD39 OPTION 
  

 

	 	 
Calendar Year in the Collaboration Budget (“Excess Costs”), will not be included in the calculation of the Innate Development Costs for the purposes of this Section 6 and
MedImmune shall have no responsibility for such Excess Costs, provided, that a given Excess Cost will be included: (a) to the extent such Excess Cost is or was attributable to: (i) a change in Applicable Law; (ii) a Force Majeure
event; (ii) variation in actual patient enrolment from projected patient enrolment not caused by the default of Innate; or (b) to the extent such Excess Cost is otherwise not incurred as a result of Innate’s failure to perform its
obligations under the Development Plan in accordance with the Innate Standards. 

  

	6.4	 Reconciliation Discussion. In the event MedImmune has any questions or concerns regarding the Innate Development Costs
reported by Innate pursuant to this Section 6, MedImmune shall promptly notify Innate with respect thereto and the Parties shall work together in good faith, to resolve such questions and concerns within [***] after the end of each Calendar
Quarter. In the event that MedImmune disagrees with, or identifies a discrepancy in, the Innate Development Costs submitted by Innate and the disagreement or discrepancy cannot be resolved or rectified between the Parties within a period of [***] of
the matter being first raised by a Party, either Party may appoint an independent, internationally recognised accountant to review the alleged discrepancy. The costs of carrying out such review shall be borne by the Party requesting it unless the
accountant finds a discrepancy which is greater than [***], in which case Innate shall bear the costs. 

  

	6.5	 True-up. Within [***] after the end of each Calendar Quarter, Innate shall
deliver to MedImmune an invoice for amounts to be reimbursed by MedImmune, and MedImmune shall pay for amounts set out in such invoice to the extent validly issued, within [***] after its receipt of such invoice. 

 

	 	7	 AUDIT AND REVIEW RIGHTS, OPTION COMMITTEE 

 

	7.1	 During the term of this Agreement, Innate shall ensure that MedImmune or its authorized representatives are entitled,
during regular business hours, with reasonable prior written notice and no more than once in any given year during the term of this Agreement (provided that MedImmune shall be entitled to audit more

  
 39 

 CD39 OPTION 
  

 

	 	 
frequently if any material areas of concern, in MedImmune’s reasonable judgment, are discovered as a result of an annual audit or otherwise) to (a) inspect the premises where any part
of the Collaboration Studies assigned to Innate under the Development Plan is being, will be or has been conducted, (b) review all Study Documentation and any other books, records and data relating to a Collaboration Study (unless to the extent
prohibited by mandatory Applicable Law regarding personal data, biological samples or similar), and (c) interview the Principal Investigator and the Study Site Staff of Innate-sponsored studies in the presence of Innate’s representatives.
Innate shall, and shall cause the Principal Investigator and the Study Site Staff to, cooperate with any such activities. Innate shall (unless to the extent prohibited by mandatory Applicable Law) promptly inform MedImmune of any inspections and the
like by authorities that may affect or relate to a Collaboration Study and shall provide MedImmune with a copy of any reports from such inspections. 

  

	7.2	 Without prejudice to the foregoing, Innate shall, during the term of this Agreement and at MedImmune’s reasonable
request, assist MedImmune as necessary to enable MedImmune to evaluate the outcome of each of the Collaboration Studies. Such assistance shall include providing MedImmune with all reasonable and material information in Innate’s possession or
control (including for the avoidance of doubt any information in its Affiliate’s or a CRO’s possession) relating to each Collaboration Study. 

  

	7.3	 With effect from the Effective Date the Parties shall establish a committee (the “Option Committee”
or “OC”) to have oversight of the CD39 Program, to provide a forum to facilitate communication between the Parties and to enable Innate to provide to MedImmune certain information in respect of the initiation, conduct and completion
of the Collaboration Studies for the purposes of MedImmune’s Evaluation with respect to the CD39 Program. The OC shall consist of six (6) members with equal numbers appointed by each Party (it being understood that a Party may appoint an
employee of its Affiliate to act as such Party’s representative on the OC). The OC members appointed by each Party shall have the requisite experience. Each Party may replace its members of the OC upon written notice to the other Party,
provided that any such substitute member shall have substantially the equivalent experience as the member that such person replaces. The chairman 

  
 40 

 CD39 OPTION 
  

 

	 	 
of the OC shall be one of Innate’s members of the OC. The OC, will have the following responsibilities: 

 

	 	(a)	 review and approve proposed actions related to any Material Issues; 

 

	 	(b)	 review and approve the Collaboration Study Protocols and the Development Plan and the Collaboration Budget, and any
amendment thereto. Should MedImmune propose any variation to the Development Plan, that proposed variation and any consequent change to the budget, shall be presented to the OC by MedImmune and discussed by the OC; 

 

	 	(c)	 discussing progress under the Development Plan, including the review of emerging clinical and biomarker data from the
Collaboration Studies, review of progress toward timelines and budget; 

  

	 	(d)	 discussing publication plan and draft scientific publications; 

 

	 	(e)	 review and approve any proposal to commence any new clinical study with any CD39 Option Product;

  

	 	(f)	 review and approve any pre-clinical activities to be performed by Innate under
the Development Plan; 

  

	 	(g)	 review and approve the appointment or replacement of the Principal Investigator(s); 

 

	 	(h)	 review and make recommendations with respect to the overall performance of the Collaboration Studies, including the
quality and timeliness of data transfers from such Collaboration Studies; 

  

	 	(i)	 review and approve the scope and content of Study Documentation with respect to the Collaboration Studies and the
Collaboration Study Preliminary Reports; 

  

	 	(j)	 review and make recommendations with respect to the conduct of

  
 41 

 CD39 OPTION 
  

 

	 	 
Manufacturing activities by MedImmune; 

  

	 	(k)	 review and approve whether either Party shall terminate a Collaboration Study; and 

 

	 	(l)	 review and approve any non-clinical toxicology activities to be performed by
Innate with respect to CD39 Option Products, 

 provided that, in the case of (b), (c), (e), (h), (i) and (k),
excluding any [***] Study or the Study Documentation, Collaboration Study Preliminary Reports with respect to any CD39 [***] Study (as applicable). 
  

	7.4	 Any decision within OC’s authority shall be made only by unanimous consent, with the MedImmune voting members
cumulatively having one (1) vote and the Innate voting members cumulatively having one (1) vote, irrespective of the number of members actually in attendance at a meeting. In the event that unanimity cannot be reached by the OC on a matter
before it for decision within [***] after the matter was first considered by it then the matter may be referred by either Party to the Senior Executives, who shall meet (in person, via internet, telephonically or by videoconference) and attempt to
resolve the matter within [***] of such referral. In the event that the Senior Executives are unable to reach consensus within such [***] period: 

  

	 	(a)	 [***]; 

  

	 	(b)	 [***]; and 

  

	 	(c)	 [***]. 

[***] 
  

	7.5	 Notwithstanding anything to the contrary set forth in this Agreement, the OC will have no authority to (a) amend,
modify or waive compliance with this Agreement or otherwise impose any obligation on the Parties in deviation from this Agreement, or (b) resolve any dispute concerning the validity, compliance with, or breach of, this Agreement.

  

	7.6	 Meetings with the OC shall be held once every [***] with at least one (1) meeting a

  
 42 

 CD39 OPTION 
  

 

	 	 
year being face-to-face and other meetings being held by video or telephone conferences or in person and more
frequently when required at such dates and times as will be mutually agreed upon by the OC. A quorum of the OC shall require the attendance of at least two of each Party’s members of the OC. OC members may be represented at any meeting by
another person designated in writing by the absent OC member. The venue for meetings of the OC shall, when held in person, alternate between the premises of the Parties. Each Party shall bear the costs associated with the activities of its members
of the OC. The OC shall be dissolved upon the termination of this Agreement, unless extended or earlier dissolved by mutual agreement of the Parties. 

  

	7.7	 For the avoidance of doubt, each Party shall have sole decision making for any 

  
 43 

 CD39 OPTION 
  

 matters relating to the conduct of the activities under the Development Plan assigned
to such Party that do not fall within the approval authority of the OC, including any matters with respect to the day-to-day operations of such Party with respect to
such activities. 
 (a)    Notwithstanding any other provision in this Agreement, in no event shall either Party
be obligated to disclose to the other Party any information with respect to any CD39 [***] Combo or CD39 [***] Bispecific being Developed by or on behalf of such Party, or any CD39 [***] Studies being performed by or on behalf of such Party, save
for such information which is: (a) necessary for the other Party to comply with its regulatory or pharmacovigilance obligations under Applicable Law, or (b) disclosed under any CD39 [***] Plan under Section 4.5. 

 

	 	8	 PAYMENTS AND TAXES 

  

	8.1	 Any amount payable by MedImmune to Innate in accordance with this Agreement (“Payments”) shall,
unless specified otherwise, be made by bank transfer in immediately available funds to Innate’s nominated bank account, within [***] of the receipt of a validly issued invoice from Innate (unless otherwise specified in this Agreement). Innate
shall provide to MedImmune its bank details, i.e. bank number and bank code and SWIFT-address, to which all Payments are to be made. 

  

	8.2	 Payments made by MedImmune to Innate pursuant to this Agreement shall [***] (and that, if applicable, all governmental
authorisations that are required to be received by the appropriate Party have been so received) at least [***] prior to the time that the Payments are due. If MedImmune [***]. This Agreement being entered into between a French resident entity and a
UK resident entity within the meaning of Article 4 of the France – UK Double Tax Treaty, the Parties acknowledge and agree in accordance with the Applicable Laws as of the Effective Date, no withholding tax shall apply to the Payments. If, in
accordance with the foregoing, [***]. In the event that (i) MedImmune assigns or otherwise transfers its rights or obligations under this Agreement to [***], then MedImmune procures that [***], provided that [***]. 

 

	8.3	 Notwithstanding anything contained in Sections 8.1 and 8.2 the following shall

  
 44 

 CD39 OPTION 
  

	 	 
apply with respect to Indirect Taxes. All amounts expressed to be payable under this Agreement (including any Payments) by any Party to this Agreement which (in whole or in part) constitute the
consideration for any supply for Indirect Tax purposes are deemed to be exclusive of any Indirect Tax which is chargeable on that supply, and accordingly, if any Indirect Tax is or becomes chargeable on any supply made by any Party to this Agreement
(the “Supplier”) and the Supplier or an Affiliate of the Supplier is required to account to the relevant Governmental Body for the Indirect Tax, the Party receiving such chargeable supply (the “Recipient”) shall pay
to the Supplier (in addition to and at the same time as paying any other consideration for such supply, or [***] after the receipt by the Recipient of an appropriate invoice in respect of such Indirect Tax) an amount equal to the amount of the
Indirect Tax. 

  

	8.4	 The Parties shall issue invoices for any payment due under this Agreement consistent with Indirect Tax requirements.
In this respect, the Parties shall cooperate and provides information or assistance as may be necessary to enable to issuance of such invoices consistent with Indirect Tax requirements. 

 

	 	9	 REGULATORY 

  

	9.1	 Clinical Study Regulatory Activities. 

 

	 	(a)	 MedImmune shall have the sole right to, and shall use Commercially Reasonable Efforts to: (i) prepare, obtain and
maintain any IND/CTA/Regulatory Approvals necessary to conduct any Collaboration Study for which MedImmune is the sponsor or is the Party contracting with a CRO to conduct any Collaboration Study (such Collaboration Studies, the “MedImmune
Collaboration Studies”), each of which shall be a new, 

  
 45 

 CD39 OPTION 
  

	 	 
separate IND/CTA/Regulatory Approval, and (ii) to conduct communications with the Regulatory Health Authorities with respect thereto, including any
pre-IND/CTA meeting, end-of-phase 1 meeting,
end-of-phase 2 meeting or pre-phase 3 meeting with the FDA in the United States or any corresponding meetings with Regulatory
Health Authorities outside the United States. MedImmune shall constitute the Lead Regulatory Party with respect to each MedImmune Collaboration Study. 

  

	 	(b)	 Innate shall have the sole right to, and shall use Commercially Reasonable Efforts to, (i) prepare, obtain and
maintain any IND/CTA/Regulatory Approvals necessary to conduct any Collaboration Study for which Innate is the sponsor or is the Party contracting with a CRO to conduct any Collaboration Study (such Collaboration Studies, the “Innate
Collaboration Studies”), each of which shall be a new, separate IND/CTA/Regulatory Approval, and (ii) conduct communications with the Regulatory Health Authorities with respect thereto, including any
pre-IND/CTA meeting, end-of-phase 1 meeting,
end-of-phase 2 meeting, pre-phase 3 meeting or any corresponding meetings with Regulatory Health Authorities. Innate shall
constitute the Lead Regulatory Party with respect to each Innate Collaboration Study. 

  

	9.2	 Regulatory Approvals and Submissions. 

 

	 	(a)	 The Lead Regulatory Party with respect to each IND/CTA or any other Regulatory Approval in respect of a Collaboration
Study shall provide for OC’s review and approval copies of all major regulatory filings and documents related to any IND/CTA or any other Regulatory Approval for which such Lead Regulatory Party is responsible. No Lead Regulatory Party shall
file any such regulatory filings or documents with the applicable Regulatory Health Authority unless and until approved by the OC. 

  

	 	(b)	 MedImmune shall provide to Innate, in a timely manner so as not to delay the filing of any IND/CTA or any other
Regulatory Approval, a complete data package with respect to CMC as is required to enable Innate, as Lead Regulatory Party, to make the relevant submission for each IND/CTA or 

  
 46 

 CD39 OPTION 
  

	 	 
any other Regulatory Approval. 

  

	 	(c)	 Except to the extent prohibited by Applicable Law, all Regulatory Documentation (including all Regulatory Approvals)
relating to a Collaboration Study developed or granted after the Effective Date shall be owned by, and be the sole property and held in the name of, the applicable Lead Regulatory Party (or its designee with respect thereto). 

Provided that, in each case (a) to (c), provision of such filings, data package or documents (as applicable) by MedImmune may be in
a form or method as enables MedImmune to retain its confidentiality in the MedImmune Manufacturing Information or with respect to any MedImmune Product. 
  

	9.3	 Communications with Regulatory Health Authorities. 

 

	 	(a)	 The Lead Regulatory Party with respect to each IND or any other Regulatory Approval in respect of a Collaboration
Study shall coordinate in good faith with the other Party with respect to scheduling all meetings, conferences or discussions (whether face-to-face or teleconference and
including any meeting of experts convened by a Regulatory Health Authority) scheduled with a Regulatory Health Authority concerning any IND or any other Regulatory Approval in the Territory for which such Lead Regulatory Party is responsible and
shall promptly (within [***]) notify the other Party of the scheduling of such meeting, conference or discussion and provide the other Party advance copies of all related documents and other relevant information relating to such meetings or other
contacts. Such other Party shall have the right to have reasonable representation present at and to participate in any such meetings, conferences and discussions. The Lead Regulatory Party shall use good faith efforts to provide the other Party with
an opportunity to be present at and participate in, to the extent practical, any unscheduled or ad-hoc meetings, conferences or discussions with any Regulatory Health Authority concerning any IND or any other
Regulatory Approval in the countries in the Territory for which such Lead Regulatory Party is responsible. Notwithstanding the foregoing, at any meeting, conference or discussion 

  
 47 

 CD39 OPTION 
  

	 	 
with, or in any communication to, the Regulatory Health Authorities in the countries in the Territory concerning a Collaboration Study at which MedImmune and Innate are present or in which both
Parties participate, MedImmune shall take the lead on matters relating to the CMC data with respect to any CD39 Option Product and at any such meeting, conference or discussion with, or in any such communication to, such Regulatory Health
Authorities concerning a CD39 Option Product at which MedImmune is not present or does not participate, Innate shall not engage in any substantive discussions pertaining to the CMC data with respect to any CD39 Option Product, including making any
commitments with respect thereto. 

  

	 	(b)	 Each Lead Regulatory Party shall promptly provide the other Party with: (i)  copies of all regulatory
correspondence to or from the Regulatory Health Authorities relating to any IND, or any other Regulatory Approval for which such Lead Regulatory Party is responsible; provided that in no event shall MedImmune be obligated to disclose any MedImmune
Manufacturing Information to Innate or any of its Affiliates and (ii) notices of any revocations of any IND or any other Regulatory Approval for which such Lead Regulatory Party is responsible. 

 

	 	(c)	 Notwithstanding the foregoing, clauses (a) and (b) above shall not apply with respect to any IND or Regulatory
Approval in respect of any CD39 [***] Studies (and any meetings, conferences and discussions scheduled with, or other communications with, a Regulatory Health Authority with respect thereto). 

 

	9.4	 Recalls, Suspensions or Withdrawals. 

 

	 	(a)	 Each Party shall notify the other Party promptly (but in no event later than [***]) following its determination that
any event, incident or circumstance has occurred that may result in the need for a recall, market suspension or market withdrawal (each, a “Recall”) of the applicable product controlled by such Party in the Territory (in the case of
Innate, any CD39 Option Product, and in the case of MedImmune, any 

  
 48 

 CD39 OPTION 
  

	 	 
MedImmune Product), and shall include in such notice the reasoning behind such determination and any supporting facts. 

 

	 	(b)	 As between the Parties, each Party shall have the sole responsibility and right to (i) determine if any Recall is
necessary with respect to any such Party’s proprietary product in the Territory (in the case of MedImmune, including any MedImmune Product), and (ii) initiate, undertake, execute and implement such Recall; provided that prior to any final
determination or implementation of such a Recall, MedImmune or Innate, as applicable, shall, to the extent practicable under the circumstances, consult with the other Party and shall consider its comments in good faith. 

 

	 	(c)	 As between the Parties, the Party undertaking any Recall pursuant to this Section 9.4 shall be solely responsible
for the execution and implementation thereof, shall bear all costs and expenses associated therewith. The other Party shall reasonably cooperate with the Party responsible for any Recall. 

 

	9.5	 Pharmacovigilance 

  

	 	(a)	 The Parties will execute a Pharmacovigilance Agreement, as soon as practical following the Effective Date of this
Agreement, which will govern the procedure for the mutual exchange of safety information within appropriate timeframes and in an appropriate format to enable the Parties to comply with the terms of this Agreement, and with any local and
international regulatory reporting obligations and to facilitate appropriate safety reviews. The Parties agree to use any such pharmacovigilance information provided by the other Party pursuant to this Agreement solely to conduct the CD39 Program
and evaluate the safety of the CD39 Option Product. Sponsor shall be responsible for all safety reporting requirements (submission of all SUSARs from the Study to the Regulatory Health Authorities where the Collaboration Study is conducted and to
the investigators in the Collaboration Study) in accordance with Applicable Law. For all other required safety reporting, such as cross reporting where applicable by Applicable Law) Innate shall be responsible for reporting to 

  
 49 

 CD39 OPTION 
  

	 	 
Innate IND/CTAs and MedImmune shall be responsible for reporting to MedImmune IND/CTA/NDA/MAH. Each Party shall promptly report to the other Party safety information which could impact the
Collaboration Study subjects safety or the conduct of the Collaboration Study or would otherwise necessitate amendments to the Collaboration Study protocol that are required to be implemented by Regulatory Health Authorities, or are implemented by
the respective Party, in each case where, in particular because of their severity, frequency or lack of reversibility, and which a Party would reasonably need to know such safety information in order to ensure patient safety and prevent unreasonable
risks in the conduct of the Collaboration Study. All such disclosures under this Section 9.5 are Confidential Information of the Party disclosing same. 

  

	 	(b)	 [***]. AstraZeneca pharmacovigilance standards will be followed for any combination use trials that include a
MedImmune Product. 

  

	 	(c)	 MedImmune may share any of the following materials or information with any of its Affiliates which may include
information containing combination use with a CD39 Option Product: 

  

	 	(i)	 any materials or information provided to MedImmune or any of its Affiliates by or on behalf of Innate or any of its
Affiliates in accordance with this Section 9.5 or under the Pharmacovigilance Agreement; and 

  

	 	(ii)	 any other materials or information provided to Medimmune or any of its Affiliates by or on behalf of Innate or any of
its Affiliates under this Agreement in respect of any actual or alleged defect in the CD39 Option Product, including (i) any injury alleged to have occurred as a result from the use or application of the CD39 Option Product, (ii) any facts
or circumstances that may give rise to any obligation or liability in respect of the CD39 Option Product, or (iii) a recall or market withdrawal or any regulatory action with respect to the CD39 

  
 50 

 CD39 OPTION 
  

 

	 	Option	 Product. 

  

	9.6	 The decision to initiate a recall of MedImmune Product will be the sole responsibility of and at the sole cost of
MedImmune. At MedImmune’s request, Innate shall provide any reasonable assistance to MedImmune, at MedImmune’s cost, for the recall of a MedImmune Product. Recalls will proceed in accordance with any clinical quality agreement entered into
between the Parties. 

  

	9.7	 If, in the reasonable opinion of Innate, a Safety or Regulatory Issue occurs prior to or during the conduct of the
Innate Collaboration Studies, Innate shall promptly notify MedImmune thereof in writing (“S/R Notice”) and take such appropriate actions as may be required to protect the health, safety or well-being of any Subject. The S/R Notice
shall include a reasonably detailed description of the Safety or Regulatory Issue. 

  

	9.8	 The Parties shall promptly upon MedImmune’s receipt of an S/R Notice meet to discuss an appropriate course of
action in good faith, including whether or not further Collaboration Studies can or should be initiated or, as the case may be, whether any or all of the Collaboration Studies should be discontinued. With respect to any and all matters pertaining to
pharmacovigilance assessments or statements on the MedImmune Product, including combination use statements, Innate shall discuss with MedImmune to agree conclusions. Should the Parties disagree, [***]. 

 

	 	10	 DATA PROTECTION 

MedImmune and Innate agree that they shall comply with their obligations under applicable Data Protection Law in connection with their
respective activities under this Agreement. Accordingly, the Parties shall, as soon as reasonably practicable after the date of this Agreement, and in any event before any Personal Data is Processed or transferred under or pursuant to this
agreement, agree the terms of a data sharing and transfer agreement between them. Such agreement shall contain usual and customary terms for an agreement of that nature. 

  
 51 

 CD39 OPTION 
  

 

	 	11	 CONFIDENTIALITY 

  

	11.1	 At all times during the term of this Agreement and for a period of [***] following termination or expiration thereof,
each Party (the “Receiving Party”) shall (i) keep confidential and not disclose to any Third Party, other than its and its Affiliates’ officers, directors, other employees, contractors and advisors on a need to know basis,
any Confidential Information provided to it by the other Party (the “Disclosing Party”) and (ii) not publish or otherwise use, directly or indirectly, for any purpose, such Confidential Information, except to the extent
permitted by the terms of this Agreement or to the extent such use is necessary for the fulfilment of the Receiving Party’s obligations under this Agreement. The Receiving Party shall cause all of its and its Affiliates’ officers,
directors, other employees, contractors and advisors to whom the Receiving Party has disclosed Confidential Information to comply with confidentiality and non-use obligations at least as restrictive as those
set out in this Agreement and shall be liable to the Disclosing Party for any breach thereof by such Affiliates, officers, directors, other employees, contractors and advisors. 

 

	11.2	 The obligations of confidentiality and non-use in Sections 11.1 and the
obligations set forth in Section 11.5 shall not extend to any Confidential Information that: (a) is or comes into the public domain without breach of this Agreement, (b) is received by the Receiving Party from a Third Party (other
than an Affiliate of the Disclosing Party) without any obligation of confidentiality and without breach of this Agreement, or (c) the Receiving Party can prove was already in its possession without any limitation on use or disclosure prior to
the Effective Date. 

  

	11.3	 Notwithstanding Section 11.1, the Receiving Party shall be entitled to use and disclose Confidential Information
to the extent reasonably required for the Receiving Party’s exercise of its rights granted to it and the performance of its obligations under this Agreement and the License Agreement. In addition each Party shall be entitled to disclose the
terms of this Agreement and the License Agreement on a confidential basis to actual or potential investors or in connection with any permitted assignment under this Agreement or in connection with any proposed grant of a sub-license by MedImmune as permitted by the License Agreement provided that in each case the Receiving Party shall cause any and all 

  
 52 

 CD39 OPTION 
  

 

	 	 
parties to whom such disclosure is made to comply with confidentiality and non- use obligations at least as restrictive as those set out in this Agreement
and shall be liable to the Disclosing Party for any breach thereof by such parties. 

  

	11.4	 This Agreement shall not restrict the Receiving Party from complying with a lawfully issued governmental order or
legal requirement or requirement under applicable stock exchange rules to produce or disclose Confidential Information; provided, however, that, in the event of governmental orders, the Receiving Party shall promptly notify the Disclosing Party to
enable the Disclosing Party to oppose the order or obtain a protective order and the Receiving Party shall cooperate fully with the Disclosing Party in any such proceeding. If the Receiving Party is legally required or required under applicable
stock exchange rules to disclose Confidential Information, the Receiving Party and the Disclosing Party will endeavour to agree to a mutually satisfactory means to disclose such information. Nothing contained herein shall prohibit either of the
Parties from immediately disclosing results of the Collaboration Studies to the extent necessary to prevent or mitigate a serious health hazard; provided, however, that the Party intending to make such disclosure shall notify the other Party prior
to and immediately after such disclosure and, to the extent it is reasonably practicable to do so, the nature and content of such disclosure shall be agreed between the Parties. 

 

	11.5	 Neither Party shall issue any other public announcement, press release or other public disclosure regarding this
Agreement or its terms without the other Party’s prior written consent, such consent not to be unreasonably withheld, delayed or conditioned, provided that such consent cannot be withheld for public announcement, press release or other public
disclosure with respect to material development milestones achieved by the CD39 Option Product (such material development milestones being the start of GLP Toxicology studies and the start of any Clinical Trial), to the extent limited to, and
consistent with, publicly available information with respect to such Clinical Trial, if the form of announcement, press release or other publication with respect to such key development milestones is in a form reasonably agreed by MedImmune, and in
any event, except for any such disclosure that is, in the opinion of the disclosing Party’s counsel, required by Applicable Law, the Listing Rules or any other rules of a stock exchange (including Paris Euronext) on which the securities of the
disclosing Party are listed (or to which 

  
 53 

 CD39 OPTION 
  

 

	 	 
an application for listing has been submitted). 

  

	11.6	 The Parties acknowledge that scientific publications must be strictly monitored as the timing, nature and content of
publications, in particular premature publication of the Study Results, may materially affect the value of the CD39 Option Product. Accordingly and without prejudice to the confidentiality obligations set forth above in this Section 11 (but
subject to Section 11.4), if either Party wishes to publish or present (including in any clinical trial registries whether or not required by Applicable Law) or otherwise disclose any Study Results or other material related to the CD39 Option
Products then: 

  

	 	(a)	 if such Party is MedImmune, MedImmune shall provide a draft of such publication, disclosure or presentation to Innate,
which will have [***] to provide comments. MedImmune shall, in good faith, consider the comments made by Innate, including any request to defer the publication or presentation for a period not exceeding [***] if a Patent may be filed using the Know-How covered in the proposed publication or communication; or 

  

	 	(b)	 if such Party is Innate, Innate shall provide a copy of any such proposed publication, disclosure or presentation to
MedImmune at least [***] prior to the intended date of publication or presentation, for MedImmune’s consent, which consent cannot be unreasonably withheld or delayed. 

Notwithstanding the foregoing, Innate may publish any publications pursuant to manuscripts submitted prior to the Effective Date (as
contained in the Innate Data Room as of the Effective Date), provided that, Innate shall provide to MedImmune any revised drafts of such manuscripts and shall take into account MedImmune’s comments with respect to such drafts in good faith. If
[***] or other Third Party notifies Innate that it wishes to publish or present any publication or presentation with respect to the CD39 Option Technology, Innate shall promptly notify MedImmune thereof (and shall provide a copy of such draft
publication or presentation to the extent available to Innate). Innate shall exercise any of its rights under the applicable agreement with such Third Party, in order to 

  
 54 

 CD39 OPTION 
  

 

 implement MedImmune’s comments (including any requests to delay or withhold such
publication or presentation) to the fullest extent possible. 
  

	11.7	 The Parties acknowledge and agree that Innate’s Background IP, the Innate Collaboration IP and the Innate Study
Results shall be deemed Innate’s Confidential Information (and Innate shall be deemed to be the Disclosing Party and MedImmune the Receiving Party with respect to such Confidential Information). 

 

	11.8	 The Parties acknowledge and agree that the Joint Collaboration IP and the terms of this Agreement shall be deemed each
Party’s Confidential Information (and each Party shall be deemed to be the Disclosing Party and also the Receiving Party with respect to such Confidential Information). 

 

	11.9	 The Parties acknowledge and agree that the MedImmune Manufacturing Information, MedImmune Collaboration IP and the
MedImmune Study Results shall be deemed MedImmune’s Confidential Information (and MedImmune shall be deemed to be the Disclosing Party and Innate the Receiving Party with respect to such Confidential Information). 

 

	 	12	 INTELLECTUAL PROPERTY RIGHTS 

 

	12.1	 During the term of this Agreement, each Party shall promptly disclose to the other Party all Intellectual Property
Rights arising and which is created by or on behalf of such Party as a result of carrying out the activities assigned to it under the Development Plan. 

  

	12.2	 As between the Parties, each Party shall retain and be the sole owner of all rights, title and interest in and to its
Background IP. 

  

	12.3	 Each Party acknowledges and agrees that: 

 

	 	(a)	 MedImmune shall own all right, title and interest in and to any: 

 

	 	(i)	 Collaboration IP generated solely by or on behalf of MedImmune; and 

  
 55 

 CD39 OPTION 
  

 

	 	(ii)	 other Collaboration IP claiming or otherwise covering any CD39 [Adenosine Pathway] Combo or any CD39 Bi-Specific Molecule which is allocated for Development by MedImmune under the Development Plan, 

together with the MedImmune Manufacturing IP, the “MedImmune Collaboration IP”; 

 

	 	(b)	 Innate shall own all right, title and interest in: 

 

	 	(i)	 any Intellectual Property Rights arising from any Exploratory Study; 

 

	 	(ii)	 Collaboration IP generated solely by or on behalf of Innate; and 

 

	 	(iii)	 other Collaboration IP claiming or otherwise covering any CD39 [***] Combo or any CD39
Bi-Specific Molecule which is allocated for Development by Innate under the Development Plan, 

(i) to (iii) together, the “Innate Collaboration IP”; and 

 

	 	(c)	 each of MedImmune and Innate shall jointly own all right, title and interest in and to any Collaboration IP generated
jointly: (i) by or on behalf of MedImmune and (ii) by or on behalf of Innate, excluding any MedImmune Collaboration IP and Innate Collaboration IP (the “Joint Collaboration IP”). 

 

	12.4	 MedImmune shall retain and be the sole owner of all rights, title and interest in and to any and all Intellectual
Property Rights relating to MedImmune’s manufacturing capabilities, as applicable (the “MedImmune Manufacturing IP”). 

  

	12.5	 MedImmune hereby grants to Innate a non-exclusive Right of Reference under the
MedImmune Study Results, and Innate hereby grants to MedImmune and its Affiliates a non-exclusive right of reference under the Innate Study Results, in each case to the extent necessary or useful for the
Development of a CD39 Option Product during the CD39 Option Period. 

  
 56 

 CD39 OPTION 
  

 

	12.6	 Each Party acknowledges and agrees that: 

 

	 	(a)	 Innate shall own all right, title and interest in and to all Study Results of the Exploratory Studies and the Innate
Collaboration Studies (the “Innate Study Results”); and 

  

	 	(b)	 MedImmune shall own all right, title and interest in and to all Study Results of the MedImmune Collaboration Studies
(the “MedImmune Study Results”). 

  

	 	 Innate shall procure that it shall have the right to grant to MedImmune the rights and licenses contemplated by the
License Agreement with respect to the Innate Study Results that are investigator sponsored studies subject in each case to the terms of any Third Party Agreement or other agreement with CROs contracted to carry out the Collaboration Studies, the
terms of which have been disclosed to MedImmune prior to the Effective Date. Innate shall cause the Principal Investigator and Study Site Staff of the Collaboration Studies sponsored by Innate to assign and transfer all their rights, title and
interest in and to the Innate Study Results throughout the world to Innate. 

  

	12.7	 MedImmune and its Affiliates shall, for the duration of the CD39 Option Period, have the right to access and use the
Innate Study Results, provided, however, always that the restrictions with regards to Confidential Information in Section 11 are observed and adhered to. Moreover, MedImmune shall for the duration of the CD39 Option Period and upon prior
written notice thereof to Innate, be entitled to engage its Affiliates and Third Party experts in respect of such activities, provided, however, always that such Affiliates and Third Party experts (i) need to know the information provided for
purposes of advising MedImmune and its Affiliates on the Evaluation, and (ii) are bound by confidentiality and non-use obligations not less restrictive than those imposed on MedImmune under this
Agreement. 

  

	12.8	 Innate and its Affiliates shall, for the duration of the CD39 Option Period, have the right to access the MedImmune
Study Results, provided that, MedImmune shall only be required to make available information with respect to any CD39 [***] Study to the extent such information is strictly necessary for Innate’s

  
 57 

 CD39 OPTION 
  

 

	 	 
compliance with any requirements of Regulatory Health Authorities (and MedImmune shall not be required to make available any other information or Study Results with respect to any CD39 [***]
Study), and further provided that, the restrictions with respect to Confidential Information in Section 11 are observed and adhered to. 

  

	12.9	 Licences. 

  

	 	(a)	 During the CD39 Option Period, the term of the License Agreement, and after the CD39 Option Period if MedImmune has
not exercised the CD39 Option prior to the expiry or termination of the CD39 Option Period, each Party shall grant to the other Party and its Affiliates a non-exclusive, royalty-free, fully paid-up, worldwide license under the Intellectual Property Rights Controlled by such Party which claims any CD39/[***] Combination Product, to the extent necessary for the other Party to research, Develop,
commercialise or otherwise Exploit the molecule which binds [***] Controlled by the other Party, but for the avoidance of doubt, without granting that other Party under this license any rights with respect to any molecule that binds CD39.

  

	 	(b)	 During the CD39 Option Period, Innate shall grant to MedImmune a non-
exclusive, royalty-free, fully paid-up, sublicensable (to MedImmune’s subcontractors only), worldwide sublicense under the [***], for MedImmune to perform its obligations under this Agreement.

  

	12.10	 For clarity, except as expressly provided herein, this Agreement does not grant any license to MedImmune under the
CD39 Option Technology, unless and until the CD39 Option has been validly exercised by MedImmune under this Agreement. 

  

	12.11	 During the CD39 Option Period, Innate shall be responsible for all costs and payments (including without limitation
upfront fees, annual fees, milestone payments and royalties) associated with all licences of Third Party intellectual property rights entered into by Innate, including under the Third Party Agreements, with respect to the CD39 Option Technology that
is required for the performance of the Collaboration Studies. MedImmune shall be responsible for all costs and 

  
 58 

 CD39 OPTION 
  

 

	 	 
payments (including without limitation upfront fees, annual fees, milestone payments and royalties) associated with all licences of Third Party intellectual property rights entered into by
MedImmune and associated with its activities pursuant to the Development Plan. 

  

	12.12	 If the Parties determine that any Patent in-licensed by Innate under a Third
Party Agreement is or becomes required to Develop, manufacture or commercialize any CD39 Option Product, and shall be an CD39 Option Patent, Innate shall include such Patent into the CD39 Option Patents following the exercise of the CD39 Option, and
when it is or becomes required, provided that, if Third Party consent is required, Innate shall, at its own expense, procure for MedImmune such consents and licences as may be required promptly following the exercise of the CD39 Option, from any
applicable Third Party to a Third Party Agreement and under any other head- license, license or agreement existing at the Effective Date and relating to the CD39 Option Technology and the CD39 Option Products (including the manufacture of the CD39
Option Products). 

  

	12.13	 If MedImmune determines that [***] in accordance with this Agreement, MedImmune may notify Innate thereof, upon which
Innate shall, [***]. 

  

	12.14	 In the event that additional head-licenses, licenses or other agreements are entered into by Innate or its Affiliates
after the Effective Date which relate to the CD39 Option Technology, CD39 Option Products or the Collaboration Studies, Innate shall use Commercially Reasonable Efforts to procure that the necessary rights or consents are included in such
head-licenses, licenses and agreements in order to give full effect to this Agreement and to enable the License Agreement to come into full effect without the need for further consent from such Third Parties. The foregoing provision shall include
using Commercially Reasonable Efforts to procure any consents necessary for Innate to grant sub-licensable licenses to CD39 Option Patents jointly owned by Innate and a Third Party. If MedImmune elects to
include the Patents which are the subject of such head-license, license or agreement in the CD39 Option Patents: (a) Innate shall consult with MedImmune in 

  
 59 

 CD39 OPTION 
  

 

	 	 
connection with, and shall use reasonable efforts to procure that MedImmune shall be involved in, the negotiations with such Third Party with respect to the terms of such head-license, license or
agreement, provided that MedImmune’s involvement shall not unreasonably delay or otherwise materially adversely impact such process, and shall only enter into such head-license, license or agreement on terms approved by MedImmune (such approval
not to be unreasonably withheld by MedImmune); and (b) upon any exercise of the CD39 Option, Innate shall be responsible for [***] of the payments due to the applicable Third Party in relation to any such head-licenses, licenses and agreements
entered into after the Effective Date, and MedImmune shall bear [***] of any such payments, in accordance with the terms of Section 12.12 of the License Agreement. If MedImmune does not elect to include such Patents in the CD39 Option Patents,
such Patents shall be excluded from the CD39 Option Patents, unless otherwise agreed between the Parties. 

  

	12.15	 Innate shall not, during the term of this Agreement: 

 

	 	(a)	 make any material changes or alterations to the Third Party Agreements or any other head-licenses, licenses or
agreements relating to the CD39 Option Technology, CD39 Option Products or the Collaboration Studies that would have a material adverse effect on the rights granted to MedImmune hereunder except with the prior written consent of MedImmune; or

  

	 	(b)	 [***]. 

  

	12.16	 Patent Prosecution. During the term of this Agreement Innate shall have the right to, and shall use Commercially
Reasonable Efforts to, file, prosecute (including any interferences, reissue proceedings and re-examinations and opposition proceedings) and maintain the Listed Patents and any Patents claiming any Innate
Collaboration IP throughout [***]. Innate shall bear all costs and expenses of filing, obtaining and maintaining such Patents, including fees and expenses paid to outside legal counsel and experts, direct costs of
in-house counsel and filing, prosecution and maintenance expenses associated therewith. In this regard Innate shall, in each case in [***]: 

 

	 	(a)	 use Commercially Reasonable Efforts to file and prosecute Patent

  
 60 

 CD39 OPTION 
  

 

	 	 
applications to secure granted Patent rights for the Listed Patents; 

  

	 	(b)	 use Commercially Reasonable Efforts to file and prosecute Patent applications to secure Patent rights for such other
patentable Innate Collaboration IP as the Parties may from time to time separately agree on in writing; 

  

	 	(c)	 use Commercially Reasonable Efforts to apply for and obtain patent protection for the CD39 Lead alone or in
combination, in accordance with best practice in the pharmaceutical industry; and 

  

	 	(d)	 upon issuance, maintain all such Patents in full force in the aforementioned countries. 

 

	12.17	 MedImmune shall have the sole right to file, maintain, prosecute, enforce and defend any Patent claiming or covering
any MedImmune Collaboration IP, and the first right to file, maintain, prosecute, enforce and defend any Patent claiming or covering Joint Collaboration IP, at MedImmune’s sole costs. If MedImmune does not intend to file, maintain, prosecute,
enforce and defend any Collaboration IP, MedImmune shall notify Innate with sufficient advance notice but not less than within [***] before an action need to be taken with respect to such filing, maintain, prosecution, enforcement or defence, and
upon the receipt of such notice, Innate shall have the right to take such actions, at Innate’s sole costs. The Party taking the lead of such actions shall consult with the other Party as set forth in Sections 12.18 to 12.20 which shall apply
mutatis mutandis. 

  

	12.18	 Innate shall have the sole right to file, maintain, prosecute, enforce and defend

  
 61 

 CD39 OPTION 
  

 

	 	 
any Patent claiming any Innate Collaboration IP. Prior to [***]. 

  

	12.19	 Innate shall consult with MedImmune as to the strategy and prosecution of Patent applications and the maintenance or
extension of the Patents referred to in Section 12.16. Innate shall cause its patent attorneys and agents to consult with MedImmune (so far as practicable) on all material issues relating to the filing, prosecution (including any interferences,
reissue proceedings and re-examinations and opposition proceedings) and maintenance of such Patents. In this regard, Innate shall, through its patent attorneys and agents, cooperate with MedImmune, through its
patent attorneys and agents, as follows: Innate shall provide MedImmune with a reasonable opportunity to review and comment on the nature and text of new or pending applications, amendments, registrations, filings, submissions, pleadings, responses
or correspondence with any patent authorities with respect to the Patents referred to in Section 12.16 and shall, in advance of submitting or communicating any of the foregoing to the patent authorities, consider in good faith any reasonable
comments provided by MedImmune. Without prejudice to the foregoing, Innate shall (a) notify MedImmune as early as reasonably practicable in advance of all meetings and significant communications with any patent authorities concerning the
aforementioned Patents and, so far as reasonably practical and provided Innate has the right to allow such participation, shall permit, MedImmune to participate in such meetings, (b) promptly prepare and 

  
 62 

 CD39 OPTION 
  

 

	 	 
deliver to MedImmune minutes of any such meeting or communications, and (c) promptly forward to MedImmune copies of all office actions and material written communications received from any
patent authorities with respect to the aforementioned Patents upon receipt therefrom. The Parties shall each appoint a single patent coordinator to coordinate the Patent activities under this Agreement. 

 

	12.20	 If Innate elects not (a) to pursue or continue the filing, prosecution (including any interferences, reissue
proceedings and re-examinations) or maintenance of the Listed Patents in a particular country, or (b) to take any other action with respect to the aforementioned Patents in a particular country that is
necessary or useful to establish, preserve or extend rights thereto, including by seeking any Patent term extension, restoration or the like that may be available now or in the future, then in each such case Innate shall so notify MedImmune in
writing not less than [***] before any deadlines by which an action must be taken to establish or preserve any such rights in such Patent in such country. Such notice may also, in Innate’s discretion, offer MedImmune the right through counsel
of its choosing, to pursue the filing or registration, or support the continued prosecution in Innate’s name (including any interferences, reissue proceedings and re-examinations) or maintenance, of such
Patent at MedImmune’s expense in such country. 

  

	12.21	 Innate will notify MedImmune as soon as possible following Innate becoming aware of any actual or potential
infringement of or challenge to a CD39 Option Patent by a Third Party (“Patent Action”). Innate will have the sole right to take such steps as it deems appropriate with regard to any such Patent Action provided that Innate will keep
MedImmune informed with regard to any action it does take and before taking any such action will consult with MedImmune and take MedImmune’s reasonable comments into account. 

 

	12.22	 MedImmune shall appoint a mutually agreeable patent attorney to prosecute, maintain and extend the Patents in the
Joint Collaboration IP, and shall consult with Innate as to the strategy and prosecution of Patent applications and the maintenance or extension of the Patents in the Joint Collaboration IP. MedImmune shall cause its patent attorneys and agents to
consult with Innate (so far as practicable) on all material issues relating to the filing, prosecution (including any interferences, reissue proceedings and re-examinations and opposition

  
 63 

 CD39 OPTION 
  

 

	 	 
proceedings) and maintenance of such Patents. In this regard, the Parties shall co- operate, through such mutually agreed external patent attorney, as
follows: MedImmune shall provide Innate with a reasonable opportunity to review and comment on the nature and text of new or pending applications, amendments, registrations, filings, submissions, pleadings, responses or correspondence with any
patent authorities with respect to the Patents in the Joint Collaboration IP and shall, in advance of submitting or communicating any of the foregoing to the patent authorities, consider in good faith any reasonable comments provided by Innate.
Without prejudice to the foregoing, MedImmune shall (a) notify Innate as early as reasonably practicable in advance of all meetings and significant communications with any patent authorities concerning the aforementioned Patents and, so far as
reasonably practical and provided such external patent attorney has the right to allow such participation, shall permit Innate to participate in such meetings, (b) promptly prepare and deliver to Innate minutes of any such meeting or
communications, and (c) promptly forward to Innate copies of all office actions and material written communications received from any patent authorities with respect to the aforementioned Patents upon receipt therefrom. 

 

	12.23	 Head License. 

  

	 	(a)	 [***]. 

  

	 	(b)	 Innate shall not modify or amend any Head License in any way that would adversely affect MedImmune’s rights or
interest under this Agreement or under the License Agreement, and shall not terminate any Head License (whether in whole or in part), without MedImmune’s prior written consent Innate shall provide MedImmune a copy of all modifications or
amendments of any Head License. 

  

	 	(c)	 Innate shall provide MedImmune with reasonable advance, written notice prior to exercising any right (including rights
of consultation or participation) or enforcing or waiving any obligation, or electing to forego such exercise or enforcement, under any Head License that could affect in 

  
 64 

 CD39 OPTION 
  

 

	 	 
any respect MedImmune’s rights or interests under the this Agreement or the License Agreement. 

  

	 	(d)	 [***], or otherwise provide of assistance in relation to any negotiations with the head licensors (as applicable)), as
may be necessary or as MedImmune may reasonably request in order to ensure that MedImmune enjoys the continued benefit of the rights with respect to Intellectual Property Rights licensed under the License Agreement. 

 

	 	13	 EXCLUSIVITY 

  

	 	 Exclusivity 

  

	13.1	 During the term of this Agreement Innate shall not, and shall ensure that its Affiliates shall not, sell, transfer,
assign, out-license, encumber or otherwise grant or offer any rights to (in whole or in part) the CD39 Option Technology and the Study Results in a manner inconsistent with this Agreement and the License
Agreement, to any Person other than MedImmune or MedImmune’s Affiliates, as directed by MedImmune, or initiate or conduct any discussions or negotiations regarding such grant or offer with any such Person; provided, however, that this
Section 13.1 shall not prevent Innate from granting licenses to the CD39 Option Technology and Study Results to Third Parties to allow for contract research or development services as necessary or desirable in connection with its performance of
this Agreement or for the purposes of carrying out the Development Plan, including the Collaboration Studies. 

  

	13.2	 During the CD39 Option Period, neither Party nor any of its Affiliates (each, a

  
 65 

 CD39 OPTION 
  

 

	 	 
“Restricted Party”) shall, either by itself or through a Third Party, conduct any clinical development or commercialisation in respect of any CD39 Competing Product, except for
any activities contemplated under the Development Plan. 

  

	13.3	 [***]. 

  

	13.4	 Notwithstanding the foregoing, a Restricted Party’s direct or indirect acquisition by/of, or merger with, in
whole or in part, a Person (or group of companies) or the business of a Person (or group of companies) having any activity contravening the covenants set forth above in Sections 13.2 or 13.3, shall not constitute a breach of such covenants, if:

  

	 	(a)	 [***]. 

  

	 	 	 [***]. 

  

	 	(b)	 [***]. 

  

	13.5	 Other than in publications in accordance with Section 11.6, Innate shall not, and shall ensure that its
Affiliates shall not, disclose any non-public information relating to CD39 Lead, or contained in the CD39 Option Know–How or Study Results to any Person other than MedImmune, except (a) as necessary
for the conduct of the Development Plan (including the Collaboration Studies) or as necessary or desirable in connection with its performance of this Agreement; (b) in the ordinary course of Innate’s or its Affiliates’ business to
their head licensors or contractors; (c) as legally required by Applicable Law or required by applicable stock exchange rules, provided, however, always that any disclosure as per (a) or (b) is, except to the extent prohibited by
Applicable Law, made pursuant to written agreements imposing confidentiality and non-use obligations on the recipients substantially similar to those imposed on Innate hereunder and, further, that Innate shall
be liable to MedImmune for any breach of such obligations by such recipients. Innate will notify MedImmune in writing if Innate wishes to supply or is otherwise requested to supply any CD39 Option Product to a Third Party in order to enable that
Third Party to carry out combination studies using the CD39 Option Product 

  
 66 

 CD39 OPTION 
  

 

	 	 
with another product owned or controlled by that Third Party. Innate shall not make any such supply without first obtaining MedImmune’s prior written consent which if given will provide a
limited exception to the exclusivity provisions set out above. If any such consent is given it will be conditional on MedImmune having the right to approve the terms of any such supply and on Innate ensuring that any supply of a CD39 Option Product
to a Third Party will not adversely impact Innate’s ability to carry out the Collaboration Studies in accordance with this Agreement. 

  

	13.6	 The Parties agree that the restrictions contained in this Section 13 are reasonable and necessary for the
protection of the Parties’ respective Confidential Information and business and investment in the CD39 Option Technology and CD39 Option Products, that such restrictions are reasonable in all the circumstances and that the Parties would not
have entered into this Agreement without the protections afforded to them under this Section 13. 

  
 67 

 CD39 OPTION 
  

 

	14	 REPRESENTATIONS AND WARRANTIES 

 

	14.1	 Each Party represents, warrants and covenants to the other Party that, as of the Effective Date (or as of such other
dates or time periods as may be specified below or as the context requires): 

  

	 	(a)	 Corporate Power. It is duly organized, validly existing and in good standing under the laws of its jurisdiction
of incorporation or formation, has full legal power to grant the rights granted to MedImmune under this Agreement and the License Agreement, and has full corporate power and authority to enter into this Agreement and the License Agreement and to
carry out the provisions thereof. 

  

	 	(b)	 Due Authorisation. The execution, delivery, and performance of the Agreement and the License Agreement by it
does not, and would not, conflict with any agreement, instrument, or understanding, oral or written, to which it is a party or by which it is bound, nor violate any material law or regulation of any court, Governmental Body, or administrative or
other agency having jurisdiction over it. 

  

	 	(c)	 Binding Agreement. This Agreement is a legal and valid obligation binding upon such Party and enforceable in
accordance with its terms. 

  

	14.2	 Innate represents, warrants and covenants the following to MedImmune, as of the Effective Date (or as of such other
dates or time periods as may be specified below or as the context requires). For the avoidance of doubt, Innate shall not be liable for facts and circumstances fairly disclosed to MedImmune prior to the Effective Date. 

 

	    	 Intellectual Property 

 

	 	(a)	 Innate is: (i) the sole and exclusive owner of the entire right, title and interest in the CD39 Option Patents
listed in Schedule 14.2(a)(i) (the “Owned Patents”), (ii) the sole and exclusive licensee of the CD39 Option
Patents    listed    in    Schedule    14.2(a)(ii)    (the    “Exclusively Licensed

  
 68 

 CD39 OPTION 
  

 

	 	 
Patents”), but limited to the extent of the grant of licence in connection with the CD39 Program Antibodies, (iii) the non-exclusive
licensee of the CD39 Option Patents listed in Schedule 14.2(a)(iii) (the “Non-Exclusively Licensed Patents”), but limited to the extent of the grant of licence in connection with the
CD39 Option Products, and (iv) either itself or through its Affiliates, the sole and exclusive owner or licensee of the entire right, title and interest in the Intellectual Property Rights subsisting in the CD39 Option Know-How listed in Schedule 14.2(a)(iv) and has the right to grant an exclusive license to MedImmune under the Owned Patents and the Exclusively Licensed Patents, and a
non-exclusive license to MedImmune under the Non-Exclusively Licensed Patents, under the terms of the License Agreement (or, if applicable, this Agreement). To the
extent any rights, title or interests in the CD39 Option Know-How are owned by its Affiliates, Innate shall procure that such rights are transferred to Innate such that MedImmune shall receive from Innate all
rights and licenses granted to it under this Agreement and such that Innate shall be entitled without restriction to grant the rights to MedImmune specified in License Agreement. 

 

	 	(b)	 Other than for the restrictions set forth in the Third Party Agreements, which have been disclosed to MedImmune prior
to the Effective Date, none of the CD39 Option Patents is subject to any encumbrance or lien permitted by Innate and none of the Owned Patents is subject to any encumbrance or lien permitted by Innate or, to Innate’s knowledge, to any claim of
ownership by any Third Party. For the duration of this Agreement, Innate shall not encumber the rights granted to MedImmune hereunder with respect to the CD39 Option Technology in a manner that would have a material adverse effect on
MedImmune’s rights hereunder. 

  

	 	(c)	 The Third Party Agreements and the Head Licenses are in full force and effect and Innate has no knowledge of any
circumstances that may lead to the termination of such agreements. Without limiting the foregoing, Innate has not received any notices from any licensor under the Head Licenses notifying Innate of any intention of such licensor to terminate the
applicable Head License. 

  
 69 

 CD39 OPTION 
  

 

	 	(d)	 As at the Effective Date, Innate does not own or in-license any Product
Trademarks, Know-How or Patents, other than the CD39 Option Technology, that are necessary for the Research, Development and Exploitation of the CD39 Option Products as currently contemplated and cannot be
included in the CD39 Option Technology pursuant Section 12.12. The Patents specified in Schedules 14.2(a)(i), 14.2(a)(ii) and 14.2(a)(iii) constitute all of the CD39 Option Patents existing at the Effective Date. To Innate’s and its
Affiliates’ knowledge, the CD39 Option Patents have as of the Effective Date been diligently and properly filed, prosecuted and maintained in accordance with Applicable Law and where applicable in the course of normal patent prosecution of
patents that are intended to be maintained, all applicable fees have been paid on or before the due date for payment. 

  

	 	(e)	 To the knowledge of Innate’s and its Affiliates’ personnel responsible for patent matters, in respect of all
US patent applications in the Listed Patents, Innate (or, as appropriate, its licensor) has submitted all material prior art of which it is aware in accordance with the requirements of the United States Patent and Trademark Office.

  

	 	(f)	 To Innate’s and its Affiliates’ knowledge, as of the Effective Date, the CD39 Option Patents properly
identify each and every inventor of the claims of the CD39 Option Patents. To Innate’s and its Affiliates’ knowledge, each Person who has contributed to the conception of inventions claimed in the CD39 Option Patents existing as of the
Effective Date, has duly assigned and has executed an agreement assigning to Innate, or as appropriate, Innate’s licensor, such Person’s entire right, title and interest in and to such CD39 Option Patents. 

 

	 	(g)	 Where CD39 Option Know-How has been disclosed to a Third Party under terms of
confidentiality, to Innate’s knowledge no breach of such confidentiality obligations has been committed by any such Third Party. MedImmune shall not, before, on or after the Effective Date, have any obligation to contribute to any remuneration
of any inventor employed or previously employed by Innate or any of its Affiliates in respect of the CD39 

  
 70 

 CD39 OPTION 
  

 

	 	 
Option Patents or CD39 Option Know-How. Innate or its Affiliates are solely responsible for paying all such remuneration and neither Innate nor any of its
Affiliates has received notification that such payments are insufficient compensation. 

  

	 	(h)	 Innate and its Affiliates have no knowledge of any actual or threatened infringements or misappropriation of the CD39
Option Technology. 

  

	 	(i)	 Innate and its Affiliates have not been notified of any threatened or pending proceedings in any court, arbitration,
patent office, administrative or other tribunal which are concerned with (a) the ownership of any of the CD39 Option Technology, or (b) the validity of any of the CD39 Option Patents (other than pending Patent applications), and, in both
cases, to Innate’s and its Affiliates’ knowledge, there have been no allegations or assertions by a Third Party which are likely to give rise to a claim by such Third Party for ownership or invalidity of the CD39 Option Patents.

  

	 	    	 Third Party Rights 

  

	 	(j)	 The conception, development and reduction to practice of the CD39 Option
Know-How and CD39 Option Patents existing as of the Effective Date has not, to Innate’s knowledge, constituted or involved the misappropriation of trade secrets of any Person. Other than the amounts owed
by Innate under the Third Party Agreements, there are no claims, judgments or settlements against or amounts with respect thereto owed by Innate or any of its Affiliates as of the Effective Date relating to the Regulatory Documentation, Listed
Patents or CD39 Option Know-How, or amounts owed by Innate or its Affiliates with respect to any such claims, judgments or settlements. 

 

	 	(k)	 To Innate’s and its Affiliates’ knowledge, as of the Effective Date, the Development and the
commercialization of the CD39 Option Products does not infringe or misappropriate the Patents, of any Third Party, and there is no claim or litigation brought or threatened by written notice to Innate

  
 71 

 CD39 OPTION 
  

 

	 	 
as of the Effective Date by any Person making such allegations. 

  

	 	(l)	 MedImmune shall not, before, on or after the Effective Date, have any obligation to pay any fees, charges or other
sums due to a Third Party under the Third Party Agreements in relation to CD39 Option Products. 

  

	 	(m)	 Each Head License is valid, binding on the parties thereto and in full force and effect. 

 

	 	(n)	 None of Innate or its Affiliates is party to any other agreement or arrangements regarding the CD39 Option Products
other than pursuant to the Head Licenses. 

  

	 	(o)	 None of Innate, its Affiliates, or, to Innate’s knowledge, the applicable licensor, is in breach of any of its
obligations under any Head License, and Innate has not received any notice relating to any alleged, threated or actual breach by Innate under such Head License, and has no knowledge of any event or circumstance that has occurred that, with a notice
or lapse of time, would constitute a breach of a Head License that may lead to the termination of the Head License. 

  

	 	(p)	 [***]. 

  

	 	    	 Regulatory and Compliance 

 

	 	(q)	 As of the Effective Date, Innate, its Affiliates and, to their knowledge, their contractors, have at all times
(a) researched and developed the CD39 Option Product in accordance with all Applicable Laws, and (b) undertaken clinical trials and prepared, maintained and retained all Regulatory Documentation in accordance with GLP, GCP, regulations and
other Applicable Laws. 

  

	 	(r)	 Innate has made available to MedImmune all Regulatory Documentation,

  
 72 

 CD39 OPTION 
  

 

	 	 
CD39 Option Know-How and other information in its Control as of the Effective Date regarding or related to any CD39 Program Antibody or CD39 Option Product
that MedImmune has specifically requested, with reasonable clarity, in writing to Innate to make available or that Innate would reasonably consider based on the information available at the Effective Date to be material to MedImmune’s
evaluation of whether to enter this Agreement and all such items are true, complete and correct. 

  

	 	(s)	 All Regulatory Documentation that are the material regulatory filings or approvals held by Innate or its Affiliates in
relation to the Research, Development and Manufacture of the CD39 Option Products have been provided to MedImmune prior to the Effective Date. 

  

	 	(t)	 Innate and its Affiliates have not knowingly withheld from a Regulatory Health Authority or from MedImmune any
material information, including CMC Know-How, Serious Adverse Events and results from clinical trials (whether or not completed) relating to the safety, toxicity, quality or efficacy of the CD39 Option
Products. 

  

	 	(u)	 Innate and its Affiliates have the right to refer to and use any data that has been created by the manufacturers of
the CD39 Option Product which is necessary for the use and registration of the CD39 Option Product and MedImmune will have the same rights under this Agreement. 

 

	 	(v)	 In the course of the Development of the CD39 Option Product, Innate has not knowingly used, any employee or consultant
that is debarred by any Regulatory Health Authority or, to its knowledge, is the subject of debarment proceedings by any Regulatory Health Authority. 

  

	 	(w)	 The information provided by Innate to MedImmune (for the purposes of MedImmune’s assessment as to whether or not
filing is required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to this Agreement or the transactions contemplated herein) regarding Innate’s and its Affiliates’ corporate structure and financial
status is correct, complete and not misleading. 

  
 73 

 CD39 OPTION 
  

 

	 	(x)	 Neither Innate nor any Innate Affiliate is engaged in any litigation, opposition or arbitration affecting or relating
to the CD39 Option Products and, as to Innate and its Affiliates’ knowledge as at the Effective Date, there are no such litigation, opposition or arbitration pending or threatened by written notice to Innate and no material facts which are
likely to result in a material judgment against Innate or its Affiliates relating to the CD39 Option Products. 

  

	 	(y)	 The rights granted to MedImmune under this Agreement are not subject to any right, license or interest under the CD39
Option Patents in favour of any government due to funding obtained with respect to CD39 Option Products or clinical trials carried out in government owned hospitals which would conflict with the rights granted to MedImmune under this Agreement.

  

	 	    	 General 

  

	 	(z)	 Innate has access to sufficient funds, resources and expertise to complete the Collaboration Studies in accordance
with this Agreement. 

  

	 	    	 Data Protection 

  

	 	(aa)	 Innate represents, warrants and covenants to MedImmune that: 

 

	 	(i)	 It and its Affiliates shall, and shall cause any of their respective agents or permitted sub-contractors to: 

  

	 	(A)	 Process the Transferred Data in accordance with Data Protection Law; and 

 

	 	(B)	 Process the Transferred Data only for purposes compatible with the purposes for which it was Processed as of the
transfer date, except to the extent Innate has obtained consent from the relevant Data Subject with respect to any new purpose for Processing or it is otherwise compliant with Data Protection Law; and 

  
 74 

 CD39 OPTION 
  

 

	 	(ii)	 It has in place and shall maintain appropriate technical and organisational measures (a) to protect Personal Data
against accidental or unlawful destruction, loss, alteration, unauthorised disclosure or access and (b) that provide a level of security appropriate to the risk represented by the Processing and the nature of the Transferred Data.

  

	14.3	 MedImmune Warranties. MedImmune provides the following representations, warranties and covenants to Innate as
of the Effective Date (or as of such other dates or time periods as may be specified below). 

  

	 	(bb)	 The information provided by MedImmune to Innate (for the purposes of Innate’s assessment as to whether or not
filing is required under the Hart- Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to this Agreement or the transactions contemplated herein) regarding MedImmune’s and its Affiliates’ corporate structure and
financial status is correct, complete and not misleading. 

 DISCLAIMER OF WARRANTY. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN SECTION 14
NEITHER PARTY MAKES ANY REPRESENTATIONS OR GRANTS ANY WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR
IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE NON- INFRINGEMENT OF ANY INTELLECTUAL PROPERTY
RIGHTS OF THIRD PARTIES. 
  

	 	15	 INDEMNIFICATION AND INSURANCE 

 

	15.1	 Innate shall indemnify and hold MedImmune its officers, Affiliates, agents and employees (the “MedImmune
Indemnitees”) harmless from and against all claims and proceedings made or brought by or on behalf of Subjects for personal injury (including death) [***] for, loss, damages, costs and expenses (including reasonable legal costs and
expenses) (whether successfully or otherwise) arising out of the conduct 

  
 75 

 CD39 OPTION 
  

 

	 	 of any activities hereunder, including any activities assigned to Innate pursuant to the Development Plan
(“MedImmune Third Party Claim”), save where such claims and proceedings, loss, damage, costs or expenses arise as a direct consequence of the gross negligence of MedImmune or any of the MedImmune Indemnitees or as a consequence of a
breach of this Agreement by MedImmune. 

  

	15.2	 MedImmune shall indemnify and hold Innate its officers, Affiliates, agents and employees (the “Innate
Indemnitees”) harmless from and against all claims and proceedings made or brought by or on behalf of Subjects for personal injury (including death) or any other Third Party for, loss, damages, costs and expenses (including reasonable legal
costs and expenses) (whether successfully or otherwise) arising out of the conduct of any activities assigned to MedImmune pursuant to the Development Plan hereunder (“Innate Third Party Claim”), save where such claims and
proceedings, loss, damage, costs or expenses arise as a direct consequence of the gross negligence of Innate or any of the Innate Indemnitees or as a consequence of a breach of this Agreement by Innate. [***]. 

 

	15.3	 Mechanism. In the event that a Party (the “Indemnified Party”) is seeking indemnification under
Section 15.1 or 15.2 as the case may be, it shall notify the other Party (the “Indemnifying Party”) in writing of the relevant Third Party Claim and the relevant Loss for which indemnification is sought as soon as reasonably
practicable after becoming aware of such claim. Such notices shall contain a description of the Third Party Claim and the nature and amount of the Loss (to the extent known). The Indemnified Party shall furnish promptly to the Indemnifying Party
copies of all papers and official documents received in respect of such Third Party Claim or Losses. For the avoidance of doubt, all indemnification claims in respect of a Party, its Affiliates, and each of its and their respective employees,
officers, directors and agents shall be made solely by such Party to this Agreement. To the extent that the Indemnifying Party irrevocably commits to indemnify any Indemnified Party in respect of the Third Party Claim, the Indemnified Party shall
permit the Indemnifying Party to assume direction and control of the defense of 

  
 76 

 CD39 OPTION 
  

 

 the relevant Third Party Claim (including without limitation the right to settle the
claim solely for monetary consideration), and shall cooperate as requested (at the expense of the Indemnifying Party) in the defense of the claim. 
  

	15.4	 Notwithstanding Section 15.3, the failure to give timely notice to the Indemnifying Party shall not release the
Indemnifying Party from liability to the Indemnified Party to the extent the Indemnifying Party is not prejudiced thereby and, for the avoidance of doubt, the Indemnifying Party shall not be liable to the extent any Loss is caused by any delay by
the Indemnified Party in providing such notice. Notwithstanding the provisions of Section 15.3 requiring the Indemnified Party to tender to the Indemnifying Party the exclusive ability to defend such claim, if the Indemnifying Party does not
satisfy the condition set forth in Section 15.3, or declines to or fails to timely assume control of the relevant Third Party Claim, the Indemnified Party shall be entitled to assume such control, conduct the defense of, and settle such claim,
all at the sole costs and expense of the Indemnifying Party; provided, however, that neither Party shall settle or dispose of any such claim in any manner that would adversely affect the rights or interests or admit fault, of the other Party without
the prior written consent of such other Party, which shall not be unreasonably withheld, delayed or conditioned. Each Party, at the other Party’s expense and reasonable request, shall cooperate with such other Party and its counsel in the
course of the defense or settlement of any such claim, such cooperation to include without limitation using reasonable efforts to provide or make available documents, information, and witnesses. 

 

	15.5	 LIMITATION OF LIABILITY. EXCEPT IN CIRCUMSTANCES OF NEGLIGENCE OR INTENTIONAL MISCONDUCT BY A PARTY OR ITS AFFILIATES,
OR WITH RESPECT TO THIRD PARTY CLAIMS UNDER SECTIONS 15.1 and 15.2, IN NO EVENT SHALL EITHER PARTY OR ITS RESPECTIVE AFFILIATES AND SUBLICENSEES BE LIABLE FOR INDIRECT OR CONSEQUENTIAL LOSSES, WHETHER IN CONTRACT, WARRANTY, TORT, STRICT LIABILITY,
OR OTHERWISE. This Section 15.5 shall not limit either Party’s liability under Section 11. 

  

	15.6	 Each Party shall insure against any potential liabilities it may have in connection with their activities hereunder
and shall, upon the reasonable written request of the other Party provide such evidence of compliance as such other Party reasonably 

  
 77 

 CD39 OPTION 
  

 

	 	 
deems sufficient, it being understood that self-insurance by MedImmune or any of its Affiliates shall discharge its obligations under this Section 15.6. 

 

	 	16	 TERM AND TERMINATION 

 

	16.1	 This Agreement shall enter into effect on the Effective Date and shall, unless earlier terminated pursuant to this
Section 16, remain in full force and effect until the earliest of: 

  

	 	(a)	 the entry into force of the License Agreement; 

 

	 	(b)	 the end of the CD39 Option Period, provided that a CD39 Option Notice has not been delivered to Innate within the CD39
Option Period; and 

  

	 	(c)	 termination as set forth in Section 16.2 to 16.4 below. 

 

	16.2	 Termination Without Cause. MedImmune may, at its sole discretion and without having to explain the reasons for doing
so, terminate this Agreement in its entirety effective following a [***] prior written notice to Innate. 

  

	16.3	 Termination for Breach. Each of MedImmune and Innate may terminate this Agreement effective immediately at any time
upon written notice to the other Party if the other Party is: 

  

	 	(a)	 in material breach of this Agreement and, where such breach is capable of being cured, fails to remedy such breach
within [***] after having been given a written request for such remedy, including notice that the Agreement may otherwise be terminated; or 

  

	 	(b)	 (i) judicially declared insolvent, or (ii) has an administrator or receiver appointed (or equivalent in the
applicable country) over all or parts of its assets, or (iii) has ceased to cease to carry on its business as a going concern without a successor. 

  

	16.4	 Termination by Innate for Patent Challenge. Except to the extent the following is

  
 78 

 CD39 OPTION 
  

 

	 	 
not enforceable under the law of a particular jurisdiction, this Agreement may be terminated by Innate in its entirety upon written notice to that effect to MedImmune, if MedImmune or any of its
Affiliates has challenged the validity, enforceability or scope of any CD39 Option Patent (an “IP Challenge”) and failed to withdraw the IP Challenge within [***] after having received Innate’s written notice of the IP
Challenge requiring such IP Challenge to be withdrawn (including notice of Innate’s intention to otherwise terminate this Agreement). This Section 16.4 shall not apply in relation to any IP Challenge made by MedImmune as a counterclaim or
defence in response to an action brought by Innate, its Affiliates or any Third Party licensee or licensor of Innate or its Affiliates alleging infringement of a CD39 Option Patent by MedImmune for activities that do not relate to the CD39 Option
Products. 

  

	 	17	 CONSEQUENCES OF TERMINATION 

 

	17.1	 Upon expiration or earlier termination of this Agreement the Receiving Party shall return to the Disclosing Party all
Confidential Information and Know-How from the Disclosing Party or any Third Party on behalf of the Disclosing Party, including any Study Documentation, Study Results, CTA Materials, received from that
Disclosing Party, save for one copy thereof, which the Receiving Party may retain for archival purposes and for the purpose of determining its obligations under Section 11. Notwithstanding the foregoing, (a) in case of expiry of this
Agreement pursuant to Section 16.1(a) the Receiving Party shall retain and be allowed to disclose and use, subject to the terms of the License Agreement, all Confidential Information and Know-How received
from the Disclosing Party or any Third Party on behalf of the Disclosing Party, including any Study Documentation, Study Results, CTA Materials, without restriction under this Agreement but in accordance with the terms and conditions of the License
Agreement; and (b) in case of expiry or termination of this Agreement for any other reason Innate shall retain all rights, title and interest in and to and be free to Exploit or otherwise dispose of the CD39 Option Technology and all Study
Documentation, Study Results and CTA Materials (in each case, with respect to Innate Collaboration Studies), without restriction and without any requirement to account to MedImmune (subject to Section 4.13). 

 

	17.2	 Termination or expiry of this Agreement shall not affect any rights and obligations

  
 79 

 CD39 OPTION 
  

 

	 	 
of the Parties that accrued prior to termination. The respective rights and obligations of the Parties under [***]: 

 

	 	(a)	 [***]; or 

  

	 	(b)	 [***]. 

  

	17.3	 MedImmune shall pay to Innate any reasonable and documented Costs incurred by Innate in the performance of the
Development Plan prior to the effective date of termination of this Agreement as well as those reasonably committed that cannot be cancelled, to the extent such Costs do not exceed [***] of the aggregate Innate Development Costs allocated under the
Collaboration Budget with respect to the applicable period. If MedImmune has not exercised the CD39 Option, from the date of expiry or termination of the CD39 Option until the earlier of: (a) [***]; and (b) [***] (the “Tech Transfer
Period”), upon Innate’s request, MedImmune shall ensure that any resulting manufacturing process for the relevant CD39 Option Product (excluding any CD39 Bi-Specific Molecule) is transferable to
Innate or its designee for the purposes of manufacturing, testing, validating, releasing or Exploiting that CD39 Option Product, and MedImmune shall make available 1 FTE of its personnel to support such technology transfer activities (the
“Tech Transfer FTE”). In particular, during the Tech Transfer Period and Innate’s request, MedImmune shall (i) promptly provide to Innate all support, documentation and information as is useful for an orderly,
uninterrupted transfer of the Manufacturing activities 

  
 80 

 CD39 OPTION 
  

 

	 	 
of such CD39 Option Product to Innate or its designee, including, any and all documentation, quality and testing, working instructions, process and analysis related to IND-Enabling studies, Manufacturing, Quality and Control procedures, including but not limited to, analytical methods, and all regulatory documentation including Regulatory Health Authorities’ assessments,
meeting minutes, MedImmune responses and commitments linked to CMC submissions and consultations (ii) grant to Innate the right to observe the Manufacturing at a facility of MedImmune’s manufacturing contractors and send the appropriate
resources at Innate’s or its subcontractor’s manufacturing facility during the technology transfer to support Innate until the end of the Tech Transfer Period, (iii)  promptly transfer to Innate any remaining materials related to
the Manufacturing activities of the CD39 Option Product (including MCB, WCB, reference material, raw materials), any drug substance and drug product batches, at (provided that Innate reimburses MedImmune for such remaining materials at Cost), (iv)
grant to Innate a non-exclusive, perpetual, royalty free, worldwide license, with the right to grant sublicenses to use any confidential manufacturing or CMC related information owned by or licensed to
MedImmune which are used in relation to the CD39 Option Product at the date of the expiry or termination of the CD39 Option solely to practice the Manufacturing activities of the CD39 Option Product; (v) provide to Innate access to its batch
records at its premises. Innate shall bear the Costs of the manufacturing technology transfer to Innate, save for the Tech Transfer FTE provided by MedImmune at its Cost. Innate shall have the right to disclose under a confidentiality agreement all
such information to Third Parties solely for purposes of allowing Innate to assess the feasibility of such Third Parties Manufacturing the CD39 Option Product and to allow such Manufacturing, provided that, such Third Parties shall be subject to
confidentiality obligations no less stringent than those set out in Section 11. During the Tech Transfer Period, the Parties shall cooperate to obtain all necessary assurances and cooperation from any Third Party contract manufacturers of the
CD39 Option Product with respect to the foregoing material transfer activities. MedImmune covenants to Innate that any Third Party agreements under which MedImmune engages such Third Party to Manufacture the CD39 Option Product contain provisions
regarding the allocation of Intellectual Property Rights and to perform its rights. If MedImmune has not exercised the CD39 Option, at Innate’s request, after the expiry or termination of the CD39 Option until the earlier of: (i) the
completion 

  
 81 

 CD39 OPTION 
  

 

	 	 
of the technology transfer under this Section 17.3; and (ii) the second (2nd) anniversary of the date of the expiry or termination of the CD39 Option Period, MedImmune shall continue
the manufacturing and testing of the requirements of the CD39 Option Product of Innate in the form of drug substance, drug product and finished product, pursuant to a service and supply agreement at reasonable terms and conditions consistent with
the biotechnology industry practices, which will be negotiated in good faith by the Parties. Innate shall use diligent efforts to cease reliance on MedImmune to supply and test such CD39 Option Product, and to procure that such manufacturing and
testing shall be transferred to Innate or its contract manufacturer as soon as reasonably practicable, and shall keep MedImmune reasonably informed and updated of such efforts and plans. 

 

	17.4	 If MedImmune has not exercised the CD39 Option by the date of expiry or termination of the CD39 Option, and if at the
time of such expiry or termination any MedImmune Collaboration Study has been initiated but not yet completed, then the Parties shall work together in good faith to ensure that MedImmune’s involvement in and responsibilities for such activities
will be discontinued and ceased as efficiently and promptly as possible (by way of transitioning such involvement and responsibilities to Innate or by other means agreed to by the Parties), subject to Applicable Laws, including GCP.

  

	 	18	 ASSIGNMENT; SUCCESSOR; SUBCONTRACTING 

Neither Party may assign any of its rights or obligations under this Agreement in any country in whole or in part without the prior
written consent of the other Party, except that each Party shall have the right, without such consent, (i) to perform any of its obligations and exercise any of its rights under this Agreement through, and to assign all of its rights and
obligations under this Agreement to, any of its Affiliates; and (ii) on written notice to the other Party, to assign all of its rights and obligations under this Agreement to a non-Affiliate successor in
interest, whether by merger, consolidation, reorganization, acquisition, stock purchase, asset purchase or other similar transaction, to all or substantially all of the business to which this Agreement relates. In the event that a Party performs its
obligations or exercises its rights under this Agreement through an Affiliate or assigns its rights and obligations to an Affiliate as permitted under this Section 18, doing so shall not 

  
 82 

 CD39 OPTION 
  

 

 
relieve the relevant Party of its responsibilities for the performance of its obligations under this Agreement, and the relevant Party shall remain responsible for the performance by its
Affiliates and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance). This Agreement shall survive any succession of interest permitted pursuant to this Section 18, whether by merger,
consolidation, reorganization, acquisition, stock purchase, asset purchase or other similar transaction, provided, that, in the event of such merger, consolidation, reorganization, acquisition, stock purchase, asset purchase or other similar
transaction, no Intellectual Property Rights of the acquiring corporation and its Affiliates (other than a Party and its Affiliates prior to such acquisition) shall be included in the technology licensed hereunder, unless such Intellectual Property
Rights arise as a result of the performance of this Agreement by such corporation after such transaction becomes effective. 
 Innate
may not subcontract its obligations with respect to any Development activity assigned to it under the Development Plan to any Third Party apart from a CRO, and any such subcontracting shall not relieve Innate of any of its obligations under this
Agreement, and Innate shall remain responsible for the performance of its obligations under and in accordance with this Agreement. 
  

	 	19	 ANTI-CORRUPTION LAWS 

 

	19.1	 Both Parties shall ensure that in connection with this Agreement, they shall conduct their activities in a manner that
is consistent with the Anti-Corruption Laws. Each Party further undertakes that none of its or its Affiliates’ employees, directors or officers shall, directly or indirectly, engage in any activities that violate any Anti- Corruption Law
(a) in order to influence official action of any Government Official, or (b) with the intention of or as a condition to inducing any person to carry out a duty or function improperly or to reach a favourable decision on an improper basis,
in each case in connection with the activities contemplated under this Agreement. 

  

	19.2	 Innate shall promptly provide MedImmune with written notice of (a) becoming aware of a Material Anti-Corruption
Law Violation by it or any of its or its Affiliates’ employees, directors or officers with respect to the subject matter of this Agreement, or (b) upon receiving a formal notification that it or any of its or its

  
 83 

 CD39 OPTION 
  

 

	 	 
Affiliates’ employees, directors or officers is the target of a formal investigation by any Governmental Body for a Material Anti-Corruption Law Violation. 

 

	19.3	 Innate acknowledges that its undertakings given in this Section 19.3 are material to MedImmune in entering into
this Agreement. Notwithstanding any other provision of this Agreement, if MedImmune becomes aware of what it determines, acting reasonably, to be a breach of these undertakings, then MedImmune shall be entitled to terminate this Agreement in its
entirety and to terminate any other agreement between the Parties, on notice with immediate effect. Subject to the accrued rights of the Parties pursuant to termination, MedImmune shall have no liability to Innate for any fees, reimbursements or
other compensation or for any loss, cost, claim or damage resulting, directly or indirectly, from such termination. At the sole discretion of MedImmune, any breach of an Innate obligation with respect to its obligation in this Section 19.3 may
be cured (if capable of being cured) within a reasonable period of time after learning of such material breach or Material Anti-Corruption Law Violation. 

  

	 	20	 GOVERNING LAW AND ARBITRATION 

 

	20.1	 Governing Law. The interpretation and construction of this Agreement (including
non-contractual disputes and the arbitration clause set out in Section 20.2) shall be governed by the laws of England and Wales excluding any conflicts or choice of law rule or principle that might
otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. 

  

	20.2	 Arbitration. Any dispute arising out of or in connection with this Agreement, including any question regarding its
existence, validity or termination, shall be referred to and finally resolved by arbitration under the Arbitration Rules of the International Chamber of Commerce (ICC), which Rules are deemed to be incorporated by reference into this clause. One or
more arbitrators shall be appointed in accordance with the said Rules. The seat, or legal place, of arbitration shall be London. The language to be used in the arbitral proceedings shall be English. 

  
 84 

 CD39 OPTION 
  

 

	 	21	 NOTICES 

Any notice, request, or other communication permitted or required under this Agreement shall be in writing, shall refer specifically to
this Agreement, and shall be deemed given only if hand delivered, sent by an internationally recognised overnight delivery service, costs prepaid, or sent by email (providing such email is read receipted and such notice is also despatched by an
internationally recognised overnight delivery service, costs prepaid, on same day) to the Party to whom notice is to be given at the following address (or at such other address such Party may have provided to the other Party in accordance with this
Section 21): 
 If to MedImmune: 

MedImmune LLC 
 One
MedImmune Way 
 Gaithersburg 

MD 20878 
 USA 

[***] 
 with a copy
(which shall not constitute effective notice) to: 
 [***] 

and with a copy (which shall not constitute effective notice) to: 

  
 85 

 CD39 OPTION 
  

 

 [***] 

If to Innate: 

Address: 
 Innate
Pharma S.A. 
 17, Avenue de Luminy - BP 30191 

13276 Marseille Cedex 09 FRANCE 

[***] 
 Such
notice, shall be deemed to have been given as of the date delivered by hand, or on the second business day (at the place of delivery) after deposit with an internationally recognised overnight delivery service, whichever is the earlier. 

 

	 	22	 WAIVER 

A Party’s failure to enforce, at any time or for any period of time, any provision of this Agreement, or to exercise any right or
remedy shall not constitute a waiver of that provision, right or remedy or prevent such Party from enforcing any or all provisions of this Agreement and exercising any rights or remedies. To be effective any waiver must be in writing. 

  
 86 

 CD39 OPTION 
  

 

	 	23	 SEVERABILITY 

If any provision of this Agreement is held to be invalid, illegal or unenforceable, in any respect, then such provision will be given
no effect by the Parties and shall not form part of this Agreement. To the fullest extent permitted by Applicable Law and if the rights and obligations of a Party will not be materially and adversely affected all other provisions of this Agreement
shall remain in full force and effect and the Parties will use all reasonable efforts to negotiate a provision in replacement of the provision held invalid, illegal or unenforceable that is consistent with Applicable Law and achieves, as nearly as
possible, the original intention of the Parties. To the fullest extent permitted by Applicable Law, the Parties waive any provision of law that would render any provision in this Agreement invalid, illegal or unenforceable in any respect. 

 

	 	24	 FURTHER ASSURANCE 

Each Party shall perform all further acts and things and execute and deliver such further documents as may be necessary or as the other
Party may reasonably require to implement or give effect to this Agreement. 
  

	 	25	 ENTIRE AGREEMENT 

This Agreement, including without limitation all schedules attached hereto, constitutes the entire agreement between the Parties with
respect to the subject matter of the Agreement. This Agreement supersedes all prior agreements, whether written or oral, with respect to the subject matter of the Agreement. Each Party confirms that it is not relying on any representations,
warranties or covenants of the other Party except as specifically set out in this Agreement. Nothing in this Agreement is intended to limit or exclude any liability for fraud. All Schedules referred to in this Agreement are intended to be and are
hereby specifically incorporated into and made a part of this Agreement. In the event of any inconsistency between any such Schedules and this Agreement, the terms of this Agreement shall govern, provided that upon the entry into force of a License
Agreement the terms of the License Agreement shall govern the Parties’ relationship with respect to the subject matter of the License Agreement. 

  
 87 

 CD39 OPTION 
  

 

	 	26	 AMENDMENT 

Any amendment or modification of this Agreement must be in writing and signed by authorised representatives of both Parties. 

 

	 	27	 COUNTERPARTS 

This Agreement may be executed in any number of counterparts, each of which shall be deemed an original and all of which taken together
shall be deemed to constitute one and the same instrument. 
  

	 	28	 NO PARTNERSHIP 

It is expressly agreed that the relationship between Innate and MedImmune shall not constitute a partnership, joint venture, or agency.
Neither Innate nor MedImmune shall have the authority to make any statements, representations, or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior consent of such other Party to do so. 

[Signature page overleaf] 

  
 88 

 CD39 OPTION 
  

 

 THIS AGREEMENT IS EXECUTED by the authorised representatives of the Parties as of the date first
written above. 

					
	 SIGNED for and on behalf of
	  	                	  	SIGNED for and on behalf of
			
	 Innate Pharma S.A.
	  		  	MedImmune Limited
			
	  
	  		  	  

			
	 Signature
	  		  	 Signature

			
	  
	  		  	  

			
	 Name
	  		  	 Name

			
	  
	  		  	  

			
	 Title
	  		  	 Title

  

  
 89 

 CD39 OPTION 
  

 

 SCHEDULES OPTION CD 39 
  

			
	 Schedule 1.12

 
	  	CD39 Back-Ups
	 Schedule 1.80

 
	  	License Agreement
	 Schedule 1.81

 
	  	CD39 Option Listed Patents
	 Schedule 1.135

 
	  	Third Party Agreements
	 Schedule 4.13

 
	  	Total Reimbursement Costs
	 Schedule 14.2 (a) (i)

 
	  	Owned Patents
	 Schedule14.2 (a) (ii)

 
	  	Exclusively Licensed Patents
	 Schedule 14.2 (a) (iii)

 
	  	Non-Exclusively Licensed Patents
	 Schedule 14.2 (a) (iv)

 
	  	Owned and Licensed Know-How

  

 SCHEDULE 1.12 

CD39 BACK-UPS 

[***] 

 SCHEDULE 1.80 

LICENSE AGREEMENT 
 See attachment 

[***] 

  
 59 

 SCHEDULE 1.81 

LISTED PATENTS 
 [***] 

 SCHEDULE 1.135 

THIRD PARTY AGREEMENTS 
 [***] 

 Schedule 4.13 

Total Reimbursement Costs 
 [***] 

  

 SCHEDULE 14.2 (a) (i) 

OWNED PATENTS 
 [***] 

  

 SCHEDULE 14.2 (a) (ii) 

EXCLUSIVELY LICENSED PATENTS 
 [***]

  

 SCHEDULE 14.2 (a) (iii) 

NON-EXCLUSIVELY LICENSED PATENTS 

[***] 

  

 SCHEDULE 14.2(a)(iv) 

OPTION KNOW-HOW 

[***]EX-10.4

 Exhibit 10.4 

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 
 JOINT RESEARCH, DEVELOPMENT, OPTION AND LICENSE 

AGREEMENT 
 This Joint Research,
Development, Option and License Agreement, made and effective as of March 28, 2006 is entered into by and between Novo Nordisk A/S (CVR-no. 24 25 67 90), a corporation existing under the laws of
Denmark and having its principal place of business at Novo Allé, 2880 Bagsvaerd, Denmark (hereinafter NN), and Innate Pharma SA, a corporation existing under the laws of France and having its principal place of business at Grand
Pré – 119/121, ancien chemin de Cassis, 13009 Marseille, France (hereinafter IPH); NN and IPH hereinafter are also referred to individually as “Party” and collectively as “Parties”. 

WITNESSETH 
  

			
	WHEREAS	  	NN is a pharmaceutical company with expertise in the discovery and global development of protein drugs;
		
	WHEREAS	  	IPH is a biotech company with expertise in the discovery and development of drugs and other types of therapy acting at non-conventional lymphocytes such as gamma delta T cells and natural
killer (NK) cells;
		
	WHEREAS	  	IPH Controls certain Intellectual Property Rights, and possesses research and development skills, in respect of neutralizing monoclonal antibodies;
		
	WHEREAS	  	NN Controls certain Intellectual Property Rights relating to the expression, purification, production, and formulation of proteins;
		
	WHEREAS	  	NN has research and development skills which NN believes may enable it to further develop pharmaceutical products for human therapeutic, as well as potential diagnostic or prophylactic, use utilizing Intellectual Property Rights
Controlled by IPH;
		
	WHEREAS	  	The Parties have previously entered into a collaboration governed by an agreement entitled “Research, Development and Licence Agreement” with an effective date of September 30, 2003 (the “Kirostim
Agreement”) in respect of receptors KIR 2DL1 and KIR 2DL2/3 and wish to expand that collaboration by entering into a strategic collaboration in the Collaboration Field under which IPH and NN will work, independently, jointly, and/or
together with agreed-upon Third Parties, to (a) discover or identify Drug Candidates, and (b) optimize Drug Candidates for progression to (i) Licensed Products for further development and commercialization by NN, or (ii) Niche
Candidates for further development and commercialization by NN or IPH, for all uses and purposes, including therapeutic, prophylactic and, except as otherwise expressly herein provided, diagnostic uses; and

			
	WHEREAS	  	Each Party desires to obtain from, and is willing to grant to the other, such licenses and sublicenses to specified Intellectual Property Rights Controlled by it as are necessary or useful to enable NN and IPH to exercise their
rights and perform their obligations hereunder, on the terms set out in this Agreement;
	
	NOW, THEREFORE,
		
		  	in consideration of the foregoing premises, the mutual promises and covenants set forth in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, NN and IPH, each
intending to be legally bound, hereby agree as follows:

  

	1.	 DEFINITIONS AND CONSTRUCTION 

 

	 	1.1	 Definitions. When used in this Agreement, the following capitalized terms shall have the meanings set
forth in this Section 1.1, unless the express provisions or context of their use herein clearly otherwise require: 

  

	 	1.1.1	 “Additional Kirostim Field” shall mean any human therapeutic, prophylactic or diagnostic
indications outside the Kirostim Field. 

  

	 	1.1.2	 “Affiliates” shall mean (a) any Person which directly or indirectly owns, is owned by or
is under common ownership with a Party to this Agreement to the extent of more than fifty percent (50%) of the equity (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) having
the power to vote on or direct the affairs of the entity, and (b) any Person actually controlled by, controlling or under common control with such Party. For purposes of this definition and Section 20.4, the terms “controlled
by”, “controlling” and “under common control with”, with respect to any Person, shall mean the possession, directly or indirectly, of the power or ability to direct or cause the direction of the management or policies of
that Person, or otherwise direct the affairs of such Person, whether through the ownership of equity participation, voting securities, beneficial interest, by contract relating to voting rights or corporate governance, or otherwise.

  

	 	1.1.3	 “Agreement” shall mean this Joint Research and Development, Option and License Agreement,
including all recitals and schedules hereof, which are hereby incorporated and made part of this Agreement. 

  

	 	1.1.4	 “Anti-KIR” shall mean ***. 

 

	 	1.1.5	 “Background IPH IPR” shall mean any IPR in the Collaboration Field other than the
Collaboration IPR that is necessary or useful for Commercial Optimization and is as of the date of this Agreement Controlled by IPH or any of its Affiliates with the exception of ***. All Patents within the Background IPH IPR as of the date of this
Agreement are identified and listed in the annexed Schedule 1.1.5 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 2 

	 	
(all currently known Patents within Background IPH IPR other than Background IPH Research Technology IPR) or Schedule 1.1.6 (all currently known Patents within significant Background IPH
Research Technology IPR). 

  

	 	1.1.6	 “Background IPH Research Technology IPR” shall mean the IPR identified and listed in the
annexed Schedule 1.1.6. 

  

	 	1.1.7	 “Background NN IPR” shall mean the IPR in the Collaboration Field comprised of the Patents
identified and listed in the annexed Schedule 1.1.7. In addition, if NN shall determine or IPH shall notify and demonstrate at any time during the Term that other or additional IPR (other than Collaboration IPR) Controlled by NN or its
Affiliates as of the date of this Agreement and the date of such determination or notification is necessary for IPH’s development or commercialization of a Niche Candidate, Licensed Candidate, or Residual Product authorized for IPH’s
development and commercialization under the terms of this Agreement, then (a) such IPR shall be included in the Background NN IPR (effective as of the date of such determination), and (b) Schedule 1.1.7 shall be updated accordingly,
and (c) neither Party shall have, with respect to such IPR, any liability or obligation to the other during, arising out of, or relating to the period prior to the date of such determination. Should the Parties fail to agree with respect to
such determination or demonstration, the matter shall be decided in accordance with Section 21.14. 

  

	 	1.1.8	 “Background NN Research Technology IPR” shall mean IPR identified and listed in the annexed
Schedule 1.1.8. 

  

	 	1.1.9	 “Backup Product” shall mean any Drug Candidate comprised of, modulating, interacting with, or
derived from the same Collaboration Target as another Drug Candidate (including any Licensed Product) comprised of, modulating, interacting with, or derived from the same Collaboration Target. The adoption of an alternative to or replacement of any
Drug Candidate may be due to factors that include such alternative’s or replacement’s possession of a better drug profile than the prior Drug Candidate, or toxicity issues, formulation problems, lack of efficacy, safety issues or any other
factor having an adverse effect upon the ability to effectively develop or commercialize such prior Drug Candidate with the exercise of Commercially Reasonable Efforts. For the avoidance of doubt, no Drug Candidate comprised of, modulating,
interacting with or derived from NKG2A shall be a Backup Product for Anti-KIR. 

  

	 	1.1.10	 “Biological Target” shall mean any molecular structure, including any protein (such as any NK
cell or NK target cell receptor or receptor fragment), any lipid or any glycolipid, or any fragment or derivative of any of the foregoing, such molecular structure being a target for any molecule with pharmaceutical activity. For purposes of
illustration, and not limitation, such molecules with pharmaceutical activity include, but are not limited to, antibodies, soluble receptors and other proteins, and any fragments or derivatives of any thereof, and any small molecule.

  
 3 

	 	1.1.11	 “Class A Licensed Products” shall mean Licensed Products comprised of,
modulating, interacting with, or derived from the Collaboration Targets identified in the annexed Schedule 1.1.11. 

  

	 	1.1.12	 “Class B Licensed Products” shall mean Licensed Products comprised of,
modulating, interacting with, or derived from any of the Collaboration Targets identified in the annexed Schedule 1.1.12, as the same may be amended from time to time by written agreement of the Parties or pursuant to the terms of this
Agreement. Class B Licensed Products shall not include naturally occurring ligands for Collaboration Targets, or any variants of such ligands, or any derivatives of such ligands or variants, or antibodies to such ligands, except in the case
that the Background IPH IPR comprises a Valid Claim that would be infringed by the manufacture, use, sale, offer for sale, importation, or exportation of such ligand, variant, derivative, or antibody. 

 

	 	1.1.13	 “Class C Licensed Products” shall mean Licensed Products comprised of,
modulating, interacting with, or derived from any of the Collaboration Targets identified in the annexed Schedule 1.1.13 as the same may be updated or otherwise amended from time to time by written agreement of the Parties, and shall include
any other Licensed Products that are not Class A Licensed Products or Class B Licensed Products pursuant to the terms of this Agreement. 

  

	 	1.1.14	 “Collaboration” shall mean the Parties’ collective enterprise during the Collaboration
Term pursuant to this Agreement to: 

  

	 	(a)	 research, discover and identify Biological Targets in the Collaboration Field (as hereinafter defined) as
Collaboration Targets and further develop and progress such Collaboration Targets themselves or ligands or other molecules, compositions or formulations that interact with such Collaboration Targets to Drug Candidates in accordance with the Target
Discovery Plan; and 

  

	 	(b)	 conduct additional and other research and development to optimize such Drug Candidates and further develop and
progress them to M1 status in accordance with the Drug Discovery Plan. 

  

	 	1.1.15	 “Collaboration Field” shall mean any projects, activities, biological materials (including
Biological Targets), Know-How (including Materials and Research Technology), IPR and other subject matter the use of which can result inthe modulation of the activity of isolated NK cells (for example
resulting in the modulation of the production of cytokine or in the modulation of any biological (including any cell-regulatory) activity of NK cells), as observable in a bioassay comprising only purified NK cells or NK cell lines, with or

  
 4 

	 	
without any target cells, such modulation being triggered by the binding of any ligand or molecule to any of the cell surface receptors expressed on NK cells or to any of their ligands. These
include, but are not limited to: 

  

	 	  	 *** 

  

	 	(f)	 the NK cell surface receptors and ligands thereof identified as Collaboration Targets, including but not
limited to those listed in Schedule 1.1.11; 1.1.12 or 1.1.13, as well as other potential targets discovered during the course of the Collaboration, including new NK cell surface receptors and ligands thereof; 

 

	 	  	 and the use of any of the foregoing (in each case (a) through (f)), for any purpose, including any
prophylactic, diagnostic or therapeutic use or purpose. 

 Subject Matter Not Included in the Collaboration Field.
Notwithstanding any other provision of this Agreement, unless the Parties shall otherwise hereafter expressly agree in writing, the Collaboration Field shall not include any: 
  

	 	(i)	 *** 

  

	 	(ii)	 *** 

  

	 	(iii)	 *** 

  

	 	(iv)	 *** 

  

	 	(v)	 *** 

  

	 	(vi)	 *** 

  

	 	(vii)	 *** 

  

	 	1.1.16	 “Collaboration IPR” shall mean IPR (including Collaboration
Know-How) that is: 

  

	 	(a)	 generated or acquired (by assignment, license or otherwise) by or on behalf of either or both of the Parties or
their Affiliates during the Collaboration Term and (i) is in the Collaboration Field or (ii) originates from activities undertaken in the Collaboration Field (regardless of whether such IPR is in or outside the Collaboration Field), or

  

	 	(b)	 expressly identified in, or identified or developed pursuant to, any of the Collaboration Plans, and is
generated or acquired (by assignment, license, or otherwise) during the *** period following the expiry or earlier termination of the Collaboration Term; 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 5 

 by or on behalf of either or both of the Parties and includes the IPR listed in Schedule
1.1.16. 
  

	 	1.1.17	 “Collaboration Know-How” shall mean Know-How generated or acquired during the Collaboration Term by either or both of the Parties or their Affiliates and shall include such Know-How that is recorded in the
records of the Joint Steering Committee or the Development and Commercialization Committee. For the avoidance of doubt Collaboration Know-How includes but is not limited to that
Know-How listed in Schedule 1.1.17, which Schedule shall amended or updated from time to time by the Joint Steering Committee. 

 

	 	1.1.18	 “Collaboration Patent” shall mean any Patent within the Collaboration IPR.

  

	 	1.1.19	 “Collaboration Plans” shall mean the Target Discovery Plan or Drug Discovery Plan.

  

	 	1.1.20	 “Collaboration Research Goal” shall mean ***. 

 

	 	1.1.21	 “Collaboration Research Technology IPR” shall mean any IPR within the Collaboration IPR
that is solely in respect of Research Technology. 

  

	 	1.1.22	 “Collaboration Targets” shall mean the Biological Targets listed in Schedule 1.1.22 as
may be updated or amended by the joint Steering Committee pursuant to Article 4. 

  

	 	1.1.23	 “Collaboration Term” shall mean ***. For the avoidance of doubt, unless otherwise expressly
provided, all references in this Agreement to acts, events or occurrences taking place within a specified period after the expiration or earlier termination of the Collaboration Term shall mean the Collaboration Term excluding the aforementioned, or
any other, additional holdover negotiation period. 

  

	 	1.1.24	 “Collaboration Year” shall mean such annual period during the Collaboration Term as commences
upon the date of this Agreement (“Collaboration Year 1”) or upon the anniversary of the date of this Agreement (“Collaboration Year 2”, ”Collaboration Year 3”, etc.). 

 

	 	1.1.25	 ”Combination Product” means any Licensed Product, Niche Candidate or Residual Product that
(a) is incorporated in a physical admixture with one or more other pharmacologically active ingredients that do not constitute Licensed Products, Niche Candidates or Residual Products, (b) is contained separately but marketed as a unit
with one or more other pharmacologically active ingredients that do not constitute Licensed Products, Niche Candidates or Residual Products, or (c) is incorporated in a physical admixture with, or contained separately but marketed as a unit
with, 

  
 Certain information has been excluded from this agreement
(indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 6 

	 	
one or more other Licensed Products, Niche Candidates or Residual Products, the Net Sales of which require the payment of a different royalty rate than the Licensed Product, Niche Candidate or
Residual Product with which they are combined or otherwise sold (by reason of different Product Class categorization under Subsections 1.1.11; 1.1.12 or 1.1.13, different applicable Scenarios pursuant to Section [7.8, or
otherwise under the terms of this Agreement). 

  

	 	1.1.26	 “Commercial Optimization” shall mean the optimal effectiveness, productivity or success of the
Collaboration, including with respect to 

  

	 	(a)	 the execution of any Pre-project, Project, Target Discovery Plan or
Drug Discovery Plan (including any project undertaken pursuant to such plans); 

  

	 	(b)	 the identification, discovery, development or commercialization of any Collaboration Targets, Drug Candidates,
Licensed Products, Niche Candidates or Residual Products (including, in each case, with respect to any assessment, testing, manufacturing, pre-clinical or clinical development or use, or FDA, EMEA or other
regulatory authority application, submission, authorization or approval with respect thereto; 

  

	 	(c)	 the generation or acquisition of IPR by or on behalf of either or both of the Parties or any of their
respective Affiliates (including any rights in respect of any Know-How, Research Technology or Patents) with respect to any of the foregoing, or the prosecution, maintenance or enforcement of any such rights
of either or both Parties or any of their respective Affiliates with respect thereto; or 

  

	 	(d)	 the exercise of any rights or licenses, performance of any obligations, or conducting of any other activities
authorized or required by this Agreement. 

  

	 	1.1.27	 “Commercially Reasonable Efforts” shall mean such commercially reasonable efforts as are
consistent with the efforts that a comparable Third Party in the pharmaceutical industry would employ for other products or, where applicable, IPR, of a similar strategic importance and commercial value. 

 

	 	1.1.28	 “Confidential Information” shall mean the specific terms of this Agreement or the Kirostim
Agreement and any of the following that are, or have been, received or otherwise obtained by a Party or its Affiliate (the ”Receiving Party”) directly or indirectly, from the other Party or the other Party’s Affiliate (the
”Disclosing Party”) at any time in connection with the Parties’ discussions and negotiations pertaining to this Agreement or upon or after the Effective Date hereof, and that comprise or regard the existing or prospective
Intellectual Property Rights, products, business, assets or objectives of the Disclosing Party, or any item or aspect thereof: 

  
 7 

	 	(i)	 Know-How, Materials and unpublished Patents (including any claims or
other contents of such Patents); 

  

	 	(ii)	 any other knowledge, concepts, ideas, information or data; 

 

	 	(iii)	 any tangible embodiments of any of the foregoing items referred to in (i) or (ii), including any
biological materials; or 

  

	 	(iv)	 any other tangible or intangible matter comprising, regarding or reflecting the Disclosing Party’s
existing or prospective Intellectual Property Rights, products, business, assets or objectives, in each case ((i) through (iv)) whether or not the items referred to are patentable. 

For the avoidance of doubt, Confidential Information shall include, without limitation, any such
Know-How, Materials, information or other matter so received or obtained by the Receiving Party as comprises or regards the Disclosing Party’s existing or prospective:
pre-clinical, clinical or other research (including any associated plans, practices, processes, protocols, data or results); discoveries or inventions; scientific, manufacturing, marketing, financing, business
or product research, developments, opportunities, plans, methods, processes or procedures; quality controls; security controls; unpublished cost, price or pricing information; financial or personnel matters; or customer, client or supplier lists or
information. 
 Notwithstanding the foregoing, Confidential Information shall not include Know-How,
information or other matter that the Receiving Party can prove by ***: 
  

	 	(a)	 was known or used by the Receiving Party prior to its date of receipt or procurement by the Receiving Party
directly or indirectly from the Disclosing Party; or 

  

	 	(b)	 either before or after the date of the receipt or procurement by the Receiving Party is lawfully disclosed to
the Receiving Party by sources other than the Disclosing Party rightfully in possession of such information or other matter and not bound by confidentiality obligations to the Disclosing Party; or 

 

	 	(c)	 either before or after the date of the receipt or procurement by the Receiving Party is or becomes published or
otherwise is or becomes part of the public domain through no breach hereof on the part of the Receiving Party; or 

  

	 	(d)	 is independently developed by or for the Receiving Party without reference to or reliance upon the Confidential
Information of the Disclosing Party as demonstrated by written records. 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 8 

	 	1.1.29	 “Control”, ”Controlled”, ”Controls” and
”Controlling” shall mean, with respect to any tangible or intangible subject matter, including, without limitation, any IPR, the possession of the legal right, power and ability (whether by ownership, license or otherwise) to grant
any access to, possession or use of, or assignment, license, sublicense or other authorization or right with respect to or under, such Intellectual Property Rights or other subject matter as provided for in this Agreement (independently and other
than by reason of any license, sublicense, consent or authorization by the other Party or any Affiliate of the other Party), without violating any applicable Law, agreement or arrangement, or other enforceable obligation, existing and in effect at
the time of such grant. 

  

	 	1.1.30	 “Drug Candidate” shall mean any molecule or precursor to any molecule, or any composition or
formulation of any molecule or of any precursor to any molecule, which is comprised of, modulates, interacts with, or derived from any Collaboration Target or of any ligand thereof, in the Collaboration Field. 

 

	 	1.1.31	 “Drug Discovery Plan” shall mean the Parties’ joint research plans for individual
projects in the Collaboration Field that involve Drug Candidates, in respect of one or more indications, that are post-M0 but pre-M1 and are to be actively pursued by
IPH and NN as set forth in the annexed Schedule 1.1.31 or in any update or amendment to such Schedule as may hereafter be directed by the Joint Steering Committee pursuant to the terms and conditions of this Agreement. 

 

	 	1.1.32	 “Effective Date” shall mean September 30, 2003. 

 

	 	1.1.33	 “Exploratory Targets” shall mean the Biological Targets identified in Schedule 1.1.33 and any
other Biological Targets that the Joint Steering Committee finds to be of sufficient potential interest for identification, study or assessment or future identification, study or assessment in the Collaboration and are subsequently added to Schedule
1.1.33 after the date of this Agreement. 

  

	 	1.1.34	 “Ex-vivo Cellular Therapy Candidate” shall mean any
specific molecule, composition or formulation that is hereafter classified for Independent further development for use in an ex-vivo setting pursuant to the terms and conditions of such Ex-Vivo Task Force guidelines as may hereafter be agreed to by the Parties in accordance with Section 6.2. 

  

	 	1.1.35	 “First Commercial Sale” shall mean, on a country-by-country basis, the first date that a Licensed Product, Niche Candidate or Residual Product is sold or in any other way made commercially available for marketing in such country by a Party or
any of its Affiliates or Out-licensees after having obtained the applicable regulatory marketing authorization approval. First Commercial Sales shall not include any not-for-profit disposition for charitable, promotional, pre-clinical, clinical, regulatory or governmental purposes. 

  
 9 

	 	  	 For the avoidance of doubt, (a) any reference in this Agreement to the First Commercial Sale of a product
for a specified indication shall mean solely the First Commercial Sale of such product for the specified indication; and (b) any reference herein to a First Commercial Sale as a Development Milestone shall mean a
one-time event comprised of the First Commercial Sale in any country in the Territory, such that NN shall be required to pay the specified Development Milestone amount no more than once irrespective of the
number of countries in which such First Commercial Sale is ultimately achieved. 

  

	 	1.1.36	 “Force Majeure” shall mean any event or circumstance which intervenes after the Effective Date
and is beyond the control of the affected Party or other Person rendering performance hereunder and which could not reasonably have been foreseen and not reasonably prevented by that Party or other Person and which results in or causes the failure
of that Party to perform any or all of its obligations under this Agreement. 

  

	 	1.1.37	 “Independent IPH IPR” shall mean such IPR in the Collaboration Field as is generated or
acquired (by assignment, license or otherwise) by IPH or any of its Affiliates (other than such IPR generated or acquired by any Third Party prior to it becoming an Affiliate of IPH): 

 

	 	(a)	 at any time during the portion of the Collaboration Term commencing upon the date of this Agreement; or

  

	 	(b)	 within the period of *** following immediately after the expiration or termination of the Collaboration Term;

  

	 	  	 that is not within the Collaboration IPR but is Controlled by IPH or any of its Affiliates and is necessary or
useful for Commercial Optimization of Licensed Products, Niche Candidates, or Residual Products. 

  

	 	1.1.38	 “Independent IPR” shall mean Independent IPH IPR or Independent NN IPR. 

 

	 	1.1.39	 “Independent NN IPR” shall mean such IPR in the Collaboration Field as (a) is generated
or acquired (by assignment, license or otherwise) by NN or any of its Affiliates (other than such IPR generated or acquired by any Third Party prior to it becoming an Affiliate of NN) at any time during the portion of the Term commencing upon the
date of this Agreement, and (b) is not within the Collaboration IPR but is Controlled by NN or any of its Affiliates and is necessary or useful for Commercial Optimization of such Niche Candidates, Residual Products or Licensed Products as IPH
may hereafter become authorized to commercialize pursuant to the terms and conditions of this Agreement. 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 10 

	 	1.1.40	 “Intellectual Property Rights” or ”IPR” shall mean any legally, equitably or
otherwise enforceable right, title or interest (including all rights of authorship and copyrights, provisional and other Patent rights, Trade Secret rights, registered design rights, and rights in databases and data compilations) arising from,
comprising, comprised in, or with respect to any Patents or Know-How. 

  

	 	1.1.41	 “Intermediate Discovery Milestone” shall have the meaning ascribed to it in Schedule
1.1.41. 

  

	 	1.1.42	 “Joint IPR” shall mean Collaboration IPR that is generated by one or more employees, agents,
consultants or other Persons acting on behalf of IPH or any of its Affiliates (acting independently or with one or more Third Parties), on the one hand, and NN or any of its Affiliates (acting independently or with one or more Third Parties), on the
other hand (so as to establish joint inventorship in the case of Patents), or that is otherwise jointly owned by (a) the Parties, (b) a Party and one or more Affiliates of the other Party, or (c) one or more Affiliates of a Party
together with one or more Affiliates of the other Party. 

  

	 	1.1.43	 “Joint Steering Committee” shall mean the committee established pursuant to Article 3.

  

	 	1.1.44	 “Kirostim Agreement” shall mean the Research, Development and License Agreement between IPH
and NN dated September 30, 2003. 

  

	 	1.1.45	 “Kirostim Field” shall mean any human therapeutic, prophylactic or diagnostic
indications in the following fields: 

  

	 	(a)	 *** 

  

	 	(b)	 *** 

  

	 	(c)	 *** 

  

	 	(d)	 *** 

  

	 	1.1.46	 “Know-How” shall mean any ideas, concepts, knowledge,
information, skill, experience, materials (including any Materials), Research Technology, inventions, Trade Secrets or data, whether or not confidential or proprietary, patented or patentable, copyrighted or copyrightable, or in written, electronic
or any other tangible or intangible form, that comprise or relate to, without limitation, discoveries, formulae, algorithms, computer programs, software, specifications, directions, instructions, libraries, biological or other materials including
molecules, manufactures, compounds, 

  
 Certain information has been
excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 11 

	 	
compositions, formulations, reagents or other biological or chemical entities, agents, targets, processes or materials (including, for example, antibodies, specialized tools, data compilations,
data collections or databases, models, designs, drawings, plans, prototypes, practices, methods, processes, procedures, systems, techniques, technologies or means (including high-throughput screening, gene expression, genomics, proteomics,
purification or isolation techniques, antibody generation or characterization techniques or other drug identification, research, discovery or development technologies), identification schemes, test protocols, procedures or results, data generated in
pre-clinical or clinical studies (including pharmacological, toxicological or clinical information or test data), analytical, quality control or quality assurance data, manufacturing, marketing, pricing,
distribution, cost or sales information, data or descriptions. 

  

	 	1.1.47	 “Law” shall mean any law, statute, code, treaty, convention, ordinance, rule, regulation,
judgment, award, order, directive or pronouncement of any domestic, foreign, federal, state, local or other government or governmental organ, agency or subdivision having the binding effect of law. 

 

	 	1.1.48	 “Licensed Product” shall mean any Drug Candidate that has attained *** and has been discovered
or developed, in whole or in part, pursuant to the Collaboration, and shall include, with respect to any such Drug Candidate any Backup Product or Backup Products for such Drug Candidate, and which shall together constitute but a single
”Licensed Product” for purposes of determining the milestone payments payable under Article 7 of this Agreement. For the avoidance of doubt, Anti-KIR shall be a Licensed Product for the
purpose of this Agreement. 

  

	 	1.1.49	 “Material Adverse Effect” shall mean any material adverse effect of any nature or relevance
upon the business, assets, liabilities, rights, privileges, results of operations, business or financial opportunities or prospects, or financial condition of, the affected Party or any of its Affiliates, or the ability of the Party to exercise its
rights, fulfill its warranties or perform its obligations under this Agreement or consummate the transactions contemplated hereby, either directly or through permitted other Persons. 

 

	 	1.1.50	 “Materials” shall mean all biological, chemical and other materials in the Collaboration Field
that are (a) contributed by either or both Parties to the other Party or the Parties under the Collaboration; (b) generated or acquired by one or both Parties during the Collaboration Term pursuant to activities conducted pursuant to the
Collaboration, (c) exchanged by the Parties pursuant to the Collaboration, or (d) exchanged between a Party and any Third Party pursuant to activities conducted pursuant to the Collaboration, during the Collaboration Term.

  
 Certain information has been excluded from this agreement
(indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 12 

	 	1.1.51	 “M0” shall have the meaning ascribed to it in the annexed Schedule 1.1.51.

  

	 	1.1.52	 “M1” shall have the meaning ascribed to it in the annexed Schedule 1.1.52.

  

	 	1.1.53	 “Net Sales” shall mean ***. 

 

	 	1.1.54	 “Niche Candidate” shall mean any Drug Candidate or Licensed Product that NN, in the
exercise of its sole discretion, has approved for independent further development by IPH (whether solely or with NN) pursuant to the provisions of Article 6. 

 

	 	1.1.55	 “Out-license” and ”Out-licensing” shall mean such a grant to a Third Party of some or all of the rights and obligations of a Party under this Agreement as includes the grant of a right to sell, have sold or otherwise
commercialize the Licensed Products, Niche Candidates or Residual Products for one or more applications, uses, purposes or indications. “Out-licensor” and ”Out-licensee” shall be construed accordingly. 

  

	 	1.1.56	 “Patent” shall mean any U.S., non-U.S, international
or multinational patent, patent application (petty, provisional, non-provisional and other), or other government-issued indicia of invention or industrial design ownership, including but not limited to
continuations, continuations-in-part, divisionals, continued prosecutions, utility models, extensions (including but not limited to extensions under the U.S Patent Term
Restoration Act, extensions of patents under the Japanese Patent Law, and supplementary protection certificates and any amendments thereof as well as any equivalent or other extensions in other jurisdictions), registrations, renewals, restorations,
confirmations, substitutions and additions thereof and all reissues, validations, revalidations and reexaminations thereof, including any patents issuing therefrom and any foreign counterparts thereof. 

 

	 	1.1.57	 “Person” shall mean any person, organization or entity, whether natural, legal or other,
including any individual, corporation, firm, partnership, limited liability company, joint venture, estate, trust, unincorporated association or governmental entity. 

 

	 	1.1.58	 “Pre-project” shall mean any Collaboration research
project agreed upon by the Joint Steering Committee that both (a) deals with research of a specific idea or concept through target validation and identification of at least one lead compound until achievement of M0 status, and (b) is
included in the Target Discovery Plan; and “Project” shall mean any Collaboration research project agreed upon by the Joint Steering Committee that deals with any bona fide and approved research in respect of a Drug Candidate for
one or more indications between M0 and M1 pursuant to the Drug Discovery Plan. 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 13 

	 	1.1.59	 “Product Class” shall mean any class of Licensed Product referred to in Sections 1.1.11,
1.1.12 or 1.1.13. 

  

	 	1.1.60	 “Project Review” shall mean the *** review of projects in the NN Research and
Development portfolio that take place in the spring and fall of each calendar year. 

  

	 	1.1.61	 “Research Technology” shall mean any process, or any molecule, manufacture, compound,
composition, formulation, reagent or other biological or chemical entity, agent, target or material (including, for example, any antibody), used or usable primarily as a research tool (for example, as a target for screening), as distinguished from
any actual or potential use primarily as a therapeutic, prophylactic, or commercializable diagnostic product. 

  

	 	1.1.62	 “Research Technology IPR” shall mean any IPR in respect of Research Technology. For the
avoidance of doubt, all licenses hereunder with respect to Research Technology IPR authorize use of Research Technology solely as a research tool (as opposed to use as a therapeutic, prophylactic, or commercializable diagnostic product).

  

	 	1.1.63	 “Residual Product” shall mean a Drug Candidate to which: 

 

	 	(a)  	 *** 

  

	 	(i)	 *** 

  

	 	(ii)	 *** 

  

	 	(iii)	 *** 

  

	 	(b)	   *** 

  

	 	(i)	 *** 

  

	 	(ii)	 *** 

  

	 	1.1.64	 “Sub-license” and”Sub-licensing” shall mean the grant of a sub-license to perform some of the rights and obligations under this Agreement but shall not include the grant of a right to
sell, have sold or otherwise commercialize a Licensed Product, Niche Candidate or Residual Product.”Sub-licensor” and”Sub-licensee”
shall be construed accordingly. 

  

	 	1.1.65	 “Target Discovery Plan” shall mean the joint research plans for individual projects in the
Collaboration Field that are in the pre-M0 stage of development and that are to be actively pursued by IPH and NN as set forth in the annexed Schedule 1.1.65 or in any update or amendment to such
Schedule pursuant to Article 4. 

  
 Certain information has
been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 14 

	 	1.1.66	 “Term” shall mean the period commencing upon the Effective Date, and expiring, on a Licensed Product-by-Licensed Product, Niche Candidate-by-Niche Candidate, and Residual
Product-by-Residual Product basis, upon the later to occur of the expiration, on a country-by-country basis, of: 

 

	 	(a)	 the last-to-expire Valid Claim
of all: 

  

	 	(i)	 Collaboration Patents; 

 

	 	(ii)	 Patents within the Background IPH IPR; 

 

	 	(iii)	 Patents within the Background NN IPR; 

 

	 	(iv)	 Patents within the Independent IPH IPR listed in Schedule 9.5.4(a); and 

 

	 	(v)	 Patents within the Independent NN IPR listed in Schedule 9.5.4(b); 

 

	 	  	 that would be infringed by the unlicensed manufacture, use, importation or sale in or into such country of such
Licensed Product, Niche Candidate or Residual Product, or 

  

	 	(b)	 a period of ten (10) years following immediately after the First Commercial Sale of a Licensed Product,
Niche Candidate or Residual Product in the relevant country. 

  

	 	1.1.67	 “Territory” shall mean the entire world, including all countries thereof.

  

	 	1.1.68	 “Third Party” shall mean a Person other than the Parties or their Affiliates.

  

	 	1.1.69	 “Third Party Collaboration” shall mean collaborative work undertaken by independent Third
Parties together with either Party, or both Parties, that (a) exist at the date of this Agreement and 

  

	 	  	 are listed in either Schedule 1.1.69A (NN Collaborations Relevant to this Agreement) or Schedule
1.1.69B (IPH Collaborations Relevant to this Agreement) or (b) that will be established pursuant to the terms and conditions of this Agreement. Third Party Collaborations that are entered into pursuant to the terms and conditions of this
Agreement shall be listed in Schedule 1.1.69C. 

  

	 	1.1.70	 “Third Party IPR” shall mean IPR Controlled by either or both Parties that is acquired (by
assignment, license, or otherwise) from, or that is generated as part of a collaboration with, any Third Party as a result of agreement of the Parties pursuant to Section 3.4. To the extent such IPR is Controlled by a Party, Third Party
IPR in the Collaboration Field shall constitute Collaboration IPR. 

  
 15 

	 	1.1.71	 “Trade Secret” means any idea, information, data, material or other tangible or intangible
matter, including any formula, pattern, compilation, program, device, method, technique, or process, that derives independent economic value, actual or potential, from not being generally known to, and not being readily ascertainable by proper means
by, other Persons who can obtain economic value from its use or disclosure. 

  

	 	1.1.72	 “Upside Revenue” shall mean ***. 

 

	 	1.1.73	 “Valid Claim” shall mean, on a
country-by-country basis, a claim of an issued and unexpired Patent which (a) has not been held permanently revoked, unenforceable or invalid by a decision of a
court or other governmental agency of competent jurisdiction that is unappealable or unappealed within the time allowed for appeal, and (b) has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise. As used
in this Agreement, ”expire,” “expiration” and words of similar effect, when referring to a Valid Claim or Patent shall mean any expiration, revocation, invalidation or other termination of such Valid Claim or Patent, and a Valid
Claim or Patent shall be deemed to expire at 00:00 a.m. on the date of such expiration. 

  

	 	1.2	 Definitions of other terms used in this Agreement: 

 

			
	 Term
	  	Section
	 Affected IPH Persons
	  	9.12
	 Arm’s Length Transaction
	  	1.1.53
	
Buy-In-Option
	  	6.5.1
	 Change of Control
	  	20.2
	 Claim
	  	16.1
	 Clinical Hold
	  	12.7
	 Combination Product
	  	1.1.25
	 Defending Party
	  	9.15
	 Development and Commercialization Committee
	  	4.9
	 Developing Party
	  	12.8
	 Development Milestones
	  	7.3
	 Disclosing Party
	  	1.1.28
	 Discovery Milestones
	  	7.3
	 First Offer
	  	13.3.6(a)
	 FTE
	  	3.9
	 Indemnified Party
	  	16.1
	 Indemnifying Party
	  	16.1
	 IPO
	  	14.2
	 Other Indemnitees
	  	16.1
	 Other Product
	  	1.1.53
	 Parties
	  	Introductory Paragraph
	 Party
	  	Introductory Paragraph

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 16 

					
	 Term
	  	Section	 
	 Product Marks
	  	 	9.17.1	 
	 Project
	  	 	1.1.58	 
	 Project Manager
	  	 	3.12	 
	 Receiving Party
	  	 	1.1.28	 
	 Residual Product
	  	 	1.1.53	 
	 Selling Party
	  	 	1.1.53	 
	 Share Purchase Agreement
	  	 	14.1	(b) 
	 Transfer
	  	 	20.1	 
	 ***
	  	 	5.13	 

  

	 	1.3	 Construction. As used in this Agreement, unless the express terms or context herein clearly require
otherwise: (a) words denoting the singular shall include the plural and vice versa; (b) words denoting the masculine shall include the feminine and vice-versa; (c) words denoting persons shall include bodies corporate and vice-versa;
(d) references to Recitals, Articles, Sections, Subsections and Paragraphs are to recitals, articles, sections, subsections and paragraphs of this Agreement; (e) references to Exhibits, Schedules or Appendices are to exhibits, schedules
and appendices to this Agreement; (f) references to Laws are to such Laws as they may be amended from time to time or to any successor Laws, and references to particular provisions of a Law include any corresponding provisions of any succeeding
Law; (g) references to agreements and contracts shall include any amendments and supplements thereto duly executed from time to time; (h)”include,” “including” and words of similar effect are used in the inclusive sense of
”including, without limitation”; (i) ”or” is used in the inclusive sense of ”and/or”; (j)”any” is used in the sense of ”any and/or all”; (k) section captions and headings are used for convenience of
reference only and shall not affect the interpretation of this Agreement; (l)”herein,” “hereof”, ”hereunder” and words of similar effect refer to the entirety of this Agreement; and (m)”days” refer to calendar
days. The language of this Agreement shall be construed according to its fair meaning and not strictly against either Party. In the event of any translation of this Agreement from its original written expression in English, the original, English
version of this Agreement shall control. 

  

	2.	 NATURE OF AGREEMENT AND PRIVILEGED COMMUNICATIONS 

 

	 	2.1	 Collaboration Exclusivity. Save for only such activities, personnel, resources and facilities of any
Affiliate of a Party that, prior to it’s becoming an Affiliate of such Party, have been made subject to a binding commitment that would conflict with such Affiliate’s performance of the exclusivity requirements set forth in this
Section 2.1, below: 

  

	 	2.1.1	 Exclusivity During Collaboration Term. During the Collaboration Term, the Collaboration shall be
exclusive with respect to all matters in the Collaboration Field and each Party (including each of their respective Affiliates) shall dedicate all its activities, personnel, resources and facilities in the Collaboration Field exclusively to the
Collaboration. 

  
 Certain information has been excluded from this
agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 17 

	 	2.1.2	 Exclusivity Holdover Period. Except as otherwise expressly herein provided, (a) neither Party, nor
any of such Party’s Affiliates, shall undertake or use in the Collaboration Field any such activities, personnel, resources or facilities independently of the Collaboration for *** following the expiry or earlier termination of the
Collaboration Term, and (b) neither Party, nor any of such Party’s Affiliates, shall enter into collaboration with any Third Party in respect of subject matter of any Target Discovery Plan or Drug Discovery Plan for the two years following
the expiry or earlier termination of the Collaboration Term. 

  

	 	  	 For the avoidance of doubt, after the expiration of such *** post-Collaboration Term period, each Party and its
respective Affiliates shall have the right to undertake any activities in the Collaboration Field independently of the Collaboration, whether individually or with any Third Party, including for purposes of the discovery, development or
commercialization of products in the Collaboration Field, subject only to the obligations of such Party and the rights or licenses of the other Party that, by the express terms of this Agreement, survive the expiration or termination of the
Collaboration Term, including, where applicable, the obligation to obtain and provide to the other Party the Third Party rights and licenses necessary to secure the freedom of operation to exercise its rights and licenses hereunder.

  

	 	2.2	 Joint Research Agreement. This Agreement is intended and shall serve, among other things, as a
”joint research agreement” for purposes of Section 103(c) of the U.S. Patent Act, as amended, 35 U.S.C. § 103(c), and the Parties shall render to one another all reasonable assistance and cooperation, including the preparation and
filing of such terminal disclaimers and other documents, required to procure and preserve the protections under said statute. 

  

	 	2.3	 Kirostim Agreement. This Agreement shall supersede and replace the Kirostim Agreement and all amendments
thereto. 

  

	3.	 COLLABORATION 

 

	 	3.1	 Collaboration Objective. The undertaking and objective of the Collaboration, as set out in the
Collaboration Plans, is for each Party individually, jointly with the other Party, or pursuant to one or more approved Third Party Collaborations, to research, discover and identify (i) Biological Targets within the Collaboration Field
as Collaboration Targets, and (ii) ligands and other molecules, compositions, formulations and processes modulating or interacting with such Collaboration Targets, and 

 

	 	(a)	 to further develop and progress such targets, ligands and other agents to Drug Candidates possessing M0 status
as set forth in the annexed Schedule 1.1.51, in accordance with the Target Discovery Plan; 

  

	 	(b)	 to conduct additional and other research and development to optimize such Drug Candidates and further develop
and progress them to M1 status as further set forth in the annexed Schedule 1.1.52, in accordance with the Drug Discovery Plan, in each case in accordance with the terms and conditions of this Agreement; and 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 18 

	 	(c)	 as a result of the foregoing, to enable (i) NN to further develop, and progress Licensed Products for
further development and commercialization exclusively by or on behalf of NN (or its Affiliates or Out-licensees) in accordance with its rights and licenses hereunder, and/or (ii) to license or co-license to IPH pursuant to Article 6, the exclusive or co-exclusive (with NN) right (with the rights to Sub-license and Out-license) to develop and progress such Drug Candidates as may hereafter be approved by NN as Niche Candidates for further development and commercialization. 

 

	 	3.2	 Duration of the Collaboration. The initial duration of the Collaboration shall be for a period of three
(3) years commencing upon the date of this Agreement    In addition: 

  

	 	(a)	 Optional Extensions of the Initial Collaboration Term. Irrespective of whether or not the Parties have
attained the Collaboration Research Goal on or before the third anniversary of the date of this Agreement, NN shall have the right to *** annual extensions of the initial term of the Collaboration, upon notice to be provided to IPH at least ***
prior to the third and fourth anniversaries of the date of this Agreement, respectively, for a maximum extension of two (2) years, subject to the requirement that NN continue to provide to IPH annual research funding during each such annual
extension period of no less than the amount of funding required to be provided by NN during the third year of the Collaboration pursuant to Section 3.13 (which amount shall be adjusted for inflation pursuant to the French INSEE inflation
index effective upon the commencement date of each such annual extension period) and IPH shall dedicate exclusively to the Collaboration, on a full-time basis, the corresponding number of FTEs required by that Section; 

 

	 	(b)	 Option to Discuss New Collaboration During Holdover Negotiation Period. In the event that NN shall
exercise the above renewal option for both annual extension periods, upon notice to be provided by either Party to the other at least *** prior to the expiration of the second such period, the Parties will have *** following the expiration of such
extension period to negotiate in good faith the terms of a new agreement, and for the duration of such negotiation period (and any extension of such period as may be agreed to by the Parties) the Collaboration Term shall be extended and this
Agreement shall remain in full force and effect, provided that, for the avoidance of doubt, NN shall have no research funding obligation to IPH with respect to such post-expiration holdover negotiation period. In the event that the Parties
shall fail to agree in writing to the terms of a new agreement prior to the expiry of such negotiation period, the Collaboration Term shall expire upon the close thereof; 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 19 

	 	(c)	 Revised Objectives for Extended Collaboration. If NN shall cause the initial term of the Collaboration
to be extended for any annual period pursuant to Section 3.2(a), prior to, or within *** after, the commencement of such extension period the Joint Steering Committee shall adopt specific objectives for such extension period in substitution
for the Collaboration Research Goal in accordance with the procedures set forth in Section 4.5, save that the adoption of such objectives for any such extension period shall be subject to the written approval of the senior management of
both Parties; and 

  

	 	(d)	 Failure to Attain Collaboration Research Goal. For the avoidance of doubt, and without limitation of the
Parties’ obligations to exercise Commercially Reasonable Efforts, or of any other obligations under this Agreement or remedies for the material breach thereof, the failure to attain the Collaboration Research Goal, in and of itself, shall not
constitute a breach of this Agreement. 

  

	 	3.3	 Third Party Collaborations. It is the intent of the Parties that IPR and
Know-How in the Collaboration Field that is useful for Commercial Optimization and is acquired (by license, assignment or otherwise) under or generated within any Third Party Collaboration shall be, to the
extent authorized by contract and permitted by applicable law, made available to the other Party as part of the Collaboration, during the Collaboration Term (and throughout the Term in respect of Collaboration IPR arising therefrom).

  

	 	3.3.1	 Duty to Maintain. Except as otherwise agreed to by the Parties, during the Collaboration Term, and to
the extent authorized by contract and permitted by applicable Law, any Party that is also a party to a Third Party Collaboration listed in the annexed Schedules 1.1.69A, 1.1.69B, or 1.1.69C shall use Commercially Reasonable Efforts to
maintain such Third Party Collaboration (including by, at its own expense, renewing any agreement that governs such Third Party Collaboration that may expire) during the Collaboration Term under similar terms to those that exist as of the date of
this Agreement or when such Third Party Collaboration is otherwise added to Schedule 1.1.69C). 

  

	 	  	 In the event that any such Third Party Collaboration is terminated either (a) by breach of the Party or
action of the other party thereto (without reasonable possibility for revival or replacement) or (b) otherwise by approval of the Parties, during the Collaboration Term, the original Party to such terminated Third Party Collaboration shall, to
the extent authorized by contract and permitted by applicable law, use Commercially Reasonable Efforts to promptly provide the other Party with, or assist the other Party in acquiring, the opportunity to enter into a similar Third Party
Collaboration with the other party to such terminated Third Party Collaboration. 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 20 

	 	3.3.2	 Reports on Progress in and Status of Third Party Collaborations. During the Collaboration Term and to
the extent authorized by contract and permitted by applicable Law, a Party to a Third Party Collaboration shall keep the other Party reasonably regularly notified regarding the status and progress of such Third Party Collaboration in respect of
projects in the Collaboration Field (including by reporting such progress in the context of the Joint Steering Committee). 

  

	 	3.3.3	 IPR that is or may be Acquired Under Third Party Collaborations. During the Collaboration Term, and to
the extent authorized by contract and permitted by applicable Law, any Party that is also a party to a Third Party Collaboration listed in the annexed Schedule 1.1.69A, 1.1.69B, and 1.1.69C shall 

 

	 	(a)	 promptly notify the other Party of any IPR in the Collaboration Field arising from such Third Party
Collaboration that is acquired (by license, assignment or otherwise) or generated as party of such Third Party Collaboration, and thereby Controlled by the Party (such IPR shall be, to the extent appropriate, be added to Schedule 1.1.16), and

  

	 	(b)	 in the event that an opportunity to acquire IPR as part of such Third Party Collaboration arises that the Party
to the Third Party Collaboration does not intend to pursue, promptly notify the other Party of such opportunity and provide the other Party with such opportunity in accordance with the provisions of Section 3.4. 

 

	 	3.3.4	 Procedure for New Third Party Collaborations. During the Collaboration Term, the Parties shall enter
into Third Party Collaborations only in accordance with the provisions of Section 3.4. 

  

	 	3.3.5	 Allocation of Pre-project or Project Responsibilities to Third Party
Collaborations. The Parties may, to the extent authorized by contract and permitted by applicable Law, by agreement of the Joint Steering Committee, allocate responsibilities for any Pre-project, Project
or aspect of any such Project or Pre-project to any Third Party Collaboration, in accordance with the terms and conditions of this Agreement. 

 

	 	3.3.6	 Non-interference. Except as provided for herein or otherwise
agreed by the Parties, neither Party shall interfere with any Third Party Collaboration involving the other Party or any prospective renewal or expansion of the same during the Collaboration Term. 

  
 21 

	 	3.3.7	 Third Party Collaboration Materials and Know-How. During the
Collaboration Term, any Party to a Third Party Collaboration shall, to the extent authorized by contract and permitted by applicable Law, make available to the other Party reasonable quantities of any samples of Materials or other Know-How arising from such Third Party Collaboration that may be useful for Commercial Optimization. 

  

	 	3.4	 Presentation of In-Licensing and New Third Party Collaboration
Opportunities. The Parties shall present to the Joint Steering Committee all opportunities that arise during the Collaboration Term to (a) in-license or otherwise acquire Third Party Controlled IPR in
the Collaboration Field or (b) generate or otherwise acquire IPR as part of a collaboration with any Third Party. All such opportunities shall be considered by the Joint Steering Committee on a case-by-case basis. The Parties shall have *** days after a Party’s presentation of such opportunity to decide whether or not to: (a) in-license or otherwise
acquire such IPR as Third Party IPR; or (b) establish a new Third Party Collaboration (which shall be added to Schedule 1.1.69) pursuant to which any IPR licensed or otherwise acquired under or that arises from the Third Party
Collaboration is made accessible to the other Party for the purposes of the Collaboration (any such IPR shall also be considered Third Party IPR and shall be listed in Schedule 1.1.16. The Party presenting such opportunity shall make a full
written disclosure to the other Party of all material facts known by such Party with respect to the subject matter of the proposed opportunity, in such timely fashion as to permit the other Party to make an informed decision as to how to proceed in
respect of such matters. 

  

	 	3.4.1	 Determination of Responsibility for Acquisition of Approved Third Party IPR. If one Party presents such
an opportunity to the Joint Steering Committee, then if the other Party agrees that the Collaboration should take one of the proposed actions, the Parties shall negotiate in good faith, on a case-by-case basis, which Party shall be responsible for negotiation of the relevant Third-Party IPR acquisition (including in-licensing) or collaboration opportunity
as well as whether and in which proportions the responsibility for payment for access to or acquisition of such third-party IPR shall be borne by the respective Parties. 

 

	 	3.4.2	 Impact of Acquired Approved Third Party IPR on Royalty Class. 

 

	 	(a)	 Acquisition by IPH. If the opportunity was presented by IPH and IPH wishes to negotiate and pay for the licensing-in or other acquisition of such Third-Party IPR, or if it is agreed by the Parties that IPH shall negotiate and pay, in whole or in part for the licensing-in or
other acquisition of any such Third-Party IPR, then any product the sale of which for any purpose without a license under such IPR would infringe a Valid Claim of such IPR by virtue of such IPR comprising a Valid Claim covering the product or the
prophylactic, therapeutic, or diagnostic use thereof (as opposed to the production or other use of such product), shall, except where such product already constitutes a Class A Licensed Product, constitute a Class B Licensed Product and
IPH shall be entitled to NN’s payment of the corresponding Class B Licensed Product royalties on Net Sales of such product during the Term in accordance with Section 7.6.2 and in all other events shall be classified as a
Class C Licensed Product; and 

  
 Certain information has been
excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 22 

	 	(b)	 Acquisition by NN. If the opportunity was presented by NN and NN wishes to negotiate and pay for the licensing-in or other acquisition of such Third-Party IPR, or if it is agreed by the Parties that NN shall negotiate and pay, in whole or in part, for the licensing-in or
other acquisition of any such Third-Party IPR, then any product the sale of which for any purpose without a license under such IPR would infringe a Valid Claim of such IPR by virtue of such IPR comprising a Valid Claim covering the product or the
prophylactic, therapeutic, or diagnostic use thereof (as opposed to the production or other use of such product) shall, except where such product already constitutes a Class A Licensed Product or Class B Licensed Product, constitute a
Class C Licensed Product and IPH shall be entitled to NN’s payment of the corresponding Class C Licensed Product royalties on Net Sales of such product during the Term in accordance with Section 7.6.3.

  

	 	3.4.3	 Non-Agreed-Upon Third-Party IPR. 

 

	 	(a)	 Right of Acquisition by Presenting Party. If, pursuant to the procedures set forth in Subsection
3.4.2, the Party that is not presenting the in-licensing or other acquisition opportunity does not wish the IPR of or collaboration with the Third Party to be included in the Collaboration, then the
Party presenting such opportunity to the Joint Steering Committee shall have the exclusive right to take such action(s) at its own expense and on its own behalf. In the event that such Party does so, any IPR acquired or arising pursuant to such
proposed in-licensing, other acquisition or Third Party collaboration shall be deemed (i) Independent IPH IPR if IPH is the Party taking such action or (ii) Independent NN IPR if NN is the Party
taking such action. 

  

	 	(b)	 Exclusive Rights of Acquiring Party. In such event, the Party that acquires (by assignment, license or
otherwise), or enters into a collaboration with a Third Party with respect to, such IPR pursuant to this Subsection 3.4.3, that Party shall have the exclusive right throughout the Territory, with the right to
Sub-license and Out-License, to develop and commercialize products (in general or for one or more specific indications) encompassed by a Valid Claim in such IPR, without
obligation to pay or provide any royalty or other consideration to the other Party except with respect to the Net Sales of such products the sale of which are covered by a Valid Claim of a Collaboration Patent or (i) if NN or one of its
Affiliates is commercializing such product, a Valid Claim of a Patent within the Background IPH IPR or Independent IPH IPR; and (ii) if IPH or one of its Affiliates is commercializing such product, a Valid Claim of a Patent within the
Background NN IPR or Independent NN IPR. 

  
 23 

	 	  	 Such products covered by such Valid Claims shall be subject to the payment of either a royalty of *** on the
Net Sales thereof or alternatively *** of all royalties received by either of the Parties or any of their Affiliates in respect of Net Sales during the Term by its Out-licensees of such products, as
calculated, mutatis mutandis, pursuant to Subsection 1.1.53. Payment obligations in respect of royalties received from Out-licensees shall be subject to the
Out-licensing Party’s obligation to pay to the other Party a minimum royalty equal to ***, and a maximum royalty equal to ***, of the Out-licensee’s Net Sales
of such products. Any of such payments shall be made on a product-by-product and
country-by-country basis until the expiration of the last to expire of the aforementioned Valid Claim covering such product in such country. For the avoidance of doubt,
(a) the foregoing payment obligation is in lieu of, and not in addition to, any potential or actual Upside Revenue payment obligation, (b) the foregoing royalty obligation shall not be subject to the alternative ten- (10-) year royalty payment period prescribed by Section 1.1.66, and (c) the Party commercializing such product shall have no obligation to pay or provide
any milestone fee or other consideration to the other Party in connection with its development or commercialization thereof. 

  

	 	(c)	 No NN Funding of Non-Collaboration Activities. For the avoidance
of doubt, NN shall have no research funding obligation with respect to, and IPH shall not assign any FTEs funded by NN hereunder to, any activities in connection with the research, development or commercialization of or under any IPR (or any Know-How, Biological Target or other subject matter encompassed by such IPR) that is in-licensed or otherwise acquired by IPH pursuant to this Subsection 3.4.3.

  

	 	3.5	 Obligation to Diligently Seek Sub-License Rights in All
Collaborations with Third Parties. During the Collaboration Term, each Party shall, in negotiating any in-licensing, collaboration, partnering or other agreements or arrangements in the Collaboration
Field, exercise diligent efforts to obtain the right to grant to the other Party (by license, sublicense or other transfer) the rights and licenses acquired by such Party (by assignment, license or otherwise) in the Collaboration Field pursuant to
such Third Party agreements or arrangements (including Third Party Collaborations) for purposes of Commercial Optimization, and to avoid, and if such avoidance is not possible, to minimize, any requirement to provide additional consideration to such
third-parties for obtaining or exercising such right. 

  

	 	3.6	 Collaboration Plans. The Target Discovery Plan and Drug Discovery Plan, including detailed work plans
and performance criteria with respect to the Parties’ respective responsibilities and obligations thereunder, as contemplated by the Parties as of the date of this Agreement, are set out, respectively in Schedules 1.1.65 and
1.1.32. 

  
 Certain information has been excluded from this
agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 24 

	 	3.7	 Commercially Reasonable Efforts. Each Party shall use Commercially Reasonable Efforts during the
Collaboration Term: 

  

	 	(a)	 to fulfil the responsibilities assigned to such Party in the Collaboration in accordance with the applicable
Target Discovery Plan or Drug Discovery Plan as the same may be amended by the Joint Steering Committee from time to time; 

  

	 	(b)	 to perform its obligations under the Collaboration in good faith in a commercially reasonable and workmanlike
manner; 

  

	 	(c)	 as appropriate and to the extent authorized by contract and permitted by applicable Law, to make available to
the other Party resources that are necessary or useful for Commercial Optimization (without limitation of either Party’s specific performance obligations hereunder, including the affirmative obligation to provide or make accessible to the other
Party any Know-How (including reasonable quantities of samples of any relevant Materials) Controlled by the first Party that are necessary or useful for such Commercial Optimization); and

  

	 	(d)	 to carry out all work done in the course of the Collaboration in material compliance with the Target Discovery
Plan and Drug Discovery Plan and all applicable Laws and professional standards governing the conduct of such work. 

  

	 	3.8	 Legal Compliance. In the course of carrying out any work under this Agreement, each Party will comply
with all applicable Laws regarding the conducting of tests in animals for laboratory research purposes. IPH shall at NN’s expense comply with any additional requirements requested by NN in accordance with NN’s policy for use of animals for
laboratory research purposes as set forth in the annexed Schedule 3.8 as the same may be amended by NN from time to time. 

  

	 	3.9	 Research Personnel. During the Collaboration Term, 

 

	 	(a)	 each Party shall continue to contribute to the Collaboration all its research and development activities in the
Collaboration Field that are ongoing as of the date of this Agreement, which shall include the activities listed, in the case of NN, in Schedule 1.1.69A and, in the case of IPH, in Schedule 1.1.69B, and 

 

	 	(b)	 each Party shall further contribute to the Collaboration as follows: 

 

	 	(i)	 IPH shall deploy and dedicate to the Collaboration, on a full-time basis at least *** of its full-time
employees (“FTEs”) during Collaboration Year 1 *** of whom shall be assigned on a full-time basis to the continuation of projects under the former Kirostim Agreement) and at least *** of its FTEs during each of Collaboration Years 2
and 3, with no fewer than *** of such FTEs involved in the Drug Discovery Projects at any given time during the Collaboration, and with the precise allocation and deployment of IPH FTEs to be determined by the Joint Steering Committee twice each
year during the Collaboration Term for the following six-(6) month period. In its deployment of FTEs to the Collaboration pursuant to this paragraph, IPH shall 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 25 

	 	
maintain an FTE ratio of at least *** with an academic degree from a higher institution of learning (e.g., a university or an engineering school or engineering institute) to *** at all times
during the Collaboration. IPH shall further dedicate to the Collaboration appropriately ample time and involvement by IPH management, including regular participation in various Collaboration committees (e.g., the Joint Steering Committee), and
provide and ensure the full participation of Project Managers for each project defined by the Joint Steering Committee. 

  

	 	(ii)	 During each of Collaboration Years 1 through 3 and, if the Collaboration is thereafter extended, during each of
the first two (2) annual extensions of the Collaboration Term, NN shall, in addition to its research funding of IPH pursuant to Section 3.13, provide sufficient annual research funding to cover its own research costs in relation to
the Target Discovery and Drug Discovery Plans, including, but not limited to, the funding of *** NN FTEs. 

  

	 	3.10	 Project and Pre-Project Groups. The Parties shall form one
project group for each project and one ore more Pre-project Group(s) (as determined by the Joint Steering Committee) for each or all Pre-Project(s), identified in the
Collaboration Plans. Each such Project group or Pre-project group shall be composed of at least *** and *** representative appointed by each Party who shall have the appropriate experience, expertise, and
familiarity with the scientific or intellectual property issues confronted by the Project group to which he or she has been assigned. Each Project group or Pre-project group shall meet at least once per
calendar quarter in order to manage effectively each aspect of the Target Discovery Plan or Drug Discovery Plan being implemented by the Project or Pre-project to which it has been assigned.

  

	 	3.11	 Project Managers. For each Project and for one or more
Pre-projects (as the Joint Steering Committee shall decide) , each Party shall appoint a head of its research team (a ”Project Manager”) who shall act as the primary contact between the
Parties during the Collaboration and shall be responsible for: 

  

	 	(a)	 the internal management of each Collaboration project pursuant to the Collaboration Plans;

  

	 	(b)	 the coordination of each project with the other Party’s Project Manager; 

 

	 	(c)	 the facilitation of communication between the Parties on a regular basis to discuss the progress of each
Project or Pre-project; 

  

	 	(d)	 ensuring that all raw data and results generated by or though the Project or
Pre-project are freely exchanged between the Parties pursuant to the terms of this Agreement; and 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 26 

	 	(e)	 the provision of regular progress reports and input to the Joint Steering Committee and the Parties’
respective management teams, including the preparation of written project reports, including all summaries and analyses of Project or Pre-project data, on a monthly basis throughout the Collaboration Term, and
submission thereof to NN and IPH management. Such project reports shall 

  

	 	(i)	 describe all research, development and other Collaboration activities that have been performed, or caused to be
performed, since the last such report, 

  

	 	(ii)	 evaluate the work performed in relation to the goals of the Collaboration and the applicable Target Discovery
Plan or Drug Discovery Plan, and 

  

	 	(iii)	 provide such other information as may be required by this Agreement or the applicable Target Discovery Plan or
Drug Discovery Plan, or that is reasonably requested by the other Party. 

  

	 	3.12	 Research Funding. With the sole exception of the following annual research funding contributions to be
made by NN to IPH to ensure IPH’s compliance with its obligation to deploy, on a full-time basis, the number and quality of full time employees required pursuant to Section 3.9, NN and IPH shall each pay all costs and expenses of
the activities it is responsible to perform pursuant to the terms of this Agreement and the relevant Collaboration Plans: 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	  	 With the exception of the above-noted pre-paid research funding for
Collaboration Year 1, NN shall pay to IPH, as NN’s annual research funding contribution for each of the first three years of the Collaboration, *** for each of the above-specified IPH FTEs deployed by IPH on a full-time basis in compliance with
Section 3.9. With the exception of the above-noted pr-paid research funding for Collaboration Year 1, NN shall pay in full the annual research funding contribution to IPH for Collaboration Year 1
upon the Parties’ execution and delivery of this Agreement on the date of this Agreement. Commencing with the first anniversary of the date of this Agreement, with respect to each remaining Collaboration Year of the Collaboration Term, NN shall
pay the annual research funding contribution to IPH for each such Collaboration Year in advance, upon the anniversary of the date of this Agreement. NN shall have no research funding obligation to IPH after the expiration of the Collaboration Term,
irrespective of any continuation of this Agreement thereafter during any holdover period, as set forth in Section 3.2(b). 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 27 

	4.	 MANAGEMENT OF THE COLLABORATION 

 

	 	4.1	 Project Group Decisions. Decisions in the project groups will be taken by consensus of the Parties’
respective Project Managers and any dispute that may arise between them as to such decisions shall be referred for resolution to the Joint Steering Committee in accordance with Section 4.5. 

 

	 	4.2	 Joint Steering Committee. The Parties have previously established a Steering Committee pursuant to the
Kirostim Agreement. Within *** days after the date of this Agreement, the Parties shall form a Joint Steering Committee under this Agreement. The Joint Steering Committee will function throughout the Collaboration Term as the key coordination,
supervisory and liaison body in relation to the Collaboration and shall, upon its formation, supersede, replace and undertake the duties of the Steering Committee formed under the Kirostim Agreement, which Steering Committee shall be dissolved,
automatically and without further action by the Parties, effective upon the formation of the Joint Steering Committee. The Joint Steering Committee shall: 

  

	 	(a)	 consist of *** members having requisite skills to enable them to make recommendations to the Parties’
management with respect to the Collaboration, *** of whom shall be appointed by and represent NN, and *** of whom shall be appointed by and represent IPH, as notified by each Party to the other from time to time in writing; 

 

	 	(b)	 accord one vote to each Party; 

 

	 	(c)	 be chaired by *** representative (for administrative purposes), as chosen by ***; 

 

	 	(d)	 hold meetings in person as frequently as the members of the Joint Steering Committee may agree shall be
necessary during the period of the Collaboration, or more frequently upon the reasonable request of either Party, but in any event no less frequently than four (4) times in any Collaboration Year, two (2) of which meetings shall take
place, if at all practicable, within one month prior to an NN semi-annual Project Review. Dates of Joint Steering Committee meetings to be held in person shall be agreed upon by the Joint Steering Committee not less than *** days beforehand;
responsibility for arranging the meetings, including providing notice and an agenda shall rest with the chair of the Joint Steering Committee; 

  

	 	(e)	 establish its own procedural rules for the Joint Steering Committee’s operation, except as to the
specifications and procedures expressly set forth in this Section 4.2; 

  

	 	(f)	 designate individuals who shall be responsible for sending draft minutes of each meeting to each of the Joint
Steering Committee members without undue delay and ensuring that all such minutes are submitted for written approval by both Parties; and 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 28 

	 	(g)	 be dissolved automatically and without further action by the Parties, upon the expiration of three
(3) months after the effective date of the expiration or earlier termination of the Collaboration Term. 

  

	 	4.3	 Duties of Joint Steering Committee. The Joint Steering Committee shall have the following, among other,
duties and responsibilities: 

  

	 	(a)	 Following the first meeting of the Joint Steering Committee preparing a Target Discovery Plan for Projects in
the Collaboration Field that are in the pre-M0 stage of development and that are to be actively pursued by one or both of the Parties or their respective Affiliates (alone or with one or more Third Parties)
and annexing such Target Discovery Plan hereto as Schedule 1.1.65; 

  

	 	(b)	 monitoring and managing the progress of the Target Discovery Plan and the Drug Discovery Plan, including, but
not limited to, updating all associated work plans, allocating IPH’s FTEs among projects, and providing recommendations respecting the allocation of NN’s FTEs among projects; 

 

	 	(c)	 managing the deployment, allocation and use of Collaboration Know-How
or other Materials and Know-How contributed by the Parties to, or generated or acquired (by assignment, license or otherwise) by, the Parties pursuant to the Collaboration; 

 

	 	(d)	 classifying Pre-projects or Projects within any of the Collaboration
Plans, or any associated or other project or aspect thereof (including any activities in respect of the discovery or development of any Drug Candidate) as being active, suspended or terminated; 

 

	 	(e)	 identifying and assessing Exploratory Targets and updating Schedule 1.1.33 accordingly;

  

	 	(f)	 reviewing, and preparing proposed updates or other amendments (as necessary) to, Schedules 1.1.12 and
1.1.13 for review and written approval by the Parties’ respective management to record the addition and proper classification of Licensed Products; 

  

	 	(g)	 preparing, within *** days prior to the expiry or effective date of the termination of the Collaboration Term,
the final version of Schedules 1.1.12 and 1.1.13 for review and written approval by the Parties’ respective management; 

  

	 	(h)	 considering and, if necessary updating, Schedule 1.1.22 (Collaboration Targets) (a) no less
frequently than once during each *** period in the Collaboration Term, (b) within *** after receipt of the written request of either Party during the Collaboration Term, and (c) in a final version of such Schedule to be fixed and final as
of the date of the expiration or earlier termination of the Collaboration Term; 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 29 

	 	(i)	 reviewing, and preparing proposed updates or other amendments (as necessary) to Collaboration Plans for review
and written approval by the Parties’ respective management; 

  

	 	(j)	 assessing, evaluating and making recommendations to the management of the Parties regarding Third Party
Collaborations, Third Party IPR in-licensing and acquisition opportunities, and other IPR in-licensing and acquisition opportunities in the Collaboration Field vis-à-vis any Third Party; 

  

	 	(k)	 receiving IPH’s requests, and initiating and monitoring the process by which a Drug Candidate may be
referred to NN’s management for the determination, in the sole discretion of NN’s management, whether or not to classify and approve such Drug Candidate as a Niche Candidate for independent development by IPH under this Agreement;

  

	 	(l)	 prioritizing the discovery and research activities of the Collaboration; 

 

	 	(m)	 identifying which disease states, indications and conditions might best be targeted by the Collaboration;

  

	 	(n)	 establishing such subcommittees as the Joint Steering Committee may deem appropriate without extending the
rights or obligations of the Parties under this Agreement; 

  

	 	(o)	 making proposals to the management of the Parties for the review or amendment of the Target Discovery Plan,
Drug Discovery Plan, or any other work plans or time schedules under the Collaboration; 

  

	 	(p)	 liaising with the Ex-Vivo Task Force with respect to development of ex-vivo applications of Drug Candidates pursuant to Section 6.2; 

  

	 	(q)	 developing, agreeing upon and recording procedures for issuing publications and press releases with regard to
the Collaboration, subject to the terms of this Agreement set forth in Article 18; and 

  

	 	(r)	 establishing a Joint Patent Committee to oversee, coordinate and monitor Patent and other IPR management,
development, maintenance and enforcement efforts and strategies in accordance with Article 9, and to report to the Joint Steering Committee with respect thereto; 

 

	 	(s)	 evaluating and making proposals and recommendations to the management of the Parties with respect to the number
of FTEs required to implement current and planned projects under the Collaboration Plans, including, where applicable, the retention and deployment of additional FTEs; 

  
 30 

	 	(t)	 performing such other functions and responsibilities as the Parties may hereafter agree to in writing,
provided that, for the avoidance of doubt, it is hereby acknowledged and agreed that the Joint Steering Committee shall have no authority to countermand, modify or amend the terms of this Agreement or of any other written agreement between
the Parties, or to cause the Parties’ obligations (including any payment obligation) to be otherwise than as stated herein or therein; and 

  

	 	(u)	 updating Schedule 1.1.17 (containing Collaboration Know-How.

  

	 	4.4	 Participation in Committee Meetings. The Joint Steering Committee and each of its members shall have
power to invite persons whose special skills or influence might advance the Collaboration to attend and address meetings of the Joint Steering Committee. Persons invited may, but are not required to be, employed by the inviting Party or its
Affiliates. The inviting Party shall have the obligation to secure that such persons are bound by obligations of confidentiality that are at least as stringent as those set forth in this Agreement. The Joint Steering Committee shall decide on a case-by-case basis who shall be responsible for the expenses incurred by the invitation. For the avoidance of doubt, it is agreed that such invited persons shall not be a
member, and shall not have a right to vote or participate in the decision-making process of, the Joint Steering Committee. 

  

	 	4.5	 Decision-making Procedures. The Joint Steering Committee shall form a quorum when two representatives of
each Party are present. Decisions of the Joint Steering Committee shall be made by unanimous consent of the Parties, with each Party having a single vote, irrespective of the number of representatives actually in attendance at a meeting, or by
written resolution signed by one designated representative of each of the Parties. Draft minutes shall be prepared and circulated to the Parties for approval and signature without undue delay after each Joint Steering Committee meeting. If any issue
remains unresolved after *** following the formal consideration of such issue by the Joint Steering Committee, either Party may by written notice to the other refer that issue to the Chief Scientific Officer of NN and the Chief Executive Officer of
IPH, who shall in good faith negotiate to resolve that issue within *** of such notice. Except with respect to the specific issues expressly identified in Section 3.4 (which shall be decided in accordance with the terms and conditions of
that Section), in the event that said officers fail to reach agreement within ***, or for such other period as the Joint Steering Committee may agree, such issue shall be determined by ***, in the good faith exercise of its sole discretion and such
determination shall be final and binding upon the Parties. 

  

	 	4.6	 Disputes and Continued Performance. For the avoidance of doubt, notwithstanding any failure of the Joint
Steering Committee, or the Chief Science Officer of NN and Chief Executive Officer of IPH, to reach agreement resolving any dispute presented to them, the existence of any disputes between the Parties shall not excuse either Party from rendering
full performance of its obligations under this Agreement. During the pendency of any such dispute and unless and until this Agreement is terminated in accordance with the express terms and conditions of Article 12, the provisions of this
Agreement shall remain in full force and effect and the Parties shall be obligated to perform their 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 31 

	 	
respective obligations and be entitled to their respective rights under this Agreement. Not withstanding the foregoing, or any other, provision of this Agreement: (a) in the event that this
Agreement is terminated by either Party, the Parties shall be entitled to such rights and licenses, and bear such obligations, as survive such termination pursuant to the express terms hereof, and (b) no such termination shall take effect
during the pendency of any dispute as to the right of the terminating Party to terminate this Agreement, provided that such dispute is submitted to arbitration in accordance with Section 21.14 within *** days after the effective
date of such termination. 

  

	 	4.7	 Expenses. ***. 

 

	 	4.8	 Limited Authority. For the avoidance of doubt, the Joint Steering Committee shall have no competency to
increase or decrease the total number of IPH or NN FTEs required by this Agreement or to make any other change in the Collaboration which would materially affect the scope, costs or other terms thereof as set forth in this Agreement. Any such change
shall require a written agreement between the Parties. 

  

	 	4.9	 Development and Commercialization Committee. The Parties have previously established a Development and
Commercialization Committee pursuant to the Kirostim Agreement. Within *** after the date of this Agreement, the Parties shall form a committee to be designated as the “Development and Commercialization Committee” that shall, upon
its formation, supersede, replace and assume the duties of the Development and Commercialization Committee established under the Kirostim Agreement, which prior Development and Commercialization Committee shall be thereupon be dissolved
automatically without further action of the Parties. The Development and Commercialization Committee shall function throughout the Term as a forum for the Parties’ communication and discussion concerning
(a) post-M1 development and commercialization, both during and after the Collaboration Term, of all Licensed Products, including all products discovered or developed pursuant to the Kirostim Agreement,
and (b) any Niche Candidates. The Parties shall agree on the rules and procedures for such a Development and Commercialization Committee, which shall in any event: 

 

	 	(a)	 consist of three (3) ordinary representatives of each Party, as may be designated by each Party to the
other Party from time to time in writing; 

  

	 	(b)	 be chaired by an additional *** representative to be chosen by *** and who shall constitute the seventh (7th) member of the Development and Commercialization Committee; 

  

	 	(c)	 hold meetings in person as frequently as the members of the Development and Commercialization Committee may
agree shall be necessary but in any event no less frequently than once every ***. Dates of meetings to be held in person shall be agreed by the parties not less than *** beforehand with the first meeting to take place before December 31, 2006,
with responsibility for arranging the meetings, including providing notice and an agenda, resting with the chairman; 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 32 

	 	(d)	 appoint a representative as secretary who shall be responsible for preparing and circulating to the Parties,
for their required review and approval, draft minutes of each meeting without undue delay after each Development and Commercialization Committee meeting. 

  

	5.	 GRANT OF RIGHTS 

 

	 	5.1	 NN Licenses in the Field. IPH hereby grants to NN, and NN hereby accepts: 

 

	 	(a)	 an exclusive (even as to IPH) right and license during the Term, to practice, exercise and use all Background
IPH IPR other than Background IPH Research Technology IPR; 

  

	 	(b)	 an exclusive (even as to IPH) right and license during the Collaboration Term, and non-exclusive right and license during the balance of the Term remaining after the expiration or earlier termination of the Collaboration Term, to practice, exercise and use all Background IPH Research Technology
IPR; and 

  

	 	(c)	 an exclusive (even as to IPH) right and license during the Term, to practice, exercise and use all
Collaboration IPR Controlled by IPH (including, for clarity, any Joint IPR or Third-Party IPR); 

  

	 	  	 in the Collaboration Field and throughout the Territory, in each case ((a) through (c)), with the right to Sub-license and Out-license, for purposes of achieving Commercial Optimization, including the right and license to conduct research with and of, discover, develop, use,
manufacture, have manufactured, register, package, sample, distribute, promote, market, offer for sale, import, export, sell and have sold Licensed Products, Niche Candidates and Residual Products for all uses and purposes, subject to the terms and
conditions of this Agreement, including the rights and licenses granted back, or agreed to be granted back, to IPH pursuant to Sections 5.3 and 5.5(a), below. 

 

	 	5.2	 NN License to Collaboration IPR Outside the Collaboration Field. IPH hereby further grants to NN, and NN
hereby accepts, a non-exclusive, Sub-licensable right and license, without the right to Out-license, to practice exercise and use
throughout the Territory during the Term, any Collaboration Research Technology IPR Controlled by IPH, for purposes of NN’s and its Affiliates’ use for the discovery, development or commercialization of biologics or other products or
processes outside the Collaboration Field. In the event that NN wishes to Out-license such IPR, it shall notify IPH of its desire to do so in a written request setting forth in reasonable detail the
contemplated nature and terms of, and parties to, the proposed Out-license, and the Parties shall negotiate in good faith a separate license agreement providing for such
Out-license, any such agreement being subject to the final management approval of each Party. 

  

	 	5.3	 Grant Backs to IPH. NN hereby grants back to IPH, and IPH hereby accepts for no additional
consideration, a non-exclusive right and license, with the right to Sub-license (but without the right to Out-License),
throughout the Territory, to practice, exercise and use (a) during the Collaboration Term, Background IPH 

  
 33 

	 	
IPR licensed to NN pursuant to Section 5.1, and (b) during the Term, all Research Technology IPR licensed to NN during the Term pursuant to Section 5.1, in each case
((a) and (b)) solely to conduct research and development for purposes of Commercial Optimization. 

  

	 	5.4	 IPH Licenses to NN Background Research Technology IPR and NN Controlled Collaboration IPR. NN hereby
grants to IPH, and IPH hereby accepts, a non-exclusive right and license, with the right to Sub-license (but without the right to
Out-License), throughout the Territory during the Term, to practice, exercise and use any Background NN Research Technology IPR or Collaboration IPR that is Controlled by NN, solely to conduct research and
development for purposes of Commercial Optimization. 

  

	 	5.5	 Future IPH License in the Field for Niche Candidates. NN hereby agrees to grant or grant back to IPH an
exclusive right and license, including the right to Sub-license and Out-license, throughout the Territory during the Term, to develop and commercialize in the
Collaboration Field solely such specific Niche Candidates as IPH may hereafter be authorized to commercialize pursuant to the terms and conditions of Article 6 hereof: 

 

	 	(a)	 under all Intellectual Property Rights licensed exclusively to NN pursuant to Section 5.1; and

  

	 	(b)	 under all Background NN IPR and Collaboration IPR Controlled by NN, 

 

	 	  	 to the extent that such rights and licenses are necessary or useful for purposes of achieving Commercial
Optimization with respect to such specific Niche Candidates in approved indication(s). Notwithstanding the foregoing or any other provision of this Agreement, NN shall not be required to grant or grant back to IPH any such right or license if
to do so is not authorized by contract or permitted by applicable Law or will require NN to pay or provide any consideration (including any royalty, sublicense fee or other payment) to any Person, save that, in the event that NN shall decline to pay
or provide such consideration to procure or grant such license, IPH shall have the right to do so to the extent authorized by contract and permitted by applicable Law. 

 

	 	  	 For the avoidance of doubt, the exclusivity of any license granted or granted back to IPH pursuant to this
Section 5.5 shall be comprised solely of the exclusive rights of commercialization, and development for commercialization, and only as they may hereafter apply to such specific products as IPH is hereafter authorized to develop pursuant
to Article 6, and shall not in any way limit or derogate from NN’s rights with respect to any IPR licensed to IPH under this Agreement (including any right of NN to practice, use or exploit such IPR), or any of the rights or
licenses of NN under this Agreement to practice, use or exploit any IPR licensed to NN hereunder for any purpose other than for commercializing such specific Niche Candidates for such specific indications or uses as are hereafter licensed
exclusively to IPH to commercialize pursuant to the terms and conditions of Article 6 and this Section 5.5. 

  
 34 

	 	5.6	 Sub-licensing. Except as is otherwise herein expressly provided,
and subject to the terms of this Agreement, each of IPH and NN shall be entitled to Sub-license their rights and obligations under this Agreement provided that (a) the Sub-licensing Party shall secure appropriate covenants, obligations and rights from any proposed Sub-licensee so as to ensure that such
Sub-licensee is able to comply with the Sub-licensing Party’s covenants and obligations hereunder, and (b) during the Collaboration Term, all such Sub-licensing by the Parties shall be subject to the prior approval of the Joint Steering Committee. 

  

	 	  	 A Party that Sub-licenses any rights, licenses or obligations hereunder
to any Person shall ensure that, prior to and as a condition of the grant of such Sub-license, the proposed Sub-licensee enters into binding obligations of
confidentiality, non-use, and IPR ownership that shall be enforceable by both Parties and at least as stringent as those set out in the text hereof, and that, with respect to Materials, shall conform to the
Material Transfer Agreement and other requirements set forth in Section 10.4. Each Party shall be liable for any such work performed by its Sub-licensees hereunder as if the work had been performed
by the Party itself. 

  

	 	  	 For the avoidance of doubt, FTEs of the Parties’ Sub-licensees who
are dedicated on a full-time basis to perform activities for or on behalf of the Collaboration and who otherwise meet the qualification requirements applicable to the respective Parties under Section 3.7 shall be counted as FTEs of the Sub-licensing Party for purposes of determining the Parties’ respective contributions of personnel to the Collaboration pursuant to that Section. 

 

	 	5.7	 Regulatory Exclusivity. For no additional consideration: 

 

	 	(a)	 IPH shall grant a license or authorization to NN (and do all such reasonable acts related thereto) under any
regulatory exclusivity (such as orphan drug exclusivity, new chemical entity exclusivity, pediatric exclusivity, and the like) and any regulatory reference rights, authorizations, or approvals held by IPH or any of its Affiliates with respect to the
development or commercialization of a Niche Candidate, Residual Product or Licensed Product that are necessary for NN to develop or commercialize any Licensed Product, Niche Candidate or Residual Product that might otherwise be barred from
regulatory approval by such exclusivity; and 

  

	 	(b)	 NN shall grant a license or authorization to IPH (and do all such reasonable acts related thereto) under any
regulatory exclusivity (such as orphan drug exclusivity, new chemical entity exclusivity, pediatric exclusivity, and the like) and any regulatory reference rights, authorizations, or approvals held by NN or any of its Affiliates with respect to any
Licensed Product, Niche Candidate or Residual Product that are necessary for IPH to develop or commercialize any Niche Candidate, Residual Product or Licensed Product authorized for commercialization by IPH hereunder that might otherwise be barred
from regulatory approval by such exclusivity. 

  
 35 

	 	5.8	 Freedom of Operation in Respect of Independent IPR. It is the Parties’ intention that each of them
have and retain throughout the Term the freedom to operate necessary to enable them to exercise their respective rights and licenses, and fulfill their respective obligations, under this Agreement for the purposes of achieving Commercial
Optimization of Licensed Products, and Niche Candidates and Residual Products. To this end, the Parties shall be obligated as follows: 

  

	 	5.8.1	 IPH License to NN of Independent IPH IPR. 

 

	 	(a)	 IPH shall, and hereby does, in each case at its own expense, grant, or shall procure for NN or its Affiliates,
or pay for the procurement by or on behalf of NN of, the grant of, non-exclusive rights and licenses (including the right to grant Sub-licenses and Out-licenses), throughout the Territory during the Term under all such Independent IPH IPR as (i) is generated or acquired (by assignment, license or otherwise) at any time during the Collaboration Term or the
*** period following immediately after the expiration or termination thereof by or on behalf of (A) IPH or any of its Affiliates, either jointly with one another or independently, or (B) IPH, or any of its Affiliates, or any Third Party
(whether independently of or jointly with IPH or any of its Affiliates) in connection with any collaboration by IPH or any of its Affiliates with such Third Party, and (ii) is necessary for the achievement of Commercial Optimization of Licensed
Products, Niche Candidates, or Residual Products, and, in particular, for NN fully to exercise its rights and licenses and fulfill its obligations under this Agreement. 

 

	 	  	 *** 

  

	 	(b)	 For the avoidance of doubt, NN shall not be required to pay or provide any fee, royalty or other consideration
(such as the payment of any premium or performance of any obligation) by reason of or in consideration of IPH’s grant or procurement of the grant to NN of any right or license pursuant to this Subsection 5.8.1, other than or in addition
to such royalty obligations as might apply to NN’s use of Independent IPH IPR pursuant to Subsection 5.8.1(a) hereof 

  

	 	(c)	 For the avoidance of doubt, it is understood that NN may need to pay or provide consideration to Third Parties
by the terms of such agreements or arrangements as NN may need to enter into (or authorize IPH to enter into) with such Third Parties to secure NN’s freedom of operation pursuant to the express, post-purchase/acquisition exclusion to IPH’s
payment obligation set forth in the second paragraph of Subsection 5.8.1(a) with respect to IPR that is first generated or acquired by IPH or an IPH Affiliate after the effective date of a purchase or acquisition of IPH.

  
 Certain information has been excluded from this agreement
(indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 36 

	 	5.8.2	 NN Assistance, and License of Independent NN IPR, to IPH for Niche Candidates or Abandoned Licensed
Products. To the extent authorized by contract and permitted by applicable Law, NN shall grant to IPH, or provide reasonable cooperation and assistance to IPH to procure the grant to IPH of, non-exclusive
rights and licenses (including the right to grant Sub-licenses and Out-licenses), throughout the Territory during the Term under all such Independent NN IPR as
(a) is generated or acquired (by assignment, license or otherwise) at any time during the Term by or on behalf of (i) NN or any of its Affiliates, either jointly with one another or independently, or (ii) NN, or any of its Affiliates,
or any Third Party (whether independently of or jointly with NN or any of its Affiliates) in connection with any collaboration by NN or any of its Affiliates with such Third Party, and (b) is necessary for (i) the achievement of Commercial
Optimization of such Niche Candidates, Licensed Products or Residual Products as IPH may hereafter be authorized to develop for commercialization (and, in particular, for IPH fully to exercise such rights and licenses in respect of such Niche
Candidates, Licensed Products or Residual Products as may hereafter be granted hereunder, and (ii) IPH to fulfill its obligations under this Agreement. In no case shall NN be required to procure or exercise the right to grant any such rights or
licenses to IPH in the event that to do so would require NN to provide or pay any consideration (including any royalty, license fee or other payment) to any Person, save that IPH may elect to pay for and obtain the right to such procurement or
exercise to the extent authorized by contract and permitted by applicable Law. 

  

	 	5.8.3	 NN License to IPH of Independent NN IPR for Residual Products. To the extent authorized by contract and
permitted by applicable Law, NN shall grant to IPH or provide reasonable cooperation and assistance to IPH to procure the grant to IPH of non-exclusive rights and licenses (including the right to grant Sub-licenses and Out-licenses), throughout the Territory during the Term under all such Independent NN IPR as (a) is generated or acquired (by assignment, license or
otherwise) at any time during the Collaboration Term or the *** period following immediately after the expiration or termination thereof (or in the case of Sections 13.4 and 13.5 during the Term) by or on behalf of (i) NN independently,
or (ii) NN or any Third Party (whether independently of or jointly with NN) in connection with any collaboration by NN with such Third Party, and (b) is necessary for the achievement of Commercial Optimization of such Residual Products as
IPH may hereafter be authorized to develop for commercialization. In no case shall NN be required to procure or exercise the right to grant any such rights or licenses to IPH in the event that to do so would require NN to provide or pay any
consideration (including any royalty, license fee or other payment) to any Person, save that IPH may elect to pay for and obtain the right to such procurement or exercise to the extent authorized by contract and permitted by applicable Law.

  
 Certain information has been excluded from this agreement
(indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 37 

	 	5.8.4	 Discussion Regarding Other Independent IPR Necessary for Freedom of Operation. Notwithstanding the time
limitations in Subsections 5.8.1(a) and 5.8.3 in respect of the obligations of the Parties to grant or procure the grant of Independent IPR, the Parties shall negotiate in good faith the terms under which any other Independent IPR
(i.e., Independent IPR arising subsequently during the Term) may be licensed during the remainder of the Term with respect to any Residual Product. 

  

	 	5.9	 Terminated Collaboration Properties and Out-licensing. Upon the
request of either Party (which request shall not, save for extraordinary circumstances, be more frequent than ***), with respect to any: 

  

	 	(a)	 terminated Collaboration Pre-projects or Projects, or any aspects or
elements of either thereof, or 

  

	 	(b)	 Collaboration IPR that the Parties agree no longer has any value for Commercial Optimization,

 the Parties shall confer to evaluate and assess: 

 

	 	  	 first, the possibility and conditions pursuant to which the grant or grant back of a license may be made
to one of the Parties as necessary for such Party independently to conduct further research, development or commercialization of the subject matter described in the above paragraph (a) or to practice, use or exploit any of the IPR described in
the above paragraph (b), in each case on written terms to be mutually agreed and satisfactory to the Parties; and 

  

	 	  	 second, the possibility of Out-licensing to a Third Party or
entering into a arrangement with a Third Party with respect to the IPR or other subject matter described in the above paragraphs (a) or (b) of this Subsection upon Arm’s Length Transaction terms. 

 

	 	5.9.1	 With respect to any such terminated Pre-projects, Projects, or any
aspect of either thereof as the Parties determine should be Out-licensed or made subject to such Third Party arrangement in order to maximize its commercial potential, the Parties shall assess and evaluate the
feasibility and desirability of such Out-licensing or arrangement upon Arm’s Length Transaction terms. 

  

	 	5.9.2	 In the event that the Parties shall decide to go forward with such Third Party
Out-licensing or arrangement in accordance with this Section 5.9, the Parties shall: 

  

	 	(a)	 agree upon the allocation of all revenues and profits that result from each such
Out-licensing or arrangement prior to the undertaking of any commitment to enter into such Out-licensing or other arrangement, which allocation shall take into account
the stage of development of, and contribution of each of the Parties with respect to, the Pre-project, project, or aspect thereof to be submitted for Out-licensing to or
arrangement with such Third Party; and 

  
 Certain information has
been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 38 

	 	(b)	 appoint one of the Parties as the Party responsible for such
Out-licensing or arrangement, who shall bear responsibility for entering into and implementing such Out-licensing or arrangement on Arm’s Length commercial terms,
and shall keep the other Party regularly and fully informed of all material activities and developments and other relevant facts in respect of such Out-licensing or Third Party arrangement, including all Net
Sales and required payments of royalties in connection therewith. 

  

	 	5.9.3	 In the event that the Parties reach no agreement regarding
Out-Licensing or other arrangement regarding such Collaboration IPR, the Party responsible for prosecution or maintenance of such IPR pursuant to Article 9 may abandon such IPR without any further
obligation to the other Party. 

  

	 	5.10	 Procedure for Terminating Background IPR. Upon the written request of either Party with respect to any
Background IPR which such Party believes no longer has any value for the development or commercial exploitation of any Licensed Products, Niche Candidates or Residual Products, (a) during the Collaboration Term, the Joint Steering Committee (by
unanimous decision), and (b) thereafter, the Parties, shall confer to evaluate and assess jointly and in good faith whether such IPR has value for purposes of such development or commercial exploitation. 

 

	 	5.10.1	 Decision Not to Terminate IPR. In the event that the Joint Steering Committee determines unanimously, or
the Parties agree, that such Background IPR has value for the development or commercial exploitation of any Licensed Products, Niche Candidates or Residual Products, then such determination or agreement shall be set forth in writing and the Party
Controlling such IPR shall retain such Control in accordance with the terms and conditions of its obligations hereunder. 

  

	 	5.10.2	 Decision to Terminate IPR. In the event that the Joint Steering Committee determines unanimously, or the
Parties agree, in writing that such IPR does not have value for the development or commercial exploitation of any Licensed Products, Niche Candidates or Residual Products, then such IPR shall no longer constitute or be licensed hereunder as
Background IPH IPR or Background NN IPR, as the case may be, and shall be deleted or otherwise excluded from the applicable IPR Schedule, and the Party in Control of such IPR (a) shall have no further obligation to retain such Control, and
(b) shall have the right to assign, license or otherwise transfer all or any part of its right, title and interest in and to such IPR, including the Control thereof, to a Third Party. 

  
 39 

	 	5.10.3	 Failure to Reach Decision Whether to Terminate IPR. If the Joint Steering Committee shall fail to reach
a unanimous decision, or the Parties shall fail to agree, within *** of receipt of the Controlling Party’s written request pursuant to this Section 5.10 (or such longer period as the Parties may hereafter agree in writing), as to
whether or not such IPR has value for the development or commercial exploitation of any Licensed Products, Niche Candidates or Residual Products, then the Joint Steering Committee or the Parties, as applicable, shall consider in good faith the
possibility and conditions pursuant to which the grant of a license or assignment, or other transfer, may be made by the Party in Control of such IPR to the other Party (or such other Party’s Affiliate) as necessary for such other Party (or its
Affiliate) independently to conduct further, research, development or commercialization of such IPR, or to practice, use or exploit such IPR, in each case on written terms to be mutually agreed and satisfactory to the Parties. In the event that the
Parties shall fail to enter into such a written agreement within *** of the Joint Steering Committee’s or other Party’s receipt of the Controlling Party’s written request pursuant to the first paragraph of this
Section 5.10, the matter shall be decided by the arbitration procedure set forth in Section 21.14, provided that: 

  

	 	(a)	 if the Party not in Control of such IPR shall fail to commence an arbitration proceeding seeking the resolution
of such matter within *** after the expiration of the aforementioned *** period, or if such arbitration proceeding is commenced within such *** period and the arbitral body deciding such matter shall determine that the IPR does not have such value,
then, in each case, it shall be conclusively established that such IPR does not have such value, this determination shall be final and binding upon the Parties, and the Party in Control of such IPR shall have all the rights set forth in Subsection
5.10.2 with respect to such IPR; and 

  

	 	(b)	 if such arbitration is commenced within such *** period and the arbitral body deciding such matter shall
determine that the IPR does have such value, and the Parties shall fail to agree, in writing, to the terms of a settlement providing for the Party in Control’s transfer of rights in the IPR to the other Party, then the Party in Control of such
IPR shall be required to retain such Control in accordance with the terms and conditions of its obligations hereunder. 

  

	 	5.11	 NN Out-licensing and Upside Revenue. Pursuant to the terms and
conditions of Section 5.1, NN shall be entitled to Out-license its rights and licenses under this Agreement with respect to Licensed Products in
Out-licensing, partnering and other agreements or arrangements, provided that it may do so only on the following conditions: 

 

	 	(a)	 If NN or any of its Affiliates Out-licenses any Licensed Product to a
Third Party before the first use of same in human clinical trials, NN shall pay to IPH *** of all Upside Revenue received by NN in consideration of its grant of such Out-license. NN shall pay all amounts due
to IPH in respect of Upside Revenue described in this Section 5.11(a) within *** after the date of actual receipt by it of any such Upside Revenue payment. 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 40 

	 	(b)	 If NN or any of its Affiliates Out-licenses any Licensed Product to a
Third Party after the first use of same in human clinical trials but prior to the start of the first use of the same in Phase III clinical trials, NN shall pay to IPH *** of all Upside Revenue received by NN in consideration of its grant of such Out-license. The payment obligations under Section 5.11(a) and this Section 5.11(b) are non-cumulative and mutually exclusive. NN shall pay all amounts due to
IPH in respect of Upside Revenue described in this Section 5.11(b) within *** days after the date of actual receipt by it of any such Upside Revenue payment. 

 

	 	(c)	 IPH shall not be entitled to any percentage of Upside Revenue received by NN in consideration of the Out-licensing of any Licensed Products, Niche Candidates or Residual Products at any time after the start of the first use of same in Phase III clinical trials. 

 

	 	5.12	 Cumulative Payments. All payment obligations set forth in this Article 5 in respect of Out-licensing shall be in addition to, and not in lieu of, any milestone, royalty, or other payment obligations expressly provided for by this Agreement. 

 

	 	5.13	 Future Obligation to Provide Licenses Under Specific Third Party Agreements if Deemed Necessary

  

	 	5.13.1	 NN Obligation to Grant Sublicense Under *** License In Respect of an NN Approved Niche Candidate. In the
event that IPH shall hereafter request to become authorized to develop and commercialize any Drug Candidate as a Niche Candidate pursuant to Article 6, then, if NN shall grant such request, and IPH shall further request, in good faith and
upon an opinion of intellectual property counsel or such other reasonable basis as shall be reasonably satisfactory to NN, that a license from *** is necessary for IPH’s development of such Niche Candidate, NN shall grant a sublicense to IPH
under the IPR Licensed to NN under the agreement between NN and *** dated October 26, 2004, within *** of such request, as necessary for the development or commercialization of such Niche Candidate, throughout the Territory and during the Term
(including the right to Sub-license and Out-license). 

  

	 	(a)	 If NN fails to grant such a sublicense for IPH, upon satisfaction of the requirements of this Subsection
5.13.1, NN shall pay to IPH an increase of *** with respect to the next Discovery Milestone payment to IPH under this Agreement. NN’s failure to grant such sublicense shall not in any event be deemed to constitute a breach of this
Agreement and the payment obligation of NN under this Subsection 5.13.1 shall be IPH’s sole remedy for NN’s failure to obtain such license. 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 41 

	 	(b)	 If NN grants such sublicense to IPH, IPH shall be responsible for complying with all obligations to *** under
such a sublicense including payment of all applicable sublicensing royalties, milestones, or maintenance fees, maintenance of requisite insurance, and compliance with applicable production requirements thereunder. 

 

	 	5.13.2	 *** IPR. In the event that the Joint Steering Committee acting in good faith recommends the grant of a non-exclusive sub-license to NN (with right to sublicense with respect to Licensed Products) of any IPR which is the subject of IPH’s agreements with *** (the
“Licensors”) dated June 24, 2005, and February 19, 2003, respectively, IPH shall, during a period of *** following immediately after such recommendation, seek to negotiate amended
sub-licensing terms under such agreements which are acceptable to IPH. IPH shall be obligated to seek such amended sublicensing terms, save that IPH not to be obligated to pay *** more than ***, respectively,
in order to obtain a sublicense including such amended terms. 

 5.13.2.1 In the event that ***, respectively, requires
payment of more than *** for the grant such sublicense including such amended terms (as IPH shall reasonably require), IPH shall promptly notify NN of such fact and NN shall thereafter have the right (without obligation) to pay such additional
amounts to obtain such sublicense(s). 
 5.13.2.2 In the event that IPH is unsuccessful in obtaining such a license within such *** period,
the sum of *** shall be deducted from the next Discovery or Development Milestone payment due to IPH under this Agreement in full and final settlement of its obligations to seek such sublicense. 

 

	 	5.13.3	 *** IPR. In the event that the Joint Steering Committee acting in good faith recommends that IPH seek to
negotiate an exclusive license including the right to sublicense to NN to any IPR which is the subject of IPH’s agreements with *** dated April 28, 2000 (reference number 97097), IPH shall during a period of *** following immediately after
such recommendation, seek to negotiate the terms of such a license acceptable to IPH. 

 5.13.3.1 In the event that IPH is
unsuccessful in obtaining such a license including such terms within such *** period the sum of *** shall be deducted from the next Discovery Milestone payment due to IPH under this Agreement in full and final settlement of its obligations to seek
such a license from ***. 
  
 Certain information has been excluded from this agreement
(indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 42 

 5.13.3.2 If *** requires a payment of more than *** in order for IPH to obtain such a license
(including such terms), IPH shall promptly notify NN of such fact and NN shall thereafter have the right (without obligation) to pay such additional amounts to obtain such licenses. 

 

	 	5.13.4	 IAP Technology. In the event that the Joint Steering Committee acting in good faith recommends that IPH
seek to negotiate a non-exclusive license to NN (without right to sublicense other than with respect to a Licensed Product) to any IPR which may be the subject of IPH’s future agreement with ***
concerning US provisional patent applications *** (and any related Patents) (the “IAP Technology”), IPH shall during a period of *** following immediately after such recommendation, seek to negotiate the terms of such a license on terms
acceptable to IPH. 

 5.13.4.1 In the event that IPH is unsuccessful in obtaining such a license including such terms
within such *** period the sum of *** shall be deducted from the next Discovery Milestone payment due to IPH under this Agreement in full and final settlement of its obligations to seek such a license from ***. 

5.13.4.2 If *** requires a payment of more than *** in order for IPH to obtain such a license (including such terms), IPH shall promptly
notify NN of such fact and NN shall therafter have the right (without obligation) to pay such additional amounts to obtain such licenses. 
  

	6.	 NICHE CANDIDATES AND EX-VIVO CELLULAR THERAPY CANDIDATES

  

	 	6.1	 Niche Candidates. 

 

	 	(a)	 Upon IPH’s request at any time during the Collaboration Term, the Joint Steering Committee shall consider
and address to the Development and Commercialization Committee whether a Drug Candidate or Licensed Product identified by IPH may be classified as a Niche Candidate for IPH’s further development and commercialization for one or more indications
specified by IPH relative to such proposed Niche Candidate. After due consideration, and in any event within *** of presentation of IPH’s request to the Joint Steering Committee (or such other period as the Parties may hereafter agree to in
writing), the Development and Commercialization Committee shall submit a recommendation or recommendations respecting the matter to NN’s senior management. NN’s senior management shall review the recommendation(s) of the Development and
Commercialization Committee and, after having given due consideration of the matter, decide, in the exercise of NN’s sole discretion, whether such Drug Candidate or Licensed Product shall be classified as a Niche Candidate for any such
indication(s), which decision shall be set forth in writing and be final and binding upon the Parties. 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 43 

	 	(b)	 Upon and subject to NN’s written approval pursuant to Section 6.1(a) of the development and
commercialization of such Drug Candidate or Licensed Product as a Niche Candidate for any indication: 

  

	 	(i)	 IPH shall have the exclusive right to conduct the development and commercialization of such Drug Candidate or
Licensed Product as a Niche Candidate solely for the indication(s) specified by such approval, and shall diligently undertake such development and commercialization pursuant to a license that shall be granted by NN to IPH in conformity with
Section 5.5 and the other terms and conditions of this Agreement. IPH shall not conduct, or cause to be conducted, any such development or commercialization of such Drug Candidate or Licensed Product as a Niche Candidate for any use or
indication without having first obtained NN’s written approval in accordance with this Section 6.1. 

  

	 	(ii)	 NN shall provide IPH with all information (regulatory, clinical, CMC and other) in its possession or control
that is necessary or useful for purposes of IPH’s development or commercialization of the such Niche Candidates for all such approved indications, and, to the extent authorized by contract and permitted by applicable Law, IPH shall have the
right to reference all NN regulatory filings (including all Drug Master Files) for IPH to pursue registrations in respect of such indications. NN’s reasonable
out-of-pocket costs connected with providing IPH such information and arranging for such rights of reference, including the use of NN staff resources shall be paid by
IPH on an hourly basis reflecting the actual cost to NN but in no circumstances shall such costs exceed a total of ***. 

  

	 	6.2	 Ex-Vivo Cellular Therapy Candidates. 

 

	 	(a)	 Upon or within *** after the date of this Agreement, the Parties shall form an
Ex-Vivo Task Force having the purpose of preparing, for submission to the Joint Steering Committee and Development and Commercialization Committee within *** after the date of this Agreement, a recommendation
or recommendations setting forth proposed substantive and procedural guidelines in respect of the further development and commercialization of ex-vivo applications of Drug Candidates, which may include, among
other relevant factors, business, market, manufacturing and regulatory considerations in respect of the development and commercialization of potential Ex-vivo Cellular Therapy Candidates. The Joint Steering
Committee and the Development and Commercialization Committee shall, upon receipt of the recommendation(s) of the Ex-Vivo Task Force, present the recommendation(s) to the senior management of the respective
Parties. 

  
 Certain information has been excluded from this
agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 44 

	 	  	 Subject to and upon the finalization and written approval by the Parties’ respective senior management of
the Ex-Vivo Task Force’s recommended guidelines described in Section 6.2(a), such guidelines will be annexed as an amendment to this Agreement. Particulars as to the objectives, mandate and
procedures of the Ex-Vivo Task Force shall be set forth in the annexed Schedule 6.2. In the event of a dispute with respect to the adoption or implementation of the
Ex-Vivo Task Force guidelines, the matter shall be referred to the Joint Steering Committee and the provisions of Sections 4.5 and 4.6 shall control. 

 

	 	6.3	 IPH Royalty Obligation. For each Niche Candidate under development and commercialization by IPH and for
which NN has not exercised its Buy-In Option rights under Section 6.5, IPH shall pay to NN royalties on Net Sales of such Niche Candidate in accordance with the schedule set forth in
Section 7.8 and the other royalty provisions of Article 7. 

  

	 	6.4	 IPH Access to Materials. In the event that IPH undertakes the development and commercialization of a
Niche Candidate in accordance with Section 6.1, IPH shall, solely for purposes of the exercise of its license pursuant to Section 5.5(b), have the right to access reasonable quantities of samples of such Materials in NN’s
Control as are (a) claimed or otherwise covered by the Collaboration IPR or Background NN Research Technology IPR licensed to IPH under Section 5.5(b), and (b) comprise or are directed to such Niche Candidate, for purposes of its
Commercial Optimization. 

  

	 	6.5	 NN Buy-In Option. The Parties shall have the following rights in
respect of such Niche Candidates as may be developed and commercialized by IPH pursuant to Section 6.1 hereof: 

  

	 	6.5.1	 NN and its Affiliates shall, with respect to each indication for each such Niche Candidate being developed and
commercialized by IPH, have the exclusive right and option, hereby irrevocably granted by IPH to participate on a co-exclusive basis with IPH in the further development and commercialization of such Niche
Candidate for such indication and to share on *** basis all profits derived from the commercial exploitation thereof (after deduction and reimbursement of the marketing and other costs expended by the respective Parties’ in developing and
commercializing such Niche Candidate after NN’s exercise of this option), subject to NN’s payment to IPH of *** of all reasonable, documented out-of-pocket
costs expended by IPH prior to NN’s exercise of this option for the development and commercialization of the subject Niche Candidate for such indication, and NN’s undertaking to share with IPH, on *** basis, responsibility for all costs
incurred for the purposes of the further development and commercialization of such Niche Candidate for such indication incurred after the exercise of this option (the ”Buy-In-Option”).

  
 Certain information has been excluded from this agreement
(indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 45 

	 	
NN may exercise this exclusive right and option any time prior to notice from IPH of IPH’s good faith intent to enter into the first Phase III clinical trial with respect to such indication
for such Niche Candidate or the expiration of *** after NN’s receipt of such notice. In each case, IPH shall, within *** after its decision to proceed to any Phase III trial, provide NN with notice of its intention to enter into such trial
together with a draft Phase III trial protocol and all preceding Phase I and Phase II trial data in respect of the Niche Candidate IPH proposes to progress to Phase III trial. 

 

	 	6.5.2	 IPH Option to Discontinue Participation In Development Upon NN Execution of
Buy-In Option. In the event that NN exercises the foregoing Buy-In-Option pursuant to Subsection 6.5.1 with respect to
any Niche Candidate, IPH shall have the option to discontinue its participation in the further development and commercialization of such Niche Candidate for the indication(s) with respect to which NN has exercised the
Buy-In-Option, which opt-out option may only be exercised by IPH’s delivery to NN of written notice thereof within *** after
IPH’s receipt of notice of NN’s exercise of the Buy-In-Option. In the event that NN exercises the Buy-In-Option and IPH exercises the foregoing opt-out right: 

  

	 	(a)	 NN or its Affiliates shall assume the sole and exclusive right and license (with the rights to Sub-license and Out-license) to further develop and commercialize such Niche Candidate for such indication(s) in the Territory during the Term, subject to NN’s payment to
IPH of (i) one hundred percent of all reasonable, documented out-of-pocket costs expended by IPH for the development and commercialization of such Niche Candidate
for such indication(s) prior to NN’s exercise of the Buy-In-Option (in lieu of and not in addition to the *** of such costs payable under Subsection 6.5.1,)
(ii) IPH’s *** share of all reasonably documented out-of-pocket costs incurred by the Parties during the period between NN’s exercise of the Buy-In-Option and the effective date of IPH’s exercise of its option to discontinue its participation in the development and commercialization of such Niche Candidate for
such indication(s)), and (iii) royalties in accordance with Subsection 7.8.3 (Scenario 3(A), 3(B) or 3(C)); and 

  

	 	(b)	 NN or its Affiliates shall bear the sole and exclusive responsibility for all costs of such further development
and commercialization, and have the exclusive right to all revenues derived from the commercialization, of such Niche Candidate for such indication(s) incurred after the effective date of IPH’s election to opt out of such further development
and commercialization pursuant to this Subsection 6.5.2; and 

  

	 	(c)	 IPH shall have no further right or license to develop or commercialize such Niche Candidate for such
indication(s) and all rights and licenses granted to IPH hereunder in respect of the relevant indication(s) for such Niche Candidate shall be granted or granted back to NN. 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 46 

	 	6.5.3	 IPH Out-License of Niche Candidates; NN Right of First Offer. In
the event that IPH desires to Out-license any Niche Candidate before its determination to initiate the first Phase III trials for such Niche Candidate for any indication(s) with respect to which IPH has
acquired exclusive rights under Section 6.1, NN and its Affiliates shall have an irrevocable first right of offer, hereby granted, to negotiate an Out-license with IPH in respect of such Niche
Candidate pursuant to the procedures set forth in Subsection 13.3.6. If such an Out-license agreement is signed by NN and IPH, IPH shall have no further right or license to develop or commercialize such
Niche Candidate in the indication(s) covered by such agreement, save that if no such agreement is executed within the period of *** after such First Offer NN shall have no further right and option under Subsection 6.5.1.

  

	 	6.6	 NN Co-Marketing Option. In addition to the foregoing rights,
save where IPH has previously Out-licensed any rights in respect of a Niche Candidate to a Third Party, NN and its Affiliates shall have the exclusive right and option, hereby irrevocably granted by IPH, to co-market any such Niche Candidate for any indication(s) with respect to which IPH has acquired exclusive rights under Section 6.1 on terms to be negotiated between the Parties in good faith, which
option may be exercised by NN at any time during the first *** following the First Commercial Sale anywhere in the Territory with respect to each such Niche Candidate for such indication(s). In the event that the Parties are unable to agree to the
terms of co-marketing in good faith any remaining disputed terms shall be determined in accordance with Section 21.14. 

 

	 	6.7	 IPH Assistance to NN Upon NN Exercise of Buy-In or Co-Marketing Option. If NN shall exercise any of its rights or options under Subsections 6.5.1 or Section 6.6, or enter into any Out-license with IPH
pursuant to Subsection 6.5.3 IPH shall provide NN with all information (regulatory, clinical, CMC and other) in its possession or control that is necessary or useful for purposes of NN’s development or commercialization of the affected
Niche Candidates for all indications concerned, and NN shall have the right to reference all IPH regulatory filings (including all Drug Master Files) for NN to pursue registrations in respect of such indications. IPH’s reasonable out-of-pocket costs connected with providing NN such information and arranging for such rights of reference, including the use of IPH staff resources shall be paid by NN on an
hourly basis reflecting the actual cost to IPH but in no circumstances shall such costs exceed a total of ***. 

  

	 	6.8	 Licenses to NN for Niche Candidates. If NN shall exercise its options pursuant to either
Section 6.5 or 6.6, IPH shall, for no additional consideration, grant to NN: 

  

	 	(a)	 the necessary licenses under any IPR under its Control that is necessary for NN to develop and commercialize
the relevant Niche Candidates pursuant to this Article 6; and 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 47 

	 	(b)	 a license under any trade mark, trade dress or similar rights held or exercised by IPH or any of its Affiliates
anywhere in the Territory in connection with the marketing of such Niche Candidates. 

  

	 	  	 With respect to co-marketing, in the event that such trade marks do not
exist, the Parties shall in good faith agree upon the adoption and use of trade marks and similar trade designations (including trade dress) for the marketing of such Niche Candidates without any obligation of further payment or consideration.

  

	 	6.9	 Exclusion of Funded FTEs. For the avoidance of doubt, references in this Agreement to IPH’s out-of-pocket costs shall not include any employee compensation or other costs or expenses that have been underwritten by any NN research funding contributions, including any
such funding contributions pursuant to Section 3.12. 

  

	7.	 TECHNOLOGY FEES, MILESTONES AND ROYALTIES 

 

	 	7.1	 Consideration. In consideration of the rights and licenses granted to NN hereunder, NN agrees to pay to
IPH the upfront technology access fee, milestone payments and royalties set forth in this Article 7 in accordance with the terms and conditions set forth therein. Notwithstanding any other provisions of this Agreement, but subject to each
Party’s obligations to pay royalties to the other Party during the ten (10) year period following First Commercial Sale, IPH and NN shall have no obligation to pay any royalty or other consideration whatsoever for or upon any Net Sales of
any product (including any Licensed Product, Niche Candidate or Residual Product) in any country, ***. 

  

	 	7.2	 Technology Access Fee. NN shall pay to IPH, upon the Parties’ execution and delivery of this
Agreement on the date of this Agreement, a total non-refundable, non-creditable technology access fee of ***. 

 

	 	7.3	 Discovery Milestones. NN shall pay to IPH the following milestone payments for the Collaboration
achievements in research set out below (“Discovery Milestones”) within *** of the achievement of each such Discovery Milestone: 

  

	 	  	 *** as defined in Schedule 1.1.51 after the date of this Agreement during the Collaboration Term
or within the *** period following immediately after the Collaboration Term: 

  

	 	  	 *** 

  

	 	  	 *** as defined in Schedule 1.1.41 after the date of this Agreement during the Collaboration Term
or within the *** period following immediately after the Collaboration Term: 

  

	 	  	 *** 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 48 

	 	  	 *** as defined in Schedule 1.1.52 after the date of this Agreement during the Collaboration Term
or within the *** period following immediately after the Collaboration Term: 

  

	 	  	 *** 

  

	 	  	 For the avoidance of doubt, the Parties acknowledge and agree that all Discovery Milestones have been paid in
full in respect of Anti-KIR. 

  

	 	7.4	 Development Milestone Payments. NN shall pay to IPH the following milestone payments for the
achievements in development set out below (“Development Milestones”) within *** of the achievement of each such Development Milestone. 

  

	 	7.4.1	 Class B Licensed Products and Class C Licensed Product Development Milestones 

 

	 	  	 Development Milestones shall be payable for each Class B Licensed Product or Class C Licensed
Product, on a one-time, non-duplicative Licensed Product-by-Licensed Product basis,
irrespective of the number of indications or Backup Products per Licensed Product and any Out-licensing or Sub-licensing by NN: 

 

	 	(a)	 *** 

  

	 	(b)	 *** 

  

	 	(c)	 *** 

  

	 	(d)	 *** 

  

	 	(e)	 *** 

  

	 	(f)	 *** 

  

	 	(g)	 *** 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 49 

	 	7.4.1.1	 Milestone Payment Terms. All the above Development Milestone payments (specified in
Section 7.4.1) are: 

  

	 	(a)	 *** 

  

	 	(b)	 *** 

  

	 	(c)	 *** 

  

	 	7.4.2	 Class A Licensed Product Development Milestones. 

 

	 	7.4.2.1	 First Developed in Kirostim Field. *** for a Class A Licensed Product first occurs in the Kirostim
Field the payment of the Development Milestones for each such Class A Licensed Product shall be, on a Licensed Product-by-Licensed Product basis, irrespective of
the number of indications or Backup Products for such Class A Licensed Product, and any Out-licensing or Sub-licensing by NN as follows: 

 

	 	(a)	 *** 

  

	 	(b)	 *** 

  

	 	(c)	 *** 

  

	 	(d)	 *** 

  

	 	(e)	 *** 

  

	 	(f)	 *** 

  

	 	(g)	 *** 

  

	 	(h)	 *** 

  

	 	  	 For the avoidance of doubt, each of the foregoing Development Milestone payments (a), (b), (c), (d), (e), (f),
(g) and (h) shall be payable only once regardless of the number of indications in the Kirostim Field for which a Class A Licensed Product is developed. 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 50 

 If a Class A Licensed Product achieves First Commercial Sale in a cancer indication in the
Kirostim Field, Development Milestone (g) shall be payable. If a Class A Licensed Product achieves First Commercial Sale in a non-cancer indication in the Kirostim Field, Development Milestone
(h) shall be payable. If a Class A Licensed Product achieves First Commercial Sale in both a cancer indication and a non-cancer indication in the Kirostim Field, Development Milestones (g) and
(h) shall both be payable. For the avoidance of doubt, if any Class A Licensed Product is first developed in the Kirostim Field, the Development Milestones will amount to a maximum of ***. 

 

	 	7.4.2.1.1	 Milestone Payment Terms. All the above Development Milestone payments (specified in Subsection
7.4.2.1) are: 

  

	 	(a)	 *** 

  

	 	(b)	 *** 

  

	 	(c)	 *** 

  

	 	7.4.2.2	 Subsequent Development in the Additional Kirostim Field. If a Class A Licensed Product has achieved
Development Milestone (a) in the table of Subsection 7.4.2.1 in respect of development in the Kirostim Field, and the development of such Class A Licensed Product in the Additional Kirostim Field commences after the achievement of
Development Milestone (a) in the Kirostim Field, then Development Milestones (c), (d), (e), (f) and (g) in the table of Subsection 7.4.2.1 shall be payable for each indication for which that Class A Licensed Product is
developed in the Additional Kirostim Field. For the avoidance of doubt, for each Class A Licensed Product developed for any given indication in the Additional Kirostim Field, the maximum Development Milestones payable shall be *** per
indication in the Additional Kirostim Field in addition to the Development Milestone payments in the Kirostim Field. 

  

	 	7.4.2.2.1	 Milestone Payment Terms. All the above Development Milestone payments (specified in Subsection
7.4.2.2) are: 

  

	 	(a)	 *** 

  

	 	(b)	 *** 

  

	 	(c)	 *** 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 51 

	 	7.4.2.3	 First Developed in Additional Kirostim Field. In the event that the *** for each Class A Licensed
Product first occurs in the Additional Kirostim Field the Development Milestones for each Class A Licensed Product, in every separate indication in the Additional Kirostim Field, on a Licensed Product-by-Licensed Product basis, irrespective of the number of Backup Products per Licensed Product and any Out-licensing or
Sub-licensing by NN shall be as follows: 

  

	 	(a)	 *** 

  

	 	(b)	 *** 

  

	 	(c)	 *** 

  

	 	(d)	 *** 

  

	 	(e)	 *** 

  

	 	(f)	 *** 

  

	 	(g)	 *** 

For the avoidance of doubt if such a Class A Licensed Product is developed in the Additional Kirostim Field in such circumstances, the
Development Milestons payable to IPH shall amount to a maximum of *** per indication in the Additional Kirostim Field. 
  

	 	7.4.2.3.1	 Milestone Payment Terms. All the above milestone payments (specified in Subsection 7.4.2.2) are:

  

	 	(a)	 *** 

  

	 	(b)	 *** 

  

	 	(c)	 *** 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 52 

	 	7.4.2.3.2	 Subsequent Development in the Kirostim Field. 

If a Class A Licensed Product has achieved Development Milestone (a) in respect of development in the Additional Kirostim Field
(under Subsection 7.4.2.3), and the development of such Class A Licensed Product in the Kirostim Field commences after the achievement of such Development Milestone (a) in respect of development in the Additional Kirostim Field,
then Development Milestones (c), (d), (e), (f), (g) and (h) in the following table shall be payable, only once per Class A Licensed Product, regardless of the number of Backup Products to such Licensed Product or the number of indications
for which such Class A Licensed Product is developed in the Kirostim Field. 
  

	 	(c)	 *** 

  

	 	(d)	 *** 

  

	 	(e)	 *** 

  

	 	(f)	 *** 

  

	 	(g)	 *** 

  

	 	(h)	 *** 

  

	 	  	 For the avoidance of doubt, the maximum Development Milestones payable under this Subsection 7.4.2.3.2
for development in the Kirostim Field shall be *** for each Class A Licensed Product based on the achievement of all of the foregoing Development Milestones (c), (d), (e), (f), (g), and (h) in addition to the Development Milestone payments
payable in the Additional Kirostim Field. 

  

	 	  	 All the above milestone payments (specified in Subsection 7.4.2.3.2) are: 

 

	 	(a)	 *** 

  

	 	(b)	 *** 

  

	 	(c)	 *** 

  

	 	7.5	 Royalty Calculation and Payments. In addition to all fees and other amounts payable by the Parties under
this Agreement, each Party shall pay to the other, on a quarterly basis throughout the Term, commencing with the First Commercial Sale by Selling Parties comprised of such Party, any of its Affiliates, or any of such Party’s or its
Affiliates’ respective Out-licensees, on a Licensed Product-by-Licensed Product, Niche Candidate-by-Niche Candidate or Residual Product-by-Residual 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 53 

	 	
Product basis (as the case may be), incremental running royalties on the aggregate Net Sales attained by such Selling Parties throughout the Territory during the immediately preceding calendar
quarter, in accordance with the schedules set forth in Sections 7.6 and 7.7 and the other terms and conditions of this Agreement. Each Party shall further calculate and pay to the other Party within *** of the end of each calendar year
during the Term all royalty payments remaining due and payable by that Party in respect of that calendar year. 

  

	 	7.6	 Royalties on Licensed Products. Each Party shall pay to the other the following percentage royalties on
all Net Sales of Licensed Products in the Territory by such Party (or its associated Selling Parties) on a Licensed-Product-by-Licensed-Product basis during the Term for
each such Licensed Product in accordance with Section 7.11: 

  

	 	7.6.1	 Percentage Royalties on Net Sales of Class A Licensed Products. Percentage royalties
on Net Sales of Class A Licensed Products (notwithstanding any royalties that such Party or its associated Selling Parties may have to pay to Third Parties with respect to the affected Licensed Products): 

 

	 	  	 *** 

  

	 	  	 For the purposes of illustration, in the event that the annual Net Sales in a calendar year are *** the
royalties payable to IPH will be calculated as follows: 

  

	 	  	 *** 

  

	 	7.6.2	 Percentage Royalties on Net Sales of Class B Licensed Products. Percentage royalties
on Net Sales of Class B Licensed Products (notwithstanding any royalty that such Party or its associated Selling Parties may have to pay to Third Parties with respect to the affected Licensed Products): 

 

	 	  	 *** 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 54 

	 	  	 *** 

  

	 	7.6.3	 Percentage Royalties on Net Sales of Class C Licensed Products. Percentage royalties
on Net Sales of Class C Licensed Products (notwithstanding any royalty that such Party or its associated Selling Parties may have to pay to Third Parties with respect to the affected Licensed Products): 

 

	 	  	 *** 

  

	 	  	 *** 

  

	 	7.7	 Royalties on Residual Products. Drug Candidates that; (a) would have been classified as being
Class A Licensed Products, Class B Licensed Products, or Class C Licensed Products provided they had passed M1; and (b) subsequently are designated as Residual Products pursuant to Subsection 1.1.63 and Article 13;
shall retain that classification and be treated as Licensed Products of the applicable Product Class for the purposes of calculating royalties payable in respect of such products except for products that would have been classified as being
Class C Licensed Products and where M0 approval has occurred less than *** prior to the expiry of the Collaboration Term, which royalty payments shall be according to Subsection 13.3.3. 

 

	 	7.8	 Royalties on Niche Candidates. Each Party identified below shall pay to the other Party the following
royalties on all Net Sales by the first Party (or any of its associated Selling Parties) in the Territory of each Niche Candidate commercialized by the first Party pursuant to Article 6 on a Niche Candidate-by-Niche Candidate basis for each such Niche Candidate (in each case notwithstanding any royalty the first Party or any of its associated Selling Parties may have to pay to Third Parties with
respect to the affected Niche Candidate) during the Term for each such Niche Candidate in accordance with Section 7.11: 

  

	 	7.8.1	 Scenario 1: IPH’s payment to NN of royalties on Net Sales of any Niche Candidate that IPH develops
independently of NN to M1 status and subsequently commercializes shall be: 

  

	 	  	 *** 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 55 

	 	7.8.2	 Scenario 2: IPH’s payment to NN of royalties on Net Sales of any Niche Candidate that IPH develops
independently of NN commencing after such Niche Candidate attains M1 status and subsequently commercializes shall be: 

  

	 	  	 *** 

  

	 	7.8.3	 Scenario 3: NN’s payment to IPH of royalties on Net Sales of any Niche Candidate with respect to
which NN has exercised its Buy-In-Option and IPH has exercised its opt out option pursuant to Subsection 6.5.2 shall be as follows: 

 

	 	7.8.3.1	 Scenario 3(A): If NN assumes exclusive development and commercialization of such Niche Candidate prior
to the filing of the first IND for such Niche Candidate: 

  

	 	  	 *** 

  

	 	7.8.3.2	 Scenario 3(B): If NN assumes exclusive development and commercialization of such Niche Candidate after
the filing of the first IND for such Niche Candidate but before the dosing of the first patient in the first Phase II trial for such Niche Candidate: 

  

	 	  	 *** 

  

	 	7.8.3.3.	 Scenario 3(C): If NN assumes exclusive development and commercialization of such Niche Candidate after
the dosing of the first patient in the first Phase II trial but prior to the expiration of *** after its receipt of notice of IPH’s decision to proceed to Phase III trials for such Niche Candidate in accordance with Subsection 6.5.1:

  

	 	  	 *** 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 56 

	 	7.9	 Records of Net Sales. Each Party shall keep complete and correct records of its Net Sales and the Net
Sales of its associated Selling Parties and shall provide to the other Party on a quarterly basis a summary report indicating all Net Sales giving rise to royalties payable to the other Party on a product-by-product and country-by-country basis for the preceding quarter. Quarterly royalty payments under this Agreement shall
be calculated at the royalty rates set out in Sections 7.6m 7.7 and 7.8 or Article 13 and 3, as applicable, save that the royalty rate(s) applicable to the whole or any portions of any quarterly royalty payment shall be
calculated by adding together on a product-by-product basis all Net Sales made by a Party and its associated Selling Parties so far during that calendar year. Such
quarterly payments shall be due and payable within *** after March 31, June 30, September 30 and December 31 of each calendar year. Exchange rates applicable for the calculation of quarterly royalty payments shall be based on
***. For the avoidance of doubt, only one (1) royalty shall be payable on the Net Sales of any item of Licensed Product, Niche Candidate or Residual Product, irrespective of (a) the number of indications for which such Licensed Product,
Niche Candidate or Residual Product, or any combination thereof, is sold or used, or (b) the number of Valid Claims that cover such Licensed Product, Niche Candidate or Residual Product, and shall end all further payment obligations to the
licensor Party in respect of the commercial exploitation of such item, including any obligation of any end user or other Person to whom or which such item is sold. 

 

	 	7.10	 Annual Recalculation and Report. Each Party shall within *** after the end of each calendar year during
the Term deliver a final report including a calculation of the annual Net Sales in the preceding calendar year and a final calculation of the total annual royalty payments due for that calendar year. Exchange rates for this calculation shall follow
that for the quarterly calculation. Any difference between the sum of the quarterly royalty payments made by a Party for the calendar year in reference and the total annual royalty payments due and payable by such Party for the calendar year shall
be paid by to the other Party within *** after delivery of the final report. 

  

	 	7.11	 Royalty Term. Except as otherwise herein expressly provided, the Parties’ respective obligations to
pay royalties on Net Sales of Licensed Products, Niche Candidates and Residual Products under this Agreement shall commence, on a product-by-product and country-by-country basis with the First Commercial Sale of such product in the relevant country and expire, on a product-by-product and country-by-country basis, with the expiration of the Term with respect to such 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 57 

	 	
product in such country, as set forth in Subection 1.1.66. After the expiration of the Term with respect to any Licensed Product, Niche Candidate or Residual Product in any country(ies),
no further royalties or other consideration shall be required to be paid or provided for or upon any Net Sales or other commercial exploitation of such Licensed Product, Niche Candidate or Residual Product in such country(ies), and the rights and
licenses granted herein with respect to such Licensed Product, Niche Candidate or Residual Product in such country(ies) shall be deemed fully paid-up and without obligation to provide any further
consideration. 

  

	 	7.12	 No Effect of Out-licensing on Royalties. Each Party shall pay
the milestones payments and royalty rates it has herein agreed to in this Agreement whether or not such Party enters into any Out-licenses with different milestones or royalty rates. 

 

	8.	 FINANCIAL PROVISIONS 

 

	 	8.1	 Payment by Wire Transfer. All amounts due under this Agreement shall be paid by wire transfer to such
bank account as the Party to whom such amounts are due may direct in writing from time to time. 

  

	 	8.2	 Currency. All payments shall be made in Euro. All amounts to be paid are intended to be net of any
deduction imposed by a government authority including any tax, duty, levy, fee or charge that may be applied to such amount. To the extent income is received or expenses are incurred in a currency other than Euro, the applicable income or expenses
shall be converted into Euro using such bona fide publicly quoted commercial rate of exchange contemporaneously in general use by the paying Party at the given time. 

 

	 	8.3	 Withholding Tax. If any payment made by a Party under this Agreement is subject to recoverable
withholding tax, the Parties shall support legal efforts of minimizing such withholding taxes, and provide each other with information about any documentation to reduce the withholding tax to a legal minimum. 

 

	 	8.4	 Audits. If either Party requests, the other Party shall allow its books and records to be audited by an
independent major certified public accountant selected by the requesting Party, to whom the other Party has no reasonable objection. The objective of such audits shall only be to examine the calculation of the royalties payable under this Agreement.
Such audits shall take place upon reasonable (but not less than ***) notice, only during normal business hours and no more than one time in any calendar year, shall not cover transactions that occurred before for more than the preceding ***, shall
not cover entries in books and records which predate the Effective Date and shall cover only the transactions relating to Net Sales under this Agreement. Such auditor shall not in any way be compensated (in whole or in part) contingent on the
outcome of the audit. Any information gathered or obtained during any such audit shall be deemed the Confidential Information of the audited Party, and the auditor must sign a confidentiality agreement undertaking that he shall not disclose to any
Person, including the Party who has requested the audit, any information obtained in the course of the audit other than information relating solely to the accuracy and validity of the royalty statements provided by the audited Party. Such audits
shall 

  
 Certain information has been excluded from this agreement
(indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 58 

	 	
be (a) conducted in accordance with generally accepted auditing standards; (b) limited to those books and records described in this Section 8.4; and (c) undertaken for
the sole purpose of verifying the accuracy and validity of the royalty information, statements and documentation information provided by the audited Party. A copy of the auditor’s report shall be furnished to each Party promptly after the
completion of such audit. 

  

	 	8.5	 Cost of Audit. The cost of any audit pursuant to Section 8.4 shall be the responsibility of
the Party that has requested such audit. In the event that such audit discloses that the royalties have not been calculated accurately and this has resulted in an underpayment of *** or more by either Party in total during a calendar year, the costs
of the audit shall be borne by the audited Party. 

  

	 	8.6	 Right to Audit Third Parties. In the event that Net Sales are generated by the Affiliates or Out-licensees of either Party, such Party shall ensure that the books of such Affiliates and Out-licenses may also be audited by the other Party in accordance with
Section 8.4 above. 

  

	9.	 INTELLECTUAL PROPERTY RIGHTS 

 

	 	9.1	 Disclosure of Know-How. During the Collaboration Term, each
Party shall promptly disclose to the other Party the conception, reduction to practice, or other generation or acquisition of potentially patentable, otherwise legally protectable, or commercially useful
Know-How in the Collaboration Field (including any relevant invention disclosures), by employees or others acting on behalf of such Party, and shall freely share data and results obtained in the Collaboration.
During the Collaboration Term, each Party shall also provide the other with such technical information and assistance as is sufficient to enable the other Party to assess the progress of the work performed by such Party pursuant to the Collaboration
and to assist the other Party in achieving Commercial Optimization. All disclosures of Know-How under this Section 9.1 shall be made at least *** prior to any public disclosure of such Know-How or any required submission to government agencies in compliance with the requirements of government supported research. Any Patent filed after the date of this Agreement (and any Patents related to any such
Patent), in respect of Know-How that is the subject matter of an invention disclosure listed as Background IPR of a Party as of the date of this Agreement in a relevant Schedule hereto shall be treated as
Background IPR of that Party. 

  

	 	9.2	 Ownership of Collaboration IPR. All right, title and interest, as between the Parties, in all
Collaboration IPR shall be owned as follows: 

  

	 	(a)	 IPH shall own all Collaboration IPR that is invented or otherwise generated or acquired solely by one or more
employees, agents, or other Persons acting on behalf of IPH, either alone or together with Persons other than NN, NN Affiliates, or any employees, agents or other Persons acting on behalf of NN or any of NN’s Affiliates; 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 59 

	 	(b)	 NN shall own all Collaboration IPR that is invented or otherwise generated or acquired solely by one or more
employees, agents or other Persons acting on behalf of NN, either alone or together with Persons other than IPH, IPH’s Affiliates, or any employees, agents or other Persons acting on behalf of IPH or any of IPH’s Affiliates; and

  

	 	(c)	 Each of IPH and NN shall jointly own all Joint IPR. 

All questions of inventorship shall be determined in accordance with United States Patent Laws (Title 35, United States Code). All
determinations of inventorship shall be documented to ensure that any divisional or continuation Patent applications reflect appropriate inventorship. The Parties acknowledge and agree that the ownership rights set out in this
Section 9.2 are subject to the rights and licenses granted pursuant to this Agreement. 
  

	 	9.3	 Disputes Regarding Inventorship or Ownership of Collaboration IPR. During the Collaboration Term, if a
dispute shall arise regarding the inventorship, ownership, validity or enforceability of any Collaboration Patent or other Collaboration IPR, the Joint Steering Committee shall establish a procedure to resolve such dispute, which may include
engaging a Third Party neutral patent attorney jointly selected by agreement of the Parties to assist them regarding the resolution of any such dispute. The Joint Steering Committee, however, shall not have the authority to resolve any such dispute.
If (a) the Joint Steering Committee or the executive officers of the Parties cannot agree upon a procedure to resolve such dispute within *** or (b) the dispute arises after the expiration or earlier termination of the Collaboration Term,
such dispute shall be submitted for resolution by arbitration in accordance with Section 21.14. 

  

	 	9.4	 Duty to Require Assignment of Collaboration IPR by Employees, Consultants, and Collaboration Partners.
Each Party shall ensure that all employees acting on behalf of itself or any of its Affiliates in performing such Party’s obligations under the Collaboration shall be obligated to assign to such Party, or as such Party shall direct, all
Collaboration IPR conceived or reduced to practice by such employees as part of the activities conducted under this Agreement. In the case of consultants, Third-Party collaboration partners and other
non-employees working with or on behalf of a Party, that Party shall exercise best efforts to obtain, at its own cost (unless hereafter otherwise decided in writing by the Joint Steering Committee or the
Parties), either an assignment or an exclusive license establishing its exclusive Control of all Collaboration IPR conceived or reduced to practice by such non-employees and, at a minimum, an exclusive option
or first right of negotiation to secure such exclusive rights. In all events, each Party shall perform its obligations pursuant to Section 5.8 to preserve the other Party’s freedom of operation to exercise its rights and fulfill its
obligations hereunder. 

  

	 	9.5	 Obligations to Maintain Control of Licensed IPR. Subject to Section 5.10, throughout the
Term: 

  

	 	9.5.1	 IPH Obligation. IPH shall maintain Control of Background IPH IPR, Collaboration IPR, and Independent IPH
IPR, to the extent such IPR is Controlled by IPH as of the date of this Agreement or acquired by IPH during the Term, throughout the Term, and 

  

	***	 Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately
with the Commission. 

  
 60 

	 	9.5.2	 NN Obligation. NN shall maintain Control of Background NN IPR, Collaboration IPR, and Independent NN
IPR, to the extent such IPR is Controlled by NN as of the date of this Agreement or acquired by NN during the Term, throughout the Term, except that NN shall have no obligation to retain Control of Independent NN IPR if doing so will require
NN’s provision or payment of any additional consideration to any Person for such retention save that IPH may pay for and obtain the right to such procurement or exercise to the extent authorized by contract and permitted by applicable Law.

  

	 	9.5.3	 Exception for Third Party Diligence Obligations. The Parties’ obligations under this Agreement to
maintain Control of IPR shall be subject to the limitations set forth in agreements with Third Parties with respect to development and commercialization diligence obligations and neither Party shall be in breach of this Agreement in the event of the
termination of rights to such IPR resulting from its failure to fulfil such diligence obligations, provided that such failure does not result from the failure of the Party to exercise Commercially Reasonable Efforts. 

 

	 	9.5.4	 Limitation of Obligation regarding Identified Independent IPR. The obligation of either Party to Control
Independent IPR shall only apply to Independent IPR that one Party has specifically identified to the other Party as being necessary for the identifying Party’s freedom of operation to commercialize products in accordance with its rights and
licenses hereunder. Independent NN IPR identified by IPH pursuant to this Section shall be listed in Schedule 9.5.4(a) and Independent IPH IPR identified by NN pursuant to this Subsection 9.5.4 shall be listed in Schedule
9.5.4(b). NN shall within *** of any reasonable request by IPH update Schedule 9.5.4(a) and IPH shall within *** of request by NN update Schedule 9.5.4(b) (e.g. to provide the serial number and publication number of related
patent applications, the patent number of related patents, and to provide the status of listed patents and patent applications to the Patents initially listed therein). At the request of a Party that is obligated to maintain Control of any
Independent IPR pursuant to this Subsection 9.5.4, the Parties shall determine in good faith whether continued maintenance of Control over such IPR is required and, in cases where the Parties agree such continued maintenance of Control is no
longer required the Party previously required to maintain such control shall have no further obligation to maintain Control of such IPR. 

  

	 	9.6	 Prosecution of Patents. 

 

	 	9.6.1	 Correspondence Regarding Proposed Patent Submissions. Subject to the terms and conditions of
Section 21.2 and the Common Interest Agreement annexed as Schedule 21.2 hereto, the Party responsible for prosecuting any Patent under this Article 9 shall promptly, and in any event no less than *** prior to any final
deadline for submission of such documents or required filing date, deliver or have delivered to the other Party copies of: 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 61 

	 	(a)	 all proposed amendments, 

 

	 	(b)	 all proposed Patents (including drafts of new original applications, proposed continuations, proposed
divisional applications, proposed reissue applications, and proposed continuations-in-part) or, in instances where several proposed Patents are substantially similar, a
representative Patent for such proposed Patents (such as in the case of national phase filing of an International (PCT) patent application), 

  

	 	(c)	 all substantive documents proposed to be filed in patent authority appeal proceedings, 

 

	 	(d)	 all substantive documents proposed to be filed in inter partes disputes (including opposition, reexamination,
or interference proceedings) before patent authorities or before any judicial body on appeal of such proceedings, and 

  

	 	(e)	 any other substantive proposed patent authority submissions reasonably and specifically requested by the other
Party, 

 in respect of such Patents (except for Patents in the Independent IPR of either Party), so as to provide the
other Party with a sufficient opportunity to review and comment on such proposed submissions. However, except as otherwise provided for in this Section 9.6, the prosecuting Party shall have no obligation to act in accordance with any
such comments. 
  

	 	9.6.2	 Patent Authority Correspondence. The Party responsible for prosecuting any Patent under this Article
9 shall with respect to such Patent (other than any Patent included in the Independent IPR of either Party): 

  

	 	(a)	 notify the other Party of receipt of all office actions or other substantive patent authority correspondence
requested by the other Party and filing of responses thereto in the prosecution of (i) any U.S., European, or Japanese patent application, (ii) any other specific patent application specifically requested by the other Party, or
(iii) patent applications of any other country, region, or patent examining authority specifically and reasonably requested by the other Party, in such Patent, and provide all copies of such documents to the other Party that are not readily
publicly available, 

  

	 	(b)	 notify the other Party of the allowance of any such Patent, giving the other Party the expected date of
issuance thereof, allowed claims, and its plans with respect to filing of any continuation, divisional, or similarly related patent application to such allowed Patent, and 

  
 62 

	 	(c)	 notify the other Party of the issuance of any such Patent. 

 

	 	9.6.3	 Patents Prosecuted by NN. NN shall, during the Term, have the exclusive right and sole discretion to
file, prosecute, and maintain Patents with respect to any discoveries or inventions encompassed by the Joint IPR, NN owned Collaboration IPR, Background NN IPR, or Independent NN IPR, provided that NN has such rights to file, prosecute, and
maintain vis-à-vis Third Parties. NN shall bear sole responsibility for the preparation of and all costs of procuring the filing, prosecution, and maintenance of
such Patents, including attorneys’ fees and payments due to Patent authorities to maintain such Patents. NN may, at its option, prepare, file, prosecute, and maintain all such Patents, including any Patents within the Joint IPR, by using
NN’s in-house patent attorneys/patent agents, and IPH acknowledges and agrees that this does not create an attorney-client relationship between NN and IPH. NN may enter into any arrangement it deems
appropriate with any relevant Third Party(ies) regarding prosecution of Patents that are owned by NN and IPH together with one or more such Third Parties, and IPH shall provide to NN all reasonable assistance with respect to entering into such
arrangements as may be requested by NN. 

  

	 	9.6.4	 IPH Prosecution of Patents in Independent IPH IPR. IPH shall, during the Term, have the exclusive right
and sole discretion (to the extent authorized by contract and permitted by applicable Law) to file, prosecute and maintain Patents with respect to any discoveries or inventions encompassed by Independent IPH IPR provided that IPH has such
rights to file, prosecute, and maintain vis-à-vis Third Parties. IPH shall bear sole responsibility for the preparation of and all costs of procuring the filing,
prosecution and maintenance of such Patents, including attorneys’ fees and payments due to Patent authorities to maintain such Patents. 

  

	 	9.6.5	 IPH Prosecution of Patents in Background IPH IPR and IPH Owned Collaboration Patents. IPH shall
be responsible for the prosecution of Patents in the Background IPH IPR and Collaboration IPR owned by IPH but not by NN. IPH shall bear sole responsibility for the preparation of and all costs of procuring the filing, prosecution, and maintenance
of such Patents, including attorneys’ fees and payments due to Patent authorities to maintain such Patents, provided that IPH has such rights to file, prosecute, and maintain
vis-à-vis Third Parties. IPH may, at its option, prepare, file, prosecute and maintain such Patents by using IPH’s
in-house patent attorneys/patent agents, and NN acknowledges and accepts this and that this does not create an attorney-client relationship between NN and IPH. 

 

	 	9.6.5.1	 NN’s Limited Right to Comment On or Direct Prosecution of Patents Prosecuted by IPH Under Subsection
9.6.5. With respect to Patents prosecuted by IPH under this Section 9.6.5, NN may, (i) any time prior to *** before the deadline for filing 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 63 

	 	
any response, application, or the like in respect of any proposed filing or submission concerning such Patents provided to NN by IPH under Subsection 9.6.1 or (ii) at any other time
with respect to prosecution of such Patents, provide comments to IPH regarding such proposed submission or prosecution. IPH shall consider NN’s comments in good faith and shall notify NN within the shorter of either *** of its receipt of such
comments or *** before any deadline for filing or submission as to whether it intends to adopt or reject NN’s suggestions. In the event that IPH notifies NN that it will not adopt NN’s suggestions, NN may at any time thereafter:

  

	 	(a)	 direct IPH to make additions, modifications, or deletions in proposed Patents and patent authority
correspondence to be filed after the date of this Agreement; and 

  

	 	(b)	 to adopt or modify the prosecution strategy for such Patents and for Patents that have already been filed by
the date of this Agreement (such as by accelerating prosecution or adding additional claims with respect to such Patents). 

IPH shall comply with any such directions provided by NN provided that such directions do not materially impact IPH’s ability to
prosecute or obtain claims of its choice in at least one related Patent in any applicable patent family in any country or region in such Patents or limit the term of such related Patent. In cases where NN has provided such directions to IPH in
respect of a Patent of a particular patent family and country or region, IPH shall have the right to file one or more continuation applications, divisional applications, or the like with respect to such Patent, wherein NN shall not have such right
to direct prosecution so long as IPH’s prosecution of such other applications does not materially limit the term of any Patent in which NN has the right to provide such directions. 

 

	 	9.6.6	 IPH Right to Pursue Patents in Joint IPR and NN-Owned Collaboration IPR
for Licensed Products, Niche Candidates or Residual Products. In the event that IPH shall become licensed hereunder to commercialize a Licensed Product, Niche Candidate or Residual Product, IPH shall, at its own expense and to the extent permitted
by contract and applicable Law, during the Term, have the exclusive right and sole discretion to file, prosecute, maintain, and defend such Joint Patents and Patents in NN solely owned Collaboration IPR that claim solely, specifically, and
exclusively, such products provided that IPH’s prosecution, maintenance, or defense of such Patents does not materially prejudice NN’s ability to obtain patent protection relevant to Licensed Products, Niche Candidates or Residual
Products licensed to NN hereunder. 

  
 Certain information has been
excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 64 

	 	9.6.7	 Rights of the Parties to Pursue Continuations of Allowed Patents. Where either Party notifies the other
of the allowance of a Patent prosecuted pursuant to this Article 9 (except for Patents within the Independent IPR of either Party) and indicates that it does not intend to pursue a continuation application, divisional application, or
similarly related patent application to such allowed Patent, the other Party shall have the right to file such a related patent application at its own expense and the notifying Party shall assign its rights in such Patent to the other Party and
provide any other assistance reasonably requested by the other Party in connection with the filing and prosecution of such related patent application (including providing the other Party with power of attorney to file and prosecute such patent
application). The other Party shall thereafter grant to the notifying Party a worldwide, non-exclusive license under such Patent for no additional consideration. 

 

	 	9.6.8	 Notice and Effects of Either Party’s Decision to Abandon; Disclaim; or Discontinue Prosecution,
Maintenance, or Defense of Patents. In the event that either Party decides in respect of any Patent for which it is responsible for prosecution hereunder (except for Patents within the Independent IPR of that Party): 

 

	 	(a)	 to discontinue the prosecution or maintenance of any Patent, 

 

	 	(b)	 to discontinue the defense of any Patent (such as by discontinuing efforts to defend a Patent that is the
subject of an opposition, reexamination, nullity, or interference proceeding), 

  

	 	(c)	 to not file a priority patent application with respect to (i) an invention disclosure in the Collaboration
IPR or (ii) any Patent to which it is the prosecuting Party (including by decision (A) not to enter the national or regional phase in any country or region that is a designated state of a PCT application filed by such Party or (B) not
to pursue an application in a country wherein an application claiming priority to another application filed by such Party may be filed), or 

  

	 	(d)	 to abandon or disclaim (in whole or in part, other than by terminal disclaimer), without possibility of
restoration, any Patent, 

 it shall provide written notice to the other Party at least *** in advance of such abandonment
or deadline for such filing – except in the case of national phase filing, in which case such notice shall be provided at least *** in advance of the date of the first applicable deadline for national phase entry – so as to allow the other
Party the opportunity to file, defend, maintain (including by payment of annuities, issue fees, maintenance fees, or the like), or continue prosecution of such Patent, at its own expense. In such an event, the notifying Party shall provide any
assistance reasonably requested of it by the other Party (including providing the other Party with power of attorney to perform such tasks) and, to the extent authorized by contract and permitted by applicable Law, assign its rights to such Patent
to the other Party. The notified Party shall thereafter grant to the notifying Party a worldwide, non-exclusive 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 65 

 
license with respect to such Patent for no additional consideration. The Parties acknowledge that any abandoned Patents listed as Background IPR as of the date of this Agreement in the applicable
Schedules hereto represent Know-How of the Party associated with such IPR and that such party shall, during the Term, be entitled to file, prosecute, and maintain Patents in respect of such subject matter and
any Patent arising therefrom shall be deemed Background IPR of such Party. 
  

	 	9.6.9	 Obligation to Provide Assistance With Respect to Other Party’s Patent Prosecution. Except with
respect to Patents in the Independent IPR of either Party, each Party shall support a prosecuting Party’s efforts to obtain Patent protection, including participating in or causing the preparation, execution, and filing of appropriate formal
documents in national and international patent offices and obtaining the cooperation of inventors in supporting Patents prosecuted pursuant to this Article 9. The other Party shall make available to such prosecuting Party (or to such
prosecuting Party’s authorized attorneys, agents or representatives) the other Party’s employees, agents, consultants, and, to the extent possible, Third Party collaboration partners to the extent necessary or reasonably useful to enable
the prosecuting Party to file, prosecute, maintain, and defend said Patents for such periods of time as are sufficient for the prosecuting Party to obtain the necessary assistance from such Persons. 

 

	 	9.6.10	 Discovered Information. Each Party shall provide the other Party with timely notification regarding any
information it discovers during the Term that may be reasonably considered to materially impact the validity, enforceability, scope or term of any Patent under this Article 9, except with respect to Patents in the Independent IPR of either
Party. 

  

	 	9.6.11	 Diligence in Patent Prosecution. Each Party shall exercise diligent endeavours in its filing,
prosecution, and maintenance of Patents for which it is the prosecuting Party under this Article 9. Such duty shall not apply, however, with respect to Patents in the Independent IPR of either Party. 

 

	 	9.7	 Updating of Patent Schedules and Patent Information. 

 

	 	9.7.1	 NN shall, (a) within *** of any reasonable request from IPH, update Schedule 1.1.7 or Schedule
1.1.8 to include Background NN IPR and Background NN Research Technology IPR, respectively (including providing the application and publication numbers for any counterparts of patent applications originally listed therein and indicating the
status of such applications and any related patents), (b) provide any information reasonably requested concerning Collaboration Patents prosecuted by NN, and (c) provide any information reasonably requested regarding Patents in Third Party IPR
acquired or licensed by NN or arising from a Third Party collaboration to which NN is a party, and 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 66 

	 	9.7.2	 IPH shall, (a) within *** of any reasonable request from NN, update Schedule 1.1.5 or Schedule
1.1.6 to include Background IPH IPR and Background IPH Research Technology IPR, respectively (including providing the application and publication numbers for any counterparts of patent applications originally listed therein and indicating the
status of such applications and any related patents), (b) provide any information reasonably requested concerning Collaboration Patents prosecuted by IPH, and (c) provide any information reasonably requested regarding Patents in Third Party IPR
acquired or licensed by NN or arising from a Third Party collaboration to which NN is a party. 

  

	 	9.7.3	 NN shall, within *** of any reasonable request by IPH, update Schedule 1.1.16 including using
information provided to it by IPH under Subsection 9.7.2. 

  

	 	9.8	 Patent Term Extension. IPH shall advise NN of any communications between IPH and any regulatory agency
(including the FDA or EMEA) or other governmental body that may be reasonably considered pertinent to an extension of the term of a Patent exclusively licensed to NN hereunder (including, without limitation, patent term restoration under the U.S.
Patent Statutes (35 U.S.C. §§1-376) and supplementary protection certificates in the member states of the European Union or European Economic Area, or Switzerland). 

 

	 	9.8.1	 NN, at its sole discretion and cost, may seek, or direct IPH to seek, where appropriate, an extension of the
term of any Patent licensed exclusively to NN hereunder or other patent Controlled by IPH covering a Licensed Product (including, without limitation, filing for patent term restoration under the U.S. Patent Statutes (35 U.S.C. §§1-376) and seeking supplementary protection certificates in the member states of the European Union or European Economic Area, or Switzerland). 

 

	 	9.8.2	 IPH shall not seek an extension of the term of any patent exclusively licensed to NN hereunder without
NN’s prior written consent. 

  

	 	9.8.3	 IPH hereby authorizes NN to act as IPH’s agent before any patent authority (including the United States
Patent and Trademark Office) and agrees that NN is entitled to rely on any activities of IPH as a marketing applicant before any Regulatory Agency in any seeking of an extension of any patent for a Licensed Product. IPH shall cooperate with any
efforts by NN to extend the term of such patent for a Licensed Product, including diligently supplying all information relating to such extension to NN, and executing supporting documents required to comply with all laws pertaining to the extension
of patent term including granting NN or its representatives any power of attorney necessary to seek such extension 

  

	 	9.9	 License Registration. Either Party may, at its own expense and to the extent possible, register
information concerning the rights licensed to it herein, in whole or in part, with appropriate patent or other government authorities, where 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 67 

	 	
necessary to fully enjoy the rights and licenses provided to it hereunder, provided that the Party proposing to do so provides the other Party with a copy of any information or documents
it proposes to file in association with such registration at least *** prior to the filing thereof. Each Party shall endeavour to maintain as much confidentiality as possible regarding this Agreement in making such disclosures. Any such disclosures,
not objected to by the other Party, and made in accordance with this Section, shall not constitute a breach of the Confidentiality Provisions of this Agreement. 

  

	 	9.10	 No Implied Rights. Except as otherwise expressly provided in this Agreement, this Agreement does not
grant, license, or otherwise transfer or convey to either Party any ownership interest or other right, title or interest in or to the Patents, other IPR, or Confidential Information of the other Party, including any Materials or Know-How Controlled by the other Party (whether or not delivered by the other Party to said Party), at any time. For the avoidance of doubt, the combination of a Licensed Product, Niche Candidate or Residual Product
with Other Products as a Combination Product shall not grant or confer any right or license to either Party in respect of such Other Products. 

  

	 	9.11	 Notice of Infringement or Misappropriation. Within *** of its discovery thereof, IPH or NN notify
the other in writing 

  

	 	(a)	 of any known, alleged or threatened (i) infringement of any Patents described in this Article 9
other than Patents in the Independent IPR of either Party (ii) infringement or misappropriation of any other IPR that threatens to have an adverse affect upon Commercial Optimization, or (iii) attempt to invalidate any Collaboration
Patent, or any other Patents described in this Article 9 other than Patents in the Independent IPR of either Party, or 

  

	 	(b)	 if either Party, or any of their respective Affiliates, is named as a defendant in a legal proceeding by a
Third Party for infringement of a Patent or infringement or misappropriation of any other IPR because of the manufacture, use, importation or sale of any Licensed Product, Niche Candidate, or Residual Product, or use of any Know-How comprised in Collaboration IPR. 

 Any notice provided under
Section 9.11 shall set forth all relevant facts (to the extent known by the Party giving notice) in reasonable detail and shall include a reasonable description of available evidence associated therewith or copies of any readily
available documentary evidence associated therewith. 
  

	 	9.12	 Exclusive First Right of Enforcement of Licensed IPR. Each Party shall have the exclusive right, without
obligation, to initiate or defend any suit, opposition, interference, other legal action (including proceedings before the US International Trade Commission), or to take other appropriate action, that it, in its sole discretion, believes is
reasonably required to protect or enforce (i.e., prevent or abate actual or threatened misappropriation or infringement of, or otherwise enforce) any Patents or other IPR to which it has been granted an exclusive license under this Agreement (in its
own name or, if authorized by contract and 

  
 Certain information
has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 68 

	 	
permitted by applicable Law and required by applicable Law, in the name of the other Party or an Affiliate of the other Party), and shall bear its own costs and expenses in respect thereof and be
represented by counsel of its choice. Where any uncertainty exists regarding which Party has the right to bring such legal action, NN shall be presumed to have the first right. 

 

	 	9.12.1	 Required Joinder. If the other Party is required under applicable law to join any such legal action
initiated pursuant to this Section 9.12 or if the failure of such other Party be a party to such suit, action, or proceeding would in the opinion of counsel of the initiating or defending Party risk dismissal thereof, the other Party
shall execute all papers and perform such other acts as may be reasonably required to permit the litigation to be initiated or conducted (including initiating a suit before a court or tribunal at the initiating or defending Party’s request or
permitting the initiating or defending Party to initiate a legal action under this Section 9.12 in the name of itself and the other Party). In such an event, the initiating or defending Party shall reimburse the other Party for its
expenses relating to its joining thereto and participation therein. If the other Party is required to be joined as a party in any such action, then upon the request of the initiating Party, it shall waive any objection to such joinder on the grounds
of personal jurisdiction, venue, or forum non conveniens. The Party joined in such proceedings shall be represented by counsel for the initiating Party in such litigation or other proceedings at the initiating Party’s cost.

  

	 	9.12.2	 Settlement. A Party initiating or defending a proceeding under Section 9.12 shall have the
exclusive right, in its sole discretion, to settle any such suit or other dispute, whether by settlement or other voluntary final disposition, without the prior written approval of the other Party or the other Party’s Affiliate, provided
that the terms of such resolution do not: 

  

	 	(a)	 enjoin any future action by the other Party or any of its Affiliates,
Out-licensees, Sub-licensees, or Third-Party collaboration partners (“Affected Persons”); 

 

	 	(b)	 derogate from or diminish any of the other Party’s rights or licenses under this Agreement;

  

	 	(c)	 require any of the Affected Persons to make any payment; 

 

	 	(d)	 fail to grant the other Parties and its Affiliates a release of all claims in the dispute;

  

	 	(e)	 require the admission or concession that any claim or aspect of any Patent Controlled by the other Party or its
Affiliates is invalid or unenforceable, or require any waiver or disclaimer of any rights with respect to such claim or Patent; or 

  
 69 

	 	(f)	 otherwise have a Material Adverse Affect upon any of the Affected Persons or any of their assets, or any IPR
licensed under this Agreement. 

  

	 	9.13	 Second (“March-In”)
Enforcement Rights. In the event a Party having an exclusive license to IPR under this Agreement does not exercise its rights to initiate or defend a proceeding under Section 9.12 within *** of its receipt of notice under
Section 9.11, the other Party shall have the exclusive right to initiate or defend such proceeding at its own expense as if it were the Party initiating proceedings in accordance with the provisions of Section 9.12 and the
other Party shall comply with the terms of that Section accordingly. 

  

	 	9.14	 Share of Recoveries. Any recoveries resulting from the enforcement of Patents or other IPR by the Party
authorized to undertake such enforcement pursuant to Section 9.12 or Section 9.13 shall first be used to cover the reasonable prosecution costs of such Party and any remaining sums shall be divided between the Parties as
follows: 

  

	 	(a)	 if the infringement has taken place before the First Commercial Sale of the Licensed Product, Niche Candidate,
or Residual Product claimed or covered by the IPR or Valid Claim(s) of the Patent enforced by such enforcing Party’s action, such remaining sums shall be (i) retained by or paid to the Party Controlling such IPR or Patent in the event that
it is not jointly owned by the Parties; and (ii) shared in the proportion *** in the event of the Parties’ joint ownership of such Patent or other IPR, or if the subject matter of such enforcement has been any Patent(s) or other IPR
Controlled by more than one of the Parties; 

  

	 	(b)	 if infringement has taken place after the First Commercial Sale or starts before First Commercial Sale but
continues after the First Commercial Sale of a Licensed Product, Niche Candidate, or Residual Product claimed or covered by the IPR or Valid Claim(s) of the Patent enforced by such enforcing Party’s action, (i) to the extent that such
recovery is expressly for, or attributable to, lost profits on lost sales of such Licensed Product, Niche Candidate, or Residual Product, such remaining sums shall be treated as Net Sales of the Party engaged in the sale (or Out-licensing to a Third Party of such sale) of such Licensed Product, Niche Candidate, or Residual Product and shall be paid to or retained by such Party subject to the payment of royalties to the other Party in
the applicable percentages set forth, respectively, in Article 7 or 13, and (ii) to the extent that the recovery is other than expressly for, or attributable to, such lost profits, it shall be allocated in accordance with the above
Section 9.14(a). 

  

	 	9.15	 Third Party Litigation. If the manufacture, use, or sale of any Licensed Product, Niche Candidate, or
Residual Product, or performance of any other activity conducted pursuant to this Agreement results in any claim, suit, or proceeding by a Third Party alleging IPR infringement or misappropriation by either Party (the ”Defending
Party”), or any of the Defending Party’s Affiliates, Sub-licensees, or 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 70 

	 	
Out-licensees, such Defending Party will within *** of its discovery notify the other Party thereof in writing. The Defending Party (or its Affiliate, Sub-licensee, or Out-licensee) shall have the exclusive right to defend and control the defense of such claim, suit or proceeding at its own expense, using counsel of its own
choice, provided that each Party shall in all events have exclusive control over the defense of any claim, suit, or proceeding, or any part thereof, that challenges any Patent or IPR that is subject to such Party’s exclusive enforcement
rights under Section 9.12, and neither the other Party nor any of its Affiliates, Sub-licensees, or Out-licensees may, without such enforcing Party’s
prior written consent, enter into any settlement or other voluntary final disposition of such claim, suit or proceeding containing terms respecting such IPR or Patent and, in particular, but without limitation, that admits or concedes that any claim
or aspect of such Patent or IPR is invalid or unenforceable or requires any waiver or disclaimer thereof. Each Party will keep the other reasonably informed of all material developments in connection with any such claim, suit, or proceeding. The
Defending Party shall provide the other Party with copies of all pleadings filed in the action and allow the other Party reasonable opportunity to participate in the defense of the claims. 

 

	 	9.16	 Cooperation in Legal Proceedings. If either Party shall become engaged in or participate in any suit or
proceeding described in this Article 9, or any investigation, claim, interference or other proceeding with any Third Party (including any proceeding before a relevant regulatory authority or government body) relating in any way to any Drug
Candidate, Licensed Product, Niche Candidate, or Residual Product, or any Know-How affecting either Party’s ability to attain Commercial Optimization, the other Party, at the request of such Party, shall
cooperate and endeavour to cause its and its Affiliates’, Sub-licensees’, and Out-licensees’ employees to cooperate, in all reasonable respects with such
Party (including by providing such documents, information, witnesses, and testimony; attending such conferences, discovery proceedings, hearings, trials and appeals; and negotiating such Third-Party licenses, as may be reasonably be requested by
such Party in connection with, and using diligent efforts to make reasonably available to such Party, free of charge (other than reimbursement of actually incurred, reasonable
out-of-pocket expenses), such employees and agents who may be helpful with respect to, such suit, investigation, claim, interference or other proceeding), and joining,
or authorizing and empowering such Party to act in its name and stead, in such suit, investigation, claim, interference or other proceeding where necessary for the effective prosecution or defense thereof or for securing full and appropriate relief
therein. 

  

	 	9.17	 Trademarks. 

  

	 	9.17.1	 Acquisition and Ownership of Product Marks. NN shall, in its sole discretion, select and own all trade
marks and service marks associated with Licensed Products (collectively, ”Product Marks”). NN shall also own any domain names associated with Licensed Products, including any domain names which contain Product Marks.

  

	 	9.17.2	 Obligation to Respect Trade Mark Rights. Except as otherwise specified herein or as the other Party may
otherwise hereafter agree in writing, at no time shall either Party or any of such Party’s Affiliates 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 71 

	 	(a)	 use or register (i) any trade marks, trade names, logos, or other designations of source, affiliation, or
sponsorship of the other Party or any of the other Party’s Affiliates, or of any of the other Party’s or its Affiliates’ respective businesses, products or services, or (ii) any trade marks, trade names, logos, or other
designations confusingly similar to, such trademarks, trade names, or other designations of the other Party or its Affiliates, used to identify any business, products, or services of itself or any of its Affiliates, or for any other commercial
purposes, or 

  

	 	(b)	 take any other action with a view to or that may reasonably be viewed as resulting in damaging the rights or
goodwill in any of such trade marks, trade names, logos, or other designations of the other Party or its Affiliates in any country. 

Notwithstanding the foregoing or any other provision of this Agreement, each Party and its Affiliates shall have the right to make truthful
references to or identifications of the other Party or its Affiliates, or to the business, services, or products of the other Party or its Affiliates, in compliance with the provisions of Article 18 hereof. 

 

	 	9.17.3	 No Implied Grant of Right or License In Respect of Trade Mark Rights. Nothing contained in this
Agreement shall be construed as conferring any rights to use in advertising, publicity, or other promotional materials or activities any name, trade name, trade mark, trade dress, or other designation of a Party hereto, including any contraction,
abbreviation, or simulation of any of the foregoing, unless the express written permission of such Party has been obtained. 

  

	 	9.18	 Determination of Patent Issues to be Made Under Applicable National Law. Except as provided for under
Section 9.2 (which shall control issues of inventorship) and Section 9.20, any dispute regarding infringement, validity or enforceability (other than based on inventorship) of Patents between the Parties shall be made under
applicable national law. 

  

	 	9.19	 Acknowledgment of Intellectual Property Rights; Termination of License with Respect to Specific Patents.
Each of the Parties hereby acknowledges and agrees that its obligation to pay royalties pursuant to this Agreement is supported by good and valuable consideration comprised, among other things, of its receipt of a license under secret, substantial
and identifiable Know-How, including Collaboration Know-How and under certain specified Patents Controlled by the other Party. 

Either Party may terminate its license to the other Party under any Patent or any Collaboration
Know-How under this Agreement immediately by notice in writing to the other Party in the event that the other Party shall challenge the validity or enforceability of any such Patent or the secret, substantial
and identified nature of the Collaboration Know-How. For the avoidance of doubt, such challenge of the validity or enforceability shall not be a breach of this Agreement. 

  
 72 

	 	  	 The Parties further acknowledge and agree that one Party may not avoid the payment of royalties to the other
during the Term on the basis that Collaboration Know-How has ceased to be secret, substantial and identified as a result of any action or omission by or on behalf of the first Party. 

 

	 	  	 The Parties acknowledge and agree that royalties payable under this Agreement shall, for the purpose of the
commercial convenience of the Parties, be payable during the Term pursuant to the terms and conditions of this Agreement. 

  

	 	9.20	 Survival. The Parties’ rights and obligations under this Article 9 shall survive the
expiration or earlier termination of this Agreement for any reason (whether before or after the expiration of the Collaboration Term), provided that, (a) neither Party shall be required to pay any royalty to the other in respect of Net
Sales of any product (including any Licensed Product, Niche Candidate or Residual Product) in any country after the expiration of the Term of this Agreement with respect to such product in such country. 

 

	10.	 CONFIDENTIAL INFORMATION AND MATERIALS 

 

	 	10.1	 Superseding of Prior Agreements. The confidentiality and use provisions of this Agreement, as set forth
in this Article 10, Subsection 1.1.28 and elsewhere in this Agreement, terminate, supersede and replace in their entirety the provisions of the Confidentiality Agreements between the Parties dated April 29, 2003, January 28,
2005 and November 10, 2005 as well as any other confidentiality and non-use agreements entered into between the Parties prior to the date of this Agreement. 

 

	 	10.2	 Confidentiality and Use Restrictions. The Receiving Party in respect of any Confidential Information
undertakes from the date of disclosure to treat all received Confidential Information as strictly confidential during the Term of this Agreement and for a minimum term of five (5) years thereafter and, therefore, not to disclose it without the
prior written and express consent of the Disclosing Party and to make no use of it, except as specifically provided for in this Article 10 without the prior written and express consent of the Disclosing Party in each case; provided
that, (a) in the event that such Confidential Information shall constitute a Trade Secret, the Receiving Party shall be obligated to continue to comply with the foregoing requirements until such time, if ever, as it shall lose its character
as a Trade Secret through no fault of the Receiving Party and (b) in the event that either Party shall enter or have obligations under an agreement with a Third Party which entails a longer period for maintaining Confidential Information the
Receiving Party shall comply with such obligations. 

  

	 	10.3	 Disclosures to Authorized Persons. The Receiving Party may disclose Confidential Information only to its
reliable employees, and to such of its agents, consultants, Sub-licensees, Out-licensees and other Third Parties it may authorize hereunder to receive such Confidential
Information, who, in each case, need to know such Confidential Information in order to carry out, or to consider carrying out, such evaluations, and other discovery, development or 

  
 73 

	 	
commercialization activities with respect to IPR, Licensed Products, Niche Candidates, Residual Products and such other subject matter as is encompassed by the Receiving Party’s rights,
licenses or performance obligations under this Agreement, provided that such Persons are bound by obligations of confidentiality and non-use to the Receiving Party that are no less protective of the Disclosing
Party’s rights or interests in respect of Confidential Information than those set forth in this Agreement. The Receiving Party shall ensure that such employees and other Persons are made fully aware of the obligations of this Agreement in
respect of Confidential Information and shall be responsible for all acts and omissions of such employees and other Persons to whom it directly or indirectly makes available, discloses or provides Confidential Information, which, if committed by the
Receiving Party, would constitute a breach of the Receiving Party’s obligations under this Article 10, and shall take appropriate action, whether by instruction, agreement or otherwise, to ensure the protection, confidentiality and
security of Confidential Information. 

  

	 	10.4	 Material Transfer Agreement. No Materials may be transferred, or caused or authorized to be transferred,
directly or indirectly to any Third Party for any research or other purposes except by a Party or its Affiliate, or the Out-licensee of a Party or its Affiliate, pursuant to a legally binding, written material
transfer agreement identical in substance to the Material Transfer Agreement annexed as Schedule 10.4. Except as provided for in Subsection 10.4.1, the Parties shall use the Material Transfer Agreement annexed as Schedule 10.4,
which may be modified by the Joint Steering Committee from time to time. 

  

	 	10.4.1	 Procedure for IPH Obtaining Approved Exceptions to Material Transfer Agreement Requirements. In the
event that IPH shall contemplate entering into a material transfer agreement that deviates in substance from the annexed Material Transfer Agreement, prior to entering into such agreement IPH shall submit a copy thereof to NN for NN’s approval.
IPH shall not enter into such agreement without having received such approval from NN, provided that, if NN shall fail to respond to IPH’s submission to NN of such proposed agreement within *** of its receipt thereof, NN shall be deemed
to have approved of IPH’s entry into such agreement. Each Party shall provide all such Third Party material transfer agreements entered into pursuant to this Section 10.4 to the other Party for archival purposes. With respect to any
Materials transferred to any Third Party pursuant to any material transfer agreement as described by this Section 10.4, in the event of a conflict between the provisions of this Article 10 or Subsection 1.1.28 with any term
or condition of such material transfer agreement that conforms to the provisions of the Material Transfer Agreement, such conforming term or condition of the material transfer agreement shall prevail. 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 74 

	 	10.5	 Additional Terms of Confidentiality. Except as expressly set forth herein the following provisions shall
apply: 

  

	 	10.5.1	 The Receiving Party shall not use Confidential Information for any purpose other than for purposes of
exercising its rights or licenses or performing its obligations under this Agreement. 

  

	 	10.5.2	 Confidential Information is the sole property of the Disclosing Party and nothing in this Agreement, other than
the licenses set forth herein, shall be construed as granting to the Receiving Party, by implication or otherwise, any right or license with respect to Confidential Information or any Patents or any claims of Patents now or hereafter filed or issued
with respect to Confidential Information and the Receiving Party shall refrain from filing applications or otherwise seeking proprietary rights and protection in respect of Confidential Information. 

 

	 	10.5.3	 The Receiving Party shall keep the Disclosing Party informed of all uses made of Confidential Information. With
the exception of such Confidential Information as is required for the Receiving Party’s exercise of such rights or performance of such obligations as survive such expiration or termination, upon the termination or expiration of this Agreement,
the Receiving Party shall return to the Disclosing Party all surviving tangible embodiments of Confidential Information received hereunder and any material, data, and results derived from such Confidential Information. 

 

	 	10.5.4	 Except as expressly set forth herein or in another written agreement relating to Confidential Information in
force between the Parties, neither Party shall incur any obligation or liability to the other Party merely by disclosing or receiving Confidential Information to or from the other Party. It is further agreed that the furnishing of Confidential
Information shall not constitute any grant, option or license under any Patent or other rights now or hereinafter held by either Party. 

  

	 	10.5.5	 At the Disclosing Party’s reasonable request, the Receiving Party shall provide to the Disclosing Party a
copy of such written agreements as have been entered into by the Receiving Party with any Persons to whom or which the Receiving Party has disclosed Confidential Information, including the provisions of such agreements that set forth such
Person’s or Persons’ agreement to be bound by the confidentiality and use obligations set forth herein. 

  

	 	10.5.6	 Except as reasonably necessary in connection with the exercise of the Receiving Party’s rights or
licenses, or the performance of its obligations, under this Agreement, the Receiving Party shall not copy or authorize the copying, in whole or in part, of any Confidential Information received by it, directly or indirectly, from the Disclosing
Party without first receiving written consent from the Disclosing Party. Any copyright, confidentiality or other proprietary notices appearing on or in connection with such Confidential Information shall be reproduced and included on all copies made
by or under the authorization of the Receiving Party. 

  
 75 

	 	10.5.7	 The Receiving Party acknowledges that all Confidential Information is provided “as is” and
without any representation or warranty, express or implied, as to the accuracy or completeness of such Confidential Information, including, without limitation, any implied warranty of merchantability or fitness for a particular purpose, or, except
as expressly provided in Article 15, any warranty that the use of Confidential Information will not infringe or violate any Patent or other proprietary rights of any Third Party. 

 

	 	10.6	 Permitted Disclosures. Notwithstanding any provisions of this Agreement to the contrary, the Receiving
Party may disclose Confidential Information: 

  

	 	10.6.1	 required to be disclosed to comply with applicable Laws, to defend or prosecute litigation or to comply with
governmental regulations, provided that the Receiving Party provides prior written notice of such disclosure to the Disclosing Party with no undue delay so that the Disclosing Party may contest such potential disclosure, and further
provided that the Receiving Party takes reasonable and lawful actions to avoid or minimize the degree of such disclosure, including without limitation by seeking confidential treatment (to the extent available) from the applicable governmental
or regulatory body; 

  

	 	10.6.2	 if the Receiving Party is the Party authorized to prosecute, maintain or enforce any Patent pursuant to Article
9, for purposes of any such action with respect to which such Party is so authorized, including for purposes of compliance with any Laws or regulations requiring any such disclosure relating to such Patent, provided that the Receiving
Party takes any and all reasonable and lawful actions to avoid or minimize the degree of such disclosure, including by seeking confidential treatment (to the extent available) from the applicable governmental or regulatory body;

  

	 	10.6.3	 on a confidential basis to its legal or financial advisors who are bound by professional obligations of
confidentiality; or 

  

	 	10.6.4	 on a confidential basis to the Receiving Party’s (a) Affiliates; (b) existing or potential acquirers
or merger candidates; (c) investment bankers; (d) existing or potential investors, venture capital firms or related financial service providers, for purposes of obtaining financing, each ((a) through (d)) of whom or which, prior to such
disclosure, shall have first entered into a binding written agreement to be bound by use and disclosure restrictions that are at least as protective as those set forth in this Article 10, provided, however, that (i) the Persons
described in clauses (b) through (d) shall only be allowed to view such Confidential Information (including this Agreement or the Share Purchase Agreement (as hereinafter defined)) at the premises of one of the Parties or its legal advisors and
shall not be allowed to make copies (electronically or in hard copy) of such Confidential Information (other than this Agreement or the Share Purchase Agreement) without the prior written approval of

  
 76 

	 	
the Disclosing Party and (ii) IPH shall not disclose any Confidential Information of NN (other than this Agreement or its terms) to any Person, including any existing or potential acquirer
or merger partner, who or that is substantially involved in the discovery, development, manufacture, sale or other exploitation of any drug candidates, biologics or other products developed, marketed or used for the same indications as any Drug
Candidates, Licensed Products, Niche Candidates, Residual Products or any other products discovered, developed or commercialized under this Agreement, without first providing NN with reasonable advance written notice of such proposed disclosure and
obtaining NN’s written consent thereto. 

  

	 	10.7	 Required Notices. The Receiving Party shall promptly notify the Disclosing Party if it becomes aware
that any Confidential Information has been made available to any Third Party, or of any breach of confidence by any Person to whom or which the Receiving Party has disclosed any of the Disclosing Party’s Confidential Information, and shall give
the Disclosing Party all reasonable assistance in connection with any action, demand, claim or proceeding that the Disclosing Party may institute against such Person in respect of such disclosure. Each Party shall keep the other Party informed in
the event that this Agreement or the Share Purchase Agreement has been made available to any Third Party. 

  

	 	10.8	 Relief. Each Party acknowledges that Confidential Information is of a special and unique nature and
agrees that the other Party’s remedies at law for a breach by it of its obligations under this Article 10 would be inadequate and that the Disclosing Party shall, without need to post any bond or prove actual damages, be entitled to seek
and, if prevailing, obtain, in arbitration pursuant to Section 21.14 (or where necessary to avoid irreparable harm, in any court of competent jurisdiction), specific performance and provisional, permanent and mandatory injunctive and
other equitable relief, as well as recovery of its court costs, expenses and reasonable attorneys’ fees, as remedies for any breach or threatened breach of any of the provisions of this Article 10. 

 

	11.	 DURATION OF THE AGREEMENT 

This Agreement shall be in full force and effect from the Effective Date and shall expire, on a product-by-product and country-by-country basis, with the Parties’ respective obligations to pay royalties on the Net Sales
of such products in such countries, pursuant to the terms and conditions of this Agreement. 
  

	12.	 MATERIAL BREACH AND TERMINATION 

 

	 	12.1	 Material Breach, Damages and Termination. Except as otherwise expressly provided in this Agreement, each
Party shall have a remedy in compensatory damages for any injuries caused by the other Party’s material breach of this Agreement. Except as otherwise expressly provided in this Article 12, (a) neither Party may terminate this Agreement,
in whole or in part, for any reason, and (b) such termination shall not be of the entirety of this Agreement, but shall be on a product-by-product, project-by-project, or country-by-country basis. 

  
 77 

	 	12.2	 Breach of Confidentiality Resulting in Loss of Patent Rights. Without limitation of the foregoing, in
the event that either Party shall at any time commit a material breach of its obligations under Articles 10 or 18 and such breach shall directly result in a material loss of Patent coverage for any Drug Candidate, Licensed Product,
Niche Candidate or Residual Product being commercialized or developed for commercialization by the other Party, then the royalty rate thereafter required to be paid by such other Party on the Net Sales of such Licensed Product, Niche Candidate or
Residual Product (or such product as results from the development of such Drug Candidate) shall be reduced by *** from the rate otherwise payable pursuant to the terms of this Agreement, and such royalty reduction shall be such commercializing
Party’s sole and exclusive remedy, and the breaching Party’s sole liability, for such breach. In this Section 12.2 whether a loss of Patent coverage is material shall be determined, in default of agreement between the Parties,
in accordance with Section 21.14. 

  

	 	12.3	 Termination for Convenience. NN may, for any reason or no reason, at any time during the Collaboration
Term terminate this Agreement, in whole or in part, on *** written notice to IPH. Termination pursuant to this Section 12.3 shall not constitute a breach of this Agreement, and NN’s only liability and obligation, and IPH’s only
rights and remedies in respect of each termination shall be those set forth in Section 13.4. 

  

	 	12.4	 Termination for Material Breach. Either Party may immediately terminate this Agreement with respect to
the affected product(s), project(s), and country(ies) upon the material breach by the other Party of any material term or material condition of this Agreement with respect to such product(s), project(s) and country(ies), if such breach continues for
*** after the receipt by the breaching Party of written notice thereof from the non-breaching Party, provided that, (other than a payment obligation) if the noticed breach is such that cure can be made,
but cannot reasonably be completed within said *** period, then the Party complaining of such breach shall have the right to terminate this Agreement by reason of such breach only if the defaulting Party shall have failed to commence to cure such
breach within the specified *** notice period and to thereafter promptly and diligently complete such cure. Notwithstanding the foregoing, if the Party in breach disputes the existence, materiality, nature or extent of any default set forth above,
(i) the Parties shall use good faith efforts to resolve the dispute amicably and, (ii) if resolution cannot be thereby reached, then the dispute shall be resolved pursuant to Section 21.14. This Agreement shall, however,
continue to remain in full force and effect during the pendency of any such dispute as to the existence, materiality, nature or extent of such breach, as set forth in Section 4.6. 

 

	 	12.5	 Establishing Materiality and Scope of Alleged Breach. For the avoidance of doubt, the Parties must agree
on whether a breach of this Agreement has been committed and, if so, the scope and effect of the alleged breach and whether such breach amounts to a material breach in any particular case. If, after exercising good faith efforts to resolve these
issues amicably, the Parties do not agree that such a breach exists or is material, or agree as to the scope of a breach, the dispute shall be resolved pursuant to the procedures described in Section 21.14. In the event that a dispute
shall arise as to whether a material breach has been committed so as to establish the right to terminate all or any 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 78 

	 	
aspect of this Agreement, the Parties shall have the continued right to exercise their rights and licenses, and shall continue to perform their obligations, hereunder during the pendency of such
dispute in respect of this Agreement or aspect, and, except as otherwise expressly permitted by this Agreement, neither Party shall commence any work in the Collaboration Field in respect of such matter(s) independently of the Collaboration (whether
individually or with any Third Party), until a final resolution has been reached either by the Parties’ written agreement or by arbitration pursuant to Section 21.14 establishing that the termination of this Agreement has been
properly effected by reason of a material breach. 

  

	 	12.6	 Termination Upon Bankruptcy. This Agreement may be terminated, in whole or in part, by either
Party upon written notice to the other: in the event that (a) the other Party (i) adopts a resolution for, or undertakes to effect, a discontinuance of its business or dissolution, or otherwise terminates or suspends its business
operations for a period of more than *** other than by reason of Force Majeure; (ii) becomes insolvent or unable to pay its debts when due; (iii) makes an assignment in bankruptcy or other assignment or general arrangement for the benefit
of its creditors; (iv) commences a proceeding, or files for or seeks relief, under any bankruptcy, insolvency or other Law of any jurisdiction, now or hereafter in effect, regarding the bankruptcy, insolvency or relief of debtors, including any
petition in bankruptcy, petition or application to any tribunal for the appointment of any custodian, receiver, trustee or similar functionary for it or a substantial part of its assets, or for any arrangement, reorganization, composition,
dissolution, liquidation, business rehabilitation, business preservation, readjustment of debt or similar relief; (v) is made subject to any attachment, seizure or other legal process against a substantial part of its assets or against any
right, title or interest in this Agreement or any material product, IPR or other subject matter of this Agreement; (vi) is made subject to any bona fide petition, application or proceeding described in (iv) above that is filed or commenced
against it, in which an order for relief is entered or which remains undismissed for a period of *** or more; or (vii) by any act or omission shall indicate its consent to, approval of or acquiescence in any such petition, application or
proceeding or order for relief, or the appointment of a custodian, receiver, trustee or similar functionary for it or any substantial part of its assets, or shall suffer any such custodianship, receivership or trusteeship to continue undischarged
for a period of *** or more; or (b) anything analogous to any of the foregoing occurs in any applicable jurisdiction. Termination shall be effective upon the date specified in such notice. 

 

	 	12.7	 Development Diligence Requirements. For the purposes of this Section 12.7, each Party shall
be obliged to promptly notify the other Party in writing of any decision to abandon the development, marketing or sale of any Licensed Product, Residual Product or Niche Candidate for any indication(s) and with respect to any country(ies) and in the
absence of notification the first Party shall be deemed to have abandoned the development of such Licensed Product, Niche Candidate, or Residual Product for such indication being developed for commercialization exclusively by or on behalf of that
Party if: 

  

	 	(i)	 *** 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 79 

	 	(ii)	 *** 

  

	 	(iii)	 *** 

provided that the time periods in (i)-(iii), above: 
  

	 	(A)	 shall not include any time period during which the relevant Licensed Product, Niche Candidate or Residual
Product shall have been subject to a Clinical Hold (as defined below) and the Party developing same shall have been using Commercially Reasonable Efforts to remove such Clinical Hold; and 

 

	 	(B)	 shall be altered by the Parties to take into consideration unforeseen delays or obstacles in continuing the
development of the relevant Licensed Product, Niche Candidate or Residual Product outside the reasonable control of the developing Party, in which case the Parties shall agree to a reasonable extension having regard to the delay, provided
that the developing Party must make a request for such extension to the other Party at the time of, and not solely after, the delay. 

Within *** of any of the occurrence of any of the events specified in (i), (ii), or (iii) above, the developing Party may, by paying to
the other Party the relevant fee provided for below, extend the deadline for achievement of the required step on an annual basis for up to a period of *** the relevant fee being: 

 

	 	(a)	 *** 

  

	 	(b)	 *** 

  

	 	(c)	 *** 

provided that the developing Party shall only have the right to such extension under two of events (a), (b) or (c) of this
Section 12.7, unless the Parties hereafter agree otherwise in writing. 
 “Clinical Hold”, as used in this
Section 12.7, shall mean a bona fide decision of the developing Party or a decision of a regulatory authority or another governmental body to suspend a clinical trial or other study when it does not believe that such clinical trial or
other study can be conducted without unreasonable risk to the subjects in such clinical trial or study, and the existence of such circumstances shall be subject to arbitration in accordance with Section 21.14. 

 

	 	12.8	 Termination for Failure to Employ Commercially Reasonable Efforts. Notwithstanding any other provision
of this Agreement, in the event of the abandonment of the development by a Party (the “Developing Party”) (by express notice to the other Party or by operation of this Section 12), or a
non-transient material failure of the Developing Party to employ Commercially Reasonable Efforts in respect of the marketing or sale of any Licensed Product, Residual Product or Niche Candidate in any country,
all licenses granted to the 

  
 Certain information has been excluded
from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 80 

	 	
Developing Party under this Agreement for the purposes of Commercial Optimization of any such Licensed Product, Residual Product or Niche Candidate a Party is authorized to develop but that has
been abandoned in such country(ies) shall terminate immediately and the following provisions shall apply: 

  

	 	(a)	 The Developing Party shall have an obligation to grant to the other Party, at the other Party’s request,
an irrevocable, world-wide, fully paid up, exclusive license under all its right, title and interest to the Collaboration IPR, Background NN IPR or Background IPH IPR (as applicable) and Independent IPR, and grant the right set out in
Section 5.7, in the county(ies) and for the specific indication(s) with respect to which such specific Licensed Product, Residual Product or Niche Candidate has been abandoned, solely for the purposes of Commercial Optimization of such
specific Licensed Product, Residual Product, or Niche Candidate for such indication(s) in such country(ies), and all supporting regulatory documentation, to the other Party only for no additional consideration other than as provided for herein; and

  

	 	(b)	 if the other Party shall, in its discretion, assume such license it shall notify the Developing Party to this
effect within *** of the Developing Party’s abandonment or the determination of abandonment, whichever is the later, upon which assumption the other Party shall have the exclusive right to exploit such IPR solely with respect to such abandoned
product(s), for such specific indication(s), in such country(ies) and for such purposes as are specified in clause (a) above, provided that such right shall not include the right or license to develop or commercialize any product comprised of,
interacting with, modulating or is derived from the same Biological Target for the same indications(s) as any (i) Licensed Product or Residual Product encompassed by the Developing Party’s exclusive rights or license hereunder; or
(ii) Niche Candidate marketed by the Developing Party (or its out-licensee) pursuant to the Buy-In-Option.

  

	 	(c)	 If the date of such abandonment is prior to the first dosing of humans in clinical trials with such abandoned
Licensed Product, Residual Product or Niche Candidate, Sections 12.8(a) and 12.8(b) shall apply, save that, in consideration of the grant of such rights, if and only if the other Party subsequently
Out-licenses such IPR within the period of *** following the date of the other Party’s assumption of rights, the other Party shall pay to the Developing Party a percentage of all revenue actually received
by IPH in respect of such license on the following basis: 

  

	 	•	 *** 

  

	 	•	 *** 

  

	 	•	 *** 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 81 

	 	•	 *** 

  

	 	•	 *** 

  

	 	(d)	 If the effective date of abandonment is after the first dosing of humans in clinical trials with such abandoned
Licensed Product, Residual Product or Niche Candidate but prior to the first dosing in Phase III, the above Sections 12.7(a) and (b) shall apply save that in consideration of the grant of such rights, if and only if the other Party
subsequently Out-licenses such IPR within the period of *** following the date of the other Party’s assumption of rights the other Party shall pay to the Developing Party a percentage of all revenue
actually received by the other Party in respect of such license on the following basis: 

  

	 	•	 *** 

  

	 	•	 *** 

  

	 	•	 *** 

  

	 	•	 *** 

  

	 	•	 *** 

  

	 	(e)	 If the date of such abandonment is after the beginning of the first dosing in Phase III then NN and IPH shall
***. 

  

	 	(f)	 In the event of its abandonment of a Licensed Product, Residual Product or Niche Candidate and irrespective of
the effective date of such abandonment, the Developing Party shall: 

  

	 	(i)	 make no further representation regarding its status as a licensee of the other Party in respect of such
abandoned Licensed Product, Residual Product or Niche Candidate for the specific indications and with respect to the specific country(ies) with respect to which it has been abandoned; 

 

	 	(ii)	 cease any activities with respect to the marketing, promotion, sale or distribution of such abandoned Licensed
Product, Residual Product or Niche Candidate for the specific indications and with respect to the specific country(ies) with respect to which it has been abandoned; 

 

	 	(iii)	 in the event that at the date of such abandonment there are ongoing clinical trials of such abandoned Licensed
Product, Residual Product or Niche Candidate, pay for the completion of such clinical trials in respect of all patients enrolled at the effective date of abandonment except if the Agreement is terminated because of adverse events in the clinical
trial(s) causing the trials(s) to cease due to regulatory requirements or regulatory considerations (including an actual or anticipated regulatory warning); 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 82 

	 	(iv)	 at the other Party’s option and at the other Party’s expense, and to the extent such transfer is
authorized by contract and permitted by applicable Law, to transfer to the other Party, the benefit of any contracts between the Developing Party and any Third Party in respect of the manufacture of such abandoned Licensed Product, Residual Product
or Niche Candidate, with respect to the supply thereof for marketing for the indication(s) and in the country(ies) with respect to which such product has been abandoned, provided that for the avoidance of doubt the Developing Party shall not
be required to cause or effect any such transfer if to do so will require the Developing Party’s payment or provision of additional consideration to any Person save that the other Party may pay for and obtain the right to such procurement or
exercise to the extent authorized by contract and permitted by applicable Law; 

  

	 	(v)	 at the other Party’s option, and at the other Party’s expense, and to the extent authorized by
contract and permitted by applicable Law, assign or cause to be assigned to IPH any regulatory submissions and approvals with respect to such abandoned Licensed Product, Residual Product or Niche Candidate and take such actions and execute such
other instruments, assignments and documents as may be necessary to effect the transfer of all rights thereunder to the other Party; 

  

	 	(vi)	 at the other Party’s option and at the other Party’s expense, provide to the other Party all pre-clinical and clinical data in respect of such abandoned Licensed Product, Residual Product or Niche Candidate and all research reagents and materials intended for use in clinical trials of such abandoned
Licensed Product, Residual Product or Niche Candidate, in the Developing Party’s possession or control; and 

  

	 	(vii)	 the other Party shall pay the Developing Party’s reasonable costs in connection with the above activities
at a reasonable hourly rate representing the actual cost of the Developing Party of providing such services up to a maximum of ***. 

  

	 	  	 Following the transfer of rights from one Party to another pursuant to this Section 12.8 the other
Party shall have no further obligations under Sections 12.7, 12.8, 12.9 or 12.10 in respect of the development, sale or marketing of any such product. 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 83 

	 	  	 Without limitation of the Parties’ obligations to exercise Commercially Reasonable Efforts, or of any
other obligations under this Agreement or remedies for the material breach thereof, the failure to attain any benchmark or objective set forth in any of Sections (i), (ii) or (iii) of Section 12.7 shall not constitute a breach of
this Agreement, and the provisions of this Section 12 prescribe the Developing Party’s sole and exclusive liability, and the other Party’s sole and exclusive remedy for such failure. 

 

	 	12.9	 Development or Marketing of Other Products. The development, sale or marketing, by a Party its
Affiliates or Out-licensees having the obligation to use Commercially Reasonable Efforts, of a product (other than a Licensed Product, Niche Candidate or Residual Product) that is directed to the same
indication as, and that results in substantial material prejudice to the development or commercialization of, a Licensed Product, Niche Candidate or Residual Product, shall constitute a failure to exercise Commercially Reasonable Efforts in respect
of such Licensed Product, Niche Candidate or Residual Product in such indication. 

  

	 	12.10	 Determination of Abandonment and Opportunity to Remedy. At any time after the end of the Collaboration
Term IPH or NN shall have the right to request a determination as to whether abandonment has occurred in respect of any Licensed Product, Residual Product, or Niche Candidate in accordance with Section 21.14 and this Article 12,
and for the purposes of Sections 12.7, 12.8 and 12.9 (except as otherwise specified in Section 12.7), a non-transient material failure to use Commercially Reasonable Efforts shall
constitute abandonment. Following a request for such determination the other Party shall have *** to seek to cure or remedy such alleged abandonment and any such efforts shall be considered as a part of such arbitration. 

 

	 	12.11	 Termination for IPH Transfer. In addition to its right to terminate this Agreement and other remedies in
the event of IPH’s material breach of the terms of Section 20.1, NN shall have the right to terminate this Agreement, in whole or in part, immediately upon notice to IPH in the event that IPH undertakes any Change of Control or
other Transfer pursuant to Section 20.2 at any time, and the sole and exclusive rights, remedies and obligations of the respective Parties in the event of such IPH Change of Control or other Transfer shall be those set forth in
Section 13.4. No Change of Control or other Transfer undertaken by either Party or any of its Affiliates in accordance with Section 20.2 shall constitute a breach of this Agreement. 

 

	 	12.12	 Survival of Terms. All provisions of this Agreement (including all terms, representations, rights and
obligations) consisting of or relating to representations, warranties, confidentiality, specified licenses, indemnification, limitations of liability, ownership rights, or defined terms, and all other provisions hereof that by their express terms or
sense and context are intended to survive the expiration or earlier termination of this Agreement, shall each survive any expiration or termination hereof for any reason. In furtherance and not in limitation of the foregoing, this
Section 12.9 and the following Articles and other Sections shall survive any such expiration or termination of this Agreement: all obligations under Article 10 (Confidential Information and Materials) or Section 20.15 (Further
Assurances) that relate to the preservation or protection of any right, title or interest that itself survives such expiration or termination. 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 84 

	13.	 CONSEQUENCES OF TERMINATION 

 

	 	13.1	 General. Except as otherwise expressly provided in this Agreement, the expiration or earlier termination
of this Agreement for any reason will not release either Party from any obligation or liability arising by reason of any breach that occurred prior to such expiration or termination, or as a result of such termination, or which may thereafter come
into being as the result of any breach of any of the terms or conditions of this Agreement that survive such expiration or termination of this Agreement in accordance with the provisions of Section 12.12 hereof. 

 

	 	13.2	 Costs for Regulatory Documentation. A Party required to provide regulatory documentation under this
Agreement shall bear the reasonable cost for providing such documentation to the other Party, up to a limit of ***. Any additional reasonable costs of obtaining such documentation shall be the responsibility of the other Party.

  

	 	13.3	 Expiration of Collaboration Term. Upon and after the expiration of the Collaboration Term:

  

	 	13.3.1	 Limitation of NN Payment Obligation Upon Expiration of Collaboration Term. NN shall have no obligation
to pay to IPH any annual research funding pursuant to Section 3.11 other than such outstanding amounts as then may be due and unpaid, or any royalties, fees or other amounts other than such royalties, fees and other amounts as are
expressly required to be paid by the terms of this Section 13.3. 

  

	 	13.3.2	 NN Retained Rights to Licensed Products, Niche Candidates and Drug Candidates Upon Expiration of
Collaboration Term. NN shall retain all rights and licenses granted to NN under this Agreement that are necessary or useful for the Commercial Optimization of Licensed Products, Niche Candidates or, subject to IPH’s rights under Subsections
13.3.4 and 13.3.5, Drug Candidates including: 

  

	 	(a)	 the exclusive rights and licenses (with the rights to Sub-license and Out-license) granted to NN pursuant to the terms and conditions of Section 5.1; and 

  

	 	(b)	 to the extent authorized by contract and permitted by applicable Law, the right, pursuant to
Section 5.8, to IPH’s grant or procurement of the grant to NN of the rights and licenses required for NN’s freedom of operation to exercise the foregoing exclusive rights and licenses, 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 85 

	 	    	 in each case without any limitation, restriction or other derogation of such rights or licenses occurring as a
result of such expiration of the Collaboration Term, provided that the exclusivity of NN’s rights and licenses under this Subsection 13.3.2 shall be subject to such, if any, of IPH’s rights and licenses as have been granted
to IPH under Article 6 and retained by IPH pursuant to Subsection 13.3.4, and further provided that, (A) with respect to Licensed Products, NN shall continue to be bound by the terms and conditions of this Agreement
in respect of the payment to IPH of (i) the applicable amount(s) specified by Section 7.3 for the achievement of the M0 status Discovery Milestone, the Intermediate Discovery Milestone and the M1 status Discovery Milestone, but only
if such milestones are achieved as of the effective date of such expiration or within the *** following immediately thereafter, (ii) the applicable amount(s) specified by Section 7.4 for the achievement of Development Milestones
with respect to the Licensed Products, (iii) royalties on Net Sales of such Licensed Products during the Term pursuant to the terms and conditions of Article 7, and (iv) the percentage of Upside Revenue realized by NN that is
applicable pursuant to the terms and conditions of Section 5.11. 

  

	 	13.3.3	 NN Residual Rights in the Field Upon Expiration of Collaboration Term. Without limitation of NN’s
rights under Subsection 13.3.2 and in addition thereto, NN shall have the exclusive right and license throughout the Territory during the Term, pursuant to the terms and conditions of the rights and licenses granted to it under Sections
5.1 and 5.8, to develop and commercialize Residual Products from Drug Candidates that have attained at least M0 status but not M1 status during the Collaboration Term or prior to the expiration of the *** period following immediately
after the effective date of the expiration of the Collaboration Term. The royalties payable to IPH on Net Sales of such Residual Products shall be governed by the terms and conditions of Article 7 save that royalties payable to IPH on
Net Sales of such Residual Products that would, upon achievement of M1, be classified as Class C Licensed Products and for which M0 status has been achieved less than *** prior to the expiry of the Collaboration Term shall be reduced by ***
from the applicable royalties set forth in Article 7. 

  

	 	13.3.4	 IPH Retained Rights to Niche Candidates Upon Expiration of Collaboration Term. IPH shall retain, throughout the
Territory during the Term: 

  

	 	(a)	 the right pursuant to the terms and conditions of Section 5.5, to the grant back by NN to IPH of an
exclusive right and license, with the rights to Sub-license and Out-license; and 

 

	 	(b)	 the right to NN’s reasonable cooperation and assistance, pursuant to the terms and conditions of
Section 5.8, in granting to IPH, or procuring the grant to IPH of, the rights and licenses required for IPH’s freedom of operation to exercise said right and license, 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 86 

	 	  	 to develop and commercialize only such, if any, Niche Candidates as IPH has, prior to the effective date of
such expiration, received exclusive authorization to develop and commercialize pursuant to the terms and conditions of Article 6 of this Agreement, without any limitation or other derogation of such rights or licenses occurring as a result of
such expiration, provided that (i) the exclusivity of IPH’s rights and licenses under this Subsection 13.3.4 shall be subject to NN’s rights and licenses under Subsection 13.3.2 and apply solely to the
commercialization and development for commercialization of those, if any, specific Niche Candidates with respect to which IPH has received such exclusive authorization to develop and commercialize pursuant to Article 6, (ii) NN’s
obligations under this Subsection 13.3.4 shall not include any requirement that NN grant to IPH or assist IPH in obtaining any grant of any rights or licenses if doing so should fail to be authorized by contract or permitted by applicable
Law, or would require NN’s payment or provision of any additional consideration to any Person save that IPH may elect to pay for and obtain the right to such procurement or exercise to the extent authorized by contract and permitted by
applicable Law, and (iii) IPH shall continue to be bound by the terms and conditions of this Agreement in respect of the payment to NN of royalties on Net Sales during the Term pursuant to the terms and conditions of Article 7.

  

	 	13.3.5	 IPH Residual Rights in the Field Upon Expiration of Collaboration Term. Without limitation of IPH’s
rights under Subsection 13.3.4 and in addition thereto, IPH shall have, throughout the Territory during the Term, under all Background NN Research Technology IPR and Collaboration IPR Controlled by NN, the exclusive right and license, with
the rights to Sub-license and Out-license, to develop and commercialize Residual Products from Drug Candidates that have not attained at least M0 status, as of the
effective date of the expiration or earlier termination of the Collaboration Term or prior to the expiration of the *** period following immediately thereafter, and shall retain, throughout the Territory during the Term, the right, pursuant to the
terms and conditions of Section 5.8, to NN’s reasonable cooperation and assistance in granting or procuring the grant to IPH of the rights and licenses required for IPH’s freedom of operation to exercise the aforementioned
exclusive right and license, provided that 

  

	 	(a)	 IPH shall pay royalties to NN on Net Sales during the Term of such Residual Products covered by a Valid Claim
of a Patent forming part of the Background NN IPR, Collaboration IPR invented solely by NN or Independent NN IPR in accordance with Scenario 1 of Section 7.8, 

 

	 	(b)	 IPH shall pay to NN (i) royalties of *** of the Net Sales by IPH or any of its Affiliates during the Term
or (ii) *** of all royalties received by IPH or any of its Affiliates in respect of Net Sales during the Term by any of their respective Out-licensees of all Residual Products resulting from the development
and commercialization of such Drug Candidates, as calculated, mutatis mutandis, pursuant to Subsection 1.1.53, which payment obligation in respect of royalties received from Out-licensees shall be
subject to IPH’s obligation to pay to NN a minimum royalty equal to ***, and maximum royalty equal to ***, of the Out-licensee’s Net Sales of such Residual Products, 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 87 

	 	(c)	 no grant of any right or license pursuant to this Subsection 13.3.5 shall include, in respect of such
right and license, the right or license to develop or commercialize any Residual Product comprised of or directed to the same Biological Target as any Licensed Product, Residual Product or Niche Candidate being developed or marketed by NN or its
Affiliates (or Out-licensee of either thereof) pursuant to the Buy-In-Option (for the avoidance of doubt, the limitations on the
licenses and rights otherwise granted to IPH, pursuant to this Subsection 13.3.5, shall not in any way impose a limitation of any other rights IPH may have to develop or commercialize such Residual Product), 

 

	 	(d)	 IPH hereby covenants and agrees that subject to the terms of this Agreement neither IPH nor any of its
Affiliates will at any time during the Term develop or commercialize, or cause or authorize to be developed or commercialized, any product comprised of or directed to the same Biological Target as any Licensed Product, Residual Product or Niche
Candidate being developed or marketed solely by NN or its Affiliates (or Out-licensees thereof). This covenant and agreement shall not apply at any time after the effective date of any purchase or acquisition
of IPH, except in respect of products that would infringe a Valid Claim of a Patent in the Collaboration IPR or Background NN IPR to the extent that NN retains exclusive rights of commercialization under this Agreement. 

 

	 	(e)	 NN’s obligations under this Subsection 13.3.5 to grant or assist in the procurement of the grant to
IPH of specified rights or licenses shall not include any requirement that NN do so if such undertaking would not be authorized by contract or permitted by applicable Law or would require NN’s payment or provision of any consideration to any
Person, save that, should NN decline to make any payment or provision of consideration required to make or obtain such grant, IPH may elect to do so and obtain the grant of such rights and licenses to the extent authorized by contract and permitted
by applicable Law, and 

  

	 	(f)	 NN and its Affiliates shall have the right of first negotiation in the event that IPH proposes to Out-License
any of its rights or licenses under this Subsection 13.3.5, to any Third Party pursuant to the provisions of Subsection 13.3.6. 

  

	 	13.3.6	 NN Right of First Negotiation In Respect of IPH Out-License of
Retained or Residual Rights Arising Upon Expiration of Collaboration Term. If IPH or any of its Affiliates intends to Out-license any of its rights or licenses under Subsections 13.3.4 or
13.3.5 at any time during the Term for any purpose, then the following provisions shall apply. 

  
 88 

	 	(a)	 First Offer to NN. IPH and its Affiliates shall, prior to offering such rights or licenses to any Third
Party, offer the same to NN and its Affiliates on such financial and other terms and conditions as IPH shall present in the form of a definitive written agreement proposal (“First Offer”). As part of the First Offer, IPH shall
include: ***. Upon receipt of the First Offer, NN may accept it as such, or request negotiations based thereon. 

  

	 	(b)	 Negotiation of Out-License. The Parties agree to negotiate in
good faith and on an exclusive basis with the objective of executing a mutually acceptable definitive written agreement granting the contemplated Out-license to NN or its designated Affiliate(s), provided
that, in the event the Parties fail within *** of IPH’s First Offer, or any separately agreed written extension of such period, to execute a mutually acceptable definitive agreement, then IPH or its Affiliates shall be free, subject to
Subsection 13.3.6(c), to enter negotiations regarding an Out-license of the subject matter of the contemplated Out-license to NN with any Third Party.

  

	 	(c)	 Limitations on IPH Entering Into Agreement More Favorable to Third Party During NN Consideration of First
Offer. Neither IPH nor any of its Affiliates shall within *** of a First Offer enter into any definitive agreement or commitment with any Person in respect of such Out-license on any terms that when taken
as a whole are, more favorable to such Person when compared to the terms proposed in NN’s or NN’s Affiliate’s last offer without first offering such terms to NN (or its Affiliates), save that after the expiry of such twelve month
period NN shall have no further rights and IPH shall have no further obligations pursuant to this Subsection 13.3.6. 

  

	 	(d)	 IPH Offer of Similar Terms to NN. In the event that IPH or any of its Affiliates is prepared to enter
into a definitive agreement with any Person other than NN or NN’s designated Affiliate(s) on such more favourable terms, IPH shall, prior to entering into such agreement, first offer such terms to NN or NN’s designated Affiliate(s). NN and
its designated Affiliate(s) shall have *** after the receipt of such offer to accept or reject it. If NN or any of its Affiliates accepts such offer, the Parties shall enter into a definitive written agreement incorporating the material substantive
terms of such offer, provided that, in the event the Parties fail within *** of such IPH offer, or any separately agreed written extension of such period, to execute a mutually acceptable definitive agreement, or if NN and its Affiliates
reject such offer, IPH and its Affiliates shall be free to enter into a definitive agreement with such other Person incorporating the material substantive terms of such offer. 

 

	 	(e)	 Any IPH Breach of Its Obligations to NN Upon Expiration of Collaboration Term is Material. The breach by
IPH of any of its obligations under this Subsection 13.3.6 shall constitute a material breach of this Agreement. If, after such Out-license agreement is 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 89 

	 	
entered into by IPH with a Third Party, NN shall have a good faith basis for believing that IPH’s entry into such agreement was in violation of NN’s rights or in breach of IPH’s
obligations under this Subsection 13.3.6, NN shall have the right to commence a proceeding pursuant to Section 21.14 for recovery of its resulting damages. 

 

	 	13.3.7	 Rights Outside the Collaboration Field Upon Expiration of Collaboration Term. In addition to, and
without limitation of, NN’s rights and licenses under Subsection 13.3.2; 

  

	 	(a)	 NN shall retain the right and license granted to NN pursuant to Section 5.2 on a perpetual,
irrevocable, fully-paid-up, royalty-free basis; and 

  

	 	(b)	 To the extent that any Collaboration IPR other than that governed by Section 5.2 has application
outside of the Collaboration Field, if either of the Parties wishes to exploit such Collaboration IPR their rights shall be as follows: 

  

	 	(i)	 if such IPR is owned solely by one of the Parties pursuant to Section 9.2(a) or 9.2(b) (i.e., is not
owned jointly with the other Party or with any of the other Party’s Affiliates) that Party shall have the exclusive right to exploit such IPR outside the Collaboration Field; 

 

	 	(ii)	 if such IPR is Joint IPR then the Parties shall negotiate in good faith on a case by case basis the terms on
which a Party shall have exclusive rights to exploit such IPR outside the Collaboration Field, which terms shall be fair and reasonable and have due regard to the relative contribution of the Parties to the discovery and development of such Joint
IPR and comparable agreements entered into by the respective Parties or observable in the industry; and 

  

	 	(iii)	 if such IPR is Third-Party IPR then (A) if such IPR was acquired in exchange for consideration provided or
paid solely by one of the Parties, that Party shall have the exclusive right to exploit such IPR outside the Collaboration Field, or (B) if such IPR was acquired in exchange for consideration provided or paid by both Parties then the Parties
shall negotiate in good faith on a case by case basis the terms on which a Party shall have exclusive rights to exploit such IPR outside the Collaboration Field, which terms shall be fair and reasonable and have due regard to the relative
contribution of the Parties to the acquisition and development of such Third Party IPR and comparable agreements entered into by the respective Parties or observable in the industry 

  
 90 

	 	13.4	 NN Termination for Convenience Prior to Expiration of Collaboration Term. In the event that this
Agreement is terminated, prior to the expiration of the Collaboration Term, by NN for convenience pursuant to Section 12.3 the following shall apply: 

 

	 	13.4.1	 NN’s Research Funding Obligation Upon NN Termination for Convenience Prior to Collaboration Term
Expiration. NN shall continue to pay to IPH all remaining unpaid amounts, if any, payable to IPH in respect of the annual research funding contribution prescribed by Section 3.11 for the Collaboration Year in which such termination
takes effect, such payment to be made pursuant to the terms and conditions of that Section. 

  

	 	13.4.2	 IPH Residual Pre-M1 Rights Upon NN Termination for Convenience Prior
to Expiration of the Collaboration Term. Subject to such rights and licenses of NN as shall survive the termination of this Agreement pursuant to this Section 13.4, IPH shall have, throughout the Territory during the Term, under all
Background NN Research Technology IPR and Collaboration IPR Controlled by NN and necessary for such purpose the exclusive right and license, with the rights to Sub-license and
Out-license, to commercialize, and develop for commercialization, Residual Products from Drug Candidates that have not attained M1 status, as of the effective date of such termination or within the *** period
following immediately thereafter, provided that 

  

	 	(a)	 IPH shall pay to NN during the Term: 

 

	 	(i)	 a flat royalty rate of *** of Net Sales of such Residual Products sold by IPH or its Affiliates as are covered
by a Valid Claim of a Patent forming part of the Background NN IPR, Collaboration IPR invented solely by NN or Independent NN IPR and a flat royalty rate of *** of Net Sales of such Residual Products sold by IPH or its Affiliates as are covered by a
Valid Claim of a Patent forming part of the Joint IPR; or 

  

	 	(ii)	 *** of all royalties received by IPH or any of its Affiliates in respect of Net Sales during the Term by their
respective Out-licensees of all such Residual Products, as calculated, mutatis mutandis, pursuant to Subsection 1.1.53, which payment obligation in respect of royalties received from Out-licensees shall be subject to IPH’s obligation to pay to NN a minimum royalty equal to ***, and maximum royalty equal to ***, of the Out-licensee’s Net Sales of
such Residual Products; and 

  

	 	(b)	 Limitations on Licenses to IPH for Such Residual Products. The foregoing rights and licenses granted to
IPH shall not include, in respect of such rights and licenses, a right or license to develop or commercialize any Residual Product comprised of or directed to 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 91 

	 	
the same Biological Target as any (i) Licensed Product, (ii) Residual Product or (iii) Niche Candidate being developed or marketed by NN (or its
Out-licensee) pursuant to the Buy-In-Option. For the avoidance of doubt, the limitations on the licenses and rights otherwise granted to IPH, pursuant to this
Subsection, shall not in any way impose a limitation of any other rights IPH may have to develop or commercialize such Residual Product. 

  

	 	(c)	 IPH’s Limited Covenant Not to Compete by Marketing or Sale of Other Products. IPH covenants and
agrees that neither IPH nor any of its Affiliates will at any time during the Term develop or commercialize any therapeutic, prophylactic or diagnostic product comprised of or directed to the same Biological Target as any Licensed Product, Residual
Product or Niche Candidate being developed or marketed solely by NN or its Affiliates (or Out-licensees thereof). This covenant and agreement shall not apply at any time after the effective date of any
purchase or acquisition of IPH except in respect of products that would infringe a Valid Claim of a Patent in the Collaboration IPR or Background NN IPR to the extent that NN retains exclusive rights of commercialization under this Agreement.

  

	 	(d)	 Limitation on NN’s Obligations to Provide Licenses. NN’s obligations under this Subsection
13.4.2 shall not include any requirement that NN grant to IPH or assist IPH in obtaining any grant of any rights or licenses if doing so should fail to be authorized by contract or permitted by applicable Law, or would require NN’s
payment or provision of any consideration to any Person save that, should NN decline to make any payment or provision or consideration required to make or obtain such grant, IPH may elect to pay for and obtain the right to such procurement or
exercise to the extent authorized by contract and permitted by applicable Law. 

  

	 	13.4.3	 NN Retained Rights Upon NN Termination for Convenience Prior to Expiration of the Collaboration Term. NN
shall retain, throughout the Territory during the Term, all rights and licenses granted to NN under this Agreement that are necessary or useful for the Commercial Optimization of Licensed Products (including Drug Candidates that have attained M1
status as of the effective date of such termination or within the *** period following immediately thereafter) or any Niche Candidates with respect to which it has been granted or acquired the exclusive right to commercialize hereunder, including:

  

	 	(a)	 the exclusive rights and licenses (with the rights to Sub-license and Out-license) granted to NN pursuant to the terms and conditions of Section 5.1; and 

  

	 	(b)	 to the extent authorized by contract and permitted by applicable Law, the right, pursuant to
Section 5.8, to IPH’s grant to NN of the rights and licenses required for NN’s freedom of operation to exercise the foregoing exclusive license throughout the Territory during the Term, 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 92 

	 	  	 in each case to develop and commercialize such Licensed Products and Niche Candidates without any limitation,
restriction or other derogation of such rights or licenses occurring as a result of such termination, provided that the exclusivity of NN’s rights and licenses under this Subsection 13.4.3 shall be subject to such, if any,
IPH’s rights and licenses as have been granted to IPH under Article 6 and retained by IPH pursuant to Subsection 13.4.5, and further provided that NN shall continue to be bound by the terms and conditions of this Agreement
in respect of the payment to IPH of (i) the applicable amount(s) specified by Section 7.3 for the achievement of the M1 milestone, but only if such milestone is achieved as of the effective date of such expiration or within the ***
following immediately thereafter, (ii) the applicable amount(s) specified by Section 7.3 for the achievement of Development Milestones with respect to the Licensed Products, in each case ((i) and (ii)) pursuant to the terms and
conditions of Sections 7.4, (iii) royalties on Net Sales of Licensed Products and Niche Candidates during the Term pursuant to the terms and conditions of Article 7, and (iv) the percentage of Upside Revenue realized by NN that is
applicable pursuant to the terms and conditions of Section 5.11. 

  

	 	13.4.4	 NN Rights Outside the Field Upon NN Termination for Convenience Prior to Expiration of the Collaboration
Term. In addition to, and without limitation of, NN’s rights and licenses under Subsection 13.4.3, NN shall retain its nonexclusive right and license under Section 5.2 to practice, exercise and use throughout the
Territory all Collaboration Research Technology IPR Controlled by IPH, for NN’s internal use outside the Collaboration Field, which right and license shall be on a perpetual, irrevocable, fully-paid-up,
royalty-free and non-exclusive basis. 

  

	 	13.4.5	 IPH Retained Rights Upon NN Termination for Convenience Prior to Expiration of the Collaboration Term.
IPH shall retain, throughout the Territory during the Term: 

  

	 	(a)	 the right pursuant to the terms and conditions of Section 5.5, to the grant back by NN to IPH of an
exclusive right and license, with the rights to Sub-license and Out-license; and 

 

	 	(b)	 the right to NN’s reasonable cooperation and assistance, pursuant to the terms and conditions of
Section 5.8, in obtaining for IPH the rights and licenses required for IPH’s freedom of operation to exercise said right and license, 

to develop and commercialize only such, if any, Niche Candidates as IPH has, prior to the effective date of such termination, received
exclusive authorization to develop and commercialize pursuant to the terms and conditions of Article 6 of this Agreement, without any limitation or other derogation of such rights or licenses occurring as a result of such termination,
provided that 
  
 Certain information has been excluded from this agreement
(indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 93 

	 	(i)	 the exclusivity of IPH’s rights and licenses under this Subsection 13.4.5 shall be subject to
NN’s rights and licenses under Subsection 13.4.3 and apply solely to the commercialization, and development for commercialization, of such, if any, specific Niche Candidates as IPH has received such exclusive authorization to develop and
commercialize pursuant to Article 6, 

  

	 	(ii)	 NN’s obligations under this Subsection 13.4.5 shall not include any requirement that NN grant to
IPH or assist IPH in obtaining any grant of any rights or licenses if doing so should fail to be authorized by contract or not permitted under applicable Law, or would require NN’s payment or provision of any consideration to any Person save
that, should NN decline to make any payment or provision or consideration required to make or obtain such grant, IPH may elect to pay for and obtain the right to such procurement or exercise to the extent authorized by contract and permitted by
applicable Law, and 

  

	 	(iii)	 IPH shall continue to be bound by the terms and conditions of this Agreement in respect of the payment to NN of
royalties on Net Sales during the Term, save that IPH shall only pay to NN either (A) royalties of *** of the Net Sales during the Term by IPH or any of its Affiliates; or alternatively (B) *** of all royalties received by IPH or any of its
Affiliates in respect of Net Sales during the Term by their respective Out-licensees of all products resulting from the development and commercialization of such Niche Candidates, as calculated, mutatis
mutandis, pursuant to Subsection 1.1.53, which payment obligation in respect of royalties received from Out-licensees shall be subject to IPH’s obligation to pay to NN a minimum royalty equal to
***, and maximum royalty equal to ***, of the Out-licensee’s Net Sales of such products in lieu of the royalties specified by Section 7.8. 

 

	 	13.4.6	 Right to Third-Party Collaborations Upon NN Termination for Convenience Prior to Expiration of the
Collaboration Term. Subject to the Parties’ respective rights, licenses and obligations hereunder that, by the terms of this Agreement, survive such termination of this Agreement, in the event that this Agreement is terminated in its
entirety pursuant to Section 12.4, IPH shall, commencing with the effective date of such termination, have the right to conduct all activities in the Collaboration Field independently of the Collaboration, both individually and with
Third Parties. 

  
 Certain information has been excluded from this
agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 94 

	 	13.4.7	 No Additional Consideration. NN and IPH shall have and enjoy their respective rights and licenses
pursuant to this Section 13.4 without requirement that either of them pay or provide any consideration other than or in addition to such consideration as is expressly specified by the applicable Subsection thereunder and, except for the
rights and licenses described in this Section 13.4 and such other rights and licenses that by their express terms shall survive the termination of this Agreement, all rights and licenses granted under this Agreement by NN to IPH or by
IPH to NN shall terminate automatically and immediately upon the effective date of such termination without requirement of any further action by the Parties. 

  

	 	13.4.8	 Exclusive IPH Remedies. The sole liability and obligations of NN and sole rights and remedies of IPH in
the event of any termination of this Agreement for convenience by NN pursuant to Section 12.3 shall be those set forth above in this Section 13.4. 

 

	 	13.5	 Termination for IPH Transfer. In the event that NN shall terminate this Agreement pursuant to
Section 12.11 for IPH’s Change of Control or other Transfer, the terms and conditions of Section 13.3 (Expiration of Collaboration Term) shall apply and the respective rights and obligations of the Parties shall
be as set forth in that Section, save that (i) the rights set forth in Subection 13.4.6 shall be enjoyed by both Parties such that both IPH and NN shall, commencing with the effective date of such termination, have the right to conduct
all activities in the Collaboration Field independently of the Collaboration, both individually and with Third Parties, and (ii) (A) NN shall be obligated to pay only the outstanding and unpaid portion of such pro rata share of the research
funding contribution for the Collaboration Year in which such notice of termination is effective as corresponds to the portion of that Collaboration Year consisting of the period commencing with the first day of such Collaboration Year and ending on
the effective date of such termination, (B) IPH shall reimburse NN for any amounts paid by NN in respect of such research funding contribution for that Collaboration Year that exceed NN’s payment obligation under the foregoing clause (A),
and (C) NN shall have no obligation to pay any additional annual research funding contribution. 

  

	 	13.6	 Termination for NN’s Material Breach. In the event that IPH shall terminate this
Agreement pursuant to Section 12.3 for NN’s Material Breach, the terms and conditions of Section 13.4 shall be incorporated, mutatis mutandis, into this Section 13.6 and the respective rights, remedies
and obligations of the Parties shall be as set forth in Section 13.4, subject solely to the following exception, modifications and addition: 

  

	 	(a)	 The provisions of Section 13.4.4 shall not apply; 

 

	 	(b)	 The royalty percentage terms set forth in Subsections 13.4.2 (a) (i) and (ii) shall
be superseded and replaced by the following: 

  

	 	(i)	 “IPH shall pay to NN during the Term a flat royalty rate of *** of Net Sales of such Residual Products
sold by IPH or its Affiliates as are covered by a Valid Claim of a Patent forming part of the IPR solely Controlled by NN or Joint IPR”; and 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 95 

	 	(ii)	 “IPH shall pay to NN (i) royalties of *** of Net Sales of such Residual Products during the Term by
IPH or any of its Affiliates; or (ii) *** of all royalties received by IPH or any of its Affiliates in respect of Net Sales during the Term by its Out-licensees of all such Residual Products, as calculated,
mutatis mutandis, pursuant to Subsection 1.1.53, which payment obligation in respect of royalties received from Out-licensees shall be subject to IPH’s obligation to pay to NN a minimum
royalty equal to ***, and maximum royalty equal to ***, of the Out-licensee’s Net Sales of such Residual Products;” 

 

	 	(c)	 The royalty percentage terms set forth in Subsection 13.4.5 shall be superseded and replaced by the
following: “(iii) IPH shall continue to be bound by the terms and conditions of this Agreement in respect of the payment to NN of royalties on Net Sales during the Term, save that IPH shall only pay to NN either (A) royalties of *** of the
Net Sales during the Term by IPH or any of its Affiliates; or alternatively (B) *** of all royalties received by IPH or any of its Affiliates in respect of Net Sales during the Term by its Out-licensees of all
products resulting from the development and commercialization of such Niche Candidates, as calculated, mutatis mutandis, pursuant to Subsection 1.1.53, which payment obligation in respect of royalties received from Out-licensees shall be subject to IPH’s obligation to pay to NN a minimum royalty equal to ***, and maximum royalty equal to ***, of the Out-licensee’s Net Sales of
such products”; and 

  

	 	(d)	 IPH Damages for NN’s Breach. In addition to the other rights and remedies of IPH under this
Section 13.6, and subject to the terms and conditions of Section 21.8, in the event that IPH shall terminate this Agreement prior to the expiration of the Collaboration Term pursuant to Section 12.4 for NN’s
material breach, IPH shall have the right to commence an arbitration proceeding against NN pursuant to Section 21.14 and to recover compensatory damages for such losses it incurs as a direct and proximate result of such breach to the
extent that such losses have not been fully remedied by its rights and remedies under this Section 13.6. 

  

	 	13.7	 Termination for IPH’s Material Breach. In the event that NN shall terminate this
Agreement prior to the expiration of the Collaboration Term pursuant to Section 12.4 for IPH’s material breach: 

  

	 	13.7.1	 Limitation of NN Payment Obligations Upon IPH’s Material Breach. NN shall have no obligation to pay
to IPH any royalties, fees or other amounts (including any research funding contribution pursuant to Section 3.11) in addition to or other than those expressly set forth 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 96 

	 	
in this Section 13.7. Further to and not by way of limitation of the foregoing, (a) NN shall be obligated to pay only the outstanding and unpaid portion of such pro rata share of
the research funding contribution for the Collaboration Year in which such notice of termination is effective as corresponds to the portion of that Collaboration Year consisting of the period commencing with the first day of such Collaboration Year
and ending on the effective date of such termination, and (b) IPH shall reimburse NN for any amounts paid by NN in respect of such research funding contribution for that Collaboration Year that exceed NN’s payment obligation under the
foregoing clause (a). 

  

	 	13.7.2	 IPH Assignment of IPR to NN Upon IPH’s Material Breach. Subject to the rights and licenses retained
by IPH under Subsection 13.7.5 and such other rights and licenses of IPH as, pursuant to the terms of this Agreement, survive such termination by NN, IPH shall, for no additional consideration, assign to NN its entire right, title and
interest in the Collaboration IPR without any limitation or restriction as to NN’s (or its transferees’) right to exercise, practice or use such Collaboration IPR within the Collaboration Field. 

 

	 	13.7.3	 NN Retained Rights to Licensed Products, Residual Products and Niche Candidates Upon IPH’s Material
Breach. NN shall retain, throughout the Territory during the Term, all rights and licenses granted to NN under this Agreement that are necessary or useful for the Commercial Optimization of Drug Candidates (or any Residual Products resulting
from the development thereof), Licensed Products or Niche Candidates, including: 

  

	 	(a)	 the exclusive rights and licenses (with the rights to Sub-license and Out-license) granted to NN pursuant to the terms and conditions of Section 5.1; and 

  

	 	(b)	 to the extent authorized by contract and permitted by applicable Law, the right, pursuant to
Section 5.8, to IPH’s grant or procurement of the grant to NN of the rights and licenses required for NN’s freedom of operation to exercise the foregoing exclusive license, to develop and commercialize such Drug Candidates,
Residual Products, Licensed Products or Niche Candidates, 

  

	 	  	 in each case without any limitation, restriction or other derogation of such rights or licenses occurring as a
result of such termination, provided that  

  

	 	(i)	 the exclusivity of NN’s rights and licenses under this Subsection 13.7.3 shall be subject to such,
if any, IPH’s rights and licenses as have been granted to IPH under Article 6 and retained by IPH pursuant to Subsection 13.7.5, and 

  

	 	(ii)	 NN shall pay to IPH: 

  
 97 

	 	(A)	 the applicable amount(s) specified by Section 7.3 pursuant to the terms and conditions of that
section for the achievement of the M1 milestone, but only if such milestone is achieved as of the effective date of such termination or within the *** period following immediately thereafter, 

 

	 	(B)	 the applicable amount(s) specified by Section 7.4 pursuant to the terms and conditions of that
section for the achievement of Development Milestones with respect to the Licensed Products,; and 

  

	 	(C)	 the all Licensed Products as of the date of termination, the royalties specified in Article 7 on Net
Sales during the Term of all Classes of Licensed Products (Classes A, B and C) on a product-by-product and country-by-country basis, in accordance with the terms and conditions of Article 7; 

  

	 	  	 *** 

  

	 	  	 NN shall also pay to IPH during the Term a flat royalty rate of *** of Net Sales of Residual Products as are
covered by a Valid Claim of a Patent forming part of the Background IPH IPR, Collaboration IPR invented solely by IPH, Joint IPR or Independent IPH IPR. 

  

	 	13.7.4	 NN Rights Outside the Field. In addition to, and without limitation of, NN’s rights and licenses
under Subsection 13.7.3, NN shall retain its nonexclusive right and license under Section 5.2 to practice, exercise and use throughout the Territory all Collaboration Research Technology IPR Controlled by IPH, for NN’s
internal use outside the Collaboration Field, which right and license shall be on a perpetual, irrevocable, fully-paid-up, royalty-free and non-exclusive basis and
without the right to Out-license, for purposes of the discovery, development and commercialization of products outside the Collaboration Field. 

 

	 	13.7.5	 IPH Retained Rights. IPH shall retain, throughout the Territory during the Term: 

 

	 	(a)	 the right pursuant to the terms and conditions of Section 5.5, to the grant back by NN to IPH of an
exclusive right and license, with the rights to Sub-license and Out-license; and 

 

	 	(b)	 the right to NN’s reasonable cooperation and assistance, pursuant to the terms and conditions of
Section 5.8, in granting to IPH, or procuring the grant to IPH of, the rights and licenses required for IPH’s freedom of operation to exercise said right and license, 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 98 

	 	
to develop and commercialize only such, if any, Niche Candidates as IPH has, prior to the effective date of such termination, received exclusive authorization to develop and commercialize
pursuant to the terms and conditions of Article 6 of this Agreement, without any limitation or other derogation of such rights or licenses occurring as a result of such termination, provided that (i) IPH’s rights and licenses
under this Subsection 13.7.5 shall be subject to NN’s rights and licenses under Subsection 13.7.3 and apply solely to the commercialization, and development for commercialization, of such, if any, specific Niche Candidates with
respect to which IPH has received such exclusive authorization to develop and commercialize pursuant to Article 6, (ii) NN’s obligations under this Subsection 13.7.5 shall not include any requirement that NN grant to IPH or assist
IPH in obtaining any grant of any rights or licenses if doing so would not be authorized by contract or permitted by applicable Law or would require NN’s payment or provision of any additional consideration to any Person save that IPH may pay
for and obtain the right to such procurement or exercise to the extent authorized by contract and permitted by applicable Law, and (iii) IPH shall continue to be bound by the terms and conditions of this Agreement in respect of the payment to
NN of royalties on Net Sales during the Term pursuant to the terms and conditions of Article 7. 

  

	 	13.7.6	 NN Damages for IPH’s Breach. In addition to the other rights and remedies of NN under this
Section 13.7, and subject to the terms and conditions of Section 21.8, in the event that NN shall terminate this Agreement prior to the expiration of the Collaboration Term pursuant to Section 12.4 for IPH’s
material breach, NN shall have the right to commence an arbitration proceeding against IPH pursuant to Section 21.14 and to recover compensatory damages for such losses it incurs as a direct and proximate result of such breach to the
extent that such losses have not been fully remedied by its rights and remedies under this Section 13.7 

  

	 	13.8	 M1 Grace Period and Audit Rights. In addition to the other consequences of termination set forth in this
Article 13, in the event that (i) the Collaboration Term expires or (ii) this Agreement is terminated prior to the expiration of the Collaboration Term by either Party for any permitted reason 

 

	 	(a)	 any Drug Candidate that shall have achieved M1 status within *** after the effective date of such termination
shall be deemed to have achieved such M1 status prior to such effective termination date for the purposes of this Article 13, and 

  

	 	(b)	 each Party, upon written request to the other Party, shall have the right to conduct an examination of all
documents, information, materials and facilities generated or maintained by or on behalf of the other Party (or of any Affiliate or Sub-licensee of the other Party) in or in connection with the Collaboration,
including all laboratory and other notebooks, records and reports, reference 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 99 

	 	
samples of Drug Candidates and Biological Targets, all assay and other test protocols, data and results, and all summaries and analyses of any of the foregoing, that relate to the discovery,
research or development of any Drug Candidate, solely for purposes of the examining Party’s determination of whether such Drug Candidate has attained M1 status prior to the effective date of such termination. 

 

	 	13.8.1	 All such examinations under this Section 13.8 shall be: (i) conducted only once with respect
to any single Drug Candidate, in each case within *** after the expiration of the *** period following immediately after the effective date of such termination; (ii) upon not less than *** prior written notice by the examining Party to the
other Party; (iii) conducted only by qualified personnel or representatives of the examining Party; and (iv) conducted without undue interference with the business or operations of the examined Party’s facility(ies) or operations.

  

	 	13.8.2	 The documents, information, materials and facilities required to be made available for purposes of such
examination shall be limited to only those that are relevant to assessing whether the Drug Candidate(s) in question have attained M1 Status prior to the effective date of such termination or during the
one-hundred-eighty day period following immediately thereafter. 

  

	 	13.8.3	 The Party made subject to any examination pursuant to this Section 13.8, whether directly or by or
through its Affiliate(s) or Sub-licensee(s), shall render, or cause to be rendered, all reasonable cooperation and assistance to the examining Party in connection with such examination. 

 

	 	13.8.4	 The examining Party shall, within *** after the completion of such examination, provide to the other Party
notice of its conclusion as to whether the Drug Candidate(s) under examination have or have not attained M1 status prior to the effective date of such termination or within the *** period following immediately thereafter, in which the examining
Party shall specify, in reasonable detail (a) the affected Drug Candidate(s), and (b) the basis for the examining Party’s conclusion as to whether or not such Drug Candidate(s) has or have attained M1 status prior to the effective
date of such termination or the following *** period. If the examined Party disagrees with such conclusion it shall, within *** after its receipt of such notice, respond to the examining Party’s conclusion with a written statement setting forth
in reasonable detail the basis for its disagreement. 

  

	 	13.8.5	 In the event that the examined Party shall fail to provide such reasonably detailed written statement of
disagreement within the above-specified *** period with respect to any Drug Candidate, it shall be deemed to have accepted and agreed to the examining Party’s conclusion as to the M1 or non-M1 status of
such Drug Candidate, and such conclusion shall be final and binding upon the Parties for purposes of determining their respective rights, licenses and obligations with respect to such Drug Candidate under this Article 13.

  
 Certain information has been excluded from this agreement
(indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 100 

	 	13.8.6	 If the examined Party shall have provided to the examining party a reasonably detailed written statement of
disagreement within the *** period specified in Subsection 13.8.4 with respect to any Drug Candidate, the Parties shall submit such disagreement for resolution pursuant to Section 21.14. 

 

	 	13.9	 Cumulative Remedies. Except as otherwise expressly provided in this Agreement, the provisions under
which this Agreement may be terminated shall be in addition to any other remedies which either Party may have hereunder or at law, in equity or otherwise, for the actual or anticipated breach of any terms hereof, and do not in any way limit any such
other remedies such Party may have. Without limitation of the generality of the foregoing, such remedies may include an award of specific performance or provisional, permanent or mandatory injunctive or other equitable remedies in those instances in
which an award of damages does not afford an adequate remedy, or where such remedies are otherwise necessary to avoid irreparable harm. Relief pursuant to the above clause may be sought from any court of competent jurisdiction in the event that the
granting of such relief is not within the authorization, power or policy of any arbitral authority selected by the Parties, or is not expressly denied on the merits by such arbitral authority but nevertheless will not adequately be enforced by the
relevant courts or be obtainable from the arbitral authority in such time and manner as will avoid irreparable harm, 

  

	14.	 EQUITY FINANCING AND FUTURE IPO 

 

	 	14.1	 Equity Investment. Subject to and conditioned upon NN’s satisfactory completion of its due
diligence review and the Parties’ execution and delivery of this Agreement: 

  

	 	(a)	 NN intends to invest *** to acquire *** newly-issued preferred shares of IPH at a purchase price of *** per
share. 

  

	 	(b)	 In the event that this transaction shall take place, it shall take effect and be governed in all respects
pursuant to the terms and conditions of a separate equity purchase agreement (the ”Share Purchase Agreement”) executed by the Parties contemporaneously with this Agreement and containing provisions customary in this type of
investment. 

  

	 	(c)	 Pursuant to the Share Purchase Agreement, in connection with the contemplated equity purchase, NN will also
receive from IPH warrants which will afford NN anti-dilution rights comparable to those provided in the warrants attached to IPH’s Series D Stock. 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 101 

	 	(d)	 The above-described equity purchase shall close *** after the date of this Agreement of this Agreement, unless
provided otherwise in the Share Purchase Agreement or the Parties hereafter agree otherwise in writing. 

  

	 	14.2	 *** 

  

	15.	 REPRESENTATIONS AND WARRANTIES 

 

	 	15.1	 Mutual Representations and Warranties. Each Party hereby covenants, represents and warrants to the other
Party that: 

  

	 	15.1.1	 Organization and Good Standing. As of the date of this Agreement such Party (a) is a corporation
duly organized, validly existing and in good standing under the Laws of its jurisdiction of incorporation and has all requisite corporate power and authority to own, lease and operate its properties and to carry on its business as now being
conducted, (b) is duly qualified or authorized to do business as a foreign corporation and is in good standing under the Laws of (i) each jurisdiction in which it leases real property and (ii) each other jurisdiction in which the
conduct of its business or the ownership of its properties requires such qualification or authorization, except where the failure to be so qualified or authorized would not have a Material Adverse Effect on such Party, the other Party, the
Collaboration, or the attainment of Commercial Optimization. 

  

	 	15.1.2	 Authority. Such Party (a) as of the date of this Agreement has, and at all times during the Term
shall have, the full right, power and authority to (i) execute and deliver this Agreement and each other agreement, document, instrument or certificate contemplated by this Agreement or required by this Agreement to be executed by such Party,
(ii) to grant all rights and licenses herein granted by such Party (including all rights to Out-license and Sub-license), and to fully perform its obligations
hereunder and thereunder; and (b) as of the date of this Agreement has taken all necessary action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder. This Agreement
has been duly and validly executed and delivered on behalf of such Party, constitutes a legal, valid and binding obligation of such Party, and is enforceable against such Party in accordance with its terms subject to the effects of bankruptcy,
insolvency or other Laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance, injunctions and other remedies, and binding public policy constraints (including
those pertaining to limitations or exclusions of liability, competition law, penalties and jurisdictional issues, including conflicts of laws). 

  

	 	15.1.3	 No Conflict. The execution and delivery of this Agreement and the performance of such Party’s
obligations hereunder do not, as of the date of this Agreement (a) conflict with or violate any requirement of applicable Law or any provision of the articles of incorporation, bylaws or any comparable charter or constitutional instrument of

  
 Certain information has been excluded from this agreement
(indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 102 

	 	
such Party, in any material way, or (b) conflict with, violate, result in a breach or termination of, or constitute a default (or, with notice or the lapse of time, become a default),
require any consent, or give rise to any ”take back” right or right of termination or acceleration or right to increase or modify the obligations under, any contractual obligation, permit or court or administrative order to which
such Party is a party or by which such Party or the properties or assets of such Party is or are bound; (c) conflict with any right previously granted by such Party to another Person; (d) constitute a violation of any law applicable to
such Party, provided that any required clearance by any EU Competition Law authority, shall have been received; or (e) result in the creation of any encumbrance upon the properties or assets of such Party, other than, in the case of
clauses (a), (b), (c) or (d), any such conflicts, violations, breaches, terminations, defaults, rights or encumbrances that, individually or in the aggregate, would not (i) have a Material Adverse Effect on such Party, the other Party, the
Collaboration or the attainment of Commercial Optimization, (ii) impair in any material respect the ability of such Party to perform its material obligations under this Agreement, or (iii) prevent or materially delay the consummation of
any of the material transactions contemplated by this Agreement. 

  

	 	15.1.4	 Warranty of No Litigation. As of the date of this Agreement there is no claim, investigation,
litigation, proceeding or dispute (including any opposition, interference or re-examination) pending or threatened with respect to, (a) for NN’s covenant, representation and warranty hereunder, the
Background NN IPR, and (b) for IPH’s covenant, representation and warranty hereunder, the Background IPH IPR, and such Party has not received any communication respecting and is not aware of any other claim, investigation, litigation or
proceeding or dispute pending or threatened against it that, individually or in the aggregate, could reasonably be expected to materially impair the ability of such Party to perform any obligation under this Agreement or have a Material Adverse
Effect upon such Party, the other Party, the Collaboration or the attainment of Commercial Optimization other than matters (i) raised in the ordinary course of Patent prosecution that are publicly available or (ii) any matter that was
disclosed to the other Party prior to the date of this Agreement. 

  

	 	15.1.5	 Consents and Approvals. As of the date of this Agreement all necessary consents, approvals, orders,
registrations and authorizations of all regulatory authorities and other Persons required to be obtained by such Party in connection with the entry into this Agreement have been obtained, except for (a) the filing with any EU Competition
Law authority, of such, if any, notifications and reports as may be required under EU Competition Law, and (b) such other consents, approvals, orders, authorizations and registrations, the failure of which to be obtained or made would not
(i) have a Material Adverse Effect on either Party, the Collaboration or the attainment of Commercial Optimization, (ii) impair in any 

  
 103 

	 	
material respect the ability of such Party to perform its obligations under this Agreement, or (iii) prevent or materially delay the consummation of any of the material transactions
contemplated by this Agreement, and such Party has obtained, or will exercise diligent, commercially reasonable efforts to obtain, all such consents, approvals, orders, authorizations and registrations required for its performance hereunder.

  

	 	15.1.6	 Legal Compliance. Such Party shall carry out, and shall cause all its Affiliates, and its and their
respective officers, employees and agents and require all its contractors, Sub-licensees and Out-licensees, and all Persons under their control or for whose actions they
are otherwise liable, to carry out all obligations and activities hereunder in material compliance with the terms and conditions of this Agreement and all material applicable Laws. 

 

	 	15.1.7	 Necessary Capacity. Such Party will use all reasonable efforts during the Collaboration Term to have the
requisite facilities, personnel, equipment, expertise, experience, knowledge and skill to timely and effectively perform the obligations contemplated to be performed by or on behalf of such Party under this Agreement in all material respects.

  

	 	15.1.8	 Disclosure. Such Party has not, in connection with the Parties’ entry into this Agreement,
communicated or otherwise provided to the other Party any statement of material fact, which it has failed to correct, or failed to communicate or otherwise provide to the other Party any material fact, the communication or omission of which is, as
of the date of this Agreement, known, or should, upon reasonable inquiry, have been known by such Party to be, false, misleading or deceptive in any material respect, including any information provided or communicated by such Party that is set forth
in this Agreement (including any Schedule hereto). Such Party has, prior to the date of this Agreement, provided, and shall throughout the Term provide, to the other Party all material information, data and documents (including any licenses,
assignments, agreements or other instruments, any documents evidencing or relating to any Patent, and any legal notices or other legal documents) that is in the possession, custody or control of such Party or any of its Affiliates, or such
Party’s Sub-licensees or Out-licensees, or, in the case of information and data, that is otherwise known to such Party or any of its Affiliates, Sub-licensees or Out-licensees, and that has been requested by the other Party with respect to, or that is otherwise material to, the Collaboration or Commercial Optimization,
including the research, development or commercialization of any Licensed Product, Niche Candidate, or Residual Product under development or commercialization by the other Party pursuant to license hereunder (including with respect to any IPR
comprising or relating to any of the foregoing), and, as of the date of this Agreement, neither such Party nor any of its Affiliates is aware, nor after reasonable inquiry should be aware, that any such information, data

  
 104 

	 	
or document is inauthentic, inaccurate, untrue or misleading in any material respect. Should such Party or any of its Affiliates become aware that any such information, data or document is
inauthentic, inaccurate, untrue or misleading, such Party will promptly notify the other Party of this fact. The provisions of this Subsection 15.1.8 are subject in all respects to the exception of such binding obligations of confidentiality
and non-disclosure to Third Parties as (a) the Parties have incurred prior to, and that remain in effect as of, the date of this Agreement, or (b) the Parties are unable to avoid or negate in their
agreements with their respective Sub-licensees or Out-licensees after having made diligent good faith efforts to do so, in each case ((a) and (b)) for so long as such
obligations shall remain in effect. 

  

	 	15.1.9	 Unauthorized Disclosure. Such Party has not delivered or otherwise made accessible, and will not deliver
or make accessible, to the other Party confidential or proprietary Know-How of any Third Party without disclosing to the other Party, in writing in advance of such disclosure, the source thereof and such
Party’s right to make such disclosure. 

  

	 	15.2	 Disclaimer of Warranty. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, no warranty is given
by either Party as to the validity of any Patents, Know-How or other IPR licensed by it under this Agreement or that any activity covered by such Patents, Know-How or
other IPR licensed hereunder will not infringe the Intellectual Property Rights of any Third Party. 

  

	 	15.3	 IPH Representations and Warranties In Respect of IPR. IPH hereby covenants, represents and warrants to
NN that: 

  

	 	15.3.1	 Exclusive Ownership and Control. 

 

	 	(a)	 As of the date of this Agreement, IPH possesses exclusive Control, within the Collaboration Field, of all
Background IPH IPR and Collaboration IPR in existence and Controlled by IPH as of the date of this Agreement, free of any security interest, lien or encumbrance other than the restrictions in IPH’s agreements with Third Parties which have
previouslybeen disclosed to NN. Subject to the other provisions of this Agreement in cases in which IPH shall, in the first instance, have or obtain such exclusive Control of Background IPH IPR, it shall retain exclusive Control throughout the Term,
and in such cases in which IPH shall, in the first instance, have or obtain non-exclusive Control of Background IPH IPR, it shall retain such non-exclusive Control, and
where necessary for Commercial Optimization, exercise diligent efforts to obtain exclusive Control, throughout the Term, and in all cases such Control shall be free of any security interest, lien or encumbrance. 

  
 105 

	 	(b)	 Except as expressly authorized pursuant Articles 5 and 6 or 13 of this Agreement, or as NN
may hereafter otherwise expressly agree in writing, IPH shall not at any time during the Term grant, transfer or convey to any Third Party any license or any other right, title or interest in respect of, or otherwise encumber, any Background IPH IPR
or Collaboration IPR, or grant, transfer or convey to any Third Party. 

  

	 	(c)	 IPH shall promptly secure and retain throughout the Term any and all licenses, assignments and transfers of all
rights required to maintain the rights of Control described in Subsections 15.3.1(a) and 15.3.1(b) or to otherwise fulfill its warranties under those Subsections. 

 

	 	15.3.2	 Patent Validity. As of the date of this Agreement, no Patent within the Background IPH IPR has, in whole
or in part, been waived, disclaimed, or held revoked, unenforceable or invalid by decision of any court or other governmental agency of competent jurisdiction, or is or has been subject to any claim, or threat to assert a claim, of invalidity in any
proceeding (other than (i) proceedings in the ordinary course of Patent prosecution as would be reflected in publicly available documents as of the date of this Agreement or (ii) that was disclosed to NN prior to the date of this
Agreement) and IPH is not aware of any reason (other than (i) proceedings in the ordinary course of Patent prosecution as would be reflected in publicly available documents as of the date of this Agreement or (ii) that was disclosed to NN
prior to the date of this Agreement) to believe that any such Patent is, in whole or in part, invalid or unenforceable, or requires any waiver or disclaimer of any rights with respect thereto. 

 

	 	15.3.3	 Infringement of Third Party IPR. As far as IPH is aware, as of the date of this Agreement, (a) none
of this Agreement or the exercise of any of the rights or licenses, or performance of any of the obligations under this Agreement, pursuant to the terms and conditions hereof, infringes, misappropriates or otherwise violates any IPR or other rights
of any Person and (b) no Person has alleged any such infringement, misappropriation or violation and there is no basis for any claim thereof. 

  

	 	15.3.4	 Patents; Third-Party Infringement. As far as IPH is aware, as of the date of this Agreement:
(a) there is no material unauthorized use, infringement or misappropriation by any Third Party of any of the Patents or other IPR within the Background IPH IPR; (b) none of the Patents within the Background IPH IPR is the subject of any
pending re-examination, opposition or interference proceedings, or any litigation or similar proceedings, and no claim has been made asserting the misuse, unregistrability, unenforceability or non-infringement of any of such Patents or challenging IPH’s or any of its Affiliates’ right to use or ownership of any of such Patents (other than (i) proceedings in the ordinary course of Patent
prosecution as 

  
 106 

	 	
would be reflected in publicly available documents as of the date of this Agreement or (ii) that was disclosed to the other Party prior to the date of this Agreement), or making any adverse
claim of ownership with respect thereto; and (c) there has been and currently is no threat of such a proceeding, or any facts that likely would be the basis for instituting any such proceeding. 

 

	 	15.3.5	 Limitations on IPH Awareness for Purposes of Section 15.3. For the purposes of
this Section 15.3, awareness of IPH shall mean the actual knowledge of ***. 

  

	16.	 INDEMNIFICATION 

 

	 	16.1	 Mutual Indemnification. Each Party (the ”Indemnifying Party”) agrees to indemnify, hold
harmless, and defend the other Party (the ”Indemnified Party”) and its Affiliates, and each of such Indemnified Party’s and its Affiliates’ respective officers, employees, and agents,
Sub-licensees and Out-licensees (collectively, the ”Other Indemnitees”), against any claims, suits, losses, damages, costs, fees and expenses against
the Indemnified Party or any of the Other Indemnitees by, or incurred by any of them to, any Third Party (collectively, ”Claim”), including reasonable legal costs, expenses and attorneys’ fees, resulting from or arising out of
or in connection with the willful misconduct of the Indemnifying Party or any of its employees, agents or other Persons for whom such Party may be held legally responsible; (b) any breach by the Indemnifying Party of any of its representations,
warranties, covenants, agreements or obligations under this Agreement, (c) the Indemnifying Party’s activities (including the exercise of its rights or performance of its obligations) under this Agreement, or (d) or the sale or use of
any Licensed Product, Niche Candidate or Residual Product by the Indemnifying Party, its Affiliates, Sub-licensees or Out-licensees, except in each case ((a) through
(d)) to the extent that such Claim results from or arises out of or in connection with the acts or omissions of the Indemnified Party or any employees, agents or other Persons for whom the Indemnified Party may be held legally responsible.

  

	 	16.2	 Indemnification Procedure. 

 

	 	16.2.1	 Notice of Claim. The Indemnified Party shall promptly notify the Indemnifying Party in writing of any
Claim or the discovery of any fact upon which the Indemnified Party intends to base a request for indemnification under Section 16.1, but the failure or delay to provide such notice shall not, however, relieve the Indemnifying Party of
any of its indemnification obligations hereunder except to the extent that the Indemnifying Party is materially prejudiced thereby. Each such notice shall contain a description of the nature and amount of the asserted Claim to the extent then known
by the Indemnified Party. The Indemnified Party shall furnish promptly to the Indemnifying Party copies of all papers and official documents received in respect of such Claim. All requests or demands for indemnification by or on behalf of the Other
Indemnitees shall be made solely by the Indemnified Party. 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 107 

	 	16.2.2	 Other Indemnification Procedures. The obligations of an Indemnifying Party under this Article 16
shall be governed by the following additional terms and conditions: 

  

	 	(a)	 Control of Defense. The Indemnifying Party shall have the obligation to assume and the right to
exclusive control of the defense of all Claims, provided that the Indemnified Party shall have the right and option to assume and control such defense by giving written notice to the Indemnifying Party of such assumption within *** after
providing the Indemnifying Party with notice of the relevant Claim under Section 16.2.1. The Party assuming the defense of a Claim shall have the right to appoint legal counsel of its own choice as lead counsel in such defense. In the
event that the Indemnified Party shall assume control of such defense, the Indemnifying Party shall be responsible for all reasonable costs and expenses (including reasonable attorneys’ and experts’ fees) incurred by the Indemnified Party
in connection therewith. Should the Indemnifying Party assume the defense of a Claim, the Indemnifying Party shall not be liable to the Indemnified Party or any of the Other Indemnitees for any legal costs or expenses subsequently incurred by such
Indemnified Party or Other Indemnitees in connection with such defense. 

  

	 	(b)	 Right to Participate in Defense. Without limitation of the Parties’ rights and obligations under
Subsection 16.2.2(a), in the event that the Indemnifying Party shall assume control of the defense of a Claim, the Indemnified Party and each of the Other Indemnitees shall be entitled to participate in, but not control, the defense of such
Claim and to employ counsel of its choice for such purpose, provided that such employment shall be at its own cost and expense unless specifically requested and authorized by the Indemnifying Party in writing. 

 

	 	(c)	 Settlement of Claims. The Party in control of the defense of a Claim shall have the exclusive right, in
its sole discretion, to settle such Claim, whether by settlement or other voluntary final disposition, without the prior written approval of the other Party (or, if the Indemnified Party controls such defense, the approval of the Other Indemnitees),
provided that the terms of such resolution do not: (a) enjoin any future action by the other Party (or, if the Indemnified Party controls such defense, such action by any of the Other Indemnitees); (b) derogate from or diminish any of
the other Party’s rights under this Agreement; (c) require the payment or provision of consideration by the other Party (or, if the Indemnified Party controls such defense, by any of the Other Indemnitees); (d) fail to grant a release of
such Claim to the other Party (and, if the Indemnified Party controls such defense, to any of the Other Indemnitees); (e) require the admission or concession that any claim or aspect of any Patent Controlled by the other Party or its Affiliates is
invalid or unenforceable, or require any waiver or disclaimer of any rights with respect to such claim or Patent; or (f) otherwise have a Material Adverse Affect upon the other Party (or, if the Indemnified Party controls such defense, on any of the
Other Indemnitees). 

  
 Certain information has been excluded from
this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 108 

	 	(d)	 Cooperation. Regardless of which Party controls the defense of any Claim, the Indemnified Party shall,
and shall diligently endeavor to cause each of the Other Indemnitees to, cooperate in the defense or prosecution thereof and shall furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery
proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith. Such cooperation shall include access during normal business hours afforded to the indemnifying Party to, and reasonable retention by the Indemnified
Party of, records and information that are reasonably relevant to such Claim, and making Indemnitees and other employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided
hereunder, and the indemnifying Party shall reimburse the Indemnified Party for all its reasonable out-of-pocket expenses in connection therewith. 

 

	 	(e)	 Expenses. In the event that the Indemnified Party assumes control of the defense of a Claim pursuant to
Subsection 16.2.2(a), the reasonable and verifiable costs and expenses, including fees and disbursements of counsel, incurred by the Indemnified Party in connection with such Claim shall be reimbursed by the Indemnifying Party on a calendar
quarter basis, without prejudice to the Indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to be obligated to indemnify
the Indemnified Party by a legally binding final decision of a court or arbitrator that is unappealable or unappealed within the time allowed for appeal. 

  

	 	(f)	 Non-Waiver. The assumption of the defense of a Claim by the
Indemnifying Party shall not be construed as an acknowledgment that the Indemnifying Party is liable to indemnify any Person in respect of the Claim, nor shall it constitute a waiver by the Indemnifying Party of any defenses it may assert against
any claim for indemnification hereunder. In the event that it is ultimately determined that the Indemnifying Party is not obligated to indemnify, defend or hold harmless an Indemnitee from and against the Claim, the Indemnified Party shall reimburse
the Indemnifying Party for any and all costs and expenses (including attorneys’ fees and costs of suit) and any and all losses, damages, liabilities, costs and expenses (including reasonable attorneys’ fees and expenses) incurred by the
Indemnifying Party in its defense of the Claim with respect to such Indemnitee. 

  
 109 

	17.	 FORCE MAJEURE 

 

	  	 Force Majeure. In the event of Force Majeure, a Party thereby prevented from performing its obligations
or duties shall not be held liable or responsible to the other Party, nor be deemed to be in default under or in breach of any provision of this Agreement, by reason thereof. The Party prevented from performing its obligations because of Force
Majeure shall promptly notify the other Party of the occurrence and particulars of such Force Majeure and shall provide such other Party, from time to time, with its best estimate of the duration of such Force Majeure and with notice of the
cessation thereof. The Party so affected shall use diligent, commercially reasonable efforts to avoid or remove such causes of nonperformance and, upon cessation of Force Majeure, shall resume performance as soon as practicable.

  

	18.	 PUBLICATIONS AND DISCLOSURES 

 

	 	18.1	 Publication. Each Party shall furnish, and shall cause its Affiliates, and to the extent authorized by
contract and permitted by applicable Law, contractually require all its new Sub-licensees and Third Party licensors, investigators and collaboration partners, to furnish, to the other Party copies of any
proposed publication or public disclosure (including any oral disclosure made with or without obligation of confidentiality) by or on behalf of such Party or other Person of any Collaboration Know-How, in
advance of such publication or disclosure. 

  

	 	  	 The receiving Party shall have *** after receipt of such proposed publication or disclosure to object to such
proposed publication or disclosure because there is patentable subject matter or other confidential information contained therein, which may need protection, and shall have the right, upon written request, to 

 

	 	(a)	 a delay in publication or presentation for up to *** in order to protect patentable subject matter,

  

	 	(b)	 propose modifications to the publication or presentation for patent or confidentiality reasons, or

  

	 	(c)	 request that the information be maintained in confidence. 

 

	 	  	 In the event that the receiving Party objects to such publication or disclosure, the other Party shall refrain
from making such publication or disclosure and shall cause its Affiliates, and to the extent authorized by contract and permitted by applicable Law, contractually require its Sub-licensees and Third Party
licensors, investigators and collaboration partners to refrain from making, such publication or disclosure, until approved by the other Party, which approval shall not be unreasonably withheld or delayed. 

 

	 	  	 In no event, shall a Party publish or present the other Party’s Confidential Information without prior
written approval of such other Party. The Parties shall obtain and maintain throughout the Term all authorizations, consents and agreements of their respective Affiliates, and employees and agents, and shall exercise diligent, commercially
reasonable efforts to obtain and maintain throughout the Term all authorizations, consents and agreements of their Sub-licensees and Third-Party licensors, investigators and collaboration partners, necessary to perform their obligations under this
Section 18.1. 

  
 Certain information has been excluded
from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 110 

	 	18.2	 Communication Guidelines. The Parties have agreed to the communication guidelines set forth in Schedule
18.2. 

  

	 	18.3	 Press Releases. Following the date of this Agreement, the Parties shall issue one or more press
releases, to be approved by both Parties, regarding this Agreement and the Share Purchase Agreement, the timing and content of which shall be mutually agreed. 

 

	 	18.3.1	 Unless agreed otherwise, no press releases or other public announcements with respect to this Agreement, the
Share Purchase Agreement, or any subject matter or terms of either of them, shall include any information about funding conditions or monetary amounts. Except to the extent required by Law or the rules of a relevant Stock Exchange or as otherwise
permitted in accordance with this Section 18.3, neither Party shall make any further press releases or other public announcements concerning this Agreement or the Share Purchase Agreement or the terms or subject matter hereof or thereof,
or that explicitly refers to the other Party or its trade name or trademark(s), without the prior written consent of the other Party, which shall not be unreasonably delayed, conditioned or withheld. 

 

	 	18.3.2	 Any copy of this Agreement or the Share Purchase Agreement required to be filed with any governmental or
regulatory authority shall, if permitted by applicable Law, be redacted to the reasonable satisfaction of both Parties; provided that, in the event that such governmental or regulatory authority objects to the redaction of any portion of the
Agreement after the initial submission, the filing Party shall consult with the other Party respecting the objections and shall in good faith respond to the objections in an effort to limit the disclosure required by such authority.

  

	 	18.3.3	 Notwithstanding the foregoing, the Parties agree that each Party may desire or be required to issue press or
other public announcements releases relating to this Agreement, the Share Purchase Agreement or activities hereunder or thereunder, and each of the Parties agrees to consult with the other Party reasonably and in good faith with respect to the text
and timing of such press releases or other public announcements and not to issue any such press releases or public announcements without the prior written consent of the other Party prior to the issuance thereof, provided that (a) a
Party may not unreasonably delay, condition or withhold consent to such press releases or public announcements, (b) either Party may issue such press releases or public announcements as it determines, based on advice of counsel, are reasonably
necessary to comply with Law or for appropriate market disclosure, and (c) the contents of any such press release or public announcement or similar publicity which has been reviewed and approved by the reviewing Party may be re-released by either Party without a requirement for re-approval. 

  
 111 

	 	18.3.4	 The principles to be observed by the Parties in any press releases or other public disclosures with respect to
this Agreement or the Share Purchase Agreement shall be: accuracy, compliance with applicable legal requirements, the requirements of confidentiality under Article 10 and as set forth in this Section 18.3 and elsewhere in this
Agreement, and normal business practice in the pharmaceutical and biotechnology industries for disclosures by companies comparable to IPH and NN. 

  

	 	18.3.5	 Notwithstanding any provision hereof to the contrary, in the event of any such proposed press release or public
announcement by IPH, NN shall be afforded a minimum of *** after its receipt thereof in which to review, comment and approve (or request modifications or conditions of approval of) such press release or public announcement, unless a shorter period
is required by applicable Law or the rules of a relevant Stock Exchange, in which event IPH shall provide NN with a copy of the contemplated press release or public announcement immediately upon the completion thereof, together with written notice
of such shorter period, unless such prior submission to NN is contrary to applicable Law or otherwise impossible due to circumstances beyond IPH’s control. 

 

	 	18.4	 Disclosure of Agreement. Except as permitted by this Agreement, and subject to applicable Law, the terms
and conditions of this Agreement, the activities hereunder and the existence of the Agreement shall be kept confidential by the Parties and shall not be disclosed in any way without the prior written approval of the other Party, provided that
each Party may disclose the contents of this Agreement to Affiliates or professional advisors who agree or are under a professional obligation to maintain the same in confidence. However, such approval shall be unnecessary if the Disclosing Party is
subject to a legal requirement to disclose the existence and terms of this Agreement. In such event, the Disclosing Party shall notify the other Party without delay and provide the other Party with a copy of the contemplated disclosure prior to its
being made, unless notifying is impossible due to circumstances beyond the Party’s control. The other Party may provide comments to the proposed disclosure and the Disclosing Party shall in such case take into consideration all such reasonable
comments. Unless otherwise agreed upon in writing with the other Party the Disclosing Party shall only disclose such information that is needed to comply with applicable Law. 

 

	19.	 NOTICES 

Except as otherwise specified herein, all notices, requests, demands, approvals, consents, tenders, offers, acceptances, rejections or other communications
required or permitted hereunder (other than routine communications lacking legal effect), must be written and in English and shall be deemed to have been duly given if (a) delivered personally, (b) mailed, certified or registered mail,
return receipt requested, postage prepaid, (c) sent by internationally recognized overnight courier service or overnight express mail, postage prepaid, or (d) sent by telecopy, followed with an original sent in accordance with (b) or
(c) above, as follows: 
  
 Certain information has been excluded from this agreement
(indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 112 

			
	 If to Novo Nordisk:
	  	 Novo Nordisk A/S
 Novo Allé

DK-2880 Bagsvaerd

Denmark
 ***

	 With a copy to:
	  	***
		
	 If to IPH:
	  	 Innate Pharma SA
 121 ancien chemin de
Cassis.
 13009 Marseille
 France

***

  

	20.	 ASSIGNMENT 

  

	 	20.1	 General. Except as set forth in Section 20.2 below, or as otherwise expressly provided with
respect to any right to Sub-license, Out-license or subcontract set forth in this Agreement, neither this Agreement nor any rights, licenses or obligations hereunder may
be sold, transferred, assigned, assumed, delegated, mortgaged, pledged, hypothecated or encumbered, in whole or in part (each of the foregoing a ”Transfer”), by either Party, without the prior written consent of the other Party,
which consent shall not unreasonably be delayed, conditioned or withheld. 

  

	 	20.2	 Permitted Transfers. Notwithstanding the provisions of the above Section 20.1, either Party
may, without the consent of the other Party, transfer or assign this Agreement and any or all of its rights, licenses and obligations hereunder (a) to any Affiliate or successor in interest, or (b) in connection with a Change of Control or
sale, merger or consolidation of all or substantially all of it’s business or assets related to this Agreement, provided that, (i) such Affiliate or other assignee, transferee or successor shall enter into a binding written
agreement by which it shall assume all of such Party’s agreements, undertakings and obligations hereunder; and (ii) NN shall, pursuant to Section 12.11, have the right to terminate this Agreement in the event of any Transfer
(including any Change of Control) by IPH pursuant to this Section 20.2. “Change of Control” for purposes of this Section 20.2 shall mean, with respect to a Party, the occurrence of any one or more of the
following: 

  

	 	(a)	 a merger or consolidation of such Party in which the Party’s shareholders or equity owners immediately
prior to such merger or consolidation do not in the aggregate own directly or indirectly at least a majority equity interest and a majority of the voting capital stock or interests in the surviving entity (if the Party is a constituent corporation
in such merger or consolidation) or in the Party (if the Party is not a constituent corporation in such merger or consolidation), as the case may be, immediately following such merger or consolidation; 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 113 

	 	(b)	 the sale, lease, exchange or other disposition (in one transaction or a series of transactions) of all or
substantially all of the assets of such Party; or 

  

	 	(c)	 any transaction, circumstance or event that would result in any Person, or any group of Persons acting in
concert, acquiring direct or indirect beneficial ownership of more than fifty percent (50%) of the equity interests or voting capital stock or interests of such Party. 

 

	 	20.3	 Deemed Approval. In the event that either Party shall propose a Transfer required to be approved by the
other Party pursuant to Section 20.1, such Transfer shall be deemed approved by the other Party in the event that said other Party shall fail to object to the proposed Transfer by written notice to the Party proposing such Transfer sent
within *** after its receipt of the Transferring Party’s written notice of the proposed Transfer setting forth in reasonable detail particulars as to the identity, financial strength and ability of the Person contemplated to receive such
Transfer to perform the agreements, undertakings and obligations of such Party under this Agreement. 

  

	 	20.4	 Noncompliant Transfers. Any Transfer not in compliance with this Article 20 will be void ab
initio and of no force or effect and shall constitute a material breach of this Agreement. 

  

	21.	 MISCELLANEOUS 

 

	 	21.1	 Obligation to Obtain Assignments. Each Party shall cause all principals, officers, employees,
contractors, Sub-licensees, Out-licensees and other Persons who or that perform any research, services or other activities on its behalf in connection with this
Agreement, including any research, discovery, development, improvement or commercialization of any Collaboration Targets, Drug Candidates, Licensed Products, Niche Candidates or Residual Products, or of any Research Technology, Research Technology
IPR, or other IPR comprising or relating to any of the foregoing, to take all actions and sign all documents and instruments (including any work-made-for-hire agreements
or assignments) required to confer upon such Party exclusive ownership of all rights arising from such research, services or activities, so as to enable such Party fully to: (a) grant the rights and licenses it has herein granted;
(b) maintain said rights and licenses in full force and effect throughout the Territory during the applicable Term of their grants hereunder, (c) exercise its rights and perform its obligations hereunder, and (d) consummate the
transactions contemplated by this Agreement. 

  

	 	21.2	 Privileged Communications. In furtherance of this Agreement, it is expected that NN and IPH will, from
time to time, disclose to one another privileged communications with counsel, including opinions, memoranda, letters and other written, electronic and verbal communications. Such disclosures shall be made with the understanding that they shall
remain confidential and that they are made in connection with the shared community of legal interests existing between NN and IPH, including the Parties’ common legal interest in avoiding infringement of any valid, enforceable Patents and
protecting the ability of the Parties to enforce any IPR that it licensed under this Agreement. In furtherance of the foregoing, 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 114 

	 	
the Parties shall enter into a mutually acceptable Common Interest Agreement on or within *** after the date of this Agreement in substantive conformity with the form annexed as Schedule
21.2 hereto and the Parties shall retain and have benefit of all applicable joint defense, common interest and other privileges and immunities with respect to such documents and information to the full extent available under applicable Law.

  

	 	21.3	 Non-Solicitation of Employees. Until the expiration of at
least *** following expiration or termination of the Agreement, neither of the Parties nor any of their respective Affiliates shall intentionally solicit for employment, employ or hire the employees of the other Party. Notwithstanding the foregoing
or any other provisions of this Agreement, neither Party nor any of its Affiliates shall be prohibited from placing help wanted advertisements in its own internal publications, its Web site or any media of general circulation, from posting position
openings at such Person’s places of business, or from hiring an employee of the other Party who answers any advertisement or who otherwise voluntarily applies for hire without having been initially personally solicited or recruited by
the hiring Party. 

  

	 	21.4	 Competition Law Submissions. If it is determined that any transaction under this Agreement needs to be
notified to the European Commission or other European Competition Law authority, the Parties shall cooperate in making such notification and in seeking a conclusion of the notification process satisfactory to both Parties. If at any time the
European Commission or controlling authority determines that any provision of this Agreement is unenforceable or otherwise not permitted under the Laws of the European Union or member states, the Parties agree to initiate good faith negotiations
aimed at modifying such provision in a manner that is acceptable to the European Commission or such member states and the Parties and that is consistent with the intent of the Parties under this Agreement. 

 

	 	21.5	 Relationship of the Parties. The relationship between NN and IPH is that of independent contractors.
This Agreement does not constitute either Party as being the agent or legal representative of the other for any purpose whatsoever. Neither Party is granted any right or authority to assume or to create any obligation or responsibility, express or
implied, on behalf of, or in the name of the other, with regard to any manner or thing whatsoever, unless otherwise specifically and expressly agreed upon in writing. No joint venture, co-venture, franchise,
business opportunity, fiduciary, partnership, employment or principal-agent relationship between the Parties is intended, established or evidenced by this Agreement, and neither Party shall have any authority or responsibility with respect to the
other Party’s employees, including in respect of the hiring, termination, compensation or employee benefits of such employees. In furtherance and not in limitation of the foregoing, no fiduciary or quasi-fiduciary relationship does or shall
exist between the Parties by reason of or in connection with this Agreement, in whole or in part, and each of the Parties hereby irrevocably waives any claims and causes of action against the other for the breach of any fiduciary or quasi-fiduciary
duty arising out of or in connection with this Agreement or any performance or non-performance hereunder. 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 115 

	 	21.6	 Effect of Rejection in Bankruptcy. The Parties expressly acknowledge and agree that the subject matter
of this Agreement, including the Intellectual Property Rights licensed hereunder, are unique and irreplaceable, and that the loss thereof cannot adequately be remedied by an award of monetary compensation or damages. Accordingly, in the event that
IPH, whether directly, or by or through a trustee or similar functionary in bankruptcy acting on behalf of its estate, terminates or rejects this Agreement or NN’s right to continue the licenses under this Agreement, it is the Parties’
express intention and agreement that NN shall continue to have the benefit of all licenses granted to it under this Agreement, which licenses shall remain in full force and effect for the stated Term regardless of any termination or rejection in
bankruptcy of this Agreement or any other terms hereof, such that NN shall have the right, should it so elect, to retain all its license rights under this Agreement under applicable Law (including any applicable principles under, or correlative to,
or no less favourable than, those set forth in Section 365(n) of the U.S. Bankruptcy Code, 11 U.S.C. § 365(n)). 

  

	 	21.7	 Costs and Expenses. Except as otherwise expressly provided in this Agreement, each Party shall bear its
own costs and expenses (including, without limitation, the fees of any attorneys, accountants, investment bankers, consultants or other representatives) incurred in connection with its entry into this Agreement, the transactions contemplated by this
Agreement (whether or not such transactions are consummated), and the exercise of its rights and licenses, and performance of its activities and obligations, hereunder, without charge or expense to the other Party. 

 

	 	21.8	 Limitation of Liability. EXCEPT FOR CLAIMS FOR INDEMNIFICATION PURSUANT TO ARTICLE 16, IN NO
EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY INJURY TO OR LOSS OF DATA, GOODWILL, REPUTATION, BUSINESS (IRRESPECTIVE OF WHETHER ANY SUCH INJURY OR LOSS IS DEEMED TO CONSTITUTE GENERAL, DIRECT OR ANY OTHER
CATEGORY OF DAMAGES), OR ANY SPECIAL, INDIRECT, PUNITIVE, EXEMPLARY, ENHANCED, TREBLED, INCIDENTAL OR CONSEQUENTIAL DAMAGES WHATSOEVER, ARISING OUT OF OR IN CONNECTION IN ANY WAY WITH THIS AGREEMENT OR ANY SUBJECT MATTER HEREOF (INCLUDING ANY
EXERCISE OF ANY RIGHTS OR LICENSES, OR PERFORMANCE, OR FAILURE TO PERFORM, ANY OBLIGATIONS OR ACTIVITIES HEREUNDER), EVEN IF THE PARTY AGAINST WHOM SUCH LIABILITY IS CLAIMED HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSSES, DAMAGES OR LIABILITIES,
AND WHETHER OR NOT OR SUCH LOSSES, DAMAGES OR LIABILITIES ARISE IN CONTRACT, WARRANTY, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, PRODUCT LIABILITY OR ANY OTHER THEORY OF LIABILITY, AND NOTWITHSTANDING THE FAILURE OF ANY AGREED OR OTHER
REMEDY OF ITS ESSENTIAL PURPOSE. IN THE EVENT THAT ANY FOREGOING EXCLUSION OR LIMITATION OF LIABILITY IS NOT ALLOWED PURSUANT TO APPLICABLE LAW IN A JURISDICTION, THE LIABILITY OF EACH PARTY IN SUCH JURISDICTION SHALL BE LIMITED TO THE
MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW. 

  
 116 

	 	21.9	 Severability. If any provision of this Agreement is adjudged to be illegal, invalid or unenforceable in
its current form or scope under any applicable present or future Law, and if the rights or obligations of either Party under this Agreement shall not be materially and adversely affected thereby, (a) such provision shall be fully severable,
(b) this Agreement shall be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this Agreement shall remain in full force and effect and shall not
be affected by the illegal, invalid or unenforceable provision or by its severance herefrom, and (d) in lieu of such severed provision, there shall be substituted as a part of this Agreement, a legal, valid and enforceable provision as similar
in terms to such severed provision as may be possible so as to effect, as closely as possible, the intent of the Parties in entering into this Agreement. 

  

	 	21.10	 IPH Financial Information. IPH agrees to keep NN informed as to its financial condition throughout the
Term of this Agreement. If at any time the financial resources of IPH are not reasonably sufficient to enable it to continue to meet its obligations hereunder for at least the coming ***, the Parties will meet to review and consider steps that might
be taken to preserve the objectives of the Agreement. 

  

	 	21.11	 Waiver. Either Party may waive any term, condition, or obligation of this Agreement which is for its
benefit, but only in a signed writing. The failure or delay of either Party to enforce at any time any provision of this Agreement, or any right with respect thereto, or to exercise any election herein provided, shall in no way be considered to be a
waiver of such provision, right or election, or in any way affect the validity of this Agreement. Except as otherwise expressly herein provided, the exercise by either Party of any right or election under the terms or covenants herein shall not
preclude or prejudice such Party from exercising the same or any other right it may have under this Agreement, irrespective of any previous action or proceeding taken by the Parties hereunder. 

 

	 	21.12	 Amendment. Except as otherwise expressly provided herein or required by Law, this Agreement may be
modified or amended only by a written document signed by both Parties. 

  

	 	21.13	 Applicable Law. Except as otherwise indicated herein, this Agreement, and the rights and obligations of
the Parties hereunder, shall be construed and governed, including, without limitation, as to validity, interpretation and effect, by the internal laws of England. 

 

	 	21.14	 Dispute Resolution. Both Parties will use their best efforts to settle all matters in dispute amicably.
In the event that a dispute of any kind related to this Agreement cannot be solved amicably by the Parties, then either Party may submit the dispute for determination by binding arbitration before a panel of three arbitrators (one arbitrator chosen
by each of the parties and the third arbitrator chosen by the first two, unless the parties agree otherwise), the third arbitrator having a minimum of *** of experience in the field of biotechnology or pharmaceuticals and shall be administered under
the WIPO Expedited Arbitration Rules except as to the number of arbitrators which shall be three (3). The venue for the arbitration shall be in London, England, conducted in the English language, and, except to the extent otherwise expressly herein
provided, the governing law shall be that of England and Wales without regard to the conflicts-of-laws provisions of such laws. The arbitrators shall have the authority
to grant 

  
 Certain information has been excluded from this
agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 117 

	 	
specific performance and to allocate between the parties the costs of arbitration, including but not limited to reasonable attorney’s fees, in such equitable manner as they determine.
Notwithstanding the foregoing dispute resolution and governing law provisions, each of Licensor and Licensee retains the right to seek judicial injunctive relief. 

 

	 	21.15	 Further Assurances. Each Party shall provide such full and continuing cooperation and assistance to the
other Party as may be reasonable and necessary to secure, perfect, defend, protect or enforce any of such other Party’s rights or licenses under this Agreement, including any right, title or interest of such other Party in respect of any
Intellectual Property Rights that are subject to the terms hereof, and shall duly execute and deliver, or cause to be duly executed and delivered, such documents and instruments and do and cause to be done such acts and things, including the
execution and filing of such assignments, agreements, powers and other documents and instruments, as may be necessary, or as the other Party may reasonably request, to carry out more effectively the provisions and purposes of, or to better assure
and confirm unto the other Party its rights and remedies under, this Agreement. 

  

	 	21.16	 Entire Agreement. This Agreement, including all annexed schedules and exhibits, together with the Share
Purchase Agreement, sets forth the entire agreement between the Parties, fully superseding any and all prior and contemporaneous negotiations, agreements, representations or understandings between them, whether oral or written, pertaining to the
subject matter hereof. The Parties hereby expressly confirm that there are no other oral or written agreements, ”side-deals,” arrangements or understandings between them with respect to the subject matter hereof other than as
expressly stated otherwise in this Agreement or the Share Purchase Agreement. 

  

	 	21.17	 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall
constitute an original for all purposes, including for purposes of any delivery of this Agreement required by the terms hereof, and all of which together shall constitute one and the same instrument with the same effect as if all Parties hereto had
signed the same document. Once this Agreement has been duly executed, any faithful reproduction by reliable means (such as by photocopying or facsimile) of a duly executed original of this document shall constitute and be effective as an original of
this Agreement for all purposes, including for purposes of any delivery of this Agreement required by the terms hereof. 

  
 118 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed, under seal, by their respective duly
authorized representatives as of the day and year first above written. 
  

					
	Marseille	 		  	Bagsvaerd
			
	Date: March 28, 2006	 		  	Date: March 28, 2006
			
	Innate Pharma SA	 		  	Novo Nordisk A/S
			
	 /s/ Hervé Brailly
	 		  	 /s/ Terje Kalland

	 By:        Hervé Brailly
	 		  	 By:        Terje Kalland

	Title:     Chief Executive Officer	 		  	Title:     Senior Vice President,
              Biopharmaceuticals Research Unit

  
 119 

 Table of Contents 

					
	 	  	Page	 
	 1.   DEFINITIONS AND CONSTRUCTION
	  	 	2	 
	 1.1  Definitions
	  	 	2	 
	 1.2  Definitions of other terms used in this Agreement:
	  	 	16	 
	 1.3  Construction
	  	 	17	 
		
	 2.   NATURE OF AGREEMENT AND PRIVILEGED COMMUNICATIONS
	  	 	17	
	 2.1  Collaboration Exclusivity
	  	 	17	 
	 2.2  Joint Research Agreement
	  	 	18	 
	 2.3  Kirostim Agreement
	  	 	18	 
		
	 3.   COLLABORATION
	  	 	18	
	 3.1  Collaboration Objective
	  	 	18	 
	 3.2  Duration of the Collaboration
	  	 	19	
	 3.3  Third Party Collaborations
	  	 	20	 
	 3.4  Presentation of In-Licensing and New Third Party Collaboration
Opportunities
	  	 	22	 
	 3.5  Obligation to Diligently Seek Sub-License Rights in All Collaborations with
Third Parties
	  	 	24	 
	 3.6  Collaboration Plans
	  	 	24	 
	 3.7  Commercially Reasonable Efforts
	  	 	25	 
	 3.8  Legal Compliance
	  	 	25	 
	 3.9  Research Personnel
	  	 	25	 
	 3.10  Project Groups
	  	 	26	 
	 3.11  Project Managers
	  	 	26	 
	 3.12  Research Funding
	  	 	27	 
		
	 4.   MANAGEMENT OF THE COLLABORATION
	  	 	28	
	 4.1  Project Group Decisions
	  	 	28	 
	 4.2  Joint Steering Committee
	  	 	28	 
	 4.3  Duties of Joint Steering Committee
	  	 	29	 
	 4.4  Participation in Committee Meetings
	  	 	31	 
	 4.5  Decision-making Procedures
	  	 	31	 
	 4.6  Disputes and Continued Performance
	  	 	31	 
	 4.7  Expenses
	  	 	32	 
	 4.8  Limited Authority
	  	 	32	 
	 4.9  Development and Commercialization Committee
	  	 	32	 
		
	 5.   GRANT OF RIGHTS
	  	 	33	 
	 5.1  NN Licenses in the Field
	  	 	33	 
	 5.2  NN License to Collaboration IPR Outside the Collaboration Field
	  	 	33	 
	 5.3  Grant Backs to IPH
	  	 	33	 
	 5.4  IPH Licenses to NN Background Research Technology IPR and NN Controlled
Collaboration IPR
	  	 	34	 
	 5.5  Future IPH License in the Field for Niche Candidates
	  	 	34	 
	 5.6  Sub-licensing
	  	 	35	 
	 5.7  Regulatory Exclusivity
	  	 	35	 

 Table of Contents 

(continued) 
  

					
	 	  	Page	 
	 5.8  Freedom of Operation
	  	 	36	 
	 5.9  Terminated Collaboration Properties and Out-licensing
	  	 	38	 
	 5.10  Procedure for Terminating Background IPR
	  	 	39	 
	 5.11  NN Out-licensing and Upside Revenue
	  	 	40	 
	 5.12  Cumulative Payments
	  	 	41	 
	 5.13  Future Obligation to Provide Licensees Under Specific Third Party Agreements
in Deemed Necessary
	  	 	41	 
		
	 6.   NICHE CANDIDATES AND EX-VIVO CELLULAR THERAPY CANDIDATES
	  	 	43	 
	 6.1  Niche Candidates
	  	 	43	 
	 6.2  Ex-Vivo Cellular Therapy Candidates
	  	 	44	 
	 6.3  IPH Royalty Obligation
	  	 	45	 
	 6.4  IPH Access to Materials
	  	 	45	 
	 6.5  NN Buy-In Option
	  	 	45	 
	 6.6  NN Co-Marketing Option
	  	 	47	 
	 6.7  IPH Assistance to NN Upon NN Exercise of Buy-In or Co-Marketing
Option
	  	 	47	 
	 6.8  Licenses to NN for Niche Candidates
	  	 	47	 
	 6.9  Exclusion of Funded FTEs
	  	 	48	 
		
	 7.   TECHNOLOGY FEES, MILESTONES AND ROYALTIES
	  	 	48	 
	 7.1  Consideration
	  	 	48	 
	 7.2  Technology Access Fee
	  	 	48	 
	 7.3  Discovery Milestones
	  	 	48	 
	 7.4  Development Milestone Payments
	  	 	49	 
	 7.5  Royalty Calculation and Payments
	  	 	53	 
	 7.6  Royalties on Licensed Products
	  	 	54	 
	 7.7  Royalties on Residual Products
	  	 	55	 
	 7.8  Royalties on Niche Candidates
	  	 	55	 
	 7.9  Records of Net Sales
	  	 	57	 
	 7.10  Annual Recalculation and Report
	  	 	57	 
	 7.11  Royalty Term
	  	 	57	 
	 7.12  No Effect of Out-licensing on Royalties
	  	 	58	 
		
	 8.   FINANCIAL PROVISIONS
	  	 	58	 
	 8.1  Payment by Wire Transfer
	  	 	58	 
	 8.2  Currency
	  	 	58	 
	 8.3  Withholding Tax
	  	 	58	 
	 8.4  Audits
	  	 	58	 
	 8.5  Cost of Audit
	  	 	59	 
	 8.6  Right to Audit Third Parties
	  	 	59	 
		
	 9.   INTELLECTUAL PROPERTY RIGHTS
	  	 	59	 
	 9.1  Disclosure of Know-How
	  	 	59	 
	 9.2  Ownership of Collaboration IPR
	  	 	59	 
	 9.3  Disputes Regarding Inventorship or Ownership of Collaboration IPR
	  	 	60	 

  
 ii 

 Table of Contents 

(continued) 
  

					
	 	  	Page	 
	 9.4  Duty to Require Assignment of Collaboration IPR by Employees, Consultants, and
Collaboration Partners
	  	 	60	 
	 9.5  Obligations to Maintain Control of Licensed IPR
	  	 	60	 
	 9.6  Prosecution of Patents
	  	 	61	 
	 9.7  Updating of Patent Schedules and Patent Information
	  	 	66	 
	 9.8  Patent Term Extension
	  	 	67	 
	 9.9  License Registration
	  	 	67	 
	 9.10  No Implied Rights
	  	 	68	 
	 9.11  Notice of Infringement or Misappropriation
	  	 	68	 
	 9.12  Exclusive First Right of Enforcement of Licensed IPR
	  	 	68	 
	 9.13  Second (“March-In”) Enforcement Rights
	  	 	70	 
	 9.14  Share of Recoveries
	  	 	70	 
	 9.15  Third Party Litigation
	  	 	70	 
	 9.16  Cooperation in Legal Proceedings
	  	 	71	 
	 9.17  Trademarks
	  	 	71	 
	 9.18  Determination of Patent Issues to be Made Under Applicable National
Law
	  	 	72	 
	 9.19  Acknowledgment of Intellectual Property Rights
	  	 	72	 
	 9.20  Survival
	  	 	73	 
		
	 10.  CONFIDENTIAL INFORMATION AND MATERIALS
	  	 	73	 
	 10.1  Superseding of Prior Agreements
	  	 	73	 
	 10.2  Confidentiality and Use Restrictions
	  	 	73	 
	 10.3  Disclosures to Authorized Persons
	  	 	73	 
	 10.4  Material Transfer Agreement
	  	 	74	 
	 10.5  Additional Terms of Confidentiality
	  	 	75	 
	 10.6  Permitted Disclosures
	  	 	76	 
	 10.7  Required Notices
	  	 	77	 
	 10.8  Relief
	  	 	77	 
		
	 11.  DURATION OF THE AGREEMENT
	  	 	77	 
		
	 12.  MATERIAL BREACH AND TERMINATION
	  	 	77	 
	 12.1  Material Breach, Damages and Termination
	  	 	77	 
	 12.2  Breach of Confidentiality Resulting in Loss of Patent Rights
	  	 	78	 
	 12.3  Termination for Convenience
	  	 	78	 
	 12.4  Termination for Material Breach
	  	 	78	 
	 12.5  Establishing Materiality and Scope of Alleged Breach
	  	 	78	 
	 12.6  Termination Upon Bankruptcy
	  	 	79	 
	 12.7  Development Diligence Requirements
	  	 	79	 
	 12.8  Termination for Failure to Employ Commercially Reasonable Efforts
	  	 	80	 
	 12.9  Development or Marketing of Other Products
	  	 	84	 
	 12.10 Determination of Abandonment and Opportunity to Remedy
	  	 	84	 
	 12.11 Termination for IPH Transfer
	  	 	84	 
	 12.12 Survival of Terms
	  	 	84	 

  
 iii 

 Table of Contents 

(continued) 
  

					
	 	  	Page	 
	 13.  CONSEQUENCES OF TERMINATION
	  	 	85	 
	 13.1  General
	  	 	85	 
	 13.2  Costs for Regulatory Documentation
	  	 	85	 
	 13.3  Expiration of Collaboration Term
	  	 	85	 
	 13.4  NN Termination for Convenience Prior to Expiration of Collaboration
Term
	  	 	91	 
	 13.5  Termination for IPH Transfer
	  	 	95	 
	 13.6  Termination for NN’s Material Breach
	  	 	95	 
	 13.7  Termination for IPH’s Material Breach
	  	 	96	 
	 13.8  M1 Grace Period and Audit Rights
	  	 	99	 
	 13.9  Cumulative Remedies
	  	 	101	 
		
	 14.  EQUITY FINANCING AND FUTURE IPO
	  	 	101	 
	 14.1  Equity Investment
	  	 	101	 
	 14.2  Underwriting of IPO
	  	 	102	 
		
	 15.  REPRESENTATIONS AND WARRANTIES
	  	 	102	 
	 15.1  Mutual Representations and Warranties
	  	 	102	 
	 15.2  Disclaimer of Warranty
	  	 	105	 
	 15.3  IPH Representations and Warranties In Respect of IPR
	  	 	105	 
		
	 16.  INDEMNIFICATION
	  	 	107	 
	 16.1  Mutual Indemnification
	  	 	107	 
	 16.2  Indemnification Procedure
	  	 	107	 
		
	 17.  FORCE MAJEURE
	  	 	110	 
		
	 18.  PUBLICATIONS AND DISCLOSURES
	  	 	110	 
	 18.1  Publication
	  	 	110	 
	 18.2  Communication Guidelines
	  	 	111	 
	 18.4  Disclosure of Agreement
	  	 	111	 
		
	 19.  NOTICES
	  	 	112	 
		
	 20.  ASSIGNMENT
	  	 	113	 
	 20.1  General
	  	 	113	 
	 20.2  Permitted Transfers
	  	 	113	 
	 20.3  Deemed Approval
	  	 	114	 
	 20.4  Noncompliant Transfers
	  	 	114	 
		
	 21.  MISCELLANEOUS
	  	 	114	 
	 21.1  Obligation to Obtain Assignments
	  	 	114	 
	 21.2  Privileged Communications
	  	 	114	 
	 21.3  Non-Solicitation
	  	 	115	 
	 21.4  Competition Law Submissions
	  	 	115	 
	 21.5  Relationship of the Parties
	  	 	115	 
	 21.6  Effect of Rejection in Bankruptcy
	  	 	116	 

  
 iv 

 Table of Contents 

(continued) 
  

					
	 	  	Page	 
	 21.7  Costs and Expenses
	  	 	116	 
	 21.8  Limitation of Liability
	  	 	116	 
	 21.9  Severability
	  	 	117	 
	 21.10  IPH Financial Information
	  	 	117	 
	 21.11  Waiver
	  	 	117	 
	 21.12  Amendment
	  	 	117	 
	 21.13  Applicable Law
	  	 	117	 
	 21.14  Dispute Resolution
	  	 	117	 
	 21.15  Further Assurances
	  	 	118	 
	 21.16  Entire Agreement
	  	 	118	 
	 21.17  Counterparts
	  	 	118	 

  
 v 

 GUIDE TO SCHEDULES 

 

							
	 Number
	  	 Subject Matter
	  	 Content on 
date of Agreement
	  	 Updating Obligation

	1.1.5	  	Background IPH IPR	  	Yes	  	For inclusion of related Patents (continuations, foreign counterparts, issued patents, etc.) or removal of Patents (due to abandonment, etc.) only (§9.7.1)
				
	1.1.6	  	Background IPH Research Technology IPR	  	Yes	  	For inclusion of related Patents or removal of Patents only (§9.7.1)
				
	1.1.7	  	Background NN IPR	  	Yes	  	For either inclusion of related Patents or removal of Patents (§9.7.2) or to include certain other identified Patents (§1.1.7)
				
	1.1.8	  	Background NN Research Technology IPR	  	Yes	  	For either inclusion of related Patents or removal of Patents only (§9.7.2)
				
	1.1.11	  	Class A Licensed Products	  	Yes	  	None (not to be updated)
				
	1.1.12	  	Class B Licensed Products	  	Yes	  	by agreement of Parties (§1.1.12; §4.3(f)) or due to acquisition of certain Third Party IPR by IPH (§3.4.2(a))
				
	1.1.13	  	Class C Licensed Products	  	Yes	  	by the Joint Steering Committee (§4.3(f))
				
	1.1.15	  	Biological Targets for which IPH has previously licensed diagnostic rights	  	Yes	  	None
				
	1.1.16	  	Collaboration IPR	  	Yes (Kirostim Patents)	  	by NN using NN and IPH information (§9.7.3)
				
	1.1.17	  	Collaboration Know-How	  	Yes (Kirostim Know-How)	  	by Joint Steering Committee (§4.3(u))
				
	1.1.22	  	Collaboration Targets	  	Yes	  	by Joint Steering Committee (§4.3(h))
				
	1.1.31	  	Drug Discovery Plan	  	Yes	  	by the Parties pursuant to Joint Steering Committee recommendation (§4.3(o))

							
				
	 Number
	  	 Subject Matter
	  	 Content on 
date of Agreement
	  	 Updating Obligation

	1.1.33	  	Exploratory Targets	  	Yes	  	by the Joint Steering Committee (§1.1.33; §4.3(e))
				
	1.1.41	  	Intermediate Discovery Milestone	  	Yes	  	None
				
	1.1.51	  	M0	  	Yes	  	None
				
	1.1.52	  	M1	  	Yes	  	None
				
	1.1.65	  	Target Discovery Plan	  	No	  	by the Parties pursuant to Joint Steering Committee recommendation (§4.3 (a) and (o))
				
	1.1.69 A	  	NN Third Party Collaborations	  	Yes	  	None
				
	1.1.69 B	  	IPH Third Party Collaborations	  	Yes	  	None
				
	1.1.69 C	  	New Collaborations	  	No	  	by the Parties upon approval of Joint Steering Committee (§3.4)
				
	3.8	  	NN policy for use of animals for laboratory research purposes	  	Yes	  	Yes (§3.8)
				
	6.2	  	Ex vivo Task Force Particulars	  	No	  	Ex-vivo Task Force (§6.2)
				
	9.5.4 A	  	Independent NN IPR	  	No	  	by Parties pursuant to (§9.5.4)
				
	9.5.4 B	  	Independent IPH IPR	  	No	  	by Parties pursuant to (§9.5.4)
				
	10.4	  	Material Transfer Agreement	  	Yes	  	Joint Steering Committee may under §10.4
				
	18.2	  	Communication Guidelines	  	Yes	  	None
				
	21.2	  	Community Interest Agreement	  	Yes	  	None

 Schedule 1.1.5 

Background IPH IPR 
 ***

  
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  

 Schedule 1.1.6 

Background IPH Research Technology IPR 

*** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  

 Schedule 1.1.7 

Background NN IPR 
 *** 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  

 Schedule 1.1.8 

Background NN Research Technology IPR 

*** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  

 Schedule 1.1.11 

Class A Licensed Products 

*** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  

 Schedule 1.1.12 

Class B Licensed Products 

*** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  

 Schedule 1.1.13 

Class C Licensed Products 

*** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  

 Schedule 1.1.15 

Specified antibodies excluded from use in the Collaboration for diagnostics purposes 

*** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  

 Schedule 1.1.16 

Collaboration IPR 
 *** 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  

 Schedule 1.1.17 

Collaboration Know-How 

*** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  

 Schedule 1.1.22 

Collaboration Targets 
 ***

  
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  

 Schedule 1.1.31 

Drug Discovery Plan 
 Part 1
of 2 
 *** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  

 Schedule 1.1.31 

Drug Discovery Plan 
 Part 2
of 2 
 *** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  

 Schedule 1.1.33 

Exploratory Targets 
 ***

  
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  

 Schedule 1.1.41 

Intermediate Discovery Milestone Criteria for NKG2A and NKG2D Collaboration projects 

*** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  

 Schedule 1.1.51 

Definition of M0 criteria : NN Biopharmaceutical Research Board 

*** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  

 Schedule 1.1.52 

Definition of M1 criteria : NN Biopharmaceutical Research Board 

*** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  

 Schedule 1.1.65 

Target Discovery Plan 

Research Program: Pre-project activities 

 Schedule 1.1.69 A 

Third-Party Collaborations 

NN Collaborations Relevant to this Agreement 

*** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  

 Schedule 1.1.69 B 

Third-Party Collaborations 

Innate Pharma Collaborations Relevant to this Agreement 

*** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  

 Schedule 1.1.69 C 

Third-Party Collaborations 

 Schedule 3.8 

Novo Nordisk Principles for the Use of Animals 

*** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  

 Schedule 6.2 

Recommendations of the Ex-vivo Task Force 

 Schedule 9.5.4 A 

Independent NN IPR 

 Schedule 9.5.4 B 

Independent IPH IPR 

 Schedule 10.4 

MATERIAL TRANSFER AGREEMENT 
  

			
	Between	  	 Innate Pharma S.A.
 Gran Pre
119/121 ancien chemin de Casiss
 13009 Marseille

France
  

(hereinafter referred to as INNATE PHARMA)

	and    	  	 [XXXX]
 [Address]

 
 (hereinafter referred to as RECIPIENT)

 INNATE PHARMA and RECIPIENT are hereinafter also referred to individually as “Party” and collectively as
“Parties”. 
 PREAMBLE 
  

	WHEREAS	 INNATE PHARMA has valuable material and information concerning
non-conventional lymphocytes such as natural killer (NK) cells ; and 

  

	WHEREAS	 RECIPIENT desires to obtain such material and/or information solely for evaluation purposes;

 NOW THEREFORE, the Parties have agreed on the following terms: 

ARTICLE 1 - DEFINITIONS 
  

	1.1	 Definitions to this Agreement: 

 

	 	a)	 “Samples” shall mean those biological, chemical or other materials described in Article 2.1
and listed in Appendix A, or such other compounds and/or tangible material as INNATE PHARMA should deliver to RECIPIENT. 

  

	 	b)	 “Information” shall mean any and all information disclosed by INNATE PHARMA to RECIPIENT in
oral, visual, written, or electronic form under this Agreement. “Information” shall also mean any and all technical or non-technical information obtained in any form by RECIPIENT during observation
or examination of the foregoing or the samples, which may include, but is not limited to, technical processes, specifications, instrumentation, chemical formulae, assays, manufacturing techniques, sales and marketing information, material, or data.
This also includes any other confidential information about INNATE PHARMA obtained through the disclosure of information and samples, as well as the fact that disclosure has taken place. 

 

	 	c)	 “Samples” and “Information” are hereinafter referred to as INFORMATION.

 ARTICLE 2 - CONFIDENTIALITY 
  

	2.1	 This Agreement will come into force on the date of the last signature hereto. In consideration of any
disclosure at any time by INNATE PHARMA to RECIPIENT of INFORMATION in whatever form on the subject of natural killer cells and natural killer cell inhibitory receptors, as well as their applications in human therapeutics and diagnostics.

 RECIPIENT undertakes from the date of disclosure to treat all received INFORMATION as strictly confidential for a period
of *** from date of disclosure and therefore not to disclose it to any third party without the prior written and express consent of INNATE PHARMA and to make no use of it, except as specifically provided for in Article 4, without the prior written
and express consent of INNATE PHARMA in each case. 
  

	2.2	 RECIPIENT may disclose INFORMATION only to reliable employees who need to know in order to carry out the
evaluations under this Agreement, provided that such persons are bound by obligations of confidentiality and non-use to RECIPIENT which are equal to the terms of this Agreement. RECIPIENT shall ensure that
such employee(s) are fully aware of the obligations of this Agreement and shall be responsible for any breach of these provisions by its employee(s). 

ARTICLE 3 - NON-DISCLOSURE AND EXCEPTIONS 
  

	3.1	 The obligations set forth in Article 2 above shall not apply to: 

 

	 	a)	 INFORMATION which at the time of disclosure is already in the public domain; 

 

	 	b)	 INFORMATION which, after disclosure, becomes part of the public domain through no violation of this Agreement;

  

	 	c)	 INFORMATION which RECIPIENT is able to prove to have been in possession of prior to disclosure by INNATE
PHARMA. In this case, RECIPIENT will, in writing and within *** from the date of disclosure, demonstrate to the satisfaction of INNATE PHARMA that it was in possession of such INFORMATION; 

 

	 	d)	 INFORMATION which is hereafter lawfully disclosed by a third party to RECIPIENT, which INFORMATION such third
party did not acquire under a still effective obligation of confidentiality to INNATE PHARMA; 

  

	 	e)	 INFORMATION that can be demonstrated as independently developed or acquired by RECIPIENT without reference to
or reliance upon confidential INFORMATION defined in this Agreement, as evidenced by RECIPIENT’s written records; 

  

	 	f)	 INFORMATION disclosed to the extent required by law or regulation provided that RECIPIENT shall give INNATE
PHARMA prompt written notice and sufficient opportunity to object, time permitting, to such disclosure. 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  

	3.2	 RECIPIENT shall keep INNATE PHARMA fully and effectively indemnified against any and all losses, expenses, and
damages suffered by INNATE PHARMA arising from any unauthorised disclosure or use of any part of INFORMATION by RECIPIENT or RECIPIENT’s employees, including, but not limited to, reasonable attorney’s fees and costs. 

 

	3.3	 RECIPIENT shall not publish or otherwise disseminate such results of the disclosure of INFORMATION, or
any raw data generated thereby without the prior and express written permission of INNATE PHARMA. At least *** prior to making any submission for publication or other public disclosure in which any direct or indirect reference is made to
INFORMATION, RECIPIENT agrees to provide INNATE PHARMA with a copy thereof for review and comment. INNATE PHARMA shall be entitled to postpone the intended publication or other disclosure if in the opinion of INNATE PHARMA, publication or other
disclosure is believed to interfere with INNATE PHARMA patent work or involves know-how, results or other confidential information developed by INNATE PHARMA or RECIPIENT and relating to INFORMATION.

 ARTICLE 4 - USE OF THE INFORMATION 
  

	4.1)	 RECIPIENT hereby agrees to use INFORMATION in compliance with any and all applicable law or regulation.
RECIPIENT shall keep INNATE PHARMA informed of all uses made of INFORMATION. RECIPIENT shall provide INNATE PHARMA with a full copy of its protocol and study design for approval by INNATE PHARMA prior to the furnishing of INFORMATION. Any and all
changes in such protocol and study design shall forthwith be submitted, in writing, to INNATE PHARMA. 

  

	4.2)	 RECIPIENT shall not use INFORMATION for any purpose other than the evaluation purposes described in this
Agreement. Samples provided under this Agreement shall not be analysed or used except to the extent necessary to carry out such evaluation. RECIPIENT also agrees not to use INFORMATION to make more compound, and not to use INFORMATION in research
subject to consulting, licensing, or other obligations, to any third party. RECIPIENT certifies that it is regularly engaged in conducting tests in vitro or in laboratory research animals. INFORMATION will be used for tests in vitro or in laboratory
research animals only and will not be administered to humans. No animal used in such tests will be used for any food purposes, as domestic pets, or as livestock. 

 

	4.3	 INFORMATION is the sole property of INNATE PHARMA and nothing in this Agreement shall be construed as
granting to RECIPIENT, by implication or otherwise, any right or license with respect to INFORMATION, or any patent applications, patents or any claims of patent now or hereafter filed or issued with respect to INFORMATION, and RECIPIENT is
obligated to refrain from filing applications or otherwise seeking proprietary rights and protection in respect of INFORMATION. 

  

	4.4	 Any and all industrial and/or intellectual property rights including, but not limited to, results, inventions,
improvements, and know-how relating to INFORMATION or use by RECIPIENT of INFORMATION shall be the sole property of INNATE PHARMA and shall be included in the secrecy obligation of this Agreement. To safeguard
the interests of INNATE PHARMA in 

  
 Certain information has been
excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  

	 	
results, inventions, improvements, and know-how, RECIPIENT shall forthwith inform INNATE PHARMA in the event of these in full detail, including all raw
data. RECIPIENT undertakes to assign free of charge to INNATE PHARMA any such result, invention, improvement, and/or know-how. RECIPIENT agrees to do any reasonable act or thing or execute any reasonably
required document to give effect to the foregoing. Upon completion of the evaluation by RECIPIENT of INFORMATION, RECIPIENT undertakes to return to INNATE PHARMA all INFORMATION received hereunder and any material, data, and results derived from
such INFORMATION and all copies hereof as well as any remaining sample. 

  

	4.5	 RECIPIENT acknowledges that INFORMATION is provided “as is” and without any representation or
warranty, express or implied, as to the accuracy or completeness of INFORMATION, including, without limitation, any implied warranty of merchantability or fitness for a particular purpose, or any warranty that the use of INFORMATION will not
infringe or violate any patent or other proprietary rights of any third party. Acceptance of INFORMATION will constitute acceptance by RECIPIENT of liability for any damages or injuries resulting from its possession or use of INFORMATION.

 ARTICLE 5 - GOVERNING LAW AND DISPUTE RESOLUTION 
  

	5.1	 Both parties will use their best efforts to settle all matters in dispute amicably. All disputes and
differences of any kind related to this Agreement, which cannot be solved amicably by the parties, shall be referred to arbitration. 

  

	5.2	 All disputes arising out of or in connection with the present contract shall be finally settled under
the Rules of Arbitration of the International Chamber of Commerce by one arbitrator appointed in accordance with the said Rules. 

  

	5.3	 The arbitration shall take place in Copenhagen and shall be conducted in the English language. The award of the
arbitrator shall be final and binding on both parties. The parties bind themselves to carry out the awards of the arbitrator. 

  

	5.4	 This contract shall be construed and interpreted pursuant to the laws of Denmark to the exclusion of any rule
that would refer the subject matter to another forum. The English wording in this Agreement shall prevail. 

 ARTICLE 6 - SIGNATURE

  

	6.1	 Each person signing below and each Party on whose behalf such person executes this Agreement warrants that he
or it, as the case may be, has the authority to enter into this Agreement and perform the obligations herein. 

 SIGNED BY: 
  

					
	Date:	 		  	Date:
			
	INNATE PHARMA A/S	 		  	 [XXXX]

			
	  
	 		  	  

	By: [Insert full name and title in print]	 		  	By: [Insert full name and title in print]

 APPENDIX A 

Complete list of samples/quantities provided to RECIPIENT: 

 Schedule 18.2 

Communication Guidelines 

*** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  

 Schedule 21.2 

Community Interest Agreement 

COMMUNITY OF INTEREST AGREEMENT BETWEEN 

NOVO NORDISK A/S AND INNATE PHARMA SA REGARDING POTENTIAL 

LITIGATION 
  

	Whereas	 Novo Nordisk A/S (“NN”) and Innate Pharma SA (“IPH”), are considering entering into a
relationship concerning certain technology relating to the Collaboration Field as defined and described in a Joint Research, Development, Option and License Agreement by and between the parties dated March 28, 2006 (TECHNOLOGY);

  

	Whereas	 NN and IPH believe that litigation concerning such TECHNOLOGY may occur; 

 

	Whereas	 NN and IPH share a common interest concerning this potential litigation concerning the TECHNOLOGY;

  

	Whereas	 NN and IPH have mutually concluded that their interests will be best served by sharing certain work product and
privileged information concerning this potential litigation in confidence for their common purpose and mutual interest and benefit; 

  

	Whereas	 NN and IPH wish to avoid any suggestion of waiver of the confidentiality of trade secret, work product and
privileged information and documents, 

 NN and IPH have agreed to enter into this COMMUNITY OF INTEREST Agreement (the
“Agreement”) regarding potential litigation concerning the TECHNOLOGY. 
  

	1.	 Definitions 

The term TECHNOLOGY includes without limitation the parties’ respective interests in and actions concerning the certain technology
discussed above, and party or non-party United States patents concerning such technology. 
 Solely
for purposes of this Agreement, the term “NN” includes any and all of its corporate affiliates. 
 Solely for purposes of this
Agreement, the term “IPH” includes any and all of its corporate affiliates. 
 The term “NN” includes (i) any
employees or agents of NN; (ii) all outside, in-house and other counsel for NN; and (iii) any experts or consultants retained by NN. 

 The term “IPH” includes (i) any employees or agents of IPH; (ii) all outside,
in-house and other counsel for IPH; and (iii) any experts or consultants retained by IPH. 
 The
term “party” refers to NN or IPH. 
 The term “parties” refers to NN and IPH. 

The term “non-party” refers to any person or entity other than the parties. 

The term “COMMUNITY OF INTEREST communications” means all ideas, information, data, materials and other tangible or intangible matter
comprising, concerning or relating to TECHNOLOGY in whatever form transmitted by and between the parties that would (if not so transmitted) otherwise be subject to the work product doctrine or the attorney-client, trade secret or any other
applicable protection or privilege. COMMUNITY OF INTEREST communications includes, but is not limited to all communications between NN and IPH including witness interviews and communications among counsel. 

 

	2.	 Agreement 

In view of the foregoing, the parties agree as follows: 

COMMUNITY OF INTEREST communications shall be used solely in connection with the preparation, prosecution or defense of potential, agreed upon
litigation concerning the TECHNOLOGY. The parties will not use one another’s COMMUNITY OF INTEREST communications or disclose one another’s COMMUNITY OF INTEREST communications to any third party without prior consent from the party who
originally provided such COMMUNITY OF INTEREST communication (the “disclosing party”). 
 It is the desire, intention, and mutual
understanding of the parties that 
  

	 	(a)	 the parties’ disclosure of COMMUNITY OF INTEREST communications to one another is not intended to, and
shall not, waive or diminish in any way the confidentiality of such COMMUNITY OF INTEREST communications or their continued protection under the attorney-client privilege, the work product doctrine or any other applicable privileges or protections,

  

	 	(b)	 all COMMUNITY OF INTEREST communications provided by a party pursuant to this Agreement that are entitled to
protection under the attorney-client privilege, the work product doctrine or other applicable privileges or protections, shall remain entitled to such protection under the joint defense doctrine and common interest privilege, and may not be
disclosed to any non-party except as provided in Paragraph 3 or 5, as applicable, and 

  

	 	(c)	 all COMMUNITY OF INTEREST communications shall be treated and maintained by the parties as privileged and
confidential communications in pursuit of their common interest. 

	3.	 Disclosure To Any Non-Party 

COMMUNITY OF INTEREST communications may not be disclosed to any non-party, except on the explicit
advance written consent of the disclosing party. 
  

	4.	 Confidentiality 

COMMUNITY OF INTEREST communications shall continue to be held confidential by the parties as joint prosecution defence communications fully
subject to the nondisclosure use and other terms and conditions of this Agreement even if adversity of interests should be subsequently be discerned or arise between the parties and regardless of whether the COMMUNITY OF INTEREST relationship
becomes inapplicable thereafter. In the event that a party determines that it no longer has a mutuality of interest with the other party with regard to litigation in respect of the TECHNOLOGY, such party shall terminate this Agreement. Each party
has a duty to terminate the Agreement when, in good faith, it reasonably believes that a commonality of interest no longer exists and to give prompt written notice of such termination to the other party pursuant to Paragraph 7. 

 

	5.	 Non-Party’s Request Of COMMUNITY OF INTEREST
Communication 

 If any non-party requests or demands, by subpoena or
otherwise, any COMMUNITY OF INTEREST communication from either party, the party receiving such request or demand will (i) immediately notify the other Party and (ii) decline to produce the requested COMMUNITY OF INTEREST communication,
unless the privilege is waived by the disclosing party. Each party shall take all steps necessary to permit the assertion of all applicable rights, privileges and protections with respect to such COMMUNITY OF INTEREST communications and the parties
shall cooperate fully with one another in any proceedings relating to the disclosure of COMMUNITY OF INTEREST communications. Nothing in this Agreement shall require either party to refuse to obey any court order which has not been stayed. 

 

	6.	 Violation Of Agreement 

A violation of this Agreement by either party shall not be deemed to destroy the COMMUNITY OF INTEREST privilege, or be deemed a waiver of the
attorney-client privilege, the work product doctrine or any other subject matter whatsoever, including any applicable doctrine or privilege. 

	7.	 Termination 

Either party may terminate its participation in this Agreement by providing notice in writing to the other party. Such notice shall become two
(2) business days after receipt of the notice of termination by the non-terminating Party and shall operate prospectively only. Such termination shall not affect the privileged nature of COMMUNITY OF
INTEREST communications made between the parties prior to the termination of this Agreement. Upon termination of this Agreement or demand, each party shall return all COMMUNITY OF INTEREST communications to the disclosing party. 

 

	8.	 Exchange Of Materials 

All materials that are exchange pursuant to this Agreement shall be marked and identified as being provided with the following language:
“Confidential and privileged communication produced pursuant to joint defence agreement.” 
  

	9.	 Disclosure of COMMUNITY OF INTERST Communications 

Each party shall provide reasonable advance notice to the other party of the identity of any counsel, experts or consultants to whom the party
intends to convey COMMUNITY OF INTEREST communications. Unless prior written consent to such disclosure is received from the disclosing party, the receiving party may not disclose any COMMUNITY OF INTEREST communications received from the disclosing
party to any counsel, experts or consultants of the receiving party except 
 (a) attorneys for the receiving party (and their legal
assistants and support staff) who are (1) directly employed by the receiving party or by an affiliate of such party (including such party’s direct or indirect parent or a direct or indirect subsidiary of a direct or indirect parent of such
party); and (2) responsible, on behalf of their employer, for agreed upon litigation concerning the TECHNOLOGY as set forth above; 

(b) outside counsel of record in such litigation for the receiving party; and 

(c) legal assistants and support staff who are directly employed by or retained by such outside counsel in the prosecution or defence
of such litigation. 
  

	10.	 Written Records 

Each party shall maintain written records identifying persons having access to COMMUNITY OF INTEREST communications received from the other
party. Any expert witness, consultant or counsel to whom COMMUNITY OF INTEREST communications are provided shall agree, in writing, to be bound by the terms of this Agreement and to ensure that those of their employees who are permitted access to
any COMMUNITY OF INTEREST communications are specifically advised of, and bound by, the terms hereof. 

	11.	 Disclosures Between The Parties 

This Agreement does not create any duty requiring disclosure between the parties. Each party retains the right to refuse to produce to the
other Party any COMMUNITY OF INTEREST communication. 
  

	12.	 Attorney-Client Relationship 

Nothing in this Agreement shall be construed to create a new attorney-client relationship whether express or implied. Each party represents and
acknowledges that it is represented exclusively by its own Attorney and agrees that nothing in this Agreement shall be construed to affect the separate and independent representation of either Party by its own respective counsel. Each Attorney
participating in the joint defence is obligated to maintain the confidentiality of information as specified in this Agreement, but each Attorney does not act on behalf of any person other than his or her own party. 

 

	13.	 Applicable Law 

This Agreement shall be construed according to and governed by the law of England, with giving effect to principles of choice or conflicts of
law. 
  

	14.	 Effective Date 

The effective date of this Agreement is _March 28, 2006__ 
  

	15.	 Entire Agreement 

This Agreement memorializes and supersedes any prior or contemporaneous oral understanding or agreement between the parties regarding COMMUNITY
OF INTEREST communications or any of the other subject matter hereof and applies to all communications and other exchanges of information (whether written or oral) between the parties prior to the execution of this Agreement that relate to
litigation in respect of the TECHNOLOGY. 
  

	16.	 Modifications And Amendments 

The provisions of this Agreement may be modified or amended only by written agreement by the parties. 

	17.	 Agreements With Third Parties 

Neither this Agreement, nor any of the provisions hereof, shall limit the freedom of either party to independently negotiate or enter into any
settlement, compromise or other agreement or arrangement with any third party respecting the TECHNOLOGY or any litigation in respect thereof, provided that the parties hereby agree to comply with the terms and conditions of this Agreement and
acknowledge that such terms and conditions do not derogate from their exercise of such freedom. 
  

	18.	 Disqualification Of Counsel 

The disqualification of counsel for a party shall not require or constitute grounds for the disqualification of counsel for the other Party by
reason of the parties’ entry into or exchange of information pursuant to this Agreement, and the party whose counsel has been disqualified hereby waives the right to seek such disqualification of the other party’s counsel by reason of such
entry into this Agreement or the sharing of such other party, or such other party’s counsel, of any COMMUNITY OF INTEREST communications pursuant to the terms hereof. 
  

	19.	 Counterparts 

This Agreement may be executed in counterparts, each of which shall be deemed an original, and all of which together will constitute one and
the same instrument. 
 NN 
  

					
		 		  	by
			
	 Bagsvaerd        March 28, 2006
	 		  	 /s/ Terje Kalland

		 		  	 Terje Kalland
 Senior Vice President,
Biopharmaceutical Research Unit

	
	IPH
			
		 		  	By
			
	 Marseille         March 28th 2006
	 		  	 /s/ Hervé Brailly

		 		  	 Hervé Brailly
 Chief Executive
Officer

 Certain information has been excluded from this agreement (indicated by “[***]”) because such
information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 
 AMENDMENT AND SUPPLEMENT NO. 1 

to the 
 JOINT RESEARCH,
DEVELOPMENT, OPTION AND LICENCE AGREEMENT 
 dated 

MARCH 28, 2006 
 between

 NOVO NORDISK A/S 

and 
 INNATE PHARMA SA

 October 6, 2008 

  

 TABLE OF CONTENTS 

 

					
	 	  	Page No.	 
		
	 1. DEFINITIONS
	  	 	4	 
		
	 2. RECLASSIFICATION OF ANTI-KIR AS A NICHE CANDIDATE
	  	 	4	 
		
	 3. AMENDMENT OF AGREEMENT TO PROVIDE FOR THE DEVELOPMENT AND COMMERCIALIZATION OF ANTI-KIR AS A
NICHE CANDIDATE BY IPH
	  	 	5	 
		
	 4. OTHER AMENDMENT OF AGREEMENT
	  	 	21	 
		
	 5. KNOW-HOW TRANSFER
	  	 	26	 
		
	 6. CLINICAL TRIALS
	  	 	27	 
		
	 7. TRANSFER OF ANTI-KIR SUPPLIES
	  	 	28	 
		
	 8. REGULATORY OR SAFETY DELAY
	  	 	30	 
		
	 9. FEES
	  	 	30	 
		
	 10. POST-DOCTORATE RESEARCH
	  	 	30	 
		
	 11. MISCELLANEOUS
	  	 	31	 
		
	 Exhibit A
	  	 	A-1	 
		
	 Exhibit B
	  	 	B-1	 
		
	 Exhibit C
	  	 	C-1	 
		
	 Exhibit D
	  	 	D-1	 
		
	 Exhibit E
	  	 	E-1	 
		
	 Exhibit F
	  	 	F-1	 
		
	 Exhibit G
	  	 	G-1	 
		
	 Exhibit H
	  	 	H-1	 

 AMENDMENT AND SUPPLEMENT NO. 1 

to the 
 JOINT RESEARCH,
DEVELOPMENT, OPTION AND LICENCE AGREEMENT 
 Amendment and Supplement dated as of October 6, 2008 (the “Amendment No.1”) to the Joint
Research, Development, Option and Licence Agreement (hereinafter the “Agreement”) dated March 28, 2006 between Novo Nordisk A/S (CVR-no. 24 25 67 90), a corporation existing under the laws of Denmark and having its principal place
of business at Novo Allé, 2880 Bagsvaerd, Denmark (hereinafter “NN”), and Innate Pharma SA, a corporation existing under the laws of France and having its principal place of business at Grand Pré – 119/121, ancien chemin
de Cassis, 13009 Marseille, France (hereinafter “IPH”). 
 WITNESSETH 

 

			
	 WHEREAS
	  	Pursuant to the Agreement, NN and IPH agreed to work, independently, jointly, and/or together with agreed-upon Third Parties, to (a) discover or identify Drug Candidates, and (b) optimize Drug Candidates for progression to
(i) Licensed Products for further development and commercialization by NN, or (ii) Niche Candidates for further development and commercialization by IPH (either alone or together with NN), in each case for all uses and purposes, including
therapeutic, prophylactic and, except as otherwise expressly therein provided, diagnostic uses;
		
	 WHEREAS
	  	NN desires to cease its development of Anti-KIR as a Licensed Product and IPH desires that Anti-KIR be reclassified as a Niche Candidate for IPH’s sole independent further development and commercialization, and NN and IPH
desire to amend and supplement the Agreement to provide for such future development of Anti-KIR;
		
	 WHEREAS
	  	NN and IPH have agreed to enter into an Amendment and Supplement No. 2 to the Agreement (“Amendment No. 2”) dated and effective as of the date hereof that provides that (i) the Agreement shall be
amended to exclude Anti-NKG2D (as defined in Amendment No. 2) from the scope of the Agreement, (ii) the Assigned IPR (as defined in Amendment No. 2) and certain assets and materials relating to Anti-NKG2D shall be assigned to NN, and (iii)
IPH shall grant NN an exclusive, royalty-free, worldwide licence under the Licensed IPR (as defined in Amendment No. 2) and a non-exclusive royalty-free, worldwide licence under the Innate Anti-NKG2D FoO IPR (as defined in Amendment No. 2)
for the purposes of research, development and commercialisation of Anti-NKG2D Products (as defined in Amendment No.2).

  
 3 

 NOW, THEREFORE, 

in consideration of the foregoing premises, the mutual promises and covenants set forth in this Amendment No.1, and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, NN and IPH, each intending to be legally bound, hereby agree as follows: 
  

	1.	 DEFINITIONS 

  

	1.1.	 Unless otherwise specifically defined herein, each term used herein that is defined in the Agreement has the
meaning assigned to such term in the Agreement. Each reference to “hereof”, “hereunder”, “herein” and “hereby” and each other similar reference and each reference to “this Agreement” and each other
similar reference contained in the Agreement shall, after the Amendment No.1 Effective Date, refer to the Agreement as amended hereby. 

  

	1.2.	 “Amendment No.1 Effective Date” shall mean the date of this Amendment No.1. 

 

	2.	 RECLASSIFICATION OF ANTI-KIR AS A NICHE CANDIDATE 

 

	2.1.	 Subject to the terms and conditions of this Amendment No.1 and with effect from the Amendment No.1 Effective
Date, NN hereby classifies Anti-KIR as a Niche Candidate for independent further development and commercialization by IPH for any human therapeutic, prophylactic or diagnostic indication or application. 

 

	2.2.	 IPH acknowledges and agrees that, with effect from the Amendment No.1 Effective Date, Anti-KIR shall be
classified as a Niche Candidate and IPH further agrees that, notwithstanding any non-compliance by either Party with the procedures set out in Section 6.1 of the Agreement, neither the discontinuation of development of Anti-KIR by NN nor the
subsequent classification by NN in this Amendment No.1 of Anti-KIR as a Niche Candidate constitutes the abandonment of any Licensed Product or Niche Candidate for the purposes of the Agreement or gives rise to any right to terminate the whole or
part of the Agreement or any of the associated remedies under Articles 12 and 13 of the Agreement. 

  

	2.3.	 Notwithstanding any provision of the Agreement, IPH acknowledges that, with effect from the Amendment No.1
Effective Date, NN shall have no further obligations under the Agreement, this Amendment No.1 or otherwise to develop or commercialize Anti-KIR and NN acknowledges that IPH shall have the exclusive right to conduct the development and
commercialisation of Anti-KIR as a Niche Candidate for any human therapeutic, prophylactic or diagnostic indication or application. 

  
 4 

	3.	 AMENDMENT OF AGREEMENT TO PROVIDE FOR THE DEVELOPMENT AND COMMERCIALIZATION OF ANTI-KIR AS A NICHE CANDIDATE
BY IPH 

  

	3.1.	 With effect from the Amendment No.1 Effective Date, Article 1 of the Agreement is hereby amended by:

  

	 	3.1.1.	 adding the following proviso to the definition of “Background NN IPR” immediately following
the current text of such definition: 

 “Provided, however, that for the purposes of the licences
granted to IPH pursuant to Section 5.5 hereof to develop and commercialize Anti-KIR as a Niche Candidate and otherwise in connection with the interpretation of this Agreement in connection with such development and commercialization by IPH of
Anti-KIR as a Niche Candidate, “Background NN IPR” shall mean only the IPR identified and listed in Schedule 1.1.7A to the Agreement. Such Schedule 1.1.7A shall not be subject to the aforementioned notification, demonstration and
updating process applicable to Schedule 1.1.7 and may not be amended except with the express consent in writing of the Parties hereto.”; 
  

	 	3.1.2.	 adding the following proviso to the definition of “Collaboration IPR” immediately following
the current text: 

 “Provided, however, that for the purposes of the licences granted to IPH pursuant
to Section 5.5 hereof to develop and commercialize Anti-KIR as a Niche Candidate and otherwise in connection with the interpretation of this Agreement in connection with such development and commercialization by IPH of Anti-KIR as a Niche Candidate,
“Collaboration IPR Controlled by NN” shall mean only the IPR comprised of (x) (i) the Patents identified and listed in Schedule 1.1.16A to the Agreement and (ii) any Patents in which any Anti-KIR Know-How is disclosed but not including any
Patent listed in Schedule 5.8.2A and (y) the Know-How listed in Schedule 1.1.17A to the Agreement. Such Schedules 1.1.16A and 1.1.17A shall not be subject to any updating process that is otherwise applicable to Schedules 1.1.16 and 1.1.17 and
may not be amended except with the express consent in writing of the Parties hereto.”; 
  

	 	3.1.3.	 deleting the final sentence from the definition of “Licensed Product”; 

 

	 	3.1.4.	 inserting the words “Anti-KIR as well as” immediately following the words “shall mean” in
the definition of “Niche Candidate”; and 

  

	 	3.1.5.	 adding the following definitions: 

“Anti-KIR Know-How” shall mean Collaboration Know-How listed in Schedule 1.1.17A. 

  
 5 

 “Anti-KIR Patent” shall mean (i) a Patent listed in Part A of Schedule 1.1.16A
and (ii) a Patent in which any Anti-KIR Know-How is disclosed but not including any Patent listed in Schedule 5.8.2 A; 
 “Anti-KIR
Product” shall mean ***. 
 “Anti-KIR Regulatory Milestones” shall have the meaning ascribed to it in Section 7.4A.

 “Anti-KIR Sales Milestones” shall have the meaning ascribed to it in Section 7.4B. 

“Anti-NKG2A Product” shall mean any product that contains fully human or humanized monoclonal antibodies, antibody fragments,
or derivatives of either thereof, which are reactive against wild type, variant or mutant human natural killer cell receptor NKG2A. 

“Anti-NKG2D Product” shall mean any product that contains fully human or humanized monoclonal antibodies, antibody fragments,
or derivatives of either thereof, which are reactive against wild type, variant or mutant human natural killer cell receptor NKG2D. 

“Continuation” shall mean, with respect to any patent or patent application, any continuation, continuation-in-part,
divisional, continued prosecution or other similar application. 
 “Medarex Sublicence” shall mean ***. 

“NN Anti-KIR FoO IPR” shall mean (a) such Patents listed in Schedule 5.8.2 A, (b) such Patents that are either (i) Controlled,
through exclusive ownership, by NN or its Affiliates during the Term and claim the benefit of a priority date on or before October 6, 2011 or (ii) Controlled, through licence or otherwise but not exclusive ownership, by NN or its Affiliates at
October 6, 2008, (c) such Know-How that is either (i) Controlled, through exclusive ownership, by NN or its Affiliates during the Term and generated on or before October 6, 2011 or (ii) Controlled, through licence or otherwise but not exclusive
ownership, by NN or its Affiliates at October 6, 2008 and (d) such Patents based in part or in whole on Know-How that is (i) Controlled, through exclusive ownership, by NN or its Affiliates during the Term and (ii) generated on or before October 6,
2011, in each of (a), (b) and (d) that are or is (y) not within the Background NN IPR or Collaboration IPR and (z) necessary for the development and commercialization of an Anti-KIR Product. 

“Shared Anti-KIR Patent” shall mean an Anti-KIR Patent listed in Part B of Schedule 1.1.16A.” 

 

	3.2.	 Background NN IPR Licensed by NN to IPH for development and commercialization by IPH of Anti-KIR as a Niche
Candidate. With effect from the Amendment No.1 Effective Date, the Agreement is hereby amended by inserting Exhibit A to this Amendment No.1 as Schedule 1.1.7A to the Agreement. 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 6 

	3.3.	 Collaboration IPR Controlled by NN and Licensed by NN to IPH for development and commercialization by IPH of
Anti-KIR as a Niche Candidate – Anti-KIR Patents and Anti-KIR Know-How. With effect from the Amendment No.1 Effective Date, the Agreement is hereby amended by inserting Exhibit B to this Amendment No.1 as Schedule 1.1.16A to the
Agreement and Exhibit C to this Amendment No. 1 as Schedule 1.1.17A to the Agreement. 

  

	3.4.	 Schedule 5.8.2A NN Anti-KIR FoO Patent. With effect from the Amendment No.1 Effective Date, the
Agreement is hereby amended by inserting Exhibit D to this Amendment No.1 as Schedule 5.8.2A to the Agreement. 

  

	3.5.	 No Exclusivity Holdover Period. With effect from the Amendment No. 1 Effective Date, Section 2.1.2
of the Agreement shall be deleted and replaced with the following: 

  

	 	“2.1.2	 [Reserved]”. 

 

	3.6.	 No Development and Commercialization Committee Input for Anti-KIR. With effect from the Amendment
No. 1 Effective Date, Section 4.9 is hereby amended by inserting the following text in the first paragraph after the words “(b) any Niche Candidates”: 

“(other than Anti-KIR)”. 
  

	3.7.	 No JSC Approval of Sub-licensing by IPH of an Anti-KIR Niche Candidate. With effect from the
Amendment No.1 Effective Date, Article 5 of the Agreement is hereby amended by deleting the words “that shall be enforceable by both Parties” from the second paragraph of Section 5.6 and by inserting the following text immediately
following Section 5.6: 

 “5.6A No JSC Approval of Sub-licensing by IPH of Anti-KIR as a Niche
Candidate. Notwithstanding Section 5.6, the JSC shall not be required to approve any Sub-licensing by IPH of its rights and obligations under this Agreement if such Sub-licensing by IPH is reasonably necessary for the development and
commercialization of Anti-KIR as a Niche Candidate or any Anti-KIR Product.” 
  

	3.8.	 No Licence by NN to IPH of Independent NN IPR for development and commercialization by IPH of Anti-KIR as a
Niche Candidate; FoO for Anti-KIR as a Niche Candidate. With effect from the Amendment No.1 Effective Date, Article 5 is hereby amended by inserting the following text immediately following Section 5.8.2: 

“5.8.2A No Licence by NN to IPH of Independent NN IPR for development and commercialization by IPH of Anti-KIR as a Niche
Candidate; FoO for Anti-KIR as a Niche Candidate. Notwithstanding 

  
 7 

 
Section 5.8.2, NN shall not be obliged to grant to IPH, or to provide reasonable cooperation and assistance to IPH to procure the grant to IPH of, non-exclusive rights and licences under any
Independent NN IPR for the purposes of IPH’s development and commercialization of Anti-KIR as a Niche Candidate or any Anti-KIR Product; provided, however, that NN shall grant to IPH a non-exclusive licence (with the right to
Sub-license and Out-license) under any NN Anti-KIR FoO IPR to develop and commercialize Anti-KIR Products for no additional consideration.” 
  

	3.9.	 No IPH Access to Materials; No NN Buy-In and Co-Marketing Options. With effect from the Amendment
No.1 Effective Date, Article 6 is hereby amended by inserting the following text immediately following Section 6.1: 

“6.1A No IPH Access to Materials. Notwithstanding Section 6.4, IPH shall have no rights to access Materials pursuant to
such Section 6.4 with respect to the development or commercialisation of Anti-KIR as a Niche Candidate pursuant to Section 6.1 hereof.

6.1B No NN Buy-In and Co-Marketing Options for Anti-KIR Niche Candidate. Notwithstanding Sections 6.5, 6.6, 6.7 and 6.8, NN
shall have no rights pursuant to such Sections 6.5, 6.6, 6.7 and 6.8 with respect to Anti-KIR as a Niche Candidate being developed and commercialized by IPH pursuant to Section 6.1 hereof. 

6.1.C IPH Access to Raw Data. If reasonably required by IPH to respond to any request from, or fulfill any requirement of, any
regulatory authority in connection with IPH’s development and commercialization of Anti-KIR as a Niche Candidate or any Anti-KIR Product, NN shall, upon reasonable notice from IPH, provide IPH or any regulatory authority with a reasonable
opportunity to review any original documentation and raw data archived by NN for no additional consideration. NN shall not destroy or otherwise dispose of any original documentation and raw data related to NN’s development of Anti-KIR that
IPH or a regulatory authority may reasonably be expected to require in connection with IPH’s development and commercialization of Anti-KIR as a Niche Candidate or any Anti-KIR Product without the prior written consent of IPH which shall not be
unreasonably delayed or withheld. 
 6.1.D Reporting Obligations. IPH shall prepare written annual reports (each a
“Development Report”) in respect of IPH’s development of Anti-KIR as a Niche Candidate during each calendar year commencing January 1, 2009 and deliver such Development Report to NN no later than *** in the calendar year
following that calendar year to which such Development Report relates. Each Development Report shall include a description of preclinical and clinical work carried out during the calendar year, any clinical trial reports received during such
calendar year and projected development time lines. Within *** days of NN receiving a Development Report and upon reasonable written notice by NN to IPH, the Anti-KIR project leader at IPH shall meet with representatives of NN to discuss such
Development Report. 
  
 *** Portions of this page have been omitted pursuant to a
request for Confidential Treatment and filed separately with the Commission. 

  
 8 

 6.1.E NN Corporate Alliance Management. NN shall, for so long as IPH shall develop
and commercialize Anti-KIR as a Niche Candidate during the Term, assign a member of its Corporate Alliance Management Department to serve as the liaison officer between NN and IPH on all matters relating to the development and commercialization of
Anti-KIR as a Niche Candidate. Such NN Corporate Alliance Management Department liaison officer shall respond in a reasonably timely manner to all reasonable requests for information made by IPH. 

 

	3.10.	 Regulatory Milestones. With effect from the Amendment No.1 Effective Date, Article 7 of the
Agreement is hereby amended by inserting the following text immediately following Section 7.4: 

 “7.4A Anti-KIR
Niche Candidate Regulatory Milestone Payments. Notwithstanding Section 7.4, in respect of Anti-KIR Products IPH shall only pay to NN the following milestone payments for the achievement of the following regulatory milestone events by an
Anti-KIR Product pursuant to IPH’s development of Anti-KIR as a Niche Candidate (“Anti-KIR Regulatory Milestones”) within *** days of the achievement of each such Anti-KIR Regulatory Milestone. 

Such milestone payments shall be made for the first Anti-KIR Product that achieves an Anti-KIR Regulatory Milestone and, subsequently, for each
Anti-KIR Product that *** previously achieved such Anti-KIR Regulatory Milestone, but ***, in each case on a one-time, non-duplicative basis, irrespective of the number of indications per Anti-KIR Product and any Out-licensing or Sub-licensing by
IPH. 
  

	 	(a)	 *** 

  

	 	(b)	 *** 

  

	 	(c)	 *** 

To the extent that IPH is required to license (or sublicense) Third Party IPR for the development and commercialization of Anti-KIR Products,
IPH shall be responsible for all costs associated with such licences (or sublicences) other than amounts previously paid by NN before the Amendment No. 1 Effective Date and there shall be no reduction in the milestone payments set forth above as a
result of such payments.” 
  

	3.11.	 Sales Milestones. With effect from the Amendment No.1 Effective Date, Article 7 of the Agreement is
hereby amended by inserting the following text immediately following Section 7.4A: 

 “7.4B Anti-KIR Niche
Candidate Sales Milestone Payments. Notwithstanding Section 7.4, in respect of Anti-KIR Products IPH shall 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 9 

 
only pay to NN the following milestone payments for the achievement of the following sales milestone events by an Anti-KIR Product pursuant to IPH’s development of Anti-KIR as a Niche
Candidate (“Anti-KIR Sales Milestones”) within *** days of the achievement of each such Anti-KIR Sales Milestone. 
 Such
milestone payments shall be made for the first Anti-KIR Product that achieves an Anti-KIR Sales Milestone and, subsequently, for each Anti-KIR Product that *** previously achieved such Anti-KIR Regulatory Milestone, but ***, in each case on a
one-time, non-duplicative basis, irrespective of the number of indications per Anti-KIR Product and any Out-licensing or Sub-licensing by IPH. 
  

	 	(a)	 *** 

  

	 	(b)	 *** 

  

	 	(c)	 *** 

To the extent that IPH is required to licence (or sublicence) Third Party IPR for the development and commercialization of Anti-KIR Products,
IPH shall be responsible for all costs associated with such licences (or sublicences) other than amounts previously paid by NN before the Amendment No. 1 Effective Date and there shall be no reduction in the milestone payments set forth above as a
result of such payments.” 
  

	3.12.	 Royalties. With effect from the Amendment No.1 Effective Date, Article 7 of the Agreement is hereby
amended by inserting the following text immediately following Section 7.8: 

 “7.8A Royalties on Anti-KIR
Products. Notwithstanding Section 7.8 hereof, in respect of Anti-KIR Products IPH shall only pay to NN the following percentage royalties on all Net Sales of the first Anti-KIR Product and, subsequently, for each Anti-KIR Product *** that
previously achieved such Anti-KIR Regulatory Milestone, but ***, in the Territory by IPH (or its associated Selling Parties) during the Term in accordance with Section 7.11 (notwithstanding any royalties that IPH or its associated Selling Parties
may have to pay to Third Parties with respect to the affected Anti-KIR Product): 
  

	 	(a)	 *** 

  

	 	(b)	 *** 

To the extent that IPH is required to licence (or sublicence) Third Party IPR for the development and commercialization of Anti-KIR Products,
IPH shall be responsible for all costs associated with such licences (or 
  
 Certain
information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 10 

 
sublicences) other than amounts previously paid by NN before the Amendment No. 1 Effective Date and there shall be no reduction in the royalty payments set forth above as a result of such
payments.” 
  

	3.13.	 Records of Net Sales. With effect from the Amendment No.1 Effective Date, Article 7 of the
Agreement is hereby further amended by inserting “and 7.8A” immediately after “7.8” in Section 7.9. 

  

	3.14.	 Anti-KIR Patents. With effect from the Amendment No.1 Effective Date, Article 9 of the Agreement is
hereby amended by inserting the following text immediately following Section 9.1: 

 “9.1A Anti-KIR
Patents. The provisions of this Section 9.1A shall apply in relation to IPH Controlled Patents (as defined below) (including Shared Anti-KIR Patents) but no other Patents. 

9.1A.1 Anti-KIR Patents. Notwithstanding anything to the contrary in this Agreement, as between the Parties: 

 

	 	(a)	 Except as otherwise set forth in Section 9.1A.1(b) hereof, IPH shall have the exclusive right and sole
discretion during the Term to prepare, file, prosecute, and maintain the Anti-KIR Patents and any Patent claiming a therapeutic, prophylactic or diagnostic use of Anti-KIR in which any NN Anti-KIR FoO IPR (but not including any Patent listed in
Schedule 5.8.2 A) is disclosed (“IPH Controlled Patents”) and to conduct any interferences, re-examinations, reissues, limitations, and oppositions with respect to such IPH Controlled Patents; provided, however, that
IPH may neither disclose any Anti-KIR Know How or NN Anti-KIR FoO IPR related to either (x) manufacturing methods, processes or procedures or (y) formulation, assay and delivery methodologies in the preparation, filing, prosecution or maintenance of
any Patent nor prepare, file or prosecute any Patent which would require the disclosure of any Anti-KIR Know How or NN Anti-KIR FoO IPR related to either (x) manufacturing methods, processes or procedures or (y) formulation, assay and delivery
methodologies. IPH shall bear sole responsibility for the preparation, filing, prosecution and maintenance of any Patent contemplated by this Section 9.1A.1 (a) and all costs associated therewith accruing after October 6, 2008, including
attorneys’ fees and payments due to patent authorities to maintain such Patents. 

  

	 	(b)	 With respect to the Shared Anti-KIR Patents, NN shall have the exclusive right and sole discretion during the
Term to (A) at NN’s sole cost and expense, direct IPH to take any steps required to ensure that all Anti-NKG2A Products, Anti-NKG2D Products and/or any other Licensed Products and their respective uses are excluded from the scope of any claims
of any Shared Anti-KIR Patents to the extent reasonably possible, and (B) at NN’s sole cost and expense, prepare, file, prosecute and maintain Continuations thereof to the extent the claims of any such Continuations cover any

  
 11 

	 	
Anti-NKG2A Products, Anti-NKG2D Products and/or any other Licensed Products or their respective uses (the “NN Continuations”) and to conduct any interferences, re-examinations,
reissues, limitations, and oppositions with respect to such NN Continuations. 

 9.1A.2 Correspondence Regarding Proposed
Patent Submissions. IPH, with respect to the Shared Anti-KIR Patents, and NN, with respect to the NN Continuations, shall promptly, and in any event no less than *** prior to any final deadline for submission of such documents or required filing
date, deliver or have delivered to the other Party copies of: 
  

	 	(a)	 all proposed amendments or other applications in relation to such Shared Anti-KIR Patents or NN Continuations
or, in instances where several such proposed amendments or applications are substantially similar (such as multiple national phase filings of a single international (PCT) application), a representative sample of such proposed amendments or
applications; 

  

	 	(b)	 all substantive documents proposed to be filed in any patent authority appeal proceedings relating to such
Shared Anti-KIR Patents, NN Continuations and any applications in relation to the foregoing; 

  

	 	(c)	 all substantive documents proposed to be filed in any inter partes disputes (including opposition,
reexamination, or interference proceedings) before any patent authority or before any judicial body on appeal of such proceedings which relate to such Shared Anti-KIR Patents, NN Continuations and any applications in relation to the foregoing; and

  

	 	(d)	 any other substantive documents proposed to be submitted to any Patent authority which relate to such Shared
Anti-KIR Patents, NN Continuations or any applications in relation to the foregoing which are reasonably requested by the other Party, 

in each case, in a manner which provides the other Party with a sufficient opportunity to review and comment on such documents. 

9.1A.3 Patent Authority Correspondence. IPH, with respect to the Shared Anti-KIR Patents, and NN, with respect to the NN Continuations,
shall: 
  

	 	(a)	 notify the other Party of its receipt of all office actions from any Patent authority or any other substantive
correspondence from any Patent authority notification of which has been requested by such other Party (and any planned responses to the foregoing) which relate to any Shared Anti-KIR Patent; NN Continuation or any applications in relation to the
foregoing, 

  

	 	(b)	 notify the other Party of the allowance of any Shared Anti-KIR Patent, NN Continuation or any applications in
relation to the 

  
 Certain information has been excluded from this
agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 12 

	 	
foregoing (including notifying such other Party of the expected date of issuance, providing copies of all allowed claims and whether or not such Party intends to file any further applications
with respect to such Shared Anti-KIR Patent or NN Continuation), and 

  

	 	(c)	 notify the other Party of the issuance of any Shared Anti-KIR Patent or NN Continuation or any applications in
relation to the foregoing. 

 9.1A.4 Limited Right to Comment. With respect to the Shared Anti-KIR Patents, IPH
shall notify NN at least *** before either any applicable deadline of any patent authority for filing, or the date that IPH intends to file, any response, application or the like in respect of any proposed filing or submission concerning any such
Shared Anti-KIR Patent. IPH shall give reasonable consideration to any comments, suggestions, recommendations or other requests (“Requests”) regarding the preparation, filing, prosecution or maintenance of any such Anti-KIR
Patent that NN shall provide to IPH at any time prior to *** before such deadline or intended filing date and IPH shall notify NN in writing within *** of its receipt of any Request (but in no event later than *** before any applicable deadline of
any patent authority for filing any response, application or the like to which such Request applies) whether it intends to adopt or reject such Request. In the event that IPH notifies NN that it will not adopt any Request of NN, and the failure
to adopt such Request would be reasonably expected to materially impair NN’s business or rights in any NN Continuations, NN may direct IPH to implement such Request at any time following the receipt of such notice and IPH shall implement any
such Request, provided that IPH shall have no obligation to implement such Request to the extent that such Request would reasonably be expected to materially impair IPH’s business or ability to prosecute or obtain claims of its choice in
at least one of the Anti-KIR Patents. 
 9.1A.5 Notice and Effects of IPH’S Decision to Abandon; Disclaim; or Discontinue
Prosecution, Maintenance, or Defense of Shared Anti-KIR Patents. In the event that IPH decides in respect of any Shared Anti-KIR Patent: 
  

	 	(a)	 to discontinue the prosecution or maintenance of such Shared Anti-KIR Patent, 

 

	 	(b)	 to discontinue the defense of such Shared Anti-KIR Patent (such as by discontinuing efforts to defend such
Shared Anti-KIR Patent in any opposition, reexamination, nullity, or interference proceeding), 

  

	 	(c)	 to not file an application for a Continuation (or, as the case may be, further Continuation) with respect to
such Shared Anti-KIR Patent (including by decision (A) not to enter the national or regional phase in any country or region that is a designated state of a PCT application filed by IPH or (B) not to pursue an application in a country wherein an
application claiming priority from a Shared Anti-KIR Patent may be filed), or 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 13 

	 	(d)	 to abandon or disclaim (in whole or in part, other than by terminal disclaimer), without possibility of
restoration, any Shared Anti-KIR Patent, 

 in each case, IPH shall provide written notice to NN at least *** in advance of
the deadline relating to any of the events described above (except in the case of national or regional phase filing, in which case such notice shall be provided at least *** in advance of the date of the first applicable deadline for national or
regional phase entry) so as to allow NN the opportunity to file, defend, maintain (including by payment of annuities, issue fees, maintenance fees, or the like), or continue prosecution of such Shared Anti-KIR Patent, at its own expense. In such an
event, IPH shall provide any assistance reasonably requested of it by NN (including providing NN with power of attorney to perform such tasks) and, to the extent authorized by contract and permitted by applicable Law, assign its rights to such
Shared Anti-KIR Patent to NN. NN shall thereafter grant to IPH a worldwide, non-exclusive licence (including the right to sub-license and further sublicense) with respect to such Shared Anti-KIR Patent for no additional consideration. 

9.1A.6 Future Limitations on Continuations. Upon the occurrence of an event following which the Laws of the United States or the Laws
now or hereinafter in effect in any jurisdiction (including any regulations of the U.S. Patent and Trademark Office or any similar foreign governmental agency) are likely to be amended in the near future to limit the number of Continuations that a
Person may file in connection with any Patent, either Party may provide written notice to the other Party of such event and the Parties shall meet in a timely manner in advance of the date such Laws are expected to become effective and negotiate in
good faith a revised paradigm addressing the manner in which any Continuations (or, as the case may be, further Continuations) of the Shared Anti-KIR Patents may be filed. From the time such notice is provided until the time the Parties agree
on such a revised paradigm, neither Party shall take any action that could limit the other Party’s right to file or prosecute any Continuations (or, as the case may be, further Continuations) of any Shared Anti-KIR Patents. 

9.1A.7 Enforcement of IPH Controlled Patents, Shared Anti-KIR Patents and NN Claims.

 

	 	(a)	 Except as otherwise provided in Sections 9.1A.7(b) and 9.1A.7(c) and subject to Sections 9.12.1 and 9.12.2, IPH
shall have the exclusive right (but not the obligation) to initiate or defend any suit, opposition, interference or other legal action (including proceedings before the US International Trade Commission) or to take other appropriate action that IPH,
in its sole discretion, 

  
 Certain information has been excluded
from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 14 

	 	
believes is reasonably required to protect or enforce (i.e., prevent or abate actual or threatened misappropriation or infringement of, or otherwise enforce) any IPH Controlled Patent (in its own
name or, if authorized by contract and permitted by applicable Law and required by applicable Law, in the name of the NN or an Affiliate of NN), and shall bear its own costs and expenses in respect thereof and be represented by counsel of its choice
and shall further indemnify NN and any of its Affiliates for any costs incurred by NN or any of its Affiliates in connection with such suit, opposition, interference or action. 

 

	 	(b)	 Notwithstanding anything to the contrary in this Agreement, except as otherwise provided in Section 9.1A.7(c)
and subject to Sections 9.12.1 and 9.12.2, IPH shall have the exclusive right (but not the obligation) to initiate or defend any suit, opposition, interference, other legal action (including proceedings before the US International Trade Commission)
or to take other appropriate action that IPH, in its sole discretion, believes is reasonably required to protect or enforce (i.e., prevent or abate actual or threatened misappropriation or infringement of, or otherwise enforce) any Shared Anti-KIR
Patent (in its own name or, if authorized by contract and permitted by applicable Law and required by applicable Law, in the name of the NN or an Affiliate of NN) against any Person for infringement of any claims of such Shared Anti-KIR Patent and
shall bear its own costs and expenses in respect thereof and be represented by counsel of its choice and shall further indemnify NN and any of its Affiliates for any costs incurred by NN or any of its Affiliates in connection with such suit,
opposition, interference or action. To the extent that such infringement relates to any Anti-NKG2A Product or Anti-NKG2D Product or their respective uses, IPH shall give reasonable consideration to any comments or suggestions of NN in
connection with any such suit, opposition, interference or legal action, including with respect to any negative impact such suit, opposition, interference or legal action could reasonably be expected to have on the Shared Anti-KIR Patents.

  

	 	(c)	 Notwithstanding anything to the contrary in this Agreement, subject to the provisions of 9.12.1 and 9.12.2, NN
shall have the exclusive right (but not the obligation) to initiate or defend any suit, opposition, interference, other legal action (including proceedings before the US International Trade Commission) or to take other appropriate action that NN, in
its sole discretion, believes is reasonably required to protect or enforce (i.e., prevent or abate actual or threatened misappropriation or infringement of, or otherwise enforce) any NN Continuation (in its own name or, if authorized by contract and
permitted by applicable Law and required by applicable Law, in the name of the IPH or an Affiliate of IPH), and shall bear its own costs and expenses in respect thereof and be represented by counsel of its choice and shall further indemnify IPH and
any of its Affiliates for any costs incurred by IPH or any of its Affiliates in connection with such suit, opposition, interference or action. 

  
 15 

 9.1A.8 Dispute Resolution. The Parties acknowledge that all disputes arising under
this Section 9.1A shall be subject to the dispute resolution procedures set forth in Section 21.14.” 
  

	3.15.	 Development Diligence Requirements for Anti-KIR as a Niche Candidate. With effect from the
Amendment No.1 Effective Date, Article 12 of the Agreement is hereby amended by inserting the following text immediately following Section 12.7 and Section 12.7 shall no longer apply to Anti-KIR as a Niche Candidate or the marketing or sale of an
Anti-KIR Product: 

 “12.7A Development Diligence Requirements for Anti-KIR Niche Candidate.
Notwithstanding Section 12.7 hereof, with respect to either the development of Anti-KIR as a Niche Candidate or the marketing or sale of an Anti-KIR Product, IPH shall be obliged to promptly notify NN in writing of any decision to abandon the
development of Anti-KIR as a Niche Candidate or the marketing or sale of an Anti-KIR Product. 
 In the absence of notification, IPH shall be
deemed to have abandoned the development of Anti-KIR as a Niche Candidate if: 
  

	 	(i)	 *** 

  

	 	(ii)	 *** 

provided that the time periods in (i)-(iii), above: 
  

	 	(A)	 shall not include any time period during which the relevant Anti-KIR Product shall have been subject to a
Clinical Hold (as defined below) and IPH shall have been using Commercially Reasonable Efforts to remove such Clinical Hold; and 

  

	 	(B)	 shall be extended by a reasonably appropriate amount of time to reflect any delays or obstacles to the
development of the relevant Anti-KIR Product that (i) occur following the designation of Anti-KIR as a Niche Candidate, (ii) result from unexpected or unclear clinical trial efficacy or safety data not reasonably forseeable by IPH at the date of the
designation of Anti-KIR as a Niche Candidate and (iii) are not caused by an inability of IPH to secure appropriate financing or a development partner, provided, however, that IPH shall have notified NN of such delays or obstacles
promptly upon such delays or obstacles becoming reasonably forseeable and shall have been using Commercially Reasonable Efforts to overcome such delay or obstacle. 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 16 

 Within *** of any of the occurrence of any of the events specified in (i), (ii), or (iii) above,
IPH may, by paying to NN the relevant fee provided for below, extend the deadline for achievement of the required step on an annual basis for up to a period of ***, the relevant fee being: 

 

	 	(a)	 *** 

  

	 	(b)	 *** 

“Clinical Hold”, as used in this Section 12.7A, shall mean a bona fide decision of IPH or a decision of a regulatory
authority or another governmental body to suspend a clinical trial or other study when it does not believe that such clinical trial or other study can be conducted without unreasonable risk to the subjects in such clinical trial or study, and the
existence of such circumstances shall be subject to arbitration in accordance with Section 21.14.” 
  

	3.16.	 Termination upon Abandonment of Development of Anti-KIR Niche Candidate. With effect from the
Amendment No.1 Effective Date, Article 12 of the Agreement is hereby amended by inserting the following text immediately following Section 12.8 and Section 12.8 shall no longer apply to Anti-KIR Products: 

“12.8A Notwithstanding Section 12.8 hereof, in the event of the abandonment by IPH of its development of Anti-KIR as a Niche Candidate (by
express notice to NN or by operation of this Article 12), the following provisions shall apply and supersede Section 12.8 with respect to such abandonment: 
  

	 	(c)	 all licences granted to IPH under this Agreement for the purposes of Commercial Optimization of Anti-KIR as a
Niche Candidate that IPH is authorized to develop and commercialize shall terminate immediately; 

  

	 	(d)	 IPH shall have an obligation to grant to NN, at NN’s request, an irrevocable, world-wide, fully paid up,
exclusive licence under all its right, title and interest to the Collaboration IPR or Background IPH IPR (as applicable) and Independent IPH IPR, and grant the right set out in Section 5.7 (including all supporting regulatory documentation), for the
development and commercialization of Anti-KIR, for no additional consideration other than as provided for herein; 

  

	 	(e)	 if NN shall, in its discretion, assume such licence it shall notify IPH to this effect within *** of IPH’s
abandonment or the determination of abandonment, whichever is the later, upon which assumption NN shall have the exclusive right to exploit such IPR for the development and commercialization of Anti-KIR; 

 

	 	(f)	 if the date of such abandonment is prior to the first dosing of humans in Phase II clinical trials of Anti-KIR
as a Niche Candidate, 

  
 Certain information has been excluded from
this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 17 

	 	
Sections 12.8A(a) and 12.8A(b) shall apply, save that, in consideration of the grant of such rights, if and only if NN subsequently Out-licences such IPR within the period of ***
following the date of NN’s assumption of rights, NN shall pay to IPH a percentage of all revenue actually received in respect of such licence on the following basis: 

 

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	(g)	 if the effective date of abandonment is after the first dosing of humans in Phase II clinical trials of
Anti-KIR as a Niche Candidate but prior to the first dosing in Phase III, the above Sections 12.8A(a) and 12.8A(b) shall apply save that in consideration of the grant of such rights, if and only if NN subsequently Out-licences such IPR
within the period of *** following the date of NN’s assumption of rights NN shall pay to IPH a percentage of all revenue actually received by NN in respect of such licence on the following basis: 

 

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	(h)	 in the event of its abandonment of the development of Anti-KIR as a Niche Candidate and irrespective of the
effective date of such abandonment, IPH shall: 

  

	 	(i)	 make no further representation regarding its status as a licencee of NN in respect of Anti-KIR;

  

	 	(ii)	 in the event that at the date of the abandonment by IPH of its development of Anti-KIR as a Niche Candidate
there are ongoing clinical trials with respect to such development, IPH shall pay for the completion of such clinical trials in respect of all patients enrolled at the effective date of abandonment except if the Agreement is terminated because of
adverse events in the clinical trial(s) 

  
 Certain information has
been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 18 

	 	
causing the trials(s) to cease due to regulatory requirements or regulatory considerations (including an actual or anticipated regulatory warning); 

 

	 	(iii)	 at NN’s option, and at NN’s expense, and to the extent authorized by contract and permitted by
applicable Law, assign or cause to be assigned to NN any regulatory submissions and approvals with respect to Anti-KIR and take such actions and execute such other instruments, assignments and documents as may be necessary to effect the transfer of
all rights thereunder to NN; 

  

	 	(iv)	 at NN’s option and at NN’s expense, provide to NN all pre-clinical and clinical data in respect of
Anti-KIR and all research reagents and materials intended for use in clinical trials of Anti-KIR in IPH’s possession or control. 

Following the transfer of rights from IPH to NN pursuant to this Section 12.8A IPH shall have no further obligations under Sections 12.7,
12.8, 12.8A, 12.8B, 12.9 or 12.10 in respect of the development or commercialization of Anti-KIR.” 
  

	3.17.	 Termination upon Abandonment of Marketing or Sale of Anti-KIR Product. With effect from the
Amendment No.1 Effective Date, Article 12 of the Agreement is hereby amended by inserting the following text immediately following Section 12.8A and Section 12.8 shall no longer apply to Anti-KIR Products: 

“12.8B Notwithstanding Section 12.8 hereof, in the event of the abandonment by IPH of its marketing or sale of any Anti-KIR Product, the
following provisions shall apply and supersede Section 12.8 with respect to such abandonment: 
  

	 	(a)	 all licences granted to IPH under this Agreement for the marketing or sale of such Anti-KIR Product, shall
terminate immediately; 

  

	 	(b)	 IPH shall have an obligation to grant to NN, at NN’s request, an irrevocable, world-wide, fully paid up,
exclusive licence under all its right, title and interest to the Collaboration IPR or Background IPH IPR (as applicable) and Independent IPH IPR, and grant the right set out in Section 5.7 (including all supporting regulatory documentation) with
respect to which such Anti-KIR Product has been abandoned, solely for the purposes of the commercialization of such specific Anti-KIR Product, for no additional consideration other than as provided for herein; 

 

	 	(c)	 if NN shall, in its discretion, assume such licence it shall notify IPH to this effect within *** of IPH’s
abandonment, upon which assumption NN shall have the exclusive right to exploit such IPR for solely with respect to such abandoned Anti-KIR Product and for such purposes as are specified in clause (a); 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 19 

	 	(d)	 the above Sections 12.8B(a) and 12.8B(b) shall apply save that in consideration of the grant of
such rights, if and only if NN subsequently Out-licences such IPR within the period of *** following the date of NN’s assumption of rights, NN shall pay to IPH a percentage of all revenue actually received by NN in respect of such licence on
the following basis: 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	(e)	 in the event of its abandonment of the marketing or sale of any Anti-KIR Product irrespective of the effective
date of such failure, IPH shall: 

  

	 	(i)	 cease any activities with respect to the marketing, promotion, sale or distribution of the Anti-KIR Product
with respect to which such abandonment has occurred; 

  

	 	(ii)	 at NN’s option and at NN’s expense, and to the extent such transfer is authorized by contract and
permitted by applicable Law, to transfer to NN the benefit of any contracts between IPH and any Third Party in respect of the manufacture of such abandoned Anti-KIR Product, with respect to the supply thereof for marketing with respect to which such
abandonment has occurred, provided that for the avoidance of doubt IPH shall not be required to cause or effect any such transfer if to do so will require IPH’s payment or provision of additional consideration to any Person save that NN
may elect to pay for and obtain the right to such procurement or exercise to the extent authorized by contract and permitted by applicable Law; 

  

	 	(iii)	 at NN’s option, and at NN’s expense, and to the extent authorized by contract and permitted by
applicable Law, assign or cause to be assigned to NN, any regulatory submissions and approvals related to the Anti-KIR Product with respect to which such abandonment has occurred and take such actions and execute such other instruments, assignments
and documents as may be necessary to effect the transfer of all rights thereunder to NN; 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 20 

	 	(iv)	 NN shall pay IPH’s reasonable costs in connection with the above activities at a reasonable hourly rate
representing the actual cost of IPH of providing such services up to a maximum of ***. 

 Following the transfer of rights
from IPH to NN pursuant to this Section 12.8B IPH shall have no further obligations under Sections 12.7, 12.8, 12.8A, 12.8B, 12.9 or 12.10 with respect to the marketing and sale of the Anti-KIR Product with respect
to which the abandonment has occurred.” 
  

	3.18.	 Publication concerning an Anti-KIR Niche Candidate. With effect from the Amendment No.1 Effective
Date, Article 18 of the Agreement is hereby amended by inserting the following text immediately following Section 18.1: 

“Section 18.1A Publication concerning Anti-KIR as a Niche Candidate or Anti-KIR Products. Notwithstanding Section 18.1,
NN shall have no rights pursuant to such Section 18.1 with respect to publications or disclosures concerning the development or commercialization of Anti-KIR as a Niche Candidate pursuant to Section 6.1 hereof or any Anti-KIR Product;
provided, however that (a) IPH shall provide to NN a copy of such publication or disclosure as soon as reasonably practicable following such publication or disclosure and (b) in no event shall IPH publish Confidential Information of NN
relating to (i) manufacturing, marketing, financing or business developments, opportunities, plans, methods, processes or procedures, (ii) quality controls, (iii) security controls, (iv) unpublished cost, price or pricing information, (v) financial
or personnel matters, or (vi) customer, client or supplier lists or information, in each case without prior written approval of NN.” 
  

	4.	 OTHER AMENDMENT OF AGREEMENT. 

 

	4.1	 With effect from the Amendment No.1 Effective Date, the Definitions “Out-license” and
“Out-licensing” (set forth in Section 1.1.55) and “Sub-license” and “Sublicensing” (set forth in Section 1.1.64) shall be interpreted by the Parties to mean the grant by a Party of an Out-licence or Sub-licence to any
Out-licensee or Sub-licensee or any further grant of a Sub-licence or Out-licence by such Out-licensee or Sub-licensee or its Out-licensees or Sub-licensees. 

  

	4.2	 With effect from the Amendment No.1 Effective Date, Article 12 of the Agreement is hereby amended by:

  

	4.2.1	 deleting the text of Section 12.7 in its entirety and replacing it with the following: 

“12.7 Development Diligence Requirements. For the purposes of this Section 12.7, each Party shall be obliged to promptly notify the
other Party in writing of any decision to abandon the development, marketing or sale of any Licensed Product, Residual Product or Niche Candidate 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 21 

 
and in the absence of notification the first Party shall be deemed to have abandoned the development of such Licensed Product, Niche Candidate, or Residual Product being developed for
commercialization exclusively by or on behalf of that Party if: 
  

	 	(i)	 *** 

  

	 	(ii)	 *** 

  

	 	(iii)	 *** 

provided that the time periods in (i)-(iii), above: 
  

	 	(C)	 shall not include any time period during which the relevant Licensed Product, Niche Candidate or Residual
Product shall have been subject to a Clinical Hold (as defined below) and the Party developing same shall have been using Commercially Reasonable Efforts to remove such Clinical Hold; and 

 

	 	(D)	 shall be altered by the Parties to take into consideration unforeseen delays or obstacles in continuing the
development of the relevant Licensed Product, Niche Candidate or Residual Product outside the reasonable control of the developing Party, in which case the Parties shall agree to a reasonable extension having regard to the delay, provided that the
developing Party must make a request for such extension to the other Party at the time of, and not solely after, the delay. 

Within *** of any of the occurrence of any of the events specified in (i), (ii), or (iii) above, the developing Party may, by paying to the
other Party the relevant fee provided for below, extend the deadline for achievement of the required step on an annual basis for up to a period of ***, the relevant fee being: 
  

	 	(a)	 *** 

  

	 	(b)	 *** 

  

	 	(c)	 *** 

provided that the developing Party shall only have the right to such extension under two of events (a), (b) or (c) of this Section 12.7,
unless the Parties hereafter agree otherwise in writing. 
 “Clinical Hold”, as used in this Section 12.7, shall mean
a bona fide decision of the developing Party or a decision of a regulatory authority or another governmental body to suspend a clinical trial or other study when it does not believe that such clinical trial or other study can be conducted without
unreasonable risk to the subjects in such clinical trial or study, and the existence of such circumstances shall be subject to arbitration in accordance with Section 21.14.” 

 
 *** Portions of this page have been omitted pursuant to a request for Confidential
Treatment and filed separately with the Commission. 

  
 22 

	4.2.2	 deleting the text of Section 12.8 in its entirety and replacing it with the following: 

“12.8 Termination for Failure to Employ Commercially Reasonable Efforts. Notwithstanding any other provision of this Agreement, in
the event of the abandonment of the development by a Party (the “Developing Party”) (by express notice to the other Party or by operation of this Article 12), or a non-transient material failure of the Developing Party to employ
Commercially Reasonable Efforts in respect of the marketing or sale of any Licensed Product, Residual Product or Niche Candidate, all licences granted to the Developing Party under this Agreement for the purposes of Commercial Optimization of any
such Licensed Product, Residual Product or Niche Candidate that a Party is authorized to develop but that has been abandoned shall terminate immediately and the following provisions shall apply: 

 

	 	(a)	 The Developing Party shall have an obligation to grant to the other Party, at the other Party’s request,
an irrevocable, world-wide, fully paid up, exclusive licence under all its right, title and interest to the Collaboration IPR, Background NN IPR or Background IPH IPR (as applicable) and Independent IPR, and grant the right set out in Section
5.7, with respect to which such specific Licensed Product, Residual Product or Niche Candidate has been abandoned, solely for the purposes of Commercial Optimization of such specific Licensed Product, Residual Product, or Niche Candidate, and
all supporting regulatory documentation, to the other Party for no additional consideration other than as provided for herein; and 

  

	 	(b)	 if the other Party shall, in its discretion, assume such licence it shall notify the Developing Party to this
effect within *** of the Developing Party’s abandonment or the determination of abandonment, whichever is the later, upon which assumption the other Party shall have the exclusive right to exploit such IPR solely with respect to such abandoned
product(s) and for such purposes as are specified in clause (a) above, provided that such right shall not include the right or licence to develop or commercialize any product comprised of, interacting with, modulating or is derived from the same
Biological Target for the same indication(s) as any (i) Licensed Product or Residual Product encompassed by the Developing Party’s exclusive rights or licences hereunder; or (ii) Niche Candidate marketed by the Developing Party (or its
Out-licencee) pursuant to the Buy-In-Option. 

  
 Certain information
has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 23 

	 	(c)	 If the date of such abandonment is prior to the first dosing of humans in clinical trials with such abandoned
Licensed Product, Residual Product or Niche Candidate, Sections 12.8(a) and 12.8(b) shall apply, save that, in consideration of the grant of such rights, if and only if the other Party subsequently Out-licences such IPR within the
period of *** following the date of the other Party’s assumption of rights, the other Party shall pay to the Developing Party a percentage of all revenue actually received in respect of such licence on the following basis:

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	(d)	 If the effective date of abandonment is after the first dosing of humans in clinical trials with such abandoned
Licensed Product, Residual Product or Niche Candidate but prior to the first dosing in Phase III, the above Sections 12.7(a) and (b) shall apply save that in consideration of the grant of such rights, if and only if the other Party
subsequently Out-licences such IPR within the period of ten years following the date of the other Party’s assumption of rights the other Party shall pay to the Developing Party a percentage of all revenue actually received by the other Party in
respect of such licence on the following basis: 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	(e)	 If the date of such abandonment is after the beginning of the first dosing in Phase III then NN and IPH shall
***. 

  

	 	(f)	 In the event of its abandonment of a Licensed Product, Residual Product or Niche Candidate and irrespective of
the effective date of such abandonment, the Developing Party shall: 

  

*** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

  
 24 

	 	(i)	 make no further representation regarding its status as a licensee of the other Party in respect of such
abandoned Licensed Product, Residual Product or Niche Candidate; 

  

	 	(ii)	 cease any activities with respect to the marketing, promotion, sale or distribution of such abandoned Licensed
Product, Residual Product or Niche Candidate; 

  

	 	(iii)	 in the event that at the date of such abandonment there are ongoing clinical trials of such abandoned Licensed
Product, Residual Product or Niche Candidate, pay for the completion of such clinical trials in respect of all patients enrolled at the effective date of abandonment except if the Agreement is terminated because of adverse events in the clinical
trial(s) causing the trials(s) to cease due to regulatory requirements or regulatory considerations (including an actual or anticipated regulatory warning); 

  

	 	(iv)	 at the other Party’s option and at the other Party’s expense, and to the extent such transfer is
authorized by contract and permitted by applicable Law, to transfer to the other Party, the benefit of any contracts between the Developing Party and any Third Party in respect of the manufacture of such abandoned Licensed Product, Residual Product
or Niche Candidate, with respect to the supply thereof for marketing, provided that for the avoidance of doubt the Developing Party shall not be required to cause or effect any such transfer if to do so will require the Developing Party’s
payment or provision of additional consideration to any Person save that the other Party may elect to pay for and obtain the right to such procurement or exercise to the extent authorized by contract and permitted by applicable Law;

  

	 	(v)	 at the other Party’s option, and at the other Party’s expense, and to the extent authorized by
contract and permitted by applicable Law, assign or cause to be assigned to IPH any regulatory submissions and approvals with respect to such abandoned Licensed Product, Residual Product or Niche Candidate and take such actions and execute such
other instruments, assignments and documents as may be necessary to effect the transfer of all rights thereunder to the other Party; 

  
 25 

	 	(vi)	 at the other Party’s option and at the other Party’s expense, provide to the other Party all
pre-clinical and clinical data in respect of such abandoned Licensed Product, Residual Product or Niche Candidate and all research reagents and materials intended for use in clinical trials of such abandoned Licensed Product, Residual Product or
Niche Candidate, in the Developing Party’s possession or control; and 

  

	 	(vii)	 the other Party shall pay the Developing Party’s reasonable costs in connection with the above activities
at a reasonable hourly rate representing the actual cost of the Developing Party of providing such services up to a maximum of ***. 

Following the transfer of rights from one Party to another pursuant to this Section 12.8 the other Party shall have no further
obligations under Sections 12.7, 12.8, 12.9 or 12.10 in respect of the development, sale or marketing of any such product. 

Without limitation of the Parties’ obligations to exercise Commercially Reasonable Efforts, or of any other obligations under this
Agreement or remedies for the material breach thereof, the failure to attain any benchmark or objective set forth in any of Subsections (i), (ii) or (iii) of Section 12.7 shall not constitute a breach of this Agreement, and the provisions of this
Article 12 prescribe the Developing Party’s sole and exclusive liability, and the other Party’s sole and exclusive remedy for such failure.” 
  

	4.2.3	 deleting the text of Section 12.9 in its entirety and replacing it with the following: 

“12.9 [Reserved]”. 
  

	5.	 KNOW-HOW TRANSFER 

 

	5.1.	 IPH has requested that NN transfer to IPH the Know-How comprising the information (regulatory, clinical, CMC
and other) listed in Exhibit C to this Amendment No.1. 

  

	5.2.	 NN shall transfer, and take such actions as are reasonably required to ensure the effective transfer of, the
Know-How listed in Exhibit C to Innate as soon as possible and in any event no later than December 30, 2008 in accordance with the terms of this Amendment No. 1 including the guidelines set out in Exhibit G. 

 

	5.3.	 In the event of any dispute between NN and IPH regarding the actions of NN that are reasonably required to
ensure the effective transfer of the Know-How listed in Exhibit C, such dispute shall in the first instance be referred to the CSO of NN and the CEO of IPH who shall seek to resolve 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 26 

	 	
such dispute. In the event that the CSO of NN and the CEO of IPH are unable to resolve the dispute, NN or IPH may seek the non-binding opinion of an expert, in accordance with the procedures
set forth in Exhibit H, on whether or not any additional actions of NN are reasonably required to effect such transfer; provided, however, that neither NN nor IPH shall be obliged to take any actions based on such expert’s
opinion. Notwithstanding the above, either Party may at any time refer any such dispute to arbitration in accordance with Section 21.14 of the Agreement. 

  

	5.4.	 If, on or before December 30, 2008, IPH gives notice to NN that IPH has identified Know-How that is (x)
Controlled by NN at that date, (y) not listed in Exhibit C and (z) necessary for the purposes of IPH’s development or commercialization of the Anti-KIR Niche Candidate, then NN shall deliver to IPH the
documents, files and materials containing such Know-How as soon as reasonably practicable. 

  

	5.5.	 IPH acknowledges and agrees that, subject to Section 5.8.2A of the Agreement (as amended by this Amendment No.
1) and Sections 5.2 and 5.4 of this Amendment No. 1, NN shall have no further obligation to transfer Know-How to IPH pursuant to Section 6.1 of the Agreement or otherwise in connection with IPH’s development and commercialization of Anti-KIR as
a Niche Candidate. 

  

	6.	 CLINICAL TRIALS 

 

	6.1.	 Definitions. The following terms, as used in this subsection herein, shall have the following meanings:

 “Clinical Trial” shall mean any of the ongoing clinical trials of ***, as further described below.

 “*** Clinical Trial” shall mean ***. 

“*** Clinical Trial” shall mean ***. 

“*** Clinical Trial” shall mean ***. 
  

	6.2.	 Each of NN and IPH shall use all reasonable endeavours to cause the sponsorship of the Clinical Trials to be
transferred to IPH no later than December 1, 2008. 

  

	6.3.	 IPH or NN, as appropriate based on the regulatory guidelines applicable, shall use reasonable endeavours to
file with the appropriate regulatory authority an application to transfer sponsorship of each Clinical Trial from NN to IPH no later than November 1, 2008, and NN or IPH, as the case may be, shall reasonably cooperate with the other Party in
the preparation of such application. 

  

	6.4.	 (a) From the date of the approval of the transfer of sponsorship from NN to IPH of a Clinical Trial, IPH shall
assume responsibility for such Clinical Trial, including any reporting obligations to appropriate regulatory authorities. 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 27 

	 	(b)	 In no event will NN be liable to IPH for any claims, suits, losses, damages, costs, fees, or expenses resulting
from the conduct of a Clinical Trial after the date of the approval of the transfer of sponsorship from NN to IPH of such Clinical Trial. 

  

	 	(c)	 IPH agrees to indemnify, hold harmless, and defend NN and its Affiliates, against any claims, suits, losses,
damages, costs, fees, or expenses resulting from the conduct of a Clinical Trial after the date of the approval of the transfer of sponsorship from NN to IPH of such Clinical Trial. 

 

	6.5.	 Where not prohibited by its terms or applicable Law, or not requiring any payment by NN, NN shall use all
reasonable endeavours to assign the rights, benefits and obligations of each agreement set forth in Exhibit F to IPH, and IPH shall accept such assignment, as and from the date on which approval of the transfer of sponsorship from NN to IPH of the
Clinical Trial to which such agreement relates is granted by the appropriate regulatory authority. Pending such assignment to IPH or where such assignment is not possible, IPH shall reimburse NN within *** of NN’s presentation of an invoice to
IPH for payments, falling due pursuant to the agreements set forth in Exhibit F from the earlier of (x) 1 November 2008 or (y) the date on which approval of the transfer of sponsorship from NN to IPH of the Clinical Trial to which such payment
or cost relates is granted by the appropriate regulatory authority. 

  

	6.6.	 IPH shall notify NN upon the completion (i.e., last patient, last visit) of each Clinical Trial.

  

	7.	 TRANSFER OF ANTI-KIR SUPPLIES 

 

	7.1.	 NN shall transfer to IPH the materials described further in Exhibit E (the “Anti-KIR
Supplies”) as follows: 

  

	 	(a)	 Subject to Section 7.3, within *** of the Amendment No. 1 Effective Date, NN shall cause those Anti-KIR
Supplies set forth in Part of A of Exhibit E to be shipped to IPH; 

  

	 	(b)	 NN shall cause those Anti-KIR Supplies set forth in Part B of Exhibit E which are reasonably required to
conduct a Clinical Trial to be shipped to IPH, or to a location directed by IPH, acting reasonably, as soon as practicable following a request by IPH; and 

  

	 	(c)	 Subject to Section 7.3, 

(i) NN shall update the “Quality Investigational Medicinal Product Dossier” or Q-IMPD documents in e-submission format related to the
implementation of the second drug product batch of 
  
 Certain information has been
excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 28 

 
the Anti-KIR Supplies set forth in Part C of Exhibit E for the re-supply of Clinical Trials *** and ***, and NN or IPH, as NN reasonably deems appropriate, shall file such updated Q-IMPD with the
appropriate regulatory authorities; and 
 (ii) NN shall label using NN labels and package the Anti-KIR Supplies set forth in Part C of
Exhibit E which are reasonably required to conduct the re-supply of Clinical Trials ***, and NN shall use all reasonable endeavours to cause such Anti-KIR Supplies to be shipped to IPH no later than 1 January 2009; provided,
however, that NN shall not cause any of such Anti-KIR Supplies to be shipped to IPH if such Anti-KIR Supplies shall fail, in NN’s reasonable determination, the stability testing ongoing at the Amendment No. 1 Effective Date. IPH
acknowledges that is it responsible for any re-labeling of such Anti-KIR Supplies as may be required by applicable regulatory guidelines in connection the use of such Anti-KIR Supplies in Clinical Trials for which sponsorship has been transferred to
IPH. 
  

	 	(d)	 NN shall transfer those Anti-KIR Supplies set forth in Part D of Exhibit E to IPH at such time as the Parties
agree but no later than January 1, 2009. 

  

	7.2.	 Title to the Anti-KIR Supplies shall transfer to IPH upon delivery of such Anti-KIR Supplies to IPH or to a
third party for shipment to IPH and IPH shall be responsible for all storage costs for such Anti-KIR Supplies as and from such date; provided, however, that NN shall be responsible for all shipment (but not including insurance) costs
with respect to such shipment of Anti-KIR Supplies. 

  

	 7.3. 
	(a)	 If the 61 gram batch of Anti-KIR active product ingredient (“API”) identified in Part A of Exhibit E as “API –
hybridoma” (the “Current Batch”) does not meet the ‘30-month appearance’ stability specification reasonably required by IPH to conduct clinical trials, NN acknowledges that IPH will reprocess the Current Batch using a
sub-contractor and IPH acknowledges that IPH will be responsible for the cost of any such reprocessing. 

  

	 	(b)	 If such reprocessing by a sub-contractor does not yield a drug product that meets the specifications reasonably
required by IPH for the conduct of clinical trials, then NN will use reasonable efforts to manufacture a new batch of API from the 146 gram batch of API at the K1-eluate step at Novo Nordisk at the Amendment No. 1 Effective Date, identified in Part
A of Exhibit E as “Hybridoma captured intermediate material”, either by using Novo Nordisk’s facilities or by seeking a sub-contractor to do so. IPH will be responsible for any direct costs associated with such manufacture. NN will
use reasonable efforts to manufacture or seek a subcontractor to manufacture such new batch of API as soon as reasonably practicable and in as cost-effective a manner as reasonably practicable. 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 29 

	7.4.	 AT THE AMENDMENT NO 1. EFFECTIVE DATE, THE ANTI-KIR SUPPLIES ARE BEING SOLD “AS IS” AND WITHOUT ANY
REPRESENTATIONS OR WARRANTIES BY NN. NN MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, OF ANY TYPE WHATSOEVER, REGARDING THE ANTI-KIR SUPPLIES, AND TO THE FULLEST EXTENT PERMITTED BY LAW, NN EXPRESSLY DISCLAIMS ANY IMPLIED
WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, CONSISTENCY OR COMPLIANCE WITH ANY SAMPLES PREVIOUSLY PROVIDED OR NONINFRINGEMENT. 

 

	8.	 REGULATORY OR SAFETY DELAY 

 

	8.1.	 Notwithstanding any provision of this Amendment No. 1: 

 

	 	(a)	 NN may delay the transfer of any Anti-KIR Know-How, any Anti-KIR Supplies or the sponsorship of any Clinical
Trial to IPH; and 

  

	 	(b)	 if transfer of any Anti-KIR Know-How, any Anti-KIR Supplies or the sponsorship of any Clinical Trial shall have
occurred, IPH shall permit access by NN to such Anti-KIR Know-How, Anti-KIR Supplies or Clinical Trial documentation; 

 in
each case as may be required, in NN’s reasonable determination, to respond to any request from, or fulfill any requirement of, any regulatory authority, or otherwise to ensure Clinical Trial patient safety. 

 

	8.2.	 IPH shall use all reasonable endeavours to cooperate with NN to permit NN to respond to any request from, or
fulfill any requirement of, any regulatory authority, or otherwise to ensure Clinical Trial patient safety. 

  

	9.	 FEES 

  

	9.1.	 Fees. In consideration of the grant by NN to IPH of the rights under this Amendment No. 1, the grant by
IPH to NN of the rights under Amendment No. 2 and the transfer of the Anti-KIR Supplies IPH shall pay to Novo Nordisk: *** in each case by wire transfer of immediately available funds to such bank account as NN may designate in writing.

  

	10.	 POST-DOCTORATE RESEARCH 

 

	10.1.	 NN has disclosed to IPH that an Employee of NN is currently working on a non-competitive Anti-KIR monoclonal
antibody. NN agrees to grant to IPH, or procure the grant to IPH of, an exclusive right and licence, including the right to Sub-license and Out-license, throughout the Territory to develop and commercialize any Anti-KIR Product under all IPR
created by such Employee (as defined below) that relates to Anti-KIR arising from his research during his employment by NN. NN shall promptly disclose to IPH the results of such research, shall not publish or otherwise disclose to a Third Party
any results arising from such research without the prior written consent of IPH and shall not utilize the results of such research that relate to Anti-KIR for any pre-clinical or clinical activity with respect to Anti-KIR. 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 30 

	10.2.	 “Employee” means any employee of NN carrying out research in relation to Anti-KIR.

  

	11.	 MISCELLANEOUS 

 

	11.1.	 Effectiveness and Integration. This Amendment shall become effective as of the Amendment No.1 Effective
Date and the amendments made to the Agreement pursuant to Article 3 and Article 4 hereof shall thereafter be deemed an integral part of the Agreement. 

  

	11.2.	 No Other Changes or Repetition of Warranties. Except as expressly set forth herein, all provisions of
the Agreement shall remain unchanged and in full force and effect. Nothing in this Amendment No.1 shall cause, or shall be deemed to cause, any representation or warranty set out in the Agreement to be repeated. 

 

	11.3.	 Conflicts Between Agreement and Amendment No.1. To the extent that the Agreement is explicitly amended
by this Amendment No.1, the terms of the Amendment No.1 will control where the terms of the Agreement are contrary to or conflict with the provisions of this Amendment. Where the Agreement is not explicitly amended by this Amendment No.1, the
terms of the Agreement will remain in force. 

  

	11.4.	 Applicable Law. This Amendment No.1 shall be construed and interpreted pursuant to the Laws stipulated
in the Agreement.

  

	11.5.	 Dispute Resolution. All disputes arising out of or in connection with this Amendment No.1 shall be
finally settled as stipulated in the Agreement. 

  

	11.6.	 Counterparts. This Amendment No.1 may be executed in two (2) or more counterparts, each of which shall
constitute an original for all purposes, including for purposes of any delivery of this Amendment No.1 required by the terms hereof, and all of which together shall constitute one and the same instrument with the same effect as if all parties hereto
had signed the same document. 

  
 31 

 IN WITNESS WHEREOF, the Parties have caused this Amendment No.1 to be executed, under seal, by their respective
duly authorized representatives as of the day and year first above written. 
  

									
	 Marseille
	 		 	Bagsvaerd
			
	 Innate Pharma SA
	 		 	Novo Nordisk A/S
			
	 /s/ Hervé Brailly
	 		 	 /s/ Jesper Brandgaard

					
	 By:
	 	Hervé Brailly	 		 	By:	 	Jesper Brandgaard
	 Title:
	 	Chief Executive Officer	 		 	Title:	 	Executive Vice President and Chief Financial Officer

  
 32 

 Exhibit A 

Schedule 1.1.7A 

Background NN IPR for the development and commercialization of Anti-KIR as a Niche Candidate 

*** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 A-1 

 Exhibit B 

Schedule 1.1.16A 
 Part
A – Anti-KIR Patents 
 *** 

Part B – Shared Anti-KIR Patents 

*** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  

 Exhibit C 

Schedule 1.1.17A 

Anti-KIR Know-How 
 [See
attached] 

  
 C-1 

 Exhibit C 

Schedule 1.1.17A 

Anti-KIR Know-How 
 ***

  
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  

 Exhibit D 

Schedule 5.8.2A 
 *** 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 D-1 

 Exhibit E 

Anti-KIR Supplies 
 ***

  
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 E-1 

 Exhibit F 

Clinical Trial Agreements 

*** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 F-1 

 Exhibit G 

Basic Guidelines for NN’s and IPH’s Collaboration on Transfer of the Anti- 

KIR Project from NN to IPH 

*** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 G-1 

 Exhibit H 

Non-Binding Opinion Procedure 

*** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 H-1 

 Certain information has been excluded from this agreement (indicated by “[***]”) because such
information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 
  

			
	DATED	  	2008
	
	  

NOVO NORDISK A/S 
 and

 INNATE PHARMA SA 
  

 
 AMENDMENT AND SUPPLEMENT NO. 2

 to the 
 JOINT
RESEARCH, DEVELOPMENT, OPTION AND LICENCE AGREEMENT 
  
  

TAYLOR WESSING LLP 
 Carmelite 

50 Victoria Embankment 
 Blackfriars

 London EC4Y 0DX 
 +44 (0)20
7300 7000 
 +44 (0)20 7300 7100 

DX41 London 
 Ref: MRB/TAW 

  

 THIS AMENDMENT AND SUPPLEMENT NO. 2 TO THE JOINT RESEARCH, DEVELOPMENT, OPTION AND LICENCE AGREEMENT (the
“Amendent”) 
 is made on    October
6th,    2008 
 BETWEEN: 

 

	(1)	 NOVO NORDISK A/S (CVR-no. 24 25 67 90), a corporation existing
under the laws of Denmark and having its principal place of business at Novo Allé, 2880 Bagsvaerd, Denmark (“NN”); and 

  

	(2)	 INNATE PHARMA SA a corporation existing under the laws of France and having its principal place of
business at Grand Pré – 119/121, ancien chemin de Cassis, 13009 Marseille, France (“IPH”). 

BACKGROUND 
  

	(A)	 NN is a pharmaceutical company with expertise in the discovery and global development of protein drugs.

  

	(B)	 IPH is a biotech company with expertise in the discovery and development of drugs and other types of therapy
acting at non-conventional lymphocytes such as gamma delta T cells and natural killer (NK) cells. 

  

	(C)	 NN and IPH have previously entered into a collaboration governed by an agreement entitled “Joint Research,
Development, Option and License Agreement” with an effective date of 28 March 2006 (the “Agreement”). 

  

	(D)	 Pursuant to the Agreement, NN and IPH agreed to work, independently, jointly, and/or together with agreed-upon
Third Parties, to (i) discover or identify Drug Candidates, and (ii) optimize Drug Candidates for progression to (a) Licensed Products for further development and commercialization by NN, or (b) Niche Candidates for further
development and commercialization by NN or IPH, for all uses and purposes, including therapeutic, prophylactic and, except as otherwise expressly therein provided, diagnostic uses. 

 

	(E)	 NN and IPH have agreed that (i) the Agreement shall be amended to remove Anti-NKG2D (as defined below)
from the scope of the Agreement, (ii) the Assigned IPR (as defined below) and certain assets and materials relating to Anti-NKG2D shall be assigned to NN, and (iii) IPH shall grant NN royalty-free, worldwide licences under Licensed IPR (as
defined below) and the IPH Anti-NKG2D FoO IPR (as defined below) for the purposes of research, development and commercialisation of Anti-NKG2D Products (as defined below). 

AGREED TERMS 
  

	1.	 DEFINITIONS 

  

	1.1	 In this Amendment (including its recitals and any Schedules), unless otherwise stated, all defined terms shall
have the meaning given to them in the Agreement. 

  

	1.2	 Without prejudice to clause 1.1, the following words and expressions shall have the following meanings,
provided that where a term is defined both in the Agreement and in this Amendment, the meaning given to that term in this Amendment shall prevail: 

  
 1 

 “Amendment No. 1” means the Amendment and Supplement
No. 1 to the Agreement, of the same date as this Amendment; 
 “Anti-NKG2D” fully human or humanized monoclonal
antibodies, antibody fragments, or derivatives of either thereof, which are reactive against wild type, variant or mutant human natural killer cell receptor NKG2D; 

“Anti-NKG2D IPR” means the Intellectual Property Rights Controlled by IPH at the Effective Date that relate exclusively to
Anti-NKG2D; 
 “Anti-NKG2D Product” means any product that contains Anti-NKG2D; 

“Anti-NKG2D Project” means the research and collaboration project relating solely to Anti-NKG2D as carried out under or
pursuant to the Agreement; 
 “Assigned Assets” means those assets listed in Schedule 1; 

“Assigned IPR” means such of the Anti-NKG2D IPR as IPH is able to assign to NN, including without limitation the
Intellectual Property Rights listed in Schedule 2; 
 “Effective Date” means the date of this Amendment; 

“IPH Anti-NKG2D FoO IPR” means: 

(a) such Patents that are either (i) Controlled, through exclusive ownership, by IPH or its Affiliates during the Term and claim the
benefit of a priority date on or before [30 September 2011] or (ii) Controlled, through licence or otherwise but not exclusive ownership, by IPH or its Affiliates at [30 September 2008], 

(b) such Know-How that is either (i) Controlled, through exclusive ownership, by IPH or its
Affiliates during the Term and generated on or before [30 September 2011] or (ii) Controlled, through licence or otherwise but not exclusive ownership, by IPH or its Affiliates at [30 September 2008], and 

(c) such Patents based in part or in whole on Know-How that is (i) Controlled, through exclusive
ownership, by IPH or its Affiliates during the Term and (ii) generated on or before [30 September 2011], 
 in each of (a) and
(c), that are or is: 
 (y) not within the Background IPH IPR or Collaboration IPR; and 

(z) necessary to conduct the research, development and commercialization of Anti-NKG2D Products; 

provided that IPH Anti-NKG2D FoO IPR shall not include any IPR that is generated or acquired by a Third Party prior to it becoming an IPH
Affiliate. 

  
 2 

 “Licensed IPR” means the Anti-NKG2D IPR other than the Assigned IPR. Licensed
IPR comprises the Patents listed in Schedule 3 and such Intellectual Property Rights covered by the licences listed in Schedule 3. 
  

	1.3	 In this Amendment (except where the context otherwise requires): 

 

	 	1.3.1	 any statute or statutory provision includes a reference to that statute or statutory provision as amended,
extended or re-enacted and to any regulation, order, instrument or subordinate legislation under the relevant statute or statutory provision; 

 

	 	1.3.2	 the singular includes a reference to the plural and vice versa; 

 

	 	1.3.3	 any paragraph of the introduction, clause, sub-clause or schedule is to
a paragraph of the introduction, clause, sub-clause or schedule (as the case may be) of or to this agreement; 

  

	 	1.3.4	 the word “include” or “including” is, unless otherwise stated, to be construed without
limitation to the generality of the preceding words; and 

  

	 	1.3.5	 any person includes any reference to a body corporate, unincorporated association or a partnership and any
reference to any party who is an individual is also deemed to include his respective legal personal representative(s). 

  

	2.	 RELATIONSHIP WITH AMENDMENT NO 1 

 

	2.1	 This Amendment shall not be effective until Amendment No. 1 is in effect. 

 

	3.	 AMENDMENT OF THE AGREEMENT WITH RESPECT TO ANTI-NKG2D 

 

	3.1	 NN and IPH agree that, with effect from the Effective Date, the Agreement shall be amended to exclude any
application to Anti-NKG2D and the Anti-NKG2D Project. In particular, and without limitation, all licences granted by one Party to another under the Agreement for the purposes of the research, development and commercialization of Anti-NKG2D shall
cease to have effect on the Effective Date. 

  

	4.	 ASSIGNMENT OF IPR  

 

	4.1	 IPH hereby assigns and transfers absolutely to NN all of its existing rights, title and interest in and to the
Assigned IPR and the Assigned Assets. 

  

	4.2	 IPH shall execute, sign and do all such further documents, acts and things as NN may reasonably require to vest
fully in it all of IPH’s right, title and interest in the Assigned IPR and the Assigned Assets. 

  

	5.	 TRANSFER OF ASSETS AND KNOW-HOW 

 

	5.1	 Within sixty (60) days of the end of the Collaboration Term, IPH shall deliver to NN:

  

	 	5.1.1	 the documents, files, materials and other assets comprised in the Assigned Assets; and 

 

	 	5.1.2	 any further materials that embody the Anti-NKG2D IPR. 

  
 3 

	5.2	 If, on or before [December 30, 2008], NN gives notice to IPH that NN has identified Know-How that is (x) Controlled by IPH at that date, (y) not set forth in Schedule [3] and (z) necessary for the purposes of NN’s research, development or commercialization of Anti-NKG2D
Products, then IPH shall deliver to NN the documents, files and materials containing such Know-How as soon as reasonably practicable. 

 

	6.	 LICENCE 

  

	6.1	 IPH hereby grants to NN an exclusive, worldwide, royalty-free licence under the Licensed IPR to conduct
research, development and commercialisation of Anti-NKG2D Products, save that the licence in respect of the antibody ON72 and US patent application No 10/898,003 is limited solely to such rights as IPH may have in respect of such assets,.

  

	6.2	 IPH hereby grants to NN a worldwide, royalty-free non-exclusive licence
(with the right to Sub-license and Out-license) under any IPH Anti-NKG2D FoO IPR to conduct the research, development and commercialisation of Anti-NKG2D Products.

  

	7.	 NO WARRANTY  

  

	7.1	 The Assigned IPR and the Assigned Assets are assigned and transferred under this Amendment “as is”,
without any representation or warranty by IPH. 

  

	7.2	 The Licensed IPR and the IPH Anti-NKG2D FoO IPR are licensed under this Amendment “as is”, without
any representation or warranty by IPH. 

  

	7.3	 IPH makes no representation or warranty, express or implied (whether by statute, custom, trade practice or
otherwise), regarding any of the Assigned IPR, the Assigned Assets, the Licensed IPR or the IPH Anti-NKG2D FoO IPR , and to the fullest extent permitted by law, IPH expressly disclaims any implied warranties, including without limitation warranties
of merchantability fitness for a particular purpose or non-infringement. 

  

	8.	 LIMITATION OF LIABILITY 

 

	8.1	 Except for injury or loss arising from wilful misconduct, including fraud, of IPH, in no event will IPH be
liable to NN for any injury to or loss of, data, goodwill, or reputation (irrespective of whether any such injury or loss is deemed to constitute general, direct or any other category of damages), or any special, indirect, punitive, exemplary,
enhanced, trebled, incidental or consequential damages whatsoever, arising out of or in connection in any way with this Amendment or any subject matter hereof (including any exercise of any rights or licenses, or performance, or failure to perform,
any obligations or activities hereunder), even if IPH has been advised of the possibility of such losses, damages or liabilities, and whether or not or such losses, damages or liabilities arise in contract, warranty, tort (including negligence),
strict liability, product liability or any other theory of liability. In the event that any foregoing exclusion or limitation of liability is not allowed pursuant to applicable law in a jurisdiction, the liability of IPH in such jurisdiction shall
be limited to the maximum extent permitted by applicable law. 

  

	9.	 GENERAL 

  

	9.1	 Failure by a Party to exercise or enforce any right conferred by this Amendment shall not be deemed to be a
waiver of any such right nor operate so as to bar the exercise or enforcement of such right or of any other right on any other occasion. 

  
 4 

	9.2	 If any part, term or provision of this Amendment not being of a fundamental nature is held illegal or
unenforceable, the validity or enforceability of the remainder of this Amendment shall not be affected. 

  

	9.3	 This Amendment may only be modified if such modification is in writing and signed by a duly authorised
representative of each Party. 

  

	9.4	 A person who is not a party to this Amendment has no rights (and the parties hereby exclude any such rights)
under the Contracts (Rights of Third Parties) Act 1999 to enforce any term of this Amendment but this does not affect any third party right or remedy which exists or is available apart from that Act. 

 

	9.5	 This Amendment may be executed in any number of counterparts, each of which, when executed and delivered, is an
original, but all the counterparts taken together shall constitute one document. This Amendment shall not take effect until it has been executed by all the Parties. 

 

	9.6	 This Amendment shall be governed by and construed in accordance with English law. 

 

	9.7	 Both Parties will use their best efforts to settle all matters in dispute amicably. In the event that a dispute
of any kind related to this Amendment cannot be solved amicably by the Parties, then either Party may submit the dispute for determination by binding arbitration before a panel of three arbitrators (one arbitrator chosen by each of the parties and
the third arbitrator chosen by the first two, unless the parties agree otherwise), the third arbitrator having a minimum of five (5) years of experience in the field of biotechnology or pharmaceuticals and shall be administered under the WIPO
Expedited Arbitration Rules except as to the number of arbitrators which shall be three (3). The venue for the arbitration shall be in London, England, conducted in the English language, and the governing law shall be that of England and Wales
without regard to the conflicts-of-laws provisions of such laws. The arbitrators shall have the authority to grant specific performance and to allocate between the parties the costs of arbitration, including
but not limited to reasonable attorney’s fees, in such equitable manner as they determine. Notwithstanding the foregoing dispute resolution and governing law provisions, each of IPH and NN retains the right to seek judicial injunctive relief.

  

	9.8	 In the case of any conflict between the terms of this Amendment, the Agreement and Amendment No 1, the terms of
this Amendment shall prevail. 

  
 5 

 IN WITNESS WHEREOF, the Parties have caused this Amendment No.1 to be executed, under seal, by their respective
duly authorized representatives as of the day and year first above written. 
  

					
	Marseille	 		 	Bagsvaerd
			
	Innate Pharma SA	 		 	Novo Nordisk A/S
			
	 /s/ Hervé Brailly
	 		 	 /s/ Jesper Brandgaard

			
	By:            Hervé Brailly	 		 	By:            Jesper Brandgaard
	Title:         Chief Executive Officer	 		 	 Title:         Executive Vice President and Chief

Financial Offer

  
 6 

 SCHEDULE 1 

Assigned Assets 
 *** 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 7 

 SCHEDULE 2 

Assigned IPR 

*** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 8 

 SCHEDULE 3 

Licensed IPR 
 *** 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 9 

 Certain information has been excluded from this agreement (indicated by “[***]”) because such
information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 
 AMENDMENT AND SUPPLEMENT NO. 3 

to the 
 JOINT RESEARCH,
DEVELOPMENT, OPTION AND LICENSE AGREEMENT 
 With regard to the Joint Research, Development, Option and License Agreement dated March 28, 2006, as
amended by Amendment and Supplement No. 1, dated October 8, 2008, and Amendment and Supplement No. 2, dated October 8, 2008 (collectively “the Agreement”) between Innate Pharma SA, a corporation existing under the laws
of France (“IPH”), and Novo Nordisk A/S, a corporation existing under the laws of Denmark (“NN”) (NN and IPH may each individually be referred to as a “Party” and collectively as “Parties”); and 

 

	Whereas	 the Parties wish to extend the period in which NN may achieve M0 in respective of the NKp46 and LLT-1 Projects; 

  

	Whereas	 the Parties wish to simplify the management of patent prosecution matters in and arising from the
Collaboration; 

  

	Whereas	 the Parties can amend the Agreement upon written mutual agreement; and 

 

	Whereas	 The Parties have agreed to execute this amendment (the “Amendment”); 

Now, therefore, intending to be legally bound, the Parties agree as follows: 
  

	1.	 The Parties agree that the terms of this Amendment are intended to be supplemental to the terms of the
Agreement. The terms of the Agreement remain in full force and effect and shall apply to the Amendment as well. To the extent the Agreement is explicitly amended by this Amendment, the terms of this Amendment will control. 

 

	2.	 In this Amendment the phrase “Amendment and Supplement No. 3 Effective
Date” means the date of this Amendment and Supplement No. 3. 

  

	3.	 The Agreement is hereby amended as follows (for convenience all modifications are bolded, additions are
underlined, and deletions are identified by strikethroughs). 

  

	4.	 The beginning portion of Section 1.1.63 is amended by substitution with the following amended passage:

  

	 	1.1.63	 	“Residual Product” shall mean a Drug Candidate to which: 

  

	 	(a)	 	NN is granted the exclusive rights to develop and commercialize under this Agreement by virtue of such Drug Candidate having achieved at least M0 status but less than M1 status as of either

  

	 	(x)	 the expiration of the *** period following immediately after: 

 

	 	(i)	 the expiration of the Collaboration Term pursuant to Subsection 13.3.3, 

 

	 	(ii)	 NN’s termination of the Agreement prior to the expiration of the Collaboration Term for an IPH Change of
Control or other IPH Transfer, pursuant to Section 13.5, or 

  

	 	(iii)	 NN’s termination of the Agreement prior to the expiration of the Collaboration Term for IPH’s
material breach pursuant to Section 13.7; or 

  
 Certain
information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  

	 	(y)	 December 31, 2009 in the case of Drug Candidates that modulate action of NKp46 and/or LLT-1; or 

  

	5.	 Section [4.3(h)] is substituted with the following amended Section 4.3(h): 

 

	 	(h)	 	considering and, if necessary updating, Schedule 1.1.22 (Collaboration Targets) (i) no less frequently than once during each six-
(6-) month period in the Collaboration Term, (b) within fifteen (15) days after receipt of the written request of either Party during the Collaboration Term, and (c) in a final version of such
Schedule to be fixed and final as of September 28, 2009 the date of the expiration or earlier termination of the Collaboration Term, which final version shall include the
designation of CD147, NKp46 and LLT-1 as Collaboration Targets; 

  

	6.	 The beginning portion of Section 7.3 is substituted with the following amended portion:

  

	 	7.3	 	Discovery Milestones. NN shall pay to IPH the following milestone payments for the Collaboration achievements in research set out below (“Discovery Milestones”) within *** of the achievement of
each such Discovery Milestone: 

 Approval by NN of M0 status as defined in Schedule 1.1.51 after the date of this
Agreement (a) during the Collaboration Term, (b) or within the *** period following immediately after the Collaboration Term, or
(c) by December 31, 2009 in the case of achievement of M0 status for a Drug Candidate that modulates action of NKp46 and/or LLT-1: 

Each of the first three Pre-projects passing M0:
          *** 
 Each of the subsequent
Pre-projects passing M0:         *** 
  

	7.	 Section 13.3.3 is substituted with the following amended Section 13.3.3: 

 

	 	13.3.3	 	NN Residual Rights in the Field Upon Expiration of Collaboration Term. Without limitation of NN’s rights under Subsection 13.3.2 and in addition thereto, NN shall have the exclusive right and license
throughout the Territory during the Term, pursuant to the terms and conditions of the rights and licenses granted to it under Sections 5.1 and 5.8, to develop and commercialize Residual Products from Drug Candidates that have attained
at least M0 status but not M1 status during (a) the Collaboration Term, (b) or prior to the expiration of the *** period following immediately after the effective date of
the expiration of the Collaboration Term, or (c) by December 31, 2009 in the case of Drug Candidates that modulate action of NKp46 and/or
LLT-1. The royalties payable to IPH on Net Sales of such Residual Products shall be governed by the terms and conditions of Article 7 save that royalties payable to IPH on Net Sales of
such Residual Products that would, upon achievement of M1, be classified as Class C Licensed Products and for which M0 status has been achieved less than *** prior to the expiry of the Collaboration Term shall be reduced by *** from the
applicable royalties set forth in Article 7. 

  

	8.	 Section 13.3.5 is substituted with the following amended Section 13.3.5: 

 

	 	13.3.5	 	IPH Residual Rights in the Field Upon Expiration of Collaboration Term. 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  

 
Without limitation of IPH’s rights under Subsection 13.3.4 and in addition thereto, IPH shall have, throughout the Territory during the Term, under all Background NN Research
Technology IPR and Collaboration IPR Controlled by NN, the exclusive right and license, with the rights to Sub-license and Out-license, to develop and commercialize
Residual Products from Drug Candidates that have not attained at least M0 status, either (a) as of the effective date of the expiration or earlier termination of the Collaboration Term,
(b) or prior to the expiration of the *** period following immediately thereafter, or (c) by December 31, 2009 in
the case of Drug Candidates that modulate action of NKp46 and/or LLT-1, and shall retain, throughout the Territory during the Term, the right, pursuant to the terms and conditions of
Section 5.8, to NN’s reasonable cooperation and assistance in granting or procuring the grant to IPH of the rights and licenses required for IPH’s freedom of operation to exercise the aforementioned exclusive right and license,
provided that 
  

	9.	 Sections 9.1A.2, 9.1A.3, 9.1A.4, and 9.1A5 are deleted. 

 

	10.	 Section 9.6 is amended by the addition of a new Section 9.6.0: 

 

	 	9.6.0	 	Group I Patents 

 “Group I Patents” means all Patents in Schedule
1.1.5, item 1 (NKG2A Autoimmune/INNA-041228), Schedule 1.1.5 item 7 (Anti-KIR/ADCC/INNA-030724), and Schedule 1.1.16, item 2.5 (LDGL CIP/INNA-051014), and any continuations or divisionals thereof or patents
issuing from any such patent applications and all patent applications claiming priority to ***, any patent application directed to an invention made before December 31, 2009 relating to agents that modulate NKp46
and/or LLT-1 and that is based on a new original application not listed in the update to the Schedules of May 22, 2008, and any continuations or divisionals thereof or patents
issuing from any such patent applications). 
  

	11.	 Section 9.6.1 is amended by substitution with the following amended Section: 

 

	 	9.6.1	 	Correspondence Regarding Proposed Patent Submissions. Subject to the terms and conditions of Section 21.2 (and the Common Interest Agreement annexed as Schedule 21.2 hereto), the Party
responsible for prosecuting any Group I Patent under this Article 9 shall promptly, and in *** prior to any final deadline for submission of such documents or required filing date, deliver or
have delivered to the other Party copies of: 

  

	 	(a)	 all proposed amendments, 

 

	 	(b)	 all proposed Patents (including drafts of new original applications, proposed continuations, proposed
divisional applications, proposed reissue applications, and proposed continuations-in-part) or, in instances where several proposed Patents are substantially similar, a
representative Patent for such proposed Patents (such as in the case of national phase filing of an International (PCT) patent application), 

  

	 	(c)	 all substantive documents proposed to be filed in patent authority appeal proceedings, 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  

	 	(d)	 all substantive documents proposed to be filed in inter partes disputes (including opposition, reexamination,
or interference proceedings) before patent authorities or before any judicial body on appeal of such proceedings, and 

  

	 	(e)	 any other substantive proposed patent authority submissions reasonably and specifically requested by the other
Party, 

 in respect of such Group I Patents (except for Patents in the Independent IPR of either
Party), so as to provide the other Party with a sufficient opportunity to review and comment on such proposed submissions. However, except as otherwise provided for in this Section 9.6, the prosecuting Party shall have no
obligation to act in accordance with any such comments. 
  

	12.	 Section 9.6.8 is amended by substitution with the following amended section: 

 

	 	9.6.8	 	Notice and Effects of Either Party’s Decision to Abandon; Disclaim; or Discontinue Prosecution, Maintenance, or Defense of Patents. In the event that either Party decides in respect of any Patent for which
it is responsible for prosecution hereunder (except for Patents within the Independent IPR of that Party): 

  

	 	(a)	 to discontinue the prosecution or maintenance of any Patent, 

 

	 	(b)	 to discontinue the defense of any Patent (such as by discontinuing efforts to defend a Patent that is the
subject of an opposition, reexamination, nullity, or interference proceeding), 

  

	 	(c)	 to not file a priority patent application with respect to (i) an invention disclosure in the Collaboration
IPR or (ii) any Patent to which it is the prosecuting Party (including by decision (A) not to enter the national or regional phase in any country or region that is a designated state of a PCT application filed by such Party or (B) not
to pursue an application in a country wherein an application claiming priority to another application filed by such Party may be filed), or 

  

	 	(d)	 to abandon or disclaim (in whole or in part, other than by terminal disclaimer), without possibility of
restoration, any Patent, 

 it shall employ its best efforts to provide written notice to the other
Party at least *** in advance of such abandonment or deadline for such filing – except in the case of national phase filing, in which case the notifying Party shall employ its best efforts to provide such notice at least
*** in advance of the date of the first applicable deadline for national phase entry – so as to allow the other Party the opportunity to file, defend, maintain (including by payment of annuities, issue fees, maintenance fees, or the like), or
continue prosecution of such Patent, at its own expense. In such an event, the notifying Party shall provide any assistance reasonably requested of it by the other Party (including providing the other Party with power of attorney to perform such
tasks) and, to the extent authorized by contract and permitted by applicable Law, assign its rights to such Patent to the other Party. Automatically upon any such assignment, the notified Party hereby automatically grants
The notified Party shall thereafter grant to the notifying Party a worldwide, non-exclusive license, including the right to sublicense through multiple tiers, with respect
to such Patent for no additional 
  
 Certain information has been excluded from this
agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  

 
consideration. The Parties acknowledge that any abandoned Patents listed as Background IPR as of the date of this Agreement in the applicable Schedules hereto represent Know-How of the Party associated with such IPR and that such Party shall, during the Term, be entitled to file, prosecute, and maintain Patents in respect of such subject matter and any Patents arising therefrom
shall be deemed Background IPR of such Party. 
  

	13.	 With effect from the Amendment No. 3 Effective Date, Schedule 21.2 of the Agreement will be deleted and
replaced with the following Common Interest Agreement: 

 Schedule 21.2 

COMMON INTEREST AGREEMENT 

NN and IPH hereby set forth their agreement regarding the Parties’ common legal interests. 

Prosecution and maintenance of Patents under the Agreement has required, and prosecution, maintenance, enforcement, and exploitation of
Patents may in the future require, the disclosure by one Party to the other Party of privileged information including, for example, information relevant to a Party’s strategy for prosecuting, maintaining, or exploiting the Patents and/or
information regarding a Party’s proprietary business strategy, technology, products, or methods. The Parties have believed, and on the basis of currently available information continue to believe, that they share common and substantially
identical legal interests relating to the Patents and Agreement (“Joint Interest Matters”). 
 Any such exchange or disclosure of
materials among the Parties and their counsel has been done and will be done solely to further the Parties’ separate but common interests, and will be treated as confidential and protected from disclosure to any third parties by the
attorney-client privilege. It is the Parties’ mutual understanding that such exchanges or disclosures are not intended to diminish in any way the confidentiality of privileged materials. It is their additional understanding that any exchange of
privileged materials does not constitute a waiver of any otherwise available privileges and immunities. 
 The Parties agree that any
privileged materials they exchange pursuant to this Agreement will be used solely in connection with the Joint Interest Matters. 
 The
Parties also agree that nothing in this Common Interest Agreement requires any Party to make available any specific documents, materials, information, or communications, unless otherwise agreed. 

The Parties further agree to take all actions necessary to maintain the privilege of such materials unless otherwise agreed by the Parties.

 The Parties additionally agree that any Party may withdraw from this Common Interest Agreement upon written notice to the other Party at
their regular place of business and, upon such notice, this Common Interest Agreement will be terminated as to that Party; provided, however, that no such termination will affect or impair the obligations of the confidentiality or the privilege or
immunities with respect to privileged materials previously furnished pursuant to this Agreement. 
 Except as provided in this Agreement,
each Party is responsible for its own legal expenses. 
 If any person or entity requests or demands, by subpoena or otherwise, any
privileged materials from any Party, such Party will promptly notify the other Party to this Agreement of the request or demand and provide such Party with a copy of said request or demand prior to making the disclosure. The Party in receipt of the
request or demand will assert all applicable rights, privileges and objections with respect to such request or demand, and cooperate fully with the other Party, with the other Party paying the Party’s reasonable expenses, in making every
reasonable effort to prevent the disclosure of the privileged materials. 
 Nothing in this Agreement shall be construed to affect the
separate and independent representation of each Party by its respective counsel according to what its counsel believes to be in its Party’s best interest. 

This Common Interest Agreement by and between the Parties memorializes the understandings between the Parties as to the sharing of information
relating to the Joint Interest Matters. 
 Each Party understands that this Common Interest Agreement does not, and will not, create an
attorney-client relationship with the other Party’s counsel. 

	14.	 By signing below, each person signing this Amendment acknowledges his/her acceptance of the above-described
changes that are to be effective as of the day of the last to sign and that such changes will become an integral part of the Agreement. Further, each person who executes this Amendment represents and warrants that he/she has the authority to cause
the Party he or she is associated with to enter into this Amendment and be obligated to perform the obligations set forth herein. 

Signed by: 
  

			
	 Date: 2009-06-26

 
 On behalf of Novo Nordisk A/S

 
 /s/ Terje Kalland

Name: Terje Kalland
 Title: Senior Vice President,

          Biopharmaceutical Research Unit
	  	 Date: 2009-06-26

 
 On behalf of the Innate Pharma SA

 
 /s/ Hervé Brailly

Name: Hervé Brailly
 Title: Chief Executive Officer

 

 AMENDMENT NO. 4 

This Amendment No. 4 is made and entered into as of December 13th 2010 (“Effective Date of this
Amendment”) between Innate Pharma SA, a corporation existing under the laws of France (“IPH”) and Novo Nordisk A/S, a corporation existing under the laws of Denmark (“NN”) with regards to the Joint Research, Development,
Option and License Agreement dated March 28, 2006, as amended by Amendment and Supplement No. 1, dated October 8, 2008, and Amendment and Supplement No. 2, dated October 8, 2008, and Amendment and Supplement No. 3, dated June 26, 2009 (collectively
the “Agreement”). NN and IPH may each individually be referred to as “Party” and collectively as “Parties”. 
  

			
	 Whereas
	  	under the Agreement, the Parties have agreed to collaborate and conduct research on the targets LLT-1 (Lectin-like Transcript-1, also known as CLEC2D) and NKp46 (Natural Cytotoxicity triggering receptor-1, also known as NCR1).
Originally these targets were designated as Exploratory Targets according to Schedule 1.1.33 of the Agreement. However, in Amendment and Supplement No. 3 as mentioned above, the Parties agreed to designate these targets as Collaboration Targets in
Schedule 1.1.22 of the Agreement. In addition to these targets the Parties have separately agreed to collaborate and conduct research on MICA/B (MHC class I polypeptide-related sequence A and -B). LLT-1, NKp46 and MICA/B are in this Amendment No. 4
jointly referred to as the Targets.
		
	 Whereas
	  	the Parties now wish to discontinue the collaboration regarding the Targets, including discontinuing designating the Targets as Collaboration Targets and/or Exploratory Targets. Each Party will as of the Effective Date of this
Amendment have the right to freely conduct research with regards to the Targets.
		
	 Whereas
	  	NN shall have the right to use IPH’s Know-How (as defined in the Agreement) developed under the Agreement and existing as of the Effective Date of this Amendment, if any, in any future research, use or exploitation relating
to the LLT-1.
		
	 Whereas
	  	IPH shall have the right to use NN’s Know-How (as defined in the Agreement) developed under the Agreement and existing as of the Effective Date of this Amendment, if any, in any future research, use or exploitation relating
to the NKp46 and MICA/B .
		
	Whereas	  	the Parties can amend the Agreement upon written mutual agreement and have agreed to do so in this Amendment No. 4.

 Now, therefore, the Parties, intending to be legally bound agree as follows: 

 

	1.	 The terms defined in the Agreement shall have the meaning herein as therein, unless otherwise defined herein or
unless the context otherwise requires. To the 

  
 1 

	 	
extent that the Agreement is explicitly amended by this Amendment, the terms of the Amendment will control where the terms of the Agreement are contrary to or conflict with the following
provisions. Where the Agreement is not explicitly amended by this Amendment, the terms of the Agreement will remain in force.

  

	2.	 The Parties agree that the Targets, as defined above, will as of the Effective Date of this Amendment,
discontinue being part of the Parties’ collaborative research activities, including discontinuing being in the definition of Collaborative Target or Exploratory Target. As of the Effective Date of this Amendment any rights or obligations of the
Parties pertaining to (i) the Targets and (ii) the Parties collaboration under the Agreement are exclusively stipulated in this Amendment No. 4. Hence, as of the Effective Date of this Amendment, the Parties will have no rights or obligations
(including any payment obligations) under the Agreement in relation to the Targets except for what is specifically stated in this Amendment No. 4. For the sake of clarity, NN will have no obligations to make any payments to IPH relating to the
Targets (including Discovery Milestones as set out in 7.3 of Amendment No. 3). 

  

	3.	 IPH hereby grants to NN a world-wide, non-exclusive, perpetual license, with the right to sublicense, to
IPH’s Know-How relating to LLT-1 developed under the Agreement and existing as of the Effective Date of this Amendment, if any, to research, develop, make, have made, use, import, export, distribute, sell, offer for sale, and otherwise transfer
LLT-1 products. The consideration for the license granted herein is the mutual granting of the license and no payments will be made by either Party to the other Party under this Amendment or at any time for this license. For the sake of clarity,
this license does not include any rights to Know-How developed by IPH (i) outside the Agreement, or (ii) after the Effective Date of this Amendment No. 4. 

  

	4.	 NN hereby grants to IPH a world-wide, non-exclusive, perpetual license, with the right to sublicense, to
NN’s Know-How relating to NKp46 and MICA/B developed under the Agreement and existing as of the Effective Date of this Amendment, if any, to research, develop, make, have made, use, import, export, distribute, sell, offer for sale, and
otherwise transfer NKp46 and MICA/B products. The consideration for the license granted herein is the mutual granting of the license and no payments will be made by either Party to the other Party under this Amendment or at any time for this
license. For the sake of clarity, this license does not include any rights to Know-How developed by NN (i) outside the Agreement, or (ii) after the Effective Date of this Amendment No. 4. 

 

	5.	 Without limiting the aforementioned, as of the Effective Date of this Amendment, each Party, by itself or in
collaboration with any third party, has the right to (i) freely conduct any research relating to the Targets; (ii) file any patent application without providing notification to the other Party relating to the Targets. 

 

	6.	 This Amendment does not cause any of the Parties to transfer any documents, materials or other Know-How to the
other Party. 

  

	7.	 This Amendment shall be deemed an integral part of the Agreement. Except as expressly set forth herein, all
provisions of the Agreement shall remain unchanged and in full force and effect. The Parties expressly affirm their mutual intention that this Amendment to the Agreement shall constitute a legally binding Amendment to the Agreement.

  
 2 

	8.	 This Amendment shall be construed and interpreted pursuant to the laws stipulated in the Agreement. All
disputes arising out of or in connection with the present Amendment shall be finally settled by arbitration as stipulated in the Agreement. 

IN WITNESS HEREOF the Parties have executed and delivered this Amendment. 
  

			
	On behalf of Novo Nordisk A/S	  	On behalf of Innate Pharma SA
		
	 /s/ Esper Boel
	  	 /s/ Hervé Brailly

	 Name: Esper Boel
 Title: Corp. Vice
President
 Date: Jan. 5/2011
	  	 Name: Hervé Brailly
 Title: C.E.O.

Date: 16 December 2010

  
 3 

 Certain information has been excluded from this agreement (indicated by “[***]”) because such
information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 
 AMENDMENT NO. 5 

This Amendment No. 5 is made and entered into as of 13 December 2010 (“Effective Date of this Amendment”) between Innate Pharma SA, a
corporation existing under the laws of France (“IPH”) and Novo Nordisk A/S, a corporation existing under the laws of Denmark (“NN”) with regards to the Joint Research, Development, Option and License Agreement dated
March 28, 2006, as amended by Amendment and Supplement No. 1, dated October 8, 2008, and Amendment and Supplement No. 2, dated October 8, 2008, Amendment and Supplement No. 3, dated June 26, 2009, Amendment
No. 4, dated [                    ] (collectively the “Agreement”). NN and IPH may each individually be referred to as
“Party” and collectively as “Parties”. 
  

			
	 Whereas
	  	under the Amendment and Supplement No. 1, dated October 8, 2008, the Parties have agreed to classify Anti-KIR as a Niche Candidate for IPH’s sole independent further
development and commercialisation, and the Parties have inserted Exhibit B of the Amendment and Supplement No. 1, dated October 8, 2008 as Schedule 1.1.16A to the Agreement, listing the Anti-KIR
patents licensed by NN to IPH.
		
	 Whereas
	  	NN has now been assigned rights in patents filed by the Trustees of Indiana University, the patents arising out of a material transfer agreement between NN and Trustees of Indiana University dated February 27,
2007.
		
	 Whereas
	  	the Parties now wish to update Parts A and B of Schedule 1.1.16A to the Agreement to include the patents filed by the Trustees of Indiana and assigned to Novo Nordisk.
		
	 Whereas
	  	the Parties can amend the Agreement upon written mutual agreement and have agreed to do so in this Amendment No. 5.

 Now, therefore, the Parties, intending to be legally bound agree as follows: 

 

	1.	 The terms defined in the Agreement shall have the meaning herein as therein, unless otherwise defined herein or
unless the context otherwise requires. To the extent that the Agreement is explicitly amended by this Amendment, the terms of the Amendment will control where the terms of the Agreement are contrary to or conflict with the following provisions.
Where the Agreement is not explicitly amended by this Amendment, the terms of the Agreement will remain in force. 

  

	2.	 NN and IPH hereby agree that as from the Effective Date of this the following Patents shall be deemed
incorporated into Part A and Part B of Schedule 1.1.16A. 

  

							
	 Country
	  	Application No.
Filing date	 	 Title
	  	 Status

	 US
	  	***	 	Combination therapy to enhance NK cell mediated cytotoxicity	  	Abandoned
				
	 PCT
	  	***	 	Combination therapy to enhance NK cell mediated cytotoxicity	  	Pending

  

	3.	 This Amendment shall be deemed an integral part of the Agreement. Except as expressly set forth herein, all
provisions of the Agreement shall remain unchanged and in full force and effect. The Parties expressly affirm their mutual intention that this Amendment to the Agreement shall constitute a legally binding Amendment to the Agreement.

  
 Certain information has been excluded from this agreement
(indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  

	4.	 This Amendment shall be construed and interpreted pursuant to the laws stipulated in the Agreement. All
disputes arising out of or in connection with the present Amendment shall be finally settled by arbitration as stipulated in the Agreement. 

IN WITNESS HEREOF the Parties have executed and delivered this Amendment. 
  

			
	On behalf of Novo Nordisk A/S	  	On behalf of Innate Pharma SA
		
	 /s/ Esper Boel
	  	 /s/ Hervé Brailly

	 Name: Esper Boel
 Title: Corp. Vice
President
 Date: Jan. 5/2011
	  	 Name: Hervé Brailly
 Title: CEO

Date: December 16th, 2010

  
 2 

 Certain information has been excluded from this agreement (indicated by “[***]”) because such
information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 
 AMENDMENT NO. 6 

This Amendment No. 6 (the “Amendment”) is made and entered into as of 1 July, 2011 (“Amendment No. 6 Effective Date”) between Innate
Pharma SA, a corporation existing under the laws of France (“IPH”) and Novo Nordisk A/S, a corporation existing under the laws of Denmark (“NN”) with regards to the Joint Research, Development, Option and License Agreement dated
March 28, 2006, as amended by Amendment and Supplement No.1, dated October 8, 2008, Amendment and Supplement No. 2, dated October 8, 2008, Amendment and Supplement No. 3, dated June 26, 2009, Amendment No. 4, dated December 13, 2010, and Amendment
No. 5, dated December 13, 2010 (collectively, the “Agreement”). NN and IPH may each individually be referred to as “Party” and collectively as “Parties”. 

 

			
	Whereas	  	pursuant to the Agreement, NN and IPH agreed to work, independently, jointly and/or together with agreed-upon Third Parties, to (a) discover or identify Drug Candidates, and (b) optimize Drug Candidates for progression to (i)
Licensed Products for further development and commercialization by NN or (ii) Niche Candidates for further development and commercialization by IPH (either alone or together with NN), in each case for all uses and purposes, including therapeutic,
prophylactic and, except as otherwise expressly therein provided, diagnostic uses;
		
	Whereas	  	pursuant to Amendment No.1 and with effect from the Amendment No.1 Effective Date, NN classified Anti-KIR as a Niche Candidate for independent further development and commercialization by IPH for any human therapeutic, prophylactic
or diagnostic indication or application;
		
	Whereas	  	as a condition precedent to its entry into a license agreement with IPH pursuant to which Bristol-Myers Squibb Company (“BMS”) will become an Out-licensee under the Agreement (the “Outlicense”), BMS has requested
that NN and IPH further amend the Agreement to clarify certain matters with respect to the rights and obligations of the Parties and of BMS thereunder with respect to Anti-KIR; and
		
	Whereas	  	the Parties can amend the Agreement upon written mutual agreement and have agreed to do so in this Amendment No. 6.

 Now, therefore, the Parties, intending to be legally bound, agree as follows: 

 

	1.	 The terms defined in the Agreement shall have the meaning herein as therein, unless otherwise defined herein or
unless the context otherwise requires. To the extent that the Agreement is explicitly amended by this Amendment, the terms of the Amendment will control where the terms of the Agreement are contrary to or 

 

  

	 	
conflict with the following provisions. Where the Agreement is not explicitly amended by this Amendment, the terms of the Agreement will remain in force. 

 

	2.	 The Collaboration Term expired as of March 28, 2009. 

 

	3.	 With effect from the Amendment No. 1 Effective Date, Section 1.1.4 is hereby amended as follows:

 “1.1.4    “Anti-KIR” or “Anti-KIR Antibody” shall mean ***.

  

	4.	 With effect from the Amendment No. 1 Effective Date, the definition of “Anti-KIR Product” is hereby
amended as follows: 

 ““Anti-KIR Product” shall mean any pharmaceutical product containing an
Anti-KIR Antibody (alone or with any other pharmaceutically active ingredient), in all forms, presentations, formulations and dosage forms.” 
  

	5.	 Notwithstanding anything in Section 5.5 of the Agreement to the contrary but subject to amendments made
applicable to Section 5.5 in Sections 3.1.1 and 3.1.2 of Amendment No. 1, IPH obtained a grant (or grant back, as the case may be) from NN of an exclusive right and license, including the right to Sub-license and Out-license, throughout the
Territory during the Term, under (a) all Intellectual Property Rights licensed exclusively to NN pursuant to Section 5.1, and (b) all Background NN IPR and Collaboration IPR Controlled by NN, to the extent that such rights and licenses are necessary
or useful to conduct research with and of, discover, develop, use, manufacture, have manufactured, register, package, sample, distribute, promote, market, offer for sale, import, export, sell and have sold Anti-KIR Antibodies and/or Anti-KIR
Products for all uses and purposes. 

  

	6.	 BMS’s status under the Agreement as a result of the rights granted to it by IPH under the Outlicense is as
an Out-licensee and not as a Sub-licensee or Third Party Collaborator, and those provisions of the Agreement that apply to Sub-licensees or Third Party Collaborators, but not to Out-licensees, including Sections 3.3, 3.4, 3.5 and 5.6, shall not
apply to BMS. 

  

	7.	 The Anti-KIR Antibodies and Anti-KIR Products that are subject of the rights and licenses set forth in
Paragraph 5 above shall not be considered Licensed Products or Residual Products under the Agreement. 

  

	8.	 NN has provided to IPH copies of all research results developed by the NN Employee referenced in Section 10.1
of Amendment No.1 to the Agreement, and any and all Intellectual Property Rights generated by such Employee relating to Anti-KIR Antibodies are included in the scope of the grant set forth in Paragraph 5 above. 

 
  
 Certain
information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 - 2 - 

	9.	 With effect from the Amendment No. 6 Effective Date, Section 12.7A (as amended in 3.15 of the Amendment No. 1)
is hereby deleted in its entirety and replaced by the following: 

  

	 	“12.7A	 Development and Commercialization Diligence Requirements for Anti-KIR Niche
Candidate.

  

	 	(a)	 Diligent Efforts.

(i) Development. Notwithstanding Section 12.7 hereof, with respect to the Development of Anti-KIR as a Niche Candidate, IPH, by
itself or through its Affiliates, Sub-licensees or Out-licensees, shall use Diligent Efforts to Develop an Anti-KIR Antibody or Anti-KIR Product for the treatment, prevention or control of any human disease, disorder or condition for the purpose of
obtaining a Regulatory Approval in each Major Market. For clarity, it is understood and acknowledged that Diligent Efforts in the Development of Anti-KIR Antibodies and Anti-KIR Products may include sequential implementation of clinical trials or
intervals between clinical trials for data interpretation and clinical program planning and approval. IPH, by itself or through its Affiliates, Sub-licensees or Out-licensees, shall initiate at least two Phase 1 Clinical Trials with respect to
an Anti-KIR Antibody or Anti-KIR Product within twelve (12) months following the completion of IPH’s ongoing Phase 1 Clinical Trial [2102-101], provided that such twelve (12) month period shall be extended to the extent of any delay that is
attributable to any of the following factors: (I) any safety reason arising from such Phase 1 Clinical Trial [2102-101], (II) insufficient quantities of the applicable Anti-KIR Product are available to initiate and complete such two Phase 1 Clinical
Trials, (III) approval of regulatory authorities for IPH, its Affiliates, Sub-licensees or Out-licensees to conduct such Phase 1 Clinical Trials, if required by applicable law, is not received or (IV) any required consent of a Third Party
collaborator of IPH, its Affiliates, Sub-licensees or Out-licensees for the use of a compound other than an Anti-KIR Antibody or Anti-KIR Product in such Phase 1 Clinical Trial is not received. For purposes of the preceding sentence, (A) the
initiation of a Clinical Trial shall mean the first administration of the Anti-KIR Product to the first patient and (B) the completion of IPH’s Phase 1 Clinical Trial [2102-101] shall mean the availability of the full data set of such Clinical
Trial. 

  
 - 3 - 

 (ii) Commercialization. Notwithstanding Section 12.7 hereof, with respect to the
Commercialization of an Anti-KIR Product, IPH, by itself or through its Affiliates or Out-licensees, shall use Diligent Efforts to Commercialize an Anti-KIR Product in each Major Market for which IPH, its applicable Affiliate, Sub-licensee or
Out-licensee receives Approval for such Anti-KIR Product. 
  

	 	(b)	 Termination for Failure to Employ Diligent Efforts. Notwithstanding Section 12.8 hereof, and
subject to Sections 12.7A(b)(i) and 12.7A(b)(ii), NN shall have the right to terminate this Agreement with respect to Anti-KIR on a Major Market-by-Major Market basis with respect to all Anti-KIR Antibodies and Anti-KIR Products if IPH is in
material breach of its obligation to use Diligent Efforts, alone or through its Affiliates, Sub-licensees or Out-licensees, as set forth in Section 12.7A(a) with respect to such Major Market; provided however, such license shall not so terminate
unless (A) IPH is given *** prior written notice by NN of NN’s intent to terminate, stating the reasons and justification for such termination and recommending steps which NN believes IPH, alone or through its Affiliates, Sub-licensees or
Out-licensees, should take to cure such alleged breach, and (B) IPH, or its Affiliates, Out-licensees or Sub-licensees, has not (1) during the *** period following such notice, provided NN with a plan for the diligent Development or
Commercialization of Anti-KIR Products in such Major Market as set forth in Section 12.7A(a) and (2) during the *** period following such notice carried out such plan and cured such alleged breach by diligently pursuing the Development or
Commercialization of Anti-KIR Products in such Major Market as set forth in Section 12.7A(a). 

 (i) If IPH disputes in
good faith the existence or materiality of an alleged breach specified in a notice provided by NN pursuant to this Section 12.7A(b), and if IPH provides notice to NN of such dispute within the *** following such notice provided by NN, NN shall not
have the right to terminate this Agreement with respect to Anti-KIR unless and until the existence of such material breach or failure by IPH has been determined in accordance with Section 21.14 and IPH, alone or through its Affiliates, Sub-licensees
or Out-licensees, fails to cure such breach within *** following such determination. It is understood and acknowledged that during the pendency of such a dispute, all of the terms and conditions of this Agreement shall remain in effect and the
Parties shall continue to perform all of their respective obligations hereunder. 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 - 4 - 

 (ii) Notwithstanding anything herein to the contrary, in the event that: (A) NN terminates, or
has the right to terminate, this Agreement pursuant to this Section 12.7A(b) with respect to an Anti-KIR Product in the U.S., the EU, and Japan, then NN shall have the right to terminate this Agreement with respect to such Anti-KIR Product in the
entire Territory, and (B) NN has the right to terminate this Agreement pursuant to this Section 12.7A(b) with respect to an Anti-KIR Product in one or two Major European Countries, then NN may not terminate this Agreement with respect to such Major
European Country(ies); provided, that if IPH has such right to terminate this Agreement with respect to such Anti-KIR Product with respect to any three Major European Countries, then NN shall have the right to terminate this Agreement with respect
to such Anti-KIR Product in all of the EU. 
 Definitions. The following terms, as used in this Section 12.7A or in Sections
12.8A and 12.8B, shall have the following meanings: 
 “Approval” shall mean, with respect to an Anti-KIR Product in any
regulatory jurisdiction, Regulatory Approval and, where applicable, receipt of pricing and reimbursement approvals. 

“Commercialize” or “Commercialization” shall mean the marketing, promotion, sale (and offer for sale or
contract to sell), distribution, importation or other commercial exploitation (including pricing and reimbursement activities) for an Anti-KIR Product. Commercialization shall include commercial activities conducted in preparation for Anti-KIR
Product launch. 
 “Develop” or “Development” shall mean all activities that relate to (a) obtaining,
maintaining or expanding Regulatory Approval of an Anti-KIR Product and to support appropriate usage for such Anti-KIR Product, for one or more indications. This includes: (i) preclinical/nonclinical research and testing, toxicology, and
clinical trials; (ii) preparation, submission, review, and development of data or information and regulatory materials for the purpose of submission to a governmental authority to obtain, maintain or expand Regulatory Approval of an Anti-KIR Product
(including contacts with regulatory authorities), and outside counsel regulatory legal services related thereto; provided, however, that Development shall exclude Commercialization and manufacturing activities (including manufacturing activities
related to Development). 
 “Diligent Efforts” shall mean the carrying out by IPH, BMS, or their Affiliates, Sub-licensees
or Out-licensees of such obligations or 

  
 - 5 - 

 
tasks with a ***. Such efforts may take into account, without limitation, issues of safety and efficacy, regulatory authority-approved labeling, product profile, the competitiveness of
alternative products in the marketplace, pricing/reimbursement for the product in a country relative to other markets, the likely timing of the product’s entry into the market, the patent and other proprietary position, the likelihood of
regulatory approval and other relevant scientific, technical and commercial factors. 
 “Major European Countries” shall
mean ***. 
 “Major Market” shall mean each of the ***. 

“Regulatory Approval” shall mean, with respect to a country, extra-national territory, province, state, or other regulatory
jurisdiction, any and all approvals, licenses, registrations or authorizations of any regulatory authority necessary in order to commercially distribute, sell, manufacture, import, export or market a product in such country, state, province, or some
or all of such extra-national territory or regulatory jurisdiction, but which shall exclude any pricing and reimbursement approvals.”
  

	10.	 With effect from the Amendment No. 6 Effective Date, the following passage of Section 12.8A (as amended in
3.16 of Amendment No. 1): 

 12.8A Notwithstanding Section 12.8 hereof, in the event of the abandonment by IPH of its
development of Anti-KIR as a Niche Candidate (by express notice to NN or by operation of this Article 12), the following provisions shall apply and supersede Section 12.8 with respect to such abandonment: 

is hereby deleted and replaced by the below first paragraph: 

“12.8A Effects of Termination of Agreement for Failure to Employ Diligent Efforts in Development. With effect from the
Amendment No. 1 Effective Date, upon any termination pursuant to Section 12.7A(b) due to IPH’s failure, by itself or through its Affiliates, Sub-licensees or Out-licensees, to use Diligent Efforts to Develop an Anti-KIR Antibody or Anti-KIR
Product as set forth in Section 12.7A(a)(i), the following shall apply and supersede Section 12.8 with respect to the terminated Anti-KIR Antibody(ies)/Product(s) and terminated country(ies):” 

and the remainder of Section 12.8A shall remain unchanged. 
  

	11.	 With effect from the Amendment No. 6 Effective Date, the following passage of Section 12.8B (as amended in 3.17
of Amendment No. 1): 

 12.8B Notwithstanding Section 12.8 hereof, in the event of the abandonment by IPH of its
marketing or sale of any Anti-KIR Product, the following provisions shall apply and supersede Section 12.8 with respect to such abandonment: 

is hereby deleted and replaced by the below first paragraph: 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 - 6 - 

 “12.8B Effects of Termination of Agreement for Failure to Employ Diligent Efforts in
Commercialization. With effect from the Amendment No. 1 Effective Date, upon any termination pursuant to Section 12.7A(b) due to IPH’s failure, by itself or through its Affiliates or Out-licensees, to use Diligent Efforts to
Commercialize an Anti-KIR Product as set forth in Section 12.7A(a)(ii), the following shall apply and supersede Section 12.8 with respect to the terminated Anti-KIR Antibody(ies)/Product(s) and terminated country(ies):” 

and the remainder of Section 12.8B shall remain unchanged. 
  

	12.	 The provisions of Sections 12.7A(b), 12.8A and 12.8B shall be NN’s sole and exclusive remedy for any
breach by IPH of Section 12.7A(a). 

  

	13.	 Section 13.3.6 of the Agreement shall not apply to the Outlicense or to any future grant of rights thereunder
by BMS to any other person. 

  

	14.	 Notwithstanding Section 15.3.1(a) and 15.3.1(b) of the Agreement, IPH may grant to BMS a security interest,
lien or other encumbrance on any Intellectual Property Right owned by IPH and licensed by IPH to BMS under the Outlicense. 

  

	15.	 Notwithstanding Section 9.8 of the Agreement, BMS shall have the sole right, but not the obligation, to apply
for any patent term adjustment, patent term extension, supplemental patent protection or related extension of rights with respect to the Patents, set out in a list attached to this Amendment No. 6 as Attachment 1, licensed to BMS under the
Outlicense. Without limiting the foregoing, NN covenants that it will not seek patent term extensions, supplemental protection certificates, or similar rights or extensions for such Patents without the prior written consent of BMS. NN will
cooperate fully with and provide all reasonable assistance to BMS and use all Commercially Reasonable Efforts consistent with its obligations under applicable Law (including any applicable consent order or decree) in connection with obtaining any
such adjustments or extensions for such Patents. To the extent reasonably and legally required in order to obtain any such adjustment or extension in a particular country, NN will make available to BMS a copy of the necessary documentation to
enable BMS to use the same for the purpose of obtaining the adjustment or extension in such country. 

  

	16.	 NN shall not exercise its “March-In” right under Section 9.13 with respect to any IPR licensed to BMS
under the Outlicense without the prior written consent of BMS, which consent shall not be unreasonably withheld. 

  

	17.	 As of the Amendment No. 6 Effective Date, there are no information, materials or Intellectual Property Rights
controlled by UCSF, HSS, Tours and/or INSERM that are necessary or useful for the development, manufacture or commercialization of Anti-KIR Antibodies or Anti-KIR Products, which Intellectual Property Rights could become Controlled by NN and/or IPH
as the result of any action contemplated by the provisions of Section 5.13 of the Agreement. 

  
 - 7 - 

	18.	 Notwithstanding Section 21.1 or anything else in the Agreement to the contrary, BMS shall not be required,
during or following the term of the Outlicense, to maintain, grant, assign or otherwise convey to IPH, NN, or any other Third Party, any rights under any IPR that BMS or its Affiliates may own or control (other than such IPR as is licensed to BMS
under the Outlicense). 

  

	19.	 BMS may exercise any right as an Out-licensee under the Agreement and may exercise IPH’s right to cure
under Sections 12.4 and 12.7A(b) of the Agreement and any right of IPH under Article 9 with respect to the patent rights listed in Attachment 1. 

  

	20.	 BMS shall have no obligation under the Agreement other than those obligations expressly imposed on
Out-licensees and, for clarity, BMS’s obligations under Section 15.1.6 shall only apply to other terms and conditions of the Agreement that are expressly imposed on Out-Licensees.

 

	21.	 Provided that BMS becomes an Out-licensee and effective as of the Amendment No. 6 Effective Date, NN has
terminated that certain Exclusive Commercial License between NN and Medarex, Inc. (now a wholly owned subsidiary of BMS), effective as of December 7, 2004, relating to the Antibody ***. It is understood and agreed that in the proposed license
between BMS and IPH, BMS will grant to IPH the right to prosecute and maintain the patent rights that are listed in Attachment 1, in the event that BMS would discontinue such prosecution or maintenance. As between IPH and NN, in the
event that BMS discontinues the prosecution or maintenance of such patents rights, IPH shall exercise its right to prosecute and maintain such patent rights pursuant to the agreement between BMS and IPH. 

 

	22.	 BMS may disclose Confidential Information of NN relating to Anti-KIR Antibodies and IPR licensed to BMS under
the Outlicense that it obtains from IPH without any obligation to obtain consent therefor from NN. 

  

	23.	 Notwithstanding Section 15.1.8 or anything else in the Agreement to the contrary, BMS shall have no obligation
to provide any information to NN regarding any activity under the Outlicense beyond such information that BMS provides to IPH under the Outlicense. 

  

	24.	 NN has transferred to IPH ownership of all regulatory filings held by NN relating to Anti-KIR Antibodies,
including INDs and other such filings as may be necessary for the conduct of clinical trials of Anti-KIR Antibodies. 

  

	25.	 Notwithstanding anything in the Agreement to the contrary, BMS’s rights under the Outlicense shall survive
any termination of the Agreement (other than a termination directly resulting from a material breach by BMS of its obligations under the Outlicense or as an Out-licensee under the Agreement), subject to (a) the payment by BMS to NN of any milestones
or royalties with respect to Anti-KIR that IPH would have been required to pay NN under the Agreement and (b) the provision by BMS to NN of information consistent with Paragraph 23 above. 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 - 8 - 

	26.	 IPH’s obligation to make royalty payments to NN under the Agreement on the Net Sales of IPH’s
Out-licensees with respect to any Anti-KIR Antibody or Anti-KIR Product shall be cancelled and replaced by the following obligation: 

IPH shall pay to NN *** of all royalty payments based on Net Sales of Anti-KIR Products, as received by IPH from its Out-licensees. 

 

	27.	 The provisions of this Amendment confer a benefit on and are intended to be (and shall be) enforceable by BMS
in the event BMS becomes an Out-licensee by virtue of the Contracts (Rights of Third Parties) Act 1999. Otherwise no person who is not a Party shall have the right to enforce any term of this Amendment by virtue of the Contracts (Rights of
Third Parties) Act 1999. 

  

	28.	 The rights of the Parties to terminate or rescind, or agree any variation of or waiver or settlement under,
this Amendment is subject to the consent of BMS as long as BMS is an Out-licensee (and the Parties shall not do any such thing unless BMS has given its prior written consent). 

 

	29.	 BMS may assign the benefits conferred on it by this Amendment, without the consent of NN or IPH, to any Person
to which BMS also assigns the Outlicense. 

  

	30.	 Unless otherwise agreed by the Parties in writing, this Amendment shall be of no further force or effect after
the date, if any, that BMS ceases to be either an Out-licensee under the Agreement or a direct licensee of NN pursuant to Paragraph 25 above. 

  

	31.	 This Amendment shall be deemed an integral part of the Agreement. Except as expressly set forth herein, all
provisions of the Agreement shall remain unchanged and in full force and effect. The Parties expressly affirm their mutual intention that this Amendment to the Agreement shall constitute a legally binding Amendment to the Agreement.

  

	32.	 This Amendment shall be construed and interpreted pursuant to the laws stipulated in the Agreement. All
disputes arising out of or in connection with the present Amendment shall be finally settled by arbitration as stipulated in the Agreement. 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 - 9 - 

 IN WITNESS HEREOF the Parties have executed and delivered this Amendment. 

 

			
	On behalf of Novo Nordisk N/S	  	On behalf of Innate Pharma SA
		
	/s/ Lars Fruergaard Jørgensen	  	/s/ Hervé Brailly
		
	Name: Lars Fruergaard Jørgensen	  	Name: Hervé Brailly
	Title: Senior Vice President	  	Title: CEO
	Date: 1-July-2011	  	Date: 5 July 2011

  
 - 10 - 

 Attachment 1 

A. KIR-specific patents 
 1. Antibodies, antibody
fragments, and derivatives thereof that cross-react with two or more inhibitory receptors (KIR2DL1 and KIR2DL2,3) which potentiate NK cell cytotoxicity. Applicant/owner: Innate Pharma and University of Genoa. 

*** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 - 11 - 

 2. Cross-reactive (KIR2DL1 and KIR2DL2,3) anti-KIR antibodies. Applicant/owner: Novo Nordisk, Innate Pharma
and University of Genoa. 
 *** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 - 12 - 

 3. Human anti-KIR antibodies, including Anti-KIR (1-7F9). Novo Nordisk, Innate Pharma and University of
Genoa. 
 *** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 - 13 - 

 4. Treatment of viral infection, including but not limited to HIV treatment. Applicant/owner: Novo Nordisk
and Innate Pharma. 
 *** 
 5. Anti-KIR
combination treatments, including but not limited to combination with cytokines. Applicant/owner: Novo Nordisk and Innate Pharma. 
 ***

  
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 - 14 - 

 6. Non-competitive antagonist KIR-binding agents. Applicant/owner: Novo Nordisk and Innate Pharma. 

*** 
 7. Formulations and dosages of containing
Anti-KIR antibodies. Applicant/Owner: Novo Nordisk. 
 *** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 - 15 - 

 8. Anti-KIR + lenalidomide combination therapies for the treatment of cancer. Applicant/owner: Novo Nordisk 

*** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 - 16 - 

 B. Multiple target patents 

1. Use of blocking anti-KIR mAbs (as well as anti-NK receptor mAbs) in combination with depleting mAbs, where the anti-KIR mAb-mediated NK cell activation
enhances ADCC toward a target cell. Applicant/owner: Innate Pharma. (see Patent Assignment agreement of February 2006 between IPH and the University of Perugia). 

*** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 - 17 - 

 2. Use of depleting anti-KIR (and other NK receptor) mAbs for the treatment of LGL and other suitable and/or
related diseases including T-cell type LDGL, autoimmune disorders, and any other immunoproliferative or malignant disorders involving NK or other KIR-expressing lymphocytes. Applicant/owner: Innate Pharma and University of Genoa. 

*** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 - 18 - 

 3. Use of depleting Anti-KIR (and other NK receptor mAbs) mAbs for eliminating NK cells in inflammatory
indications. Applicant/Owner: Novo Nordisk, Innate Pharma and University of Genoa. 
 *** 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 - 19 - 

 Execution version 

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 
  
 AMENDMENT AND
SUPPLEMENT NO. 7 
 to the 

JOINT RESEARCH, DEVELOPMENT, OPTION AND LICENSE AGREEMENT 

Dated 
 MARCH 28,
2006 
 Between 

NOVO NORDISK A/S 
 and

 INNATE PHARMA SA 

Relating to the Buy Back of Anti-NKG2A 

February 5, 2014 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page No.	 
			
	1.	 	 DEFINITIONS
	  	 	1	 
			
	2.	 	 RECLASSIFICATION OF ANTI-NKG2A AS A NICHE CANDIDATE
	  	 	2	 
			
	3.	 	AMENDMENT OF AGREEMENT TO PROVIDE FOR THE DEVELOPMENT AND COMMERCIALIZATION OF ANTI-NKG2A AS A NICHE CANDIDATE BY IPH	  	 	2	 
			
	4.	 	 KNOW-HOW TRANSFER
	  	 	21	 
			
	5.	 	 CLINICAL TRIALS
	  	 	22	 
			
	6.	 	 TRANSFER OF ANTI-NKG2A SUPPLIES
	  	 	22	 
			
	7.	 	 NO WARRANTY
	  	 	22	 
			
	8.	 	 REGULATORY OR SAFETY DELAY
	  	 	23	 
			
	9.	 	 FINANCIAL CONSIDERATION
	  	 	24	 
			
	10.	 	 PRESS RELEASE
	  	 	24	 
			
	11.	 	 OTHER ADJUSTMENTS
	  	 	26	 
			
	12.    	 	 MISCELLANEOUS
	  	 	26	 
			
		 	 Exhibit A
	  	 	A-1	 
			
		 	 Exhibit B
	  	 	B-1	 
			
		 	 Exhibit C
	  	 	C-1	 
			
		 	 Exhibit D
	  	 	D-1	 
			
		 	 Exhibit E
	  	 	E-1	 
			
		 	 Exhibit F
	  	 	F-1	 
			
		 	 Exhibit G
	  	 	G-1	 

  
 -i- 

 AMENDMENT AND SUPPLEMENT NO. 7 

to the 
 JOINT RESEARCH,
DEVELOPMENT, OPTION AND LICENSE AGREEMENT 
 Amendment and Supplement dated as of February 5, 2014 (the “Amendment
No. 7”) to the Joint Research, Development, Option and License Agreement dated March 28, 2006 as amended (hereinafter the “Agreement”) between Novo Nordisk A/S
(CVR-no. 24 25 67 90), a corporation existing under the laws of Denmark and having its principal place of business at Novo Allé, 2880 Bagsvaerd, Denmark (hereinafter “NN”), and Innate Pharma
SA, a corporation existing under the laws of France and having its principal place of business at avenue de Luminy, 13009 Marseille, France (hereinafter “IPH”). 

WITNESSETH 
  

			
	WHEREAS	  	Pursuant to the Agreement, NN and IPH agreed to work, independently, jointly, and/or together with agreed-upon Third Parties, to (a) discover or identify Drug Candidates, and (b) optimize Drug Candidates for progression to
(i) Licensed Products for further development and commercialization by NN, or (ii) Niche Candidates for further development and commercialization by IPH (either alone or together with NN), in each case for all uses and purposes, including
therapeutic, prophylactic and, except as otherwise expressly therein provided, diagnostic uses;
		
	WHEREAS	  	NN desires to cease development of Anti-NKG2A as a Licensed Product and IPH desires to buy back the rights to Anti-NKG2A (as defined below). To that effect, the Parties have agreed that Anti-NKG2A be reclassified as a Niche
Candidate for IPH’s sole independent further development and commercialization, and NN and IPH desire to amend and supplement the Agreement to provide for NN’s grant or grant back to IPH of an exclusive right and license, including the
right to Sub-license and Out-license, throughout the Territory during the Term, under (a) all Intellectual Property Rights licensed exclusively to NN pursuant to
Section 5.1, and (b) all Background NN IPR and Collaboration IPR Controlled by NN, to the extent that such rights and licenses are necessary or useful to conduct research with and of, discover, develop, use, manufacture, have manufactured,
register, package, sample, distribute, promote, market, offer for sale, import, export, sell and have sold Anti-NKG2A Antibodies and/or Anti-NKG2A Products for all uses and purposes.
		
	NOW, THEREFORE,	  	
		
		  	in consideration of the foregoing premises, the mutual promises and covenants set forth in this Amendment No. 7, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, NN and
IPH, each intending to be legally bound, hereby agree as follows:

  

	 	1.	 DEFINITIONS 

  

	1.1	 Unless otherwise specifically defined herein, each term used herein that is defined in the Agreement has the
meaning assigned to such term in the Agreement. Each reference to “hereof”, “hereunder”, “herein” and “hereby” and each other similar reference and each reference to “this Agreement’ and each other
similar reference contained in the Agreement shall, after the Amendment No. 7 Effective Date, refer to the Agreement as amended hereby. 

	1.2	 “Amendment No. 7 Effective Date” shall mean the date of this Amendment No. 7.

  

	 	2.	 RECLASSIFICATION OF ANTI-NKG2A AS A NICHE CANDIDATE 

 

	2.1	 Subject to the terms and conditions of this Amendment No. 7 and with effect from the Amendment No. 7
Effective Date, NN hereby classifies Anti-NKG2A as a Niche Candidate for independent further development and commercialization by IPH for any therapeutic, prophylactic or diagnostic indication or application. 

 

	2.2	 IPH acknowledges and agrees that, with effect from the Amendment No. 7 Effective Date, Anti-NKG2A shall be
classified as a Niche Candidate and IPH further agrees that, notwithstanding any non-compliance by either Party with the procedures set out in Section 6.1 of the Agreement, neither the discontinuation of
development of Anti-NKG2A by NN nor the subsequent classification by NN in this Amendment No. 7 of Anti-NKG2A as a Niche Candidate constitutes the abandonment of any Licensed Product or Niche Candidate for the purposes of the Agreement or gives
rise to any right to terminate the whole or part of the Agreement or any of the associated remedies under Articles 12 and 13 of the Agreement. 

  

	2.3	 Notwithstanding any provision of the Agreement, IPH acknowledges that, with effect from the Amendment
No. 7 Effective Date, NN shall have no further obligations under the Agreement, this Amendment No. 7 or otherwise to develop or commercialize Anti-NKG2A and NN acknowledges that IPH shall have the exclusive right to conduct the development
and commercialization of Anti-NKG2A as a Niche Candidate for any therapeutic, prophylactic or diagnostic indication or application. 

  

	2.4	 The Anti-NKG2A Antibodies and Anti-NKG2A Products that are subject of the rights and licenses pursuant to this
Amendment No. 7 shall not be considered Licensed Products or Residual Products under the Agreement 

  

	 	3.	 AMENDMENT OF AGREEMENT TO PROVIDE FOR THE DEVELOPMENT AND COMMERCIALIZATION OF ANTI-NKG2A AS A NICHE
CANDIDATE BY IPH 

  

	3.1	 With effect from the Amendment No. 7 Effective Date, Article 1 of the Agreement is hereby amended by:

  

	 	3.1.1	 adding the following proviso to the definition of “Background NN IPR” immediately following the
current text of such definition: 

  
 2 

 “Provided, however, that for the purposes of the licenses granted to IPH
pursuant to Section 5.5 hereof to develop and commercialize Anti-NKG2A as a Niche Candidate and otherwise in connection with the interpretation of this Agreement in connection with such development and commercialization by IPH of Anti-NKG2A as
a Niche Candidate, “Background NN IPR” shall mean only the IPR identified and listed in Schedule 1.1.7B to the Agreement. Such Schedule 1.1.7B shall not be subject to the aforementioned notification, demonstration and updating process
applicable to Schedule 1.1.7 and may not be amended except with the express consent in writing of the Parties hereto.”; 
  

	 	3.1.2	 adding the following proviso to the definition of “Collaboration IPR” immediately following the
current text: 

 “Provided, however, that for the purposes of the licenses granted to IPH pursuant to
Section 5.5 hereof to develop and commercialize Anti-NKG2A as a Niche Candidate and otherwise in connection with the interpretation of this Agreement in connection with such development and commercialization by IPH of Anti-NKG2A as a Niche
Candidate, “Collaboration IPR Controlled by NN” shall mean only the IPR comprised of (x) (i) the Patents identified and listed in Schedule 1.1.16B (Parts A and B) to the Agreement and (ii) any Patents in which any Anti-NKG2A Know-How is disclosed but not including any Patent listed in Schedule 5.8.2B and (y) the Know-How listed in Schedule 1.1.17B to the Agreement. Such Schedules 1.1.16B and
1.1.17B shall not be subject to any updating process that is otherwise applicable to Schedules 1.1.16 and 1.1.17 and may not be amended except with the express consent in writing of the Parties hereto.”; 

 

	 	3.1.3	 deleting the final sentence from the definition of “Licensed Product”; 

 

	 	3.1.4	 inserting the words “ Anti-NKG2A as well as” immediately following the words “shall mean”
in the definition of “Niche Candidate”; and 

  

	 	3.1.5	 adding the following definitions: 

“Anti-NKG2A Know-How” shall mean Know-How
generated or acquired by either or both Parties or their Affiliates in relation to Anti-NKG2A, within the categories listed in Schedule 1.1.17B. 

“Anti-NKG2A Patent” shall mean (i) a Patent listed in Part A of Schedule 1.1.16B and (ii) a Patent in which any
Anti-NKG2A Know-How is disclosed but not including any Patent listed in Schedule 5.8.2B. “Anti-NKG2A” or “Anti-NKG2A Antibody” means any antibody or antigen-binding fragment
or derivative thereof, whether human, humanized, chimeric, murine or from another source (and including bispecific antibodies, single chain antibodies and immunoconjugated antibodies) that has been raised, engineered, or otherwise optimized to bind
Anti-NKG2A (in addition to any other target or receptor such antibody may bind to). 

  
 3 

 “Anti-NKG2A Product” means any pharmaceutical product containing any Anti-NKG2A
Antibody (alone or together with any other pharmaceutical active ingredients), in all forms, presentations, formulations and dosage forms. 

“Anti-NKG2A Regulatory Milestones” shall have the meaning ascribed to it In Section 7.4C. 

“Continuation” shall mean, with respect to any patent or patent application, any continuation,
continuation-in-part, divisional, continued prosecution or other similar application. 

“Formulation Patent” shall mean the Patents listed in Part B of Schedule 1.1.16B.” 

“*** License” shall mean the license between Novo Nordisk A/S and *** dated as of December 8, 2004. 

“*** License” shall mean the license between Novo Nordisk A/S and *** with respect to inter alia the manufacturing of any
Anti-NKG2A Antibody or Anti-NKG2A Product. 
 “NN Anti-NKG2A FoO IPR” shall mean (a) such Patents listed in Schedule
5.8.2B, (b) such Patents that are either (i) Controlled, through exclusive ownership, by NN or its Affiliates during the Term and claim the benefit of a priority date on or before February 5, 2017 or (ii) Controlled, through
license or otherwise but not exclusive ownership, by NN or its Affiliates at February 5, 2014, (c) such Know-How that is either (i) Controlled, through exclusive ownership, by NN or its Affiliates
during the Term and generated on or before February 5, 2017 or (ii) Controlled, through license or otherwise but not exclusive ownership, by NN or its Affiliates at February 5, 2014 and (d) such Patents based in part or in whole
on Know-How that is (i) Controlled, through exclusive ownership, by NN or its Affiliates during the Term and (ii) generated on or before February 5, 2017, in each of (a), (b) and (d) that
are or is (y) not within the Background NN IPR or Collaboration IPR and (z) necessary for the development and commercialization of an Anti-NKG2A Product. 
  

	3.2	 Background NN IPR Licensed by NN to IPH for development and commercialization by IPH of Anti-NKG2A as a
Niche Candidate. With effect from the Amendment No. 7 Effective Date, the Agreement is hereby amended by inserting Exhibit A to this Amendment No. 7 as Schedule 1.1.7B to the Agreement. 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 4 

	3.3	 Collaboration IPR Controlled by NN and Licensed by NN to IPH for development and commercialization by IPH of
Anti-NKG2A as a Niche Candidate — Anti-NKG2A Patents and Anti-NKG2A Know-How. With effect from the Amendment No. 7 Effective Date, the Agreement is hereby amended by inserting Exhibit B to this
Amendment No. 7 as Schedule 1.1.16B (Parts A and B) to the Agreement and Exhibit C to this Amendment No. 7 as Schedule 1.1.17B (Parts A and B) to the Agreement. 

 

	3.4	 Schedule 5.8.2B NN Anti-NKG2A FoO Patent. With effect from the Amendment No. 7 Effective Date, the
Agreement is hereby amended by inserting Exhibit D to this Amendment No. 7 as Schedule 5.8.2B to the Agreement. 

  

	3.5	 No Development and Commercialization Committee Input for Anti-NKG2A. With effect from the Amendment
No. 7 Effective Date, Section 4.9 is hereby amended by inserting the following text in the first paragraph after the words “(b) any Niche Candidates”: 

“(other than Anti-KIR and Anti-NKG2A)”. 

 

	3.6	 No JSC Approval of Sub-licensing by IPH of an Anti-NKG2A Niche
Candidate. With effect from the Amendment No. 7 Effective Date, Article 5 of the Agreement is hereby amended by deleting the words “that shall be enforceable by both Parties” from the second paragraph of Section 5.6 and by
inserting the following text immediately following Section 5.6A: 

 “5.6B No JSC Approval of Sub-licensing by IPH of Anti-NKG2A as a Niche Candidate. Notwithstanding Section 5.6, the JSC shall not be required to approve any Sub-licensing by IPH of its rights and obligations under this Agreement if
such Sub-licensing by IPH is reasonably necessary for the development and commercialization of Anti-NKG2A as a Niche Candidate or any Anti-NKG2A Product.” 

For the avoidance of doubt, it is acknowledged and agreed that the provisions of Section 5.6 shall not apply to Out-Licensing and further sublicenses by the Out-Licensee. 
  

	3.7	 No License by NN to IPH of Independent NN IPR for development and commercialization by IPH of Anti-NKG2A as
a Niche Candidate; FoO for Anti-NKG2A as a Niche Candidate. With effect from the Amendment No. 7 Effective Date, Article 5 is hereby amended by inserting the following text immediately following Section 5.8.2A: 

“5.8.2B No License by NN to IPH of Independent NN IPR for development and commercialization by IPH of Anti-NKG2A as a Niche Candidate;
FoO for Anti-NKG2A as a Niche Candidate. Notwithstanding Section 5.8.2, NN shall not be obliged to grant to IPH, or to provide reasonable cooperation and assistance to IPH to procure the grant to IPH of,
non-exclusive rights and licenses under any Independent NN IPR for the purposes of IPH’s development and commercialization of Anti-NKG2A as a Niche Candidate or any Anti-NKG2A Product; provided,
however, that NN shall grant to IPH a non-exclusive 

  
 5 

 license (with the right to Sub-license and Out-license; however, IPH shall not be entitled to Sub-license or Out-license any Patent
in-licensed by NN under the *** Agreement until the earlier of: (i) *** approval of such right to Sub-license and Out-license
(which approval NN shall use reasonable efforts to obtain by September 30, 2014, subject to no additional payments by NN in connection with such right to Sub-license and
Out-license, without prejudice to NN’s payment obligations in Section 7,8D), or (ii) the expiry of the last Valid Claim of any such Patents) under any NN Anti-NKG2A FoO IPR to develop and
commercialize Anti-NKG2A Products for no additional consideration.” 
  

	3.8	 No IPH Access to Materials; No NN Buy-in and Co-Marketing Options. With effect from the Amendment No. 7 Effective Date, Article 6 is hereby amended by inserting the following text immediately following Section 6.1E: 

“6.1F No IPH Access to Materials. Notwithstanding Section 6.4 and except as otherwise set forth in this Amendment, IPH shall
have no rights to access Materials pursuant to such Section 6.4 with respect to the development or commercialization of Anti-NKG2A as a Niche Candidate pursuant to Section 6.1 hereof. 

6.1G No NN Buy-in and Co-Marketing Options for Anti-NKG2A
Niche Candidate. Notwithstanding Sections 6.5 (NN Buy-In), 6.6 (NN Co-Marketing Options), 6.7 (IPH Assistance), 6.8 (Licenses to NN for Niche Candidates), NN shall
have no rights pursuant to such Sections 6.5, 6.6, 6.7 and 6.8 with respect to Anti-NKG2A as a Niche Candidate being developed or commercialized by IPH pursuant to Section 6.1 hereof, provided however that if within *** following the Amendment
No. 7 Effective Date, IPH intends to Out-License any Anti-NKG2A in a field that substantially relates to diabetes or inflammation (the “Restricted Field”), then NN shall have a right of first
offer as follows: 
  

	 	(i)	 IPH shall provide to NN the data package relating to such Anti-NKG2A as prepared by IPH for such Out-Licensing process and NN shall have *** to review such package and indicate to IPH whether it is interested in entering into negotiation for an Out-License;

  

	 	(ii)	 If NN notifies its interest within such *** timeline, IPH and NN shall engage in exclusive negotiations for an Out-License for *** following NN’s notice of interest (the “Exclusive Negotiation Period”); 

  

	 	(iii)	 If NN does not notify its interest within the above *** timeline or the Parties fail to enter into an Out-License within the Exclusive Negotiation Period, IPH shall be free to enter into an agreement for the Out-License such Anti-NKG2A in the Restricted Field to a Third Party
without further notice to NN, provided that for *** following the expiry of the Exclusive Negotiation Period, any such Third Party Out-License shall not be at terms that are, taken as a whole, less favorable
to IPH than the latest terms offered in writing by NN during the Exclusive Negotiation Period. 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 6 

 If the proposed Out-License does not relate
substantially to diabetes and/or inflammation but relates to any broader field including diabetes or inflammation, then the above procedure shall apply provided that the *** and *** timelines set forth above shall be reduced by half to be brought to
respectively *** and the negotiation period shall not be exclusive. For the avoidance of doubt, and by way of example, the Parties agree that if the proposed Out-License relates to any oncology indication or
to all indications, it shall not be regarded as substantially related to diabetes or inflammation. 
 6.IH IPH Access to Raw Data. If
reasonably required by IPH to respond to any request from, or fulfill any requirement of, any regulatory authority in connection with IPH’s development and commercialization of Anti-NKG2A as a Niche Candidate or any Anti-NKG2A Product, NN
shall, upon reasonable notice from IPH, provide IPH or any regulatory authority with a reasonable opportunity to review any original documentation and raw data archived by NN for no additional consideration. NN shall not destroy or otherwise dispose
of any original documentation and raw data related to NN’s development of Anti-NKG2A that IPH or a regulatory authority may reasonably be expected to require in connection with IPH’s development and commercialization of Anti-NKG2A as a
Niche Candidate or any Anti-NKG2A Product without the prior written consent of IPH which shall not be unreasonably delayed or withheld. 

6.1.I Reporting Obligations. IPH shall prepare written annual reports (each a “Development Report”) in respect of
IPH’s development of Anti-NKG2A as a Niche Candidate during each calendar year commencing January 1, 2015 and deliver such Development Report to NN no later than January 31 in the calendar year following that calendar year to which
such Development Report relates. Each Development Report shall include a high level description of clinical studies carried out during the calendar year. Anti-NKG2A 

6.1.J NN Corporate Alliance Management. In order to facilitate the transfer of Know How and supplies to IPH pursuant to this Amendment,
NN shall assign a member of its Corporate Alliance Management Department to serve as the liaison officer between NN and IPH on all matters relating to such transfer. Such NN Corporate Alliance Management Department liaison officer shall respond in a
reasonably timely manner to all reasonable requests for information made by IPH. 
  

	3.9	 Regulatory Milestones. With effect from the Amendment No. 7 Effective Date, Article 7 of the
Agreement is hereby amended by inserting the following text immediately following Section 7.4B: 

 “7.4C Anti-NKG2A
Niche Candidate Regulatory Milestone Payments. Notwithstanding Section 7.4, in respect of Anti-NKG2A Products and subject to Section 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 7 

 7.8D, IPH shall only pay to NN the following milestone payments for the achievement of the
following regulatory milestone events by an Anti-NKG2A Product pursuant to IPH’s development of Anti-NKG2A as a Niche Candidate (“Anti-NKG2A Regulatory Milestones”) within *** of the achievement of each such Anti-NKG2A
Regulatory Milestone. 
 Such milestone payments shall be made for the first Anti-NKG2A Product that achieves an Anti-NKG2A Regulatory
Milestone and, subsequently, for each Anti-NKG2A Product that includes an antibody, antibody fragment, or derivative of either thereof that is different in terms of amino acid sequence or chemical derivation from each Anti-NKG2A Product that
previously achieved such Anti-NKG2A Regulatory Milestone, but not different dosages or formulations of the Anti-NKG2A product nor any post-translational modifications arising as a result of different cell culture conditions, in each case on a one-time, non-duplicative basis, irrespective of the number of indications per Anti-NKG2A Product and any Out-licensing or Sub-licensing by IPH. 
  

	 	(a)	 *** 

  

	 	(b)	 *** 

  

	 	(c)	 *** 

  

	3.10	 Sales Milestones. With effect from the Amendment No. 7 Effective Date, Article 7 of the Agreement
is hereby amended by inserting the following text immediately following Section 7.4C: 

 “7.4D Anti-NKG2A Niche
Candidate Sales Milestone Payments. Notwithstanding Section 7.4, in respect of Anti-NKG2A Products IPH shall have no payment obligation with respect to the achievement of sales milestone events by any Anti-NKG2A Product pursuant to
IPH’s development or commercialization of Anti-NKG2A. 
  

	3.11	 Royalties. With effect from the Amendment No. 7 Effective Date, Article 7 of the Agreement is
hereby amended by inserting the following text immediately following Section 7.8: 

 “7.8C Royalties on
Anti-NKG2A Products. Notwithstanding Section 7.8 hereof and subject to Section 7.8D, 7.8E, 7.8F and 7.8 G below, in respect of Anti-NKG2A Products IPH shall during the Term pay to NN the following percentage royalties (the “Base
Royalty Rates”) on Net Sales of each Anti-NKG2A Product on an Anti-NKG2A Product by Anti-NKG2A Product basis in the Territory by IPH, its Affiliates, Sub-Licensees or
Out-Licensees (or its associated Selling Parties) in accordance with Section 7.11. For purposes of the foregoing, an Anti-NKG2A Product that includes an antibody, antibody fragment, or derivative of
either thereof and an Anti-NKG2A Product that include that an 
 antibody, antibody fragment, or derivative of either thereof is different in
terms of amino acid sequence or chemical derivation shall be regarded as two different Anti-NKG2A Products, but not Anti-NKG2A Products having solely different dosages or formulations nor any post-translational modifications arising as a result of
different cell culture conditions). 
  
 Certain information has been excluded from this
agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 8 

 With respect to aggregate Net Sales of any Anti-NKG2A Product that is Out-Licensed by IPH in any given country prior to the first administration in patient of such Anti-NKG2A Product in a Phase III Trial on a
country-by-country basis: 
 *** 

With respect to aggregate Net Sales of any Anti-NKG2A Product that is not Out-Licensed in any given
country by IPH prior to the first administration in patient of such Anti-NKG2A Product in a Phase III Trial on a country-by-country basis. 

*** 
  

	3.12	 Reductions. With effect from the Amendment No. 7 Effective Date, Article 7 of the Agreement is hereby
amended by inserting the following text immediately following Section 7.8C: 

 “7.8D *** 

Subject to the other provisions of this Section 7.8D, IPH shall bear the following payments that NN represented to IPH would be due by NN to
***, as a result of the sublicense granted by NN pursuant to this Amendment (together the “*** Fee”): 
  

	 	•	 	 starting as of calendar year 2015, a minimum yearly payment not to exceed £***; and 

 

	 	•	 	 one or two regulatory milestone payments *** upon initiation of the first phase II for each Anti-NKG2A and ***
upon initiation of the first Phase III in each clinical indication for each Anti-NKG2A). 

 Except for the *** Fee, NN
shall bear all royalty and other payments if any that would be due by NN to ***, as a result the sublicense granted by NN pursuant to this Amendment. 

IPH shall negotiate its own license with *** with respect to the Patent and Know How Controlled by *** and necessary to manufacture Anti-NKG2A
and shall bear all payments related thereto, subject to the other provisions of this Section 7.8D. 
 Notwithstanding Section 7.8
hereof, IPH shall be entitled to deduct: 
  

	 	•	 	 *** of the royalty payments due by IPH to *** in connection with Anti-NKG2A under IPH’s own license with ***
from the royalty payable by IPH to NN pursuant to Section 7.8B, provided that such deduction shall not exceed *** of Net Sales. 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 9 

	 	•	 	 each payment of the *** Fee, from any milestone payment that is subsequently payable by IPH to NN pursuant to
Section 7.4B above. 

 “7.8E Patent Expiry. If there is no Valid Claim covering any Anti-NKG2A in any given country,
the Base Royalty Rates applicable to such Anti-NKG2A in such country shall be reduced by ***. 
 “7.8F Generic Competition. During the
portion of the applicable Term in a particular country where there are one or more products being sold in such country that are Generic Products with respect to such Anti-NKG2A Product, then the applicable royalty, with respect to such Anti-NKG2A
Product shall be reduced as follows: 
 (i) by *** in the event that in any two consecutive calendar quarters such
Generic Product(s), by unit equivalent volume in such country, exceed a *** share of the market; and 
 (ii) by *** in
the event that in any two consecutive calendar quarters such Generic Product(s), by unit equivalent volume in such country, exceed a *** share of the market. 

For purposes of this Section 7.8F, “market” refers to the aggregate of the sales of the Generic Product(s) and the applicable Product
in a country. 
 “7.8G If IPH enters into an Out-License covering at least one Major Market
containing additional royalty adjustments to those set forth in Sections 7.8E and 7.8F (including a broader anti-stacking royalty adjustment) or similar royalty adjustments to those set forth in Sections 7.8E and 7.8F but with less favorable terms
to IPH, then IPH may request to NN that IPH and NN enter into good faith negotiations in order to preserve the economic balance of this Amendment with respect to the Anti-NKG2A Products and countries covered by such
Out-License, provided that the royalty mechanism resulting from this renegotiation shall not cause the royalties due by IPH to NN hereunder to be lower than *** of applicable Base Royalty Rate plus the
deductible portion of the Lonza royalty pursuant to Section 7.8D. 
  

	3.13	 Records of Net Sales. With effect from the Amendment No. 7 Effective Date, Article 7 of the
Agreement is hereby further amended by inserting “and 7.8C” immediately after “7.8” in Section 7.9. 

  

	3.14	 Anti-NKG2A Patents. With effect from the Amendment No. 7 Effective Date, Article 9 of the Agreement
is hereby amended by inserting the following text immediately following Section 9.1: 

 “9.1B1 Anti-NKG2A
Patents. The provisions of this Section 9.1B shall apply to Anti-NKG2A Patents but no other Patents. 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 10 

 9.1B2 Anti-NKG2A Patents. Notwithstanding anything to the contrary in this Agreement, as
between the Parties, IPH shall have the exclusive right and sole discretion during the Term to prepare, file, prosecute, and maintain the Anti-NKG2A Patents listed in Schedule 1.1.16B Parts A (which for avoidance of doubt excludes the Formulation
Patent) and to conduct any interferences, re-examinations, reissues, limitations, and oppositions with respect to such Anti-NKG2A Patents; provided, however, that IPH may neither disclose any
Anti-NKG2A Know How or NN Anti-NKG2A FoO IPR related to either (x) manufacturing methods, processes or procedures or (y) formulation, assay and delivery methodologies in such preparation, filing, prosecution or maintenance of any Patent
nor prepare, file or prosecute any Patent which would require the disclosure of any Anti-NKG2A Know How or NN Anti-NKG2A FoO IPR related to either (x) manufacturing methods, processes or procedures or (y) formulation, assay and delivery
methodologies. IPH shall bear sole responsibility for the preparation, filing, prosecution and maintenance of any Patent contemplated by this Section 9.1B.1 (a) and all costs associated therewith 

accruing after February 5, 2014 including attorneys’ fees and payments due to patent authorities to maintain such Patents. 

9.1B.3 Notice and Effects of NN’s Decision to Abandon; Disclaim; or Discontinue Prosecution, Maintenance, or Defense of Formulation
Patents. In the event that NN decides in respect of any Formulation Patent: 
  

	 	(a)	 to discontinue the prosecution or maintenance of such Formulation Patent, 

 

	 	(b)	 to discontinue the defense of such Formulation Patent (such as by discontinuing efforts to defend such
Formulation Patent in any opposition, reexamination, nullity, or interference proceeding), 

  

	 	(c)	 to not file an application for a Continuation (or, as the case may be, further Continuation) with respect to
such Formulation Patent (including by decision (A) not to enter the national or regional phase in any country or region that is a designated state of a PCT application filed by NN or (B) not to pursue an application in a country wherein an
application claiming priority from a Formulation Patent may be filed), or 

  

	 	(d)	 to abandon or disclaim (in whole or in part, other than by terminal disclaimer), without possibility of
restoration, any Formulation Patent, 

 in each case, NN shall provide written notice to IPH at least *** in advance of
the deadline relating to any of the events described above so as to allow IPH the opportunity to file, defend, maintain (including by payment of annuities, issue fees, maintenance fees, or the like), or continue prosecution of such Formulation
Patent, at its own expense. In such an event, NN shall provide any assistance reasonably requested of it by NN (including providing IPH with power of attorney to perform such tasks) and, to the extent authorized by 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 11 

 
contract and permitted by applicable Law, assign its rights to such Formulation Patent to IPH, IPH shall thereafter grant to NN a worldwide, non-exclusive
licence (including the right to sub-license and further sublicense) with respect to such Formulation Patent for no additional consideration. 

 

	 	9.1B.4	 Enforcement of Anti-NKG2A Patents, Formulation Patents and NN Claims. 

 

	 	(a)	 Except as otherwise provided in Sections 9.1B.4(b) and 9.1B.4(c) and subject to Sections 9.12.1 and 9.12.2, IPH
shall have the exclusive right (but not the obligation) to initiate or defend any suit, opposition, interference or other legal action (including proceedings before the US International Trade Commission) or to take other appropriate action that IPH,
in its sole discretion, believes is reasonably required to protect or enforce (i.e., prevent or abate actual or threatened misappropriation or infringement of, or otherwise enforce) any Anti- 

NKG2A Patent listed in Schedule 1.1.16B Part A (which for avoidance of doubt excludes the Formulation Patent) (in its own name or, if
authorized by contract and permitted by applicable Law and required by applicable Law, in the name of the NN or an Affiliate of NN), and shall bear its own costs and expenses in respect thereof and be represented by counsel of its choice and shall
further indemnify NN and any of its Affiliates for any costs incurred by NN or any of its Affiliates in connection with such suit, opposition, interference or action. 
  

	 	(b)	 Notwithstanding anything to the contrary in this Agreement, except as otherwise provided in Section 9.1B.4(c)
and subject to Sections 9.12.1 and 9.12.2, NN shall have the primary right (but not the obligation) to initiate or defend any suit, opposition, interference, other legal action (including proceedings before the US International Trade Commission) or
to take other appropriate action that NN, in its sole discretion, believes is reasonably required to protect or enforce (i.e., prevent or abate actual or threatened misappropriation or infringement of, or otherwise enforce) any Formulation Patent
(in its own name or, if authorized by contract and permitted by applicable Law and required by applicable Law, in the name of the NN or an Affiliate of NN) against any Per-son for infringement of
any claims of such Formulation Patent and shall bear its own costs and expenses in respect thereof and be represented by counsel of its choice and shall further indemnify IPH and any of its Affiliates for any costs incurred by IPH or any of its
Affiliates in connection with such suit, opposition, interference or action. 

  

	 	(c)	 Notwithstanding anything to the contrary in this Agreement, except as otherwise provided in Section 9.1B.4(c)
and subject to Sections 9.12.1 and 9.12.2, if within *** following IPH’s notice to NN, NN does not initiate or defend any suit, opposition, interference, other legal action (including proceedings before the US International Trade Commission),
then IPH shall 

  
 Certain information has been excluded from this
agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 12 

	 	
have the right to initiate or defend any suit, opposition, interference, other legal action (including proceedings before the US International Trade Commission) or to take other appropriate
action that IPH, in its sole discretion, believes is reasonably required to protect or enforce (i.e., prevent or abate actual or threatened misappropriation or infringement of, or otherwise enforce) any Formulation Patent (in its own name or, if
authorized by contract and permitted by applicable Law and required by applicable Law, in the name of the NN or an Affiliate of NN) against any Per-son for infringement of any claims of such
Formulation Patent , to the extent that such infringement relates to an anti-NKG2A antibody and would be materially detrimental to the development/commercialization of any Anti-NKG2A Product, or has resulted in sales by the infringing product of
excess of *** in the aggregate. IPH shall bear its own costs and expenses in 

 respect thereof and be represented by counsel
of its choice and shall further indemnify NN and any of its Affiliates for any costs incurred by NN or any of its Affiliates in connection with such suit, opposition, interference or action. 

 

	 	(d)	 Monetary Awards. Any damages or other monetary awards recovered in a legal action initiated or conducted
by IPH under Section 9.1B.4(c) will be allocated to the Parties in the following manner: (1) IPH will be reimbursed for its internal and external expenses (including reasonable attorneys’ fees and costs) incurred in the legal action; and
(2) the remaining balance from such recovery will be allocated to IPH and will be treated as Net Sales. 

 9.1B.5
Dispute Resolution. The Parties acknowledge that all disputes arising under this Section 9.1B shall be subject to the dispute resolution procedures set forth in Section 21.14.” 

 

	3.15	 Development Diligence Requirements for Anti-NKG2A as a Niche Candidate. With effect from the Amendment
No. 7 Effective Date, Article 12 of the Agreement is hereby amended by inserting the following text immediately following Section 12.7 and Section 12.7 shall no longer apply to Anti-NKG2A as a Niche Candidate or the marketing or sale
of an Anti-NKG2A Product: 

 “12.7B Development and Commercialization Diligence Requirements for Anti-NKG2A Niche
Candidate. 
  

	 	(a)	 Diligent Efforts. 

 

	 	(i)	 Development. Notwithstanding Section 12.7 hereof, with respect to the Development of Anti-NKG2A as
a Niche Candidate, IPH, by itself or through its Affiliates, Sub-licensees or Out-licensees, shall use Diligent Efforts to Develop an Anti-NKG2A Antibody or Anti-NKG2A
Product for the treatment, prevention or control of any 

  
 Certain
information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 13 

	 	
human disease, disorder or condition for the purpose of obtaining a Regulatory Approval in each Major Market. For clarity, it is understood and acknowledged that Diligent Efforts in the
Development of Anti-NKG2A Antibodies and Anti-NKG2A Products may include sequential implementation of clinical trials or intervals between clinical trials for data interpretation and clinical program planning and approval. IPH, by itself or through
its Affiliates, Sub-licensees or Out-licensees, shall initiate at least one Clinical Trial with respect to an Anti-NKG2A Antibody or Anti-NKG2A Product within ***
following later of: (i) the completion by NN of the Ongoing Clinical Trial (as defined below) and the (ii) the complete transfer by NN to IPH of all Know How and Anti-NKG2A supplies pursuant to this Amendment, provided that such *** period
shall be extended to the extent of any delay that is attributable to any of the following factors: (I) any safety reason arising from the Ongoing Clinical Trial, (II) insufficient quantities of the applicable Anti-NKG2A Product are
available to initiate and complete such two Phase 1 Clinical Trials, (III) approval of regulatory authorities for IPH, its Affiliates, Sub-licensees or
Out-licensees to conduct such Phase 1 Clinical Trials, if required by applicable law, is not received or (IV) any required consent of a Third Party collaborator of IPH, its Affiliates, Sub-licensees or Out-licensees for the use of a compound other than an Anti-NKG2A Antibody or Anti-NKG2A Product in such Phase 1 Clinical Trial is not received. For purposes
of the preceding sentence, (A) the initiation of a Clinical Trial shall mean the first administration of the Anti-NKG2A Product to the first patient and (B) the completion of the Ongoing Clinical Trial shall mean the availability of the
full data set of such Ongoing Clinical Trial. 

 (ii) Commercialization. Notwithstanding Section 12.7 hereof, with
respect to the Commercialization of an Anti-NKG2A Product, IPH, by itself or through its Affiliates or Out-licensees, shall use Diligent Efforts to Commercialize an Anti-NKG2A Product in each Major Market for
which IPH, its applicable Affiliate, Sub-licensee or Out-licensee receives Approval for such Anti-NKG2A Product. 

(b) Termination for Failure to Employ Diligent Efforts. Notwithstanding Section 12.8 hereof, and subject to Sections 12.7B(b)(i)
and 12.7B(b)(ii), NN shall have the right to terminate this Agreement with respect to Anti-NKG2A on a Major Market-by-Major Market basis with respect to all Anti-NKG2A
Antibodies and Anti-NKG2A Products if IPH is in material breach of its obligation to use Diligent Efforts, alone or through its Affiliates, Sub-licensees or
Out-licensees, as set forth in Section 12.7B(a) with respect to 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 14 

 
such Major Market; provided however, such license shall not so terminate unless (A) IPH is given *** prior written notice by NN of NN’s intent to terminate, stating the reasons and
justification for such termination and recommending steps which NN believes IPH, alone or through its Affiliates, Sub-licensees or Out-licensees, should take to cure
such alleged breach, and (B) IPH, or its Affiliates, Out-licensees or Sub-licensees, has not (1) during the *** period following such notice, provided NN with
a plan for the diligent Development or Commercialization of Anti-NKG2A Products in such Major Market as set forth in Section 12.7B(a) and (2) during the *** following such notice carried out such plan and cured such alleged breach by diligently
pursuing the Development 
 or Commercialization of Anti-NKG2A Products in such Major Market as set forth in Section 12.7B(a). 

(i) If IPH disputes in good faith the existence or materiality of an alleged breach specified in a notice provided by NN pursuant to this
Section 12.7B(b), and if IPH provides notice to NN of such dispute within the *** following such notice provided by NN, NN shall not have the right to terminate this Agreement with respect to Anti-NKG2A unless and until the existence of such
material breach or failure by IPH has been determined in accordance with Section 21.14 and IPH, alone or through its Affiliates, Sub-licensees or Out-licensees,
fails to cure such breach within *** following such determination. It is understood and acknowledged that during the pendency of such a dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue
to perform all of their respective obligations hereunder. 
 (ii) Notwithstanding anything herein to the contrary, in the event that:
(A) NN terminates, or has the right to terminate, this Agreement pursuant to this Section 12.7B(b) with respect to an Anti-NKG2A Product in ***, then NN shall have the right to terminate this Agreement with respect to such Anti-NKG2A Product in
the entire Territory, and (B) NN has the right to terminate this Agreement pursuant to this Section 12.7B(b) with respect to an Anti-NKG2A Product in ***, then NN may not terminate this Agreement with respect to such ***; provided, that if IPH
has such right to terminate this Agreement with respect to such Anti-NKG2A Product with respect to any *** then NN shall have the right to terminate this Agreement with respect to such Anti-NKG2A Product in all of the EU. 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 15 

 Definitions. The following terms, as used in this Section 12.7B or in Sections 12.8C and
12.8D, shall have the following meanings: 
 “Approval” shall mean, with respect to an Anti-NKG2A Product in any regulatory
jurisdiction, Regulatory Approval and, where applicable, receipt of pricing and reimbursement approvals. 
 “Commercialize”
or “Commercialization” shall mean the marketing, promotion, sale (and offer for sale or contract to sell), distribution, importation or other commercial exploitation (including pricing and 

reimbursement activities) for an Anti-NKG2A Product. Commercialization shall include commercial activities conducted in preparation for
Anti-NKG2A Product launch. 
 “Develop” or “Development” shall mean all activities that relate to
(a) obtaining, maintaining or expanding Regulatory Approval of an Anti-NKG2A Product and to support appropriate usage for such Anti-NKG2A Product, for one or more indications. This includes: (i) preclinical/nonclinical research and
testing, toxicology, and clinical trials; (ii) preparation, submission, review, and development of data or information and regulatory materials for the purpose of submission to a governmental authority to obtain, maintain or expand Regulatory
Approval of an Anti-NKG2A Product (including contacts with regulatory authorities), and outside counsel regulatory legal services related thereto; provided, however, that Development shall exclude Commercialization and manufacturing activities
(including manufacturing activities related to Development). 
 “Diligent Efforts” shall mean the carrying out by IPH, or
its Affiliates, Sub-licensees or Out-licensees of such obligations or tasks with a level of effort and resources consistent with the commercially reasonable practices
devoted by the applicable entity for the research, development, manufacture or commercialization of a pharmaceutical product owned by it (or to which it has rights) at a similar stage of development or commercialization and of similar market
potential, profit potential and strategic value, based on conditions then prevailing. Such efforts may take into account, without limitation, issues of safety and efficacy, regulatory authority-approved labeling, product profile, the competitiveness
of alternative products in the marketplace, pricing/reimbursement for the product in a country relative to other markets, the likely timing of the product’s entry into the market, the patent and other proprietary position, the likelihood of
regulatory approval and other relevant scientific, technical and commercial factors. 
 “Major European Countries” shall
mean ***. 
  
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 16 

 “Major Market” shall mean each of ***. 

“Regulatory Approval” shall mean, with respect to a country, extra-national territory, province, state, or other regulatory
jurisdiction, any and all approvals, licenses, registrations or authorizations of any regulatory authority necessary in order to commercially distribute, sell, manufacture, import, export or market a product in such country, state, province, or some
or all of such extra-national territory or regulatory jurisdiction, but which shall exclude any pricing and reimbursement approvals.” 

The provisions of Sections 12.7B(b), 12.8C and 12.8D shall be NN’s sole and exclusive remedy for any breach by IPH of Section 12.7B(a).

  

	3.16	 Termination upon Abandonment of Development of Anti-NKG2A Niche Candidate. With effect from the
Amendment No. 7 Effective Date, Article 12 of the Agreement is hereby amended by inserting the following text immediately following Section 12.8B and Section 12.8 shall no longer apply to Anti-NKG2A Products: 

“12.8C Effects of Termination of Agreement for Failure to Employ Diligent Efforts in Development. With effect from the Amendment
No. 1 Effective Date, upon any termination pursuant to Section 12.7B(b) due to IPH’s failure, by itself or through its Affiliates, Sub-licensees or
Out-licensees, to use Diligent Efforts to Develop an Anti-NKG2A Antibody or Anti-NKG2A Product as set forth in Section 12.7B(a)(i) (such termination may be designated for purposes as this Amendment as the
“abandonment”), the following shall apply and supersede Section 12.8 with respect to the terminated Anti-NKG2A Antibody(ies)/Product(s) and terminated country(ies):” 

 

	 	(a)	 all licenses granted to IPH under this Agreement for the purposes of Commercial Optimization of Anti-NKG2A as a
Niche Candidate that IPH is authorized to develop and commercialize shall terminate immediately; 

  

	 	(b)	 IPH shall have an obligation to grant to NN, at NN’s request, an irrevocable, world-wide, fully paid up,
exclusive license under all its right, title and interest to the Collaboration IPR or Background IPH IPR (as applicable) and Independent IPH IPR, and grant the right set out in Section 5.7 (including all supporting regulatory documentation),
for the development and commercialization of Anti-NKG2A, for no additional consideration other than as provided for herein; 

  

	 	(c)	 if NN shall, in its discretion, assume such license it shall notify IPH to this effect within *** of IPH’s
abandonment or the determination of abandonment, whichever is the later, upon which assumption NN shall have the exclusive right to exploit such IPR for the development and commercialization of Anti-NKG2A; 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 17 

	 	(d)	 if the date of such abandonment is prior to the first dosing of humans in Phase II clinical trials of
Anti-NKG2A as a Niche Candidate, Sections 12.8C(a) and 12.8C(b) shall apply, save that, in consideration of the grant of such rights, if and only if NN subsequently Out-licenses such IPR within the period of
*** following the date of NN’s assumption of rights, NN shall pay to IPH 

 a percentage of all revenue actually
received in respect of such license on the following basis: 
  

	 	•	 	 *** 

  

	 	(e)	 if the effective date of abandonment is after the first dosing of humans in Phase II clinical trials of
Anti-NKG2A as a Niche Candidate but prior to the first dosing in Phase Ill, the above Sections 12.8C(a) and 12.8C(b) shall apply save that in consideration of the grant of such rights, if and only if NN subsequently
Out-licenses such IPR within the period of *** following the date of NN’s assumption of rights NN shall pay to IPH a percentage of all revenue actually received by NN in respect of such license on the
following basis: 

  

	 	•	 	 *** 

  

	 	(f)	 in the event of its abandonment of the development of Anti-NKG2A as a Niche Candidate and irrespective of the
effective date of such abandonment, IPH shall: 

  

	 	(i)	 make no further representation regarding its status as a licensee of NN in respect of Anti-NKG2A;

  

	 	(ii)	 in the event that at the date of the abandonment by IPH of its development of Anti-NKG2A as a Niche Candidate
there are ongoing clinical trials with respect to such development, IPH shall pay for the completion of such clinical trials in respect of all patients enrolled at the effective date of abandonment except if the Agreement is terminated because of
adverse events in the clinical trial(s) causing the trials(s) to cease due to regulatory requirements or regulatory considerations (including an actual or anticipated regulatory warning); 

 

	 	(iii)	 at NN’s option, and at NN’s expense, and to the extent authorized by contract and permitted by
applicable Law, assign or cause to be assigned to NN any regulatory submissions and approvals with respect to Anti-NKG2A and take such actions and execute such other instruments, assignments and documents as may be necessary to effect the transfer
of all rights thereunder to NN; 

  
 Certain information has been
excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 18 

	 	(iv)	 at NN’s option and at NN’s expense, provide to NN all
pre-clinical and clinical data in respect of Anti-NKG2A and all research reagents and materials intended for use In clinical trials of Anti-NKG2A in IPH’s possession or control. 

Following the transfer of rights from IPH to NN pursuant to this Section 12.8C IPH shall have no further obligations under Sections 12.7, 12.8,
12.8C, 12.8D, 12.9 or 12.10 in respect of the development or commercialization of Anti-NKG2A.” 
  

	3.17	 Termination upon Abandonment of Marketing or Sale of Anti-NKG2A Product. With effect from the Amendment
No. 7 Effective Date, Article 12 of the Agreement is hereby amended by inserting the following text immediately following Section 12.8C and Section 12.8 shall no longer apply to Anti-NKG2A Products: 

“12.8D Effects of Termination of Agreement for Failure to Employ Diligent Efforts in Commercialization. With effect from the
Amendment No. 1 Effective Date, upon any termination pursuant to Section 12.7B(b) due to IPH’s failure, by itself or through its Affiliates or Out-licensees, to use Diligent Efforts to Commercialize
an Anti-NKG2A Product as set forth in Section 12.7B(a)(ii) (such termination may be designated for purposes as this Amendment as the “abandonment”), the following shall apply and supersede Section 12.8 with respect to the terminated
Anti-NKG2A Antibody(ies)/Product(s) and terminated country(ies):” 
  

	 	(a)	 all licenses granted to IPH under this Agreement for the marketing or sale of such Anti-NKG2A Product, shall
terminate immediately; 

  

	 	(b)	 IPH shall have an obligation to grant to NN, at NN’s request, an irrevocable, world-wide, fully paid up,
exclusive license under all its right, title and interest to the Collaboration IPR or Background IPH IPR (as applicable) and Independent IPH IPR, and grant the right set out in Section 5.7 (including all supporting regulatory documentation)
with respect to which such Anti-NKG2A Product has been abandoned, solely for the purposes of the commercialization of such specific Anti-NKG2A Product, for no additional consideration other than as provided for herein; 

 

	 	(c)	 if NN shall, in its discretion, assume such license it shall notify IPH to this effect within *** of IPH’s
abandonment, upon which assumption NN shall have the exclusive right to exploit such IPR for solely with respect to such abandoned Anti-NKG2A Product and for such purposes as are specified in clause (a); 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 19 

	 	(d)	 the above Sections 12.8D(a) and 12.8D(b) shall apply save that in consideration of the grant of such rights, if
and only if NN subsequently Out-licenses such IPR within the period of *** following the date of NN’s assumption of rights, NN shall pay to IPH a percentage of all revenue actually received by NN in
respect of such license on the following basis: 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	•	 	 *** 

  

	 	(e)	 in the event of its abandonment of the marketing or sale of any Anti-NKG2A Product irrespective of the
effective date of such failure, IPH shall: 

  

	 	(i)	 cease any activities with respect to the marketing, promotion, sale or distribution of the Anti-NKG2A Product
with respect to which such abandonment has occurred; 

  

	 	(ii)	 at NN’s option and at NN’s expense, and to the extent such transfer is authorized by contract and
permitted by applicable Law, to transfer to NN the benefit of any contracts between IPH and any Third Party in respect of the manufacture of such abandoned Anti-NKG2A Product, with respect to the supply thereof for marketing with respect to which
such abandonment has occurred, provided that for the avoidance of doubt IPH shall not be required to cause or effect any such transfer if to do so will require IPH’s payment or provision of additional consideration to any Person save that NN
may elect to pay for and obtain the right to such procurement or exercise to the extent authorized by contract and permitted by applicable Law; 

  

	 	(iii)	 at NN’s option, and at NN’s expense, and to the extent authorized by contract and permitted by
applicable Law, assign or cause to be assigned to NN, any regulatory submissions and approvals related to the Anti-NKG2A Product with respect to which such abandonment has occurred and take such actions and execute such other instruments,
assignments and documents as may be necessary to effect the transfer of all rights thereunder to NN; 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 20 

	 	(iv)	 NN shall pay IPH’s reasonable costs in connection with the above activities at a reasonable hourly rate
representing the actual cost of IPH of providing such services up to a maximum of ***. 

 Following the transfer of rights
from IPH to NN pursuant to this Section 12.8D, IPH shall have no further obligations under Sections 12.7, 12.8, 12.8C, 12.8D, 12.9 or 12.10 with respect to the marketing and sale of the Anti-NKG2A Product with respect to which the abandonment has
occurred.” 
  

	3.18	 Publication concerning an Anti-NKG2A Niche Candidate. With effect from the Amendment No. 7
Effective Date, Article 18 of the Agreement is hereby amended by inserting the following text immediately following Section 18.1A: 

“Section 18.1B Publication concerning Anti-NKG2A as a Niche Candidate or Anti-NKG2A Products. Notwithstanding Section 18.1, NN
shall have no rights pursuant to such Section 18.1 with respect to publications or disclosures concerning the development or commercialization of Anti-NKG2A as a Niche Candidate pursuant to Section 6.1 hereof or any Anti-NKG2A Product;
provided, however in no event shall IPH publish Confidential 
 Information of NN relating to (1) manufacturing,
marketing, financing or business developments, opportunities, plans, methods, processes or procedures, (ii) quality controls, (iii) security controls, (iv) unpublished cost, price or pricing information, (v) financial or
personnel matters, or (vi) customer, client or supplier lists or information, in each case without prior written approval of NN.” 
  

	 	4.	 KNOW-HOW TRANSFER 

 

	4.1	 IPH has requested that NN transfer to IPH the Know-How comprising the
information (regulatory, non-clinical, clinical, CMC and other) listed in Exhibit C to this Amendment No. 7. The Parties agree to update Exhibit C no later than 30 days after the Amendment No. 7
Effective Date. 

  

	4.2	 NN shall transfer, and take such actions as are reasonably required to ensure the effective transfer of, the Know-How listed in Exhibit C to Innate as soon as possible and in any event no later than June 30, 2014 and no later than October 31, 2014 with respect to the final report and database of the Ongoing
Clinical Study in accordance with the terms of this Amendment No. 7 including the guidelines set out in Exhibit F.In the event of any dispute between NN and IPH regarding the actions of NN that are reasonably required to ensure the effective
transfer of the Know-How listed in Exhibit C, such dispute shall in the first instance be referred to the CSO of NN and the CEO of IPH who shall seek to resolve such dispute. In the event that the CSO of NN
and the CEO of IPH are unable to resolve the dispute, NN or IPH may seek the non-binding opinion of an expert, in accordance with the procedures set forth in Exhibit H, on whether or not any additional actions
of NN are reasonably required to effect such transfer; provided, however, that neither NN nor IPH shall be obliged to take any actions based on such expert’s opinion. Notwithstanding the above, either Party may at any time refer
any such dispute to arbitration in accordance with Section 21.14 of the Agreement. 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 21 

	4.3	 If, on or before June 30, 2014, IPH gives notice to NN that IPH has identified Know-How that is (x) Controlled by NN at that date, (y) not listed in Exhibit C and (z) necessary for the purposes of IPH’s development or commercialization of the Anti-NKG2A Niche Candidate,
then NN shall deliver to IPH the documents, files and materials containing such Know-How as soon as reasonably practicable. 

 

	4.4	 IPH acknowledges and agrees that, subject to Section 5.8.2A of the Agreement (as amended by this Amendment
No. 7) and Sections 4, 5 and 6 of this Amendment No. 7, NN shall have no further obligation to transfer Know-How to IPH pursuant to Section 6.1 of the Agreement or otherwise in connection with
IPH’s development and commercialization of Anti-NKG2A as a Niche Candidate. 

  

	 	5.	 CLINICAL TRIALS 

 

	5.1	 Definitions. The following terms, as used in this subsection herein, shall have the following meanings:

 “Ongoing Clinical Trial” shall mean the ongoing clinical trial conducted by NN on Anti-NKG2A. 

 

	5.2	 NN shall complete the Ongoing Clinical Trial and comply with all sponsorship obligations relating thereto at
its own costs. 

  

	5.3	 NN agrees to indemnify, hold harmless, and defend IPH and its Affiliates, against any claims, suits, losses,
damages, costs, fees, or expenses resulting from the conduct of the Ongoing Clinical Trial. 

  

	5.4	 NN shall notify IPH upon the completion (i.e., last patient, last visit) of the Ongoing Clinical Trial and
shall provide IPH for prior review and comment drafts of all submissions to be made to the regulatory authorities or ethic committees and copies of all correspondance with the regulatory authorities or ethic committees in connection with the Ongoing
Clinical Trial. 

  

	 	6.	 TRANSFER OF ANTI-NKG2A SUPPLIES 

 

	6.1	 NN shall transfer to IPH the materials described further in Exhibit E (the “ Anti-NKG2A
Supplies”) as follows: 

  
 22 

	 	(a)	 Subject to Section 6.4, within *** of the Amendment No. 7 Effective Date, NN shall cause those
Anti-NKG2A Supplies set forth in Part of A of Exhibit E to be shipped to IPH; 

  

	 	(b)	 NN shall cause those Anti-NKG2A Supplies set forth in Part B of Exhibit E which are reasonably required to
conduct a Clinical Trial to be shipped to IPH, or to a location directed by IPH, acting reasonably, as soon as practicable following a request by IPH after the Innate shareholder vote as described in 9.3.2; and 

 

	 	(c)	 NN shall transfer those Anti-NKG2A Supplies set forth in Part D of Exhibit E to IPH at such time as the
Parties agree but no later than June 30, 2014 (the “In-Process Batch”). 

  

	6.2	 Title to the Anti-NKG2A Supplies shall transfer to IPH upon delivery of such Anti-NKG2A Supplies to IPH or to a
Third Party for shipment to IPH and IPH shall be responsible for all storage costs for such Anti-NKG2A Supplies as and from such date;  

provided, however, that NN shall be responsible for all shipment (but not including insurance) costs with respect to such
shipment of Anti-NKG2A Supplies. 
  

	6.3	 IPH shall reimburse NN for internal costs related to the transfer of the Anti-NKG2A Supplies to IPH of
*** to be paid within *** from receipt of an invoice from NN to be issued following the satisfactory completion of the transfer of Know How within the timelines set forth in Section 4.2, and provided that such transfer occurs within such
timelines. 

  

	6.4	 NN shall analyze all on-going stability studies relating to Anti-NKG2A
and make available to IPH all related data. After analyses NN shall transfer to IPH all stability samples. 

  

	 	7.	 NO WARRANTY 

  

	7.1	 AT THE AMENDMENT NO 7. EFFECTIVE DATE, THE Anti-NKG2A SUPPLIES ARE BEING SOLD AND THE KNOW-HOW LISTED IN EXHIBIT C AND THE Anti-NKG2A PATENTS AND THE NN Anti-NKG2A FoO IPR ARE BEING LICENSED “AS IS” AND WITHOUT ANY REPRESENTATIONS OR WARRANTIES BY NN. NN MAKES NO REPRESENTATIONS OR
WARRANTIES, EXPRESS OR IMPLIED, OF ANY TYPE WHATSOEVER, REGARDING THE Anti-NKG2A SUPPLIES, THE KNOW-HOW LISTED IN EXHIBIT C,THE Anti-NKG2A PATENTS AND THE NN Anti-NKG2A FoO IPR, AND TO THE FULLEST EXTENT
PERMITTED BY LAW, NN EXPRESSLY DISCLAIMS ANY IMPLIED WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, CONSISTENCY OR COMPLIANCE WITH ANY SAMPLES PREVIOUSLY PROVIDED OR NONINFRINGEMENT. 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 23 

	 	8.	 REGULATORY OR SAFETY DELAY 

 

	8.1	 Notwithstanding any provision of this Amendment No. 7: 

 

	 	(a)	 NN may delay the transfer of any Anti-NKG2A Know-How, any Anti-NKG2A
Supplies to IPH; and 

  

	 	(b)	 if transfer of any Anti-NKG2A Know-How, any Anti-NKG2A Supplies shall
have occurred, IPH shall permit access by NN to such Anti-NKG2A Know-How, Anti-NKG2A Supplies; 

in each case as may be required, in NN’s reasonable determination, to respond to any request from, or fulfill any requirement of, any
regulatory authority. 
  

	8.2	 IPH shall use all reasonable endeavours to cooperate with NN to permit NN to respond to any request from, or
fulfill any requirement of, any regulatory authority, or otherwise to ensure Clinical Trial patient safety. 

  

	 	9.	 FINANCIAL CONSIDERATION 

 

	9.1	 In partial consideration for the buy back of Anti-NKG2A, including the licenses and rights granted hereunder to
IPH pursuant to this Amendment, IPH shall pay to NN *** in cash within thirty (30) days of the Innate shareholder vote as described in 9.3.2. 

  

	9.2	 IPH shall also pay *** of any upfront payment(s) received by IPH in connection with the any Out-License for Anti-NKG2A to be entered into by IPH, minus *** to the extent that such difference is positive. For this avoidance of doubt, “upfront payment(s)” shall mean the payment(s) made immediately
following the execution of the Out-license in partial consideration of the grant of rights, and shall exclude any other payments (including any development or regulatory milestone payments).

  

	9.3	 In addition, IPH shall for the sale and partial cost reimbursement for the Anti-NKG2A supplies, toxicology, pre-clinical and clinical data and results owe to NN a payment of *** (the “Additional Payment”), which payment will become due and payable as follows: 

 

	 	9.3.1	 subject to the vote by its shareholders, IPH will issue and allocate to NN *** new shares forming the share
capital of IPH (the “Shares”); 

  

	 	9.3.2	 as soon as possible after this Amendment no. 7, IPH will convene an extraordinary shareholders’ meeting to
be set for March 27, 2014, for the purpose of voting on a resolution authorizing the issue of shares to NN (the “Resolution”); 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 24 

	 	9.3.3	 the chairman of the extraordinary shareholders’ meeting, which shall be the chairman of the Supervisory
Board of IPH, as per article R225-100 of the French Commercial Code, shall vote the unnamed proxies in favor of the Resolution, as provided in article L.225-106 III al.
5 of the French Commercial Code ; 

  

	 	9.3.4	 as of the date of this Amendment No. 7 and until the expiry of a 180 day period starting on the closing of
the Innate Fundraising (as defined below), NN irrevocable undertakes that neither it nor any of its Affiliates will (i) directly or indirectly, offer, transfer, issue or agree to offer, transfer, issue, the Shares or any financial instruments
giving right, of immediately or in the future to the 

 Shares, (ii) enter into any swap or other agreement that
transfers, in whole or in part, any of the economic consequences of the ownership of the Shares, whether any such transaction described in (i) or (ii) above is to be settled by delivery of the Shares or in other securities, or in cash or
otherwise; or (iii) grant options to subscribe for or purchase the Shares. 
 For the purposes of this Amendment No. 7,
“Innate Fundraising” shall mean a capital increase realized by IPH with a closing date occurring on or before December 31, 2014. For the purpose of clarity, if the Innate Fundraising does not occur by December 31, 2014,
then the restrictions set forth in this 9.3.4 shall not apply to NN with respect to the Shares. 
  

	 	9.3.5	 Subject to section 9.4, the Additional Payment shall become due and payable (“liquide et
exigible”) on the date on which IPH issues and allocates the Shares to NN, which date shall be no later than 10 business days following the approval of the resolution; 

 

	 	9.3.6	 NN shall subscribe the Shares and the subscription price shall be paid by the setoff against the Additional
Payment. IPH shall provide all necessary documents and assistance to facilitate NN’s subscription of the Shares and will take the necessary steps for the Shares to be listed on Euronext Paris. If despite such steps and NN receiving such
assistance, NN fails to subscribe the Shares as allocated to NN by IPH, and such failure is notified in writing by Innate to NN, the Additional payment shall no longer be due and payable by IPH to NN. 

 

	9.4	 If the Resolution is not approved by the shareholders of IPH on March 27, 2014, this Amendment No.
7 may be terminated by either Party upon notice to the other Party. In such event of termination, all rights, license sand obligations provided in this Amendment No. 7 shall terminate effective upon the date of the termination notice,
provided that IPH shall return to NN all materials and documents provided by NN to IPH pursuant to Section 4, Section 5 and Section 6 of this Amendment No. 7 within thirty (30) days of the termination date, except for those
materials which have been consumed by IPH prior to the termination date. 

  
 25 

	9.5	 NN shall submit an invoice to IPH corresponding to the payments of Section 9.1 and 9.3, at IPH’s
request and no later than fifteen days prior to the due date of such payments, which invoice shall include the term “reverse charge” in consideration of VAT. 

 

	9.6	 If by September 30, 2014, NN has delivered less than 500g of the
In-Process Batch, then NN shall pay to IPH liquidated damages in the amount of ***. If by September 30, 2014, NN has delivered to IPH at least 500g but less than 1000g of the In-Process Batch, then NN shall pay to IPH liquidated damages in the amount following the formula: liquidated damages (in Millions euros) = *** x quantity (in grams). By way of example: if only 750g of the In-Process Batch have been 

 delivered on September 30, 2014, the liquidated
damages amount shall be *** x 750 = ***. If by September 30, 2014, NN has delivered to IPH more than 1000g of the In-Process Batch then no liquidated damages will be due. The amount of liquidated damages,
if any, will invoiced by IPH to NN and paid by NN within *** following the receipt of such invoice. Such payment shall not be subject to any setoff right. The Parties agree that the amounts payable under this Section 9.6 are a genuine pre-estimate of the loss that IPH will suffer as a result of the failures to deliver the In-Process Batch as required by Section 6.1 (c). 

 

	 	10.	 PRESS RELEASE. 

Simultaneously with the execution of the Amendment No. 7, the Parties shall issue a joint press release on the buy back by IPH of the
Anti-NKG2A program in the form attached as Exhibit G. 
  

	 	11.	 OTHER ADJUSTMENTS 

 

	11.1	 Notwithstanding Section 15.3.1(a) and 15.3.1(b) of the Agreement, IPH may grant to any Out-Licensee a security interest, lien or other encumbrance on any Intellectual Property Right owned by IPH and licensed by IPH to any Out-Licensee under the Outlicense.

  

	11.2	 Notwithstanding Section 9.8 of the Agreement, upon execution of an
Out-License, IPH may request that its Out-Licensee shall have the sole right, but not the obligation, to apply for any patent term adjustment, patent term extension,
supplemental patent protection or related extension of rights with respect to the Patents licensed to any Out-Licensee under the Outlicense. Without limiting the foregoing, NN covenants that it will not seek
patent term extensions, supplemental protection certificates, or similar rights or extensions for such Patents without the prior written consent of IPH. NN will cooperate fully with and provide all reasonable assistance to IPH or its designated Out-Licensee and use all Commercially Reasonable Efforts consistent with its obligations under applicable Law 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 26 

	 	
(including any applicable consent order or decree) in connection with obtaining any such adjustments or extensions for such Patents. To the extent reasonably and legally required in order to
obtain any such adjustment or extension in a particular country, NN will make available to IPH or its designated Out-Licensee a copy of the necessary documentation to enable IPH or its designated Out-Licensee to use the same for the purpose of obtaining the adjustment or extension in such country. 

  

	11.3	 NN shall not exercise its “March-In” right under
Section 9.13 with respect to any IPR licensed to any Out-Licensee under the Out-license without the prior written consent of any
Out-Licensee, which consent shall not be unreasonably withheld. 

  

	11.4	 Notwithstanding Section 21.1 or anything else in the Agreement to the contrary, any Out-Licensee shall not be required, during or following the term of the Outlicense, to maintain, grant, assign or otherwise convey to IPH, NN, or any other Third Party, any rights under any IPR that any Out-Licensee or its Affiliates may own or control (other than such IPR as is licensed to any Out-Licensee under the Outlicense). 

 

	11.5	 Any Out-Licensee may exercise any right as an Out-licensee under the Agreement and may exercise IPH’s right to cure under Sections 12.4 and 12.7B(b) of the Agreement and any right of IPH under Article 9 with respect to the patent rights listed in Exhibit B
of this Amendment. 

  

	11.6	 Any Out-Licensee shall have no obligation under the Agreement other
than those obligations expressly imposed on Out-licensees and, for clarity, any Out-Licensee’s obligations under Section 15.1.6 shall only apply to other terms
and conditions of the Agreement that are expressly imposed on Out-Licensees. 

  

	11.7	 Any Out-Licensee may disclose Confidential Information of NN relating
to Anti-NKG2A Antibodies and IPR licensed to any Out-Licensee under the Outlicense that it obtains from IPH without any obligation to obtain consent therefor from NN. 

 

	11.8	 Notwithstanding Section 15.1.8 or anything else in the Agreement to the contrary, any Out-Licensee shall have no obligation to provide any information to NN regarding any activity under the Outlicense beyond such information that any Out-Licensee provides to
IPH under the Outlicense. 

  

	11.9	 Notwithstanding anything in the Agreement to the contrary, any
Out-Licensee’s rights under the Outlicense shall survive any termination of the Agreement (other than a termination directly resulting from a material breach by any
Out-Licensee of its obligations under the Outlicense or as an Out-licensee under the Agreement), subject to (a) the payment by any
Out-Licensee to NN of any milestones or royalties with respect to Anti-NKG2A that IPH would have been required to pay NN under the Agreement and (b) the provision by any
Out-Licensee to NN of information consistent with Section 11.6. 

  
 27 

	11.10	 The provisions of this Amendment confer a benefit on and are intended to be (and shall be) enforceable by any Out-Licensee in the event any Out-Licensee becomes and as long as it remains an Out-licensee by virtue of the Contracts (Rights of
Third Parties) Act 1999. Otherwise no person who is not a Party shall have the right to enforce any term of this Amendment by virtue of the Contracts (Rights of Third Parties) Act 1999. 

 

	 	12.	 MISCELLANEOUS 

 

	12.1	 Effectiveness and Integration. This Amendment shall become effective as of the Amendment No. 7
Effective Date and the amendments made to the Agreement hereunder shall thereafter be deemed an integral part of the Agreement. 

  

	12.2	 No Other Changes or Repetition of Warranties. Except as expressly set forth herein, all provisions of
the Agreement shall remain unchanged and in full force and effect. Nothing in this Amendment No. 7 shall cause, or shall be deemed to cause, any representation or warranty set out in the Agreement to be repeated. 

 

	12.3	 Conflicts Between Agreement and Amendment No. 7. To the extent that the Agreement is
explicitly amended by this Amendment No. 7, the terms of the Amendment No. 7 will control where the terms of the Agreement are contrary to or conflict with the provisions of this Amendment. Where the Agreement is not explicitly amended by
this Amendment No. 7, the terms of the Agreement will remain in force. 

  

	12.4	 Applicable Law. This Amendment No. 7 shall be construed and interpreted pursuant to the Laws
stipulated in the Agreement. 

  

	12.5	 Dispute Resolution. All disputes arising out of or in connection with this Amendment No. 7 shall be
finally settled as stipulated in the Agreement. 

  

	12.6	 Counterparts. This Amendment No. 7 may be executed in two (2) or more counterparts, each of
which shall constitute an original for all purposes, including for purposes of any delivery of this Amendment No. 7 required by the terms hereof, and all of which together shall constitute one and the same instrument with the same effect as if
all parties hereto had signed the same document. 

 [SIGNATURE PAGE FOLLOWS] 

  
 28 

 IN WITNESS WHEREOF, the Parties have caused this Amendment No. 7 to be executed by their respective duly
authorized representatives as of the day and year first above written. 
  

					
	 Marseille
  

Innate Pharma SA
  

/s/ Herve Brailly
 By:
    Herve Brailly
 Title:  Chief Executive/Officer
	 		 	 Bagsvaerd
  

Novo Nordisk A/S
  

/s/ Lars Fruergaard Jórgensen

By:     Lars Fruergaard Jórgensen

Title:  Chief Information Officer

           Novo Nordisk A/S

 [Signature page to Amendment No. 1 to the joint Research, Development, 

Option and License Agreement] 

 Exhibit A 

Schedule 1.1.7B 

Background NN IPR for the development and commercialization of Anti-NKG2A 

as a Niche Candidate 
 To be mutually
agreed upon as needed. 

  
 Exhibit A-1 

 Exhibit B 

Schedule 1.1.16B 
 Part
A — Anti-NKG2A Patents 
 *** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 Exhibit B-1 

 Exhibit B 

Schedule 1.1.16B 
 Part B- Formulation Patent 
 *** 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 Exhibit B-2 

 Exhibit C 

Schedule 1.1.17B 

Anti-NKG2A Know-How Categories 

*** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 Exhibit C-1 

 Exhibit D 

Schedule 5.8.2B 
 *** 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 Exhibit D-1 

 Exhibit E 

Anti-NKG2A Supplies 

*** 
  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  
 Exhibit E-1 

 Exhibit F 

Basic Guidelines for NN’s and IPH’s Collaboration on Transfer of the 

Anti-NKG2A Project from NN to IPH 

*** 
 End of Document 

 
 Certain information has been excluded from this agreement (indicated by
“[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 

  
 Exhibit F-1 

 Exhibit G 

Press Release 
 INMATE PHARMA
ACQUIRES FULL RIGHTS TO ANTI-NKG2A 
 CHECKPOINT INHIBITOR FROM NOVO NORDISK A/3 

NOVO NORDISK A/S TO REINFORCE ITS EQUITY STAKE 

IN INMATE PHARMA 
  

	 	•	 	 Anti-NKG2A is a first-in-class
therapeutic mAb that is Phase II ready 

  

	 	•	 	 NKG2A is a NK and T cell checkpoint relevant in both inflammatory disorders and immuno-oncology

  

	 	•	 	 Innate Pharma will prioritize development of anti-NKG2A in immuno-oncology and trials are expected to start in
2014 

  

	 	•	 	 Agreement subject to approval by Innate’s shareholders on March 27, 2014 

Marseille, France, and Bagvaerd, Denmark, February 5, 2014  

Innate Pharma SA and Novo Nordisk A/S today announce that Innate Pharma has acquired full development and commercialization rights to the anti-NKG2A antibody
(“anti-NKG2A”), a first-in-class immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. 

Novo Nordisk conducted a large Phase I safety trial with NKG2A in patients with rheumatoid arthritis, demonstrating a good safety profile for both iv and sc
routes at single and multiple administrations. Novo Nordisk has decided to advance other compounds for further development in inflammation, including anti-NKG2D1, currently in Phase II development
and generated within the collaboration between Innate Pharma and Novo Nordisk. 
 Novo Nordisk will receive €2 million euros in cash and six
hundred thousand (600.000) shares for licencing anti-NKG2A to Innate and be eligible to a total of €20m in potential registration milestones and single-digit tiered royalties on future sales. The acquisition of the Innate shares is subject to
approval by Innate’s shareholders’ at an extraordinary general meeting on March 27, 2014. 
  

	1 	 Innate Pharrna has no remaining rights on this candidate 

  
 Exhibit G-1 

 Herve Brailly, CEO of Innate Pharma noted: “This is a superb opportunity for Innate Pharma. In addition
to lirilumab partnered to Bristol-Myers Squibb and currently in Phase II, we now have a proprietary Phase II ready, first-in-class, iminuno-modulating antibody
with favorable Phase I safety data and the promise of broad development potential. Our initial clinical development plan is in oncology and we expect to start the clinical program before the end of this year. This licence consolidates Innate
Pharma’s leadership in immnuno-modulating antibodies targeting the innate immune system”. 
 Nicolaï Wagtmann, CSO of Innate Pharma,
said: “Anti NKG2A is a very exciting immune checkpoint inhibitor targeting both NK and T cells that was selected in the Novo Nordisk - Innate Pharma research alliance for development in cancer and inflammatory disorders. We are very pleased
with the progress in the development of this drug candidate, and we look forward to now taking it forward in cancer indications where there is a great need for better treatments and where drugs of this type have shown tremendous benefit in recent
years.” 
 Per Falk, Senior Vice President Biopharmaceutical Research, Novo Nordisk A/S, added: “The new field of innate immunity
pharmacology opened by IPH has proven highly productive, as exemplified by anti-KIR and anti-NKG2D now in Phase II clinical trials. In view of recent successes with this type of drug candidates in cancer
patients, we believe that anti-NKG2A has its greatest potential in oncology and that Innate Pharma is in the best position to pursue its development.” 
  

	
	 Innate Pharma will host a
conference call today at 6:30pm [DETAILS TO BE ADDED]
  

 About IPH2201, anti-NKG2A antibody 

IPH2201 (anti-NKG2A) is a first-in-class humanized IgG4 antibody. NKG2A is a
checkpoint receptor that inhibits anti-cancer functions of cytotoxic NK and T lymphocytes. NKG2A recognizes HLA-E ligands, and by expressing HLA-E, cancer cells can
protect themselves from killing by CD94/NKG2A-positive NK-, NKT-, and T-cells (a/b and g/d). HLA-E is frequently
up-regulated on cancer cells and this occurs in patients with different types of solid tumors or haematological malignancies. In some types of cancers, high-levels of
HLA-E appear to confer poorer prognosis. IPH2201 blocks the inhibitory function of CD94/NKG2A, thereby unleashing NK and T cells to kill cancer cells, despite expression of
HLA-E. IPH2201 enhances NK and T cell killing of a variety of cancer cell types. Hence, IPH2201 may potentially re-establish a broad anti-tumor response mediated by NK
and T cells. Anti-NKG2A mAb may also enhance the cytotoxic potential of other therapeutic antibodies. In an on-going single- and multiple-dose Phase I dose-escalation safety trial in patients with rheumatoid
arthritis, IPH2201 appears to have a safe and well-tolerated profile at all doses tested. 
 IPH2201 was the third therapeutic antibody generated in the
Novo Nordisk A/S – Innate Pharma partnership to enter clinical trials, and the second targeting a checkpoint receptor (after lirilumab). Under this agreement, Novo Nordisk A/S had licenced anti-NKG2A from Innate Pharma in 2006 as part of a
multi-year research and collaboration agreement. That initial license included total milestones of €25 million and single-digit royalties. 

  
 Exhibit G-2 

 About Novo Nordisk A/S: 

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading
positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 37,000 employees in 75 countries, and markets its products in more than 180 countries. For more
information, visit novonordisk.com. 

 

 Further information 

Media: 
 Katrine Sperling 

+45 4442 6718 

krsp@novonordisk.com

 Ken Inchausti (US) 

+1 609 514 8316 
 kiau@novonordisk.com 

 

 

 

 Investors: 

Kasper Roseeuw Poulsen 
 +45
4442 4303 
 krop@novonordisk.com 

 

 Frank Daniel Mersebach 

+45 4442 0604 
 fdni@novonordisk.com

 

 

 Daniel Bohsen 

+45 3079 6376 

dabo@novonordisk.com

 Lars Borup Jacobsen 

+45 3075 3479 
 lbpj@novonordisk.com

 

  
 About Innate Pharma: 

Innate Pharma S A. is a biopharmaceutical company conducting research and development of innovative immunotherapy drug candidates for cancer and inflammatory
diseases. 

  
 Exhibit G-3 

 The company specializes in the development of
first-in-class therapeutic antibodies targeting receptors and pathways controlling the activation of the innate immune system. Three product-candidates resulting from
the company’s research platform are currently being tested in clinical trials, two of which by partners Bristol-Myers Squibb and Novo Nordisk A/S. 

Listed on Euronext-Paris, Innate Pharma is based in Marseilles, France, and had 84 employees as at September 30, 2013. Learn more about Innate Pharma at
www.innate.pharma.com. 
 Learn more about Innate Pharma at www.innate.pharma.com. 

Practical Information about Innate Pharma shares: 
  

			
	ISIN code	  	FR0010331421
		
	Ticker code	  	IPH
		
	Disclaimer:	  	

  
 Exhibit G-4 

 This press release contains certain forward-looking statements. Although the company believes its expectations
are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which
could cause the company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the
Document de Reference prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma’s website. 

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe
to shares in Innate Pharma in any country. 
 For additional information, please contact: 

 

			
	Innate Pharma	  	ATCG Press
		
	Laure-Hélène Mercier	  	Marielle Bricman
		
	Director, Investor Relations	  	
		
	Phone: +33 (0)4 30 30 30 87	  	Mob.: +33 (0)6 26 94 18 53
		
	investors@innate-pharrna.com	  	mb@atcg-partners.com

  
 Exhibit G-5 

 Certain information has been excluded from this agreement (indicated by “[***]”) because such
information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 
 CONFIDENTIAL 

FINAL 
 AMENDMENT AND SUPPLEMENT NO. 8

 to the 
 JOINT
RESEARCH, DEVELOPMENT, OPTION AND LICENSE AGREEMENT 
 Dated 

MARCH 28, 2006 
 Between

 NOVO NORDISK A/S 

and 
 INNATE PHARMA SA

 Relating to the Buy Back of Anti-NKG2A 

16 September, 2016 

  

 AMENDMENT AND SUPPLEMENT NO. 8 

to the 
 JOINT RESEARCH,
DEVELOPMENT, OPTION AND LICENSE AGREEMENT 
 Amendment and Supplement dated as of September 16, 2016 (the “Amendment No. 8”) to the
Joint Research, Development, Option and License Agreement dated March 28, 2006 as amended (hereinafter the “Agreement”) between Novo Nordisk A/S (CVR-no. 24 25 67 90), a corporation existing under the laws of Denmark and having its
principal place of business at Novo Allé, 2880 Bagsvaerd, Denmark (hereinafter “NN”), and Innate Pharma SA, a corporation existing under the laws of France and having its principal place of business at avenue de Luminy, 13009
Marseille, France (hereinafter “IPH”). 
 WITNESSETH 

 

			
	 WHEREAS
	  	NN and IPH wish to amend the Agreement in order to change the payment obligations regarding the *** License;
		
	 NOW, THEREFORE,
	  	
		
		  	in consideration of the foregoing premises, the mutual promises and covenants set forth in this Amendment No. 8, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, NN and IPH,
each intending to be legally bound, hereby agree as follows:

  

	1.1	 Unless otherwise specifically defined herein, each term used herein that is defined in the Agreement has the
meaning assigned to such term in the Agreement. Each reference to “hereof”, “hereunder”, “herein” and “hereby” and each other similar reference and each reference to “this Agreement’ and each other
similar reference contained in the Agreement shall, after the Amendment No. 8 Effective Date, refer to the Agreement as amended hereby. 

  

	1.2	 “Amendment No. 8 Effective Date” shall mean 16 September 2016. 

 

	1.3	 With effect from the Amendment No. 8 Effective Date, Subsection 7.8D (***) is deleted in its entirety and
replaced with the following wording: 

 7.8D ***. 

Subject to the other provisions of this Section 7.8D, IPH shall bear the following payments that NN represented to IPH would be due by NN to
***, as a result of the sublicense granted by NN pursuant to this Amendment (together the “*** Fee”): 
  

	 	-	 	Starting as of calendar year 2015, a minimum yearly payment not to exceed ***, and 

  

	 	-	 	as of calendar year 2017, a minimum yearly payment equal to the payment that *** is invoicing Novo Nordisk which is *** indexed to the Retail Price Index from 2004 and adjusted periodically to take account of increases
in the Retail Price Index; and 

  

	 	-	 	one regulatory milestone payment (*** upon initiation of the first Phase III in each clinical indication for each Anti-NKG2A). 

  

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 

  

 Except for the *** Fee, NN shall bear all royalty and other payments if any that would be due by
NN to ***, as a result of the sublicense granted by NN pursuant to Amendment No. 7. 
 NN shall notify IPH of the expiration of the ***
License promptly upon expiration or abandonment of the last patent that is issued from the Application (International patent application ***). 

IPH has negotiated its own license with *** with respect to the Patent and Know How Controlled by *** and necessary to manufacture Anti-NKG2A
and shall bear all payments related thereto, subject to the other provisions of this Section 7.8D. 
 Notwithstanding Section 7.8 hereof, IPH
shall be entitled to deduct: 
  

	 	-	 	*** of the royalty payments due by IPH to *** in connection with Anti-NKG2A under IPH’s own license with ***, from the royalty payable by IPH to NN pursuant to Section 7.8B, provided that such deduction shall not
exceed *** of Net Sales. 

  

	 	-	 	each payment of the *** Fee, from any milestone payment that is subsequently payable by IPH to NN pursuant to Section 7.4B above.” 

IN WITNESS WHEREOF, the Parties have caused this Amendment No. 8 to be executed by their respective duly authorized representatives as of the day and year
first above written. 
  

									
	 Marseille
	 		 	Bagsvaerd
			
	 Innate Pharma SA
	 		 	Novo Nordisk A/S
			
	 /s/ Herve Brailly
	 		 	 /s/ Peter Haahr

					
	 By:
	 	Herve Brailly	 		 	By:	 	Peter Haahr
	 Title:
	 	Chief Executive/Officer	 		 	Title:	 	Corporate Vice President

  
 Certain information has been excluded from this
agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]